{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "65e2f1cdf2220e4443afe0001b98bf23",
    "title": "Morgan Stanley | RESEARCH",
    "source_uri": "25.9月 普通个人版/9.1 普通个人版/MS/Biopharma July oncology sales performanceBiopharma July oncology sales performance_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T12:24:19.711900",
      "extracted_at": "2025-10-26T12:24:19.711917"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 59,
        "successful_pages": 59,
        "date": "2025-08-29",
        "publication": "25.9月 普通个人版/9.1 普通个人版/MS",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 2,
          "reduction_ratio": 0.017757708748208367
        },
        "input_relative_path": "25.9月 普通个人版/9.1 普通个人版/MS"
      }
    }
  },
  "passages": [
    {
      "passage_id": "55f427e51f3c473d",
      "text": "August 29, 2025 12:53 PM GMT",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "60eca7998afd74c4",
      "text": "We provide comprehensive IQV4 oncology figures & charts. July data were released on August 29. Drugs are organized by MOA: IO, ALK+ROS1, androgen+GnRH, BTK, CDK4/6 & PI3K, CD3 x C20, CD19+79, CD38, DLL 3, EGFR, FLT- 3, FRa, HER2, kinase, KRAS, PARP, proteasome, SLAMF7, TROP- 2 and thalidomide.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d121ab3cbe80bb95",
      "text": "I/O: YoY Bristol Myers' Opdivo sales growth was \\(+17\\%\\) and Yervoy was \\(+13\\%\\) Merck's Keytruda sales growth was \\(+6\\%\\) . Sequentially from June to July, Opdivo sales growth was \\(+1\\%\\) and Yervoy was \\(- 1\\%\\) ; Keytruda sales growth was \\(- 3\\%\\) . See Exhibit 6 for IO drugs YoY and sequential growth.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "33a1976053bcc2d5",
      "text": "See Exhibit 5 for reported sales by indication for Bristol Myers' Opdivo and Merck's Keytruda per respective company's disclosures as available. In 2Q25, lung cancer comprised \\(\\sim 28\\%\\) (MS est.) \\((\\sim \\$ 430\\mathrm{nm})\\) of US Opdivo sales and in range of \\(25\\% - 30\\% (\\sim \\$ 1,306\\mathrm{nm}\\) based on assumption of \\(27.5\\%\\) of US Keytruda sales.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3097fa720ee221ae",
      "text": "BTK Inhibitors: Abbvie's Imbruvica July YoY sales growth was \\(- 2\\%\\) ; AstraZeneca's Calquence sales growth was \\(+42\\%\\) ; BeiGene's Brukinsa sales growth was \\(+56\\%\\) . Sequentially from June to July, Imbruvica sales growth was \\(- 4\\%\\) ; Calquence sales growth was \\(- 5\\%\\) ; Brukinsa sales growth was \\(- 1\\%\\) . See Exhibit 25. Weekly TRx growth for Imbruvica for the week ending Aug 22 was \\(8\\%\\) vs. 12- wk rolling growth of \\(- 9\\%\\) (Exhibit 27). Calquence weekly TRx growth was \\(+26\\%\\) vs. 12- wk rolling growth of \\(+18\\%\\) (Exhibit 28). Brukinsa weekly TRx growth was \\(+21\\%\\) vs. 12- wk rolling growth of \\(+25\\%\\) (Exhibit 30). Brukinsa was approved in CLL on 1/19/23 and has been gaining share since then. LLY's Jaypirca (pirtobrutinib) was launched in January 2023 and has been rising steadily. Our take on Jaypirca head- to- head trial results here.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "aecf4983b2b2c550",
      "text": "bRituxan (Exhibit 104): Pfizer's Ruxience was launched on January 23, 2020 and had sales of \\(\\sim \\$ 55\\mathrm{nm}\\) and had share of \\(\\sim 26\\%\\) in July. The label lack's rheumatoid arthritis (RA) and PV indications. Per Roche, RA comprises \\(>20\\%\\) of branded Rituxan sales. Commentary suggests that skin- labels are more of an issue for physicians than payers. Abbvie/ Amgen's Riabni was approved on Dec. 17, 2020 and reported sales of \\(\\sim\\) \\(13\\mathrm{nm}\\) ( \\(\\sim 6\\%\\) share) for the month of July. Riabni has been approved for RA on June 6, 2022. Avastin (Exhibit 102): In July, Amgen's Mvasi recorded \\(\\sim \\$ 68\\mathrm{nm}\\) sales \\(\\sim 47\\%\\) share). Pfizer's Zirabev was launched on December 31, 2019 and generated sales of \\(\\sim \\$ 32\\mathrm{nm}\\) ( \\(\\sim 22\\%\\) share). Amneal's Alymsys, which was approved in April 2022, launched in October 2022 recorded sales of \\(\\sim\\) \\(9\\mathrm{nm}\\) ( \\(\\sim 6\\%\\) share) in July. bHerceptin (Exhibit 103): In July, Amgen's Kanjinti recorded \\(\\sim \\$ 19\\mathrm{nm}\\)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d662b79132286d0d",
      "text": "bHerceptin (Exhibit 103): In July, Amgen's Kanjinti recorded \\(\\sim \\$ 19\\mathrm{nm}\\)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "51003d9459b6064f",
      "text": "North America Industry View In- Line BIOTECHNOLOGY North America Industry View Attractive",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "de5db0a04b8a293d",
      "text": "Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ce4e97388df9df73",
      "text": "For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "416b0c17040a2faf",
      "text": "sales (\\~7% share). Biocon's Ogivri was launched on December 2, 2019 and generated sales of \\~\\$21mn (\\~8% share); Pfizer's Trazimera was launched on February 19, 2020 and generated sales of \\~\\$18mn (\\~6%); Organon/Samsung Bioepis's Ontruzant was launched on April 15, 2020, and IQVIA had sales of \\~\\$2mn (\\~1%). Other charts include bNeulasta (Exhibit 100 & Exhibit 101), bNeupogen (Exhibit 105 & Exhibit 106) and bEpogen (Exhibit 107 & Exhibit 108).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "9228c84b31d244d5",
      "text": "AstraZeneca/Merck's Lynparza sales were - 2% sequentially in July vs +6% in June and 0% in May (Exhibit 81). YoY Lynparza grew +19% in July vs +24% in June and +19% in May. Lynparza received additional approval as a first- line maintenance therapy in combination with Avastin for homologous recombination deficiency (HRD)- positive ovarian cancer on May 8, 2020 and homologous recombination repair (HRR) gene- mutated metastatic castration- resistant prostate cancer on May 20, 2020. Merck and AstraZeneca co- develop and co- commercialize Lynparza for multiple cancer types. Merck books its share of sales, net of commercialization costs, as alliance revenue.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "463a7da3ca076cf3",
      "text": "This report is organized by mechanism of action (MOA). The sections are: IO, ALK +ROS1, androgen+GnRH, BTK, CDK4/6, CD19+79, CD38, FLT- 3, kinase, PARP, proteasome, SLAMF7, TROP- 2 and thalidomide analogues. Each section includes a table showing the drugs with their combinations, route of administration, and approved indications.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "0ce6521d5f812971",
      "text": "For IQVIA monthly sales trends, we normalize March, June, September, and December sales figures. IQVIA reports sales data for a given month at the end of the subsequent month. Within a quarter, monthly sales are reported on 4- 4- 5 (weeks) basis so we normalize March, June, September, and December sales to a 4- week basis to assess trends.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "88cfe183971ffffb",
      "text": "Exhibit 1: Total Oncology sales trend",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ae4c014065bef8ef",
      "text": "Exhibit 2: YoY growth for the latest three months—note that we normalize March, June, September, and December to four weeks",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "310257fdc9f5024a",
      "text": "YoY monthly growthMayJuneJulyIMMUNO ONCOLOGYBavencio (PFE/MRK.DE)-40%-36%Imfinzi (AZN)33%44%42%Keytruda (MRK)5%10%6%Libtayo (REGN/SNY)-98%-98%-20%Opdivo (BMY)8%9%17%Opdualag (BMY)9%20%17%Tecentriq (ROG)-12%-2%-7%Yervoy (BMY)7%22%13%Pedgev (PFE)16675%22884%20940%ANDROGEN + GNRHINHIBITORSErleada (JNJ)44%50%40%Nubeqa (BAYN)88%102%96%Orgovyx (MYOV)115%126%104%Xtandi (PFE)50%48%37%Zytiga (JNJ)-19%-44%-37%ALK/ROS1 INHIBITORSAlecensa (ROG)20%23%23%Alunbrig (Takeda)40%54%23%Lorbrena (PFE)54%71%66%Rozlytrek (ROG)-1%16%18%Xalkori (PFE)-4%-3%7%Zykadia (NVS)20%0%-11%BTK INHIBITORSBrukinsa (ONC)50%36%56%Calquence (AZN)34%62%42%Imbruvica (ABBV/JNJ)3%-3%-2%Venclexta (ABBV/ROG)18%23%13%CD 30 INHIBITORSAdcetris (SEGN)3665%5265%4470%CD 38 INHIBITORSDarzalex Franchise (JNJ)21%29%26%Sarclisa (SNY)28%38%37%CDK 4/6 + PI3KIbrance (PFE)1%5%7%Kisqali (NVS)100%109%115%Verzenio (LLY)11%11%13%CD19/CD79Monjui (Incyte/Morphosys)30%-3%7%Polivy (Roche)25%28%20%CD3 X CD 20Columvi (Roche)-99%-100%-99%Epkinly (GMAB/ABBV)67%-33%-4%DLL 3Imdelltra (AMGN)NANANAEGFR EXON-20Rybreatn (Johnson125%117%82%Johnson)FLT-3Vanflyta (Daiichi)NA98%49%Xospata (Astellas)13%30%13%FRA",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "57e5207884a079e3",
      "text": "Morgan Stanley | RESEARCH",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "609c09394a1c8135",
      "text": "Elahere (Abbvie)-99%-97%-98%HER2Enhertu (Daiichi)26%27%31%KINASE INHIBITORSAugtyro (BMY)222%170%179%Balversa (JNJ)8%41%55%Cabometyx (EXEL)19%25%24%Inlyta (PFE)-3%3%6%Sutent (PFE)21%-13%-26%Nexavar (BAYN)-44%-64%-60%Retevmo (LLY)34%35%32%Lenvima (Eisai)16%22%17%Vitrakvi (BAYN)27%17%25%Inrebi (BMY)14%18%-1%Gavreto (BPMC)26%35%16%KRASKrazati (Mirati)3968%1367%1013%Lumakras (Amgen)15%27%15%PARP INHIBITORSLynparza (AZN)19%24%19%Rubraca (CLVS)-24%-17%-20%Talzenna (PFE)98%88%64%Zejula (GSK)6%3%2%PROTEASOME INHIBITORSKyprolis (AMGN)-6%13%-8%Ninlaro (Takeda)9%10%7%Velcade (Takeda)-14%10%-5%SLAMF7Empliciti (BMY)-7%1%-12%THALIDOMIDE ANALOGUESPomalyst (BMY)67%109%62%Revlimid (BMY)45%113%22%Thalomid (BMY)106%140%68%TROP-2Trodelvy (GILD)-7%1%4%",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b56a570639119498",
      "text": "*A reporting restriction has been removed starting November 2024 which was implemented in the mail channel for a portion of the sales and prescription volumes for Pomalyst, Revlimid and Thalomid starting April 2021.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a5c616f5c74c0a68",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4 or 5 week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "f4f71d6b02fc2600",
      "text": "Exhibit 3: MoM growth for the latest three months—note that we normalize",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "83ba1a7c9d7cad80",
      "text": "March, June, September, and December to four weeks",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "fdd6559d6b1ed363",
      "text": "MoM sequential growthMayJuneJulyIMMUNO ONCOLOGYBavencio (PFE/MRK.DE)0%0%-8%Imfinzi (AZN)7%7%-2%Keytruda (MRK)0%-2%-3%Libtayo (REGN/SNY)34%-26%-11%Opdivo (BMY)-2%0%1%Opdualag (BMY)-4%3%2%",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "23406a5a0ca4b591",
      "text": "Tecentriq (ROG)3%18%-19%Yervoy (BMY)1%4%-1%Pedgev (PFE)-4%1%-8%ANDROGEN + GNRHINHIBITORSErleada (JNJ)4%6%-4%Nubeqa (BAYN)7%8%3%Orgovyx (MYOV)4%10%-1%Xtandi (PFE)0%4%-4%Zytiga (JNJ)-4%-29%-1%ALK/ROS1 INHIBITORSAlecensa (ROG)-1%1%4%Alunbrig (Takeda)-5%10%-14%Lorbrena (PFE)4%5%4%Rozlytrek (ROG)-6%3%12%Xalkori (PFE)-4%5%-1%Zykadia (NVS)8%1%-15%BTK INHIBITORSBrukinsa (ONC)1%4%-1%Calquence (AZN)0%8%-5%Imbruvica (ABBV/JNJ)1%-1%-4%Venclexta (ABBV/ROG)1%8%-6%CD 30 INHIBITORSAdcetris (SEGN)-25%48%8%CD 38 INHIBITORSDarzalex Franchise (JNJ)1%4%-3%Sarclisa (SNY)2%8%0%CDK 4/6 + PI3KIbrance (PFE)-1%2%-1%Kisqali (NVS)3%6%2%Verzenio (LLY)-2%3%-3%CD19/CD79Monjui (Incyte/ Morphosys)1%9%0%Polivy (Roche)5%-4%2%CD3 X CD 20Columvi (Roche)44%-97%1704%Epkinly (GMAB/ABBV)-5%-4%-17%DLL 3Imdelltra (AMGN)4%10%9%EGFR EXON-20Rybrevan (Johnson Johnson)4%5%-2%FLT-3Vanflyta (Daiichi)-24%17%-20%Xospata (Astellas)3%23%-17%FRAElahere (Abbvie)1%89%-24%HER2Enhertu (Daiichi)1%-2%5%KINASE INHIBITORSAugtyro (BMY)8%4%-6%Balversa (JNJ)-17%32%-1%Cabometryx (EXEL)0%3%2%Inlyta (PFE)-4%8%-3%Sutent (PFE)10%-12%-14%",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "f819edcb498530d3",
      "text": "Nexavar (BAYN)50%-38%-29%Retevmo (LLY)5%2%-1%Lenvima (Eisai)-5%7%-1%Vitravki (BAYN)2%3%7%Inrebi (BMY)19%-8%-5%Gavreto (BPMC)14%7%-2%KRASKrazati (Mirati)1%3%-3%Lumakras (Amgen)1%6%-8%PARP INHIBITORSLynparza (AZN)0%6%-2%Rubraca (CLVS)-13%4%-2%Talzenna (PFE)3%4%-4%Zejula (GSK)-3%-1%-4%PROTEASOMEINHIBITORSKyprolis (AMGN)7%17%-20%Ninlaro (Takeda)0%6%-6%Velcade (Takeda)-2%20%-8%SLAMF7Empliciti (BMY)-4%7%-3%THALIDOMIDEANALOGUESPomalyst (BMY)2%28%-24%Revlimid (BMY)-5%35%-41%Thalomid (BMY)-5%35%-27%TROP-2Trodelvy (GILD)-1%4%0%",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "cc55dd7c465069f6",
      "text": "*A reporting restriction has been removed starting November 2024 which was implemented in the mail channel for a portion of the sales and prescription volumes for Pomalyst, Revlimid and Thalomid starting April 2021.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c1c5f0b870e6ed5b",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4 or 5 week 'months.' The weeks start in January, so the 5 week month falls at the end of each quarter: March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "266babf6a70c1ed5",
      "text": "Exhibit 4: I-O drugs with their combinations, route and approved indications",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "59f780e15ff54a9a",
      "text": "Drug nameCombination if anyRouteMOAIndicationBavencio (PFE/MRK KGaA)Inlyta (Pfizer)IVPD-L1MCC (metastatic), Urothelial Carcinoma (locally advanced or metastatic), RCC (advanced; + Inlyta)Imfinzi (AZN)-IVPD-L1NSCLC (unresectable, stage 3), SCLCKeytruda (MRK)Inlyta (Pfizer), chemoIVPD-1Melanoma (unresectable or metastatic, adjuvant), NSCLC (PD-L1+, metastatic nonsquamous, metastatic squamous; +/- chemo), SCLC (metastatic), HNSCC (unresectable or metastatic; +/- chemo), cHL (refractory/relapsed), PMBCL (refractory), Urothelial Carcinoma (locally advanced or metastatic), MSI-H / dMMR Cancer (unresectable or metastatic), Gastric Cancer (recurrent locally advanced or metastatic), Cervical Cancer (recurrent or metastatic &amp;amp;PD-L1+), HCC, MCC (locally advanced or metastatic), RCC (advanced; + Inlyta), Esophageal Squamous Cell Carcinoma (locally advanced or metastatic &amp;amp;PD-L1+), Solid Tumor, ESCC, Endometrial carcinoma, TMB-H, cSCC, Colorectal Cancer, TNBC, cHLLibtayo (REGN/SNY)-IVPD-1SCCC (cutaneous squamous cell carcinoma), BCC (Basal Cell Carcinoma), NSCLC (PD-L1+, metastatic)Opdivo (BMY)Yervoy (BMY), chemoIVPD-1Melanoma (unresectable or metastatic, adjuvant, +/- Yervoy), NSCLC (metastatic; +/- chemo), SCLC (metastatic), RCC (advanced; +/- Yervoy), cHL, HNSCC (recurrent or metastatic), Urothelial Carcinoma (locally advanced or metastatic), MSI-H / dMMR Colorectal Cancer (metastatic; + Yervoy), HCC, ESCC, Gastric Cancer, MPMOpdualag (BMY)-IVPD-1 &amp;amp; LAG-3 comboMelanoma (unresectable or metastatic)Tecentriq (ROG)Avastin (Roche)IVPD-L1NSCLC (metastatic and/or non-squamous; +/- Avastin &amp;amp; chemo), TNBC (unresectable locally advanced or metastatic &amp;amp; PD-L1+; + chemo), SCLC (extensive-stage), HCC, MelanomaYervoy (BMY)Opdivo (BMY)IVCTLA-4Melanoma (unresectable or metastatic, adjuvant), RCC (advanced; + Opdivo), MSI-H or dMMR Colorectal Cancer (metastatic; + Opdivo), HCC, NSCLC, MPMPedcev (SGEN)Avastin (Roche)IVNectin-4Urothelial Carcinoma (locally advanced or metastatic), inpatients who have received a PD-1/PD-L1, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "112729fbdafd5738",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1d9f9c661f39b2e0",
      "text": "Exhibit 5: Opdivo and Keytruda sales by indication. Percentage of total US sales in blue indicates MS estimates and green indicates company reported. Where company reports a range we included midpoint of the range.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "48c34982a5acda2f",
      "text": "2015A2016A2017A2018A2019A2020A2021A2022A2023A2024A1Q:25A2Q:25AOpdivo (BMY)9423,7744,9486,7357,2046,9927,5238,2499,0099,3042,2732,588U.S.(Dec 2028)8232,6643,1024,2394,3443,9454,2024,8125,2835,3501,3401,534ex-US (EU'30, Japan '31)1191,1101,8462,4962,8603,0473,3213,4373,4723,9549331,054Opdivo US sales by indicationNSCLC2131,1101,5621,5259918081,0081,1441,2961,365375430Melanoma6021,2934621,1271,2931,2031,1951,1511,1091,177295337RCC82055558481,0299861,0081,1551,1751,216308353SCCHN--4021221715812614415414814700Upper GI-Bladder1755921,2295621,416362414Others05748352881478968962629928000Adjuvant000Opdualag US - melanoma252617870228252Total BMY melanoma1,4031,7262,047523589Total BMY+MRK mel2,3552,8593,387846946Opdivo % of total US salesNSCLC26%42%50%36%23%20%24%24%25%26%28%28%Melanoma73%49%15%27%30%31%28%24%21%22%22%22%RCC1%8%18%20%24%25%24%24%22%23%23%23%SCCHN5%5%4%3%3%3%3%0%0%Upper GI-Bladder4%12%24%26%27%27%Others0%2%16%12%19%20%16%13%6%1%0%0%Adjuvant0%0%0%Opdivo ex-US sales by indicationNSCLC---1,2961,2281,0111,006959866926196221Melanoma368179482643738837704762932243274RCC-46224440530686738782753750168190SCCHN---532792431571371491583742Upper GI-Bladder681652713066574Others---225180369515690685881224253Adjuvant0Opdualag ex-US - melanoma010582532Total BMY melanoma704812990268306Total BMY+MRK mel1,5291,8102,151557627Opdivo % of total ex-US salesNSCLC2%6%10%19%22%24%25%20%23%23%21%21%MelanomaRCC4%12%18%19%23%22%23%23%20%19%18%18%SCCHN2%4%4%4%4%Upper GI-Bladder2%5%7%8%7%7%Others9%6%12%16%20%24%22%24%24%AdjuvantKeytruda (MRK)5651,4023,8087,16911,08414,38117,18620,93725,01229,4837,2057,956U.S. (Dec 2028)3937922,3084,1496,3058,3529,76512,68615,11517,8724,3084,749yoy growth102%191%80%52%32%17%30%19%18.2%5%8%ex-US (EU'31, Japan '32)1726101,5003,0204,7796,0297,4218,2519,89711,6112,8973,207yoy growth255%146%101%58%26%23%11%20%17%2%12%Key. US sales by indicationNSCLC41921,1582,6313,9224,2154,5064,4224,9325,3411,1851,306Melanoma3894975215056317797329511,1341,340323356H&N-562152073154747329511,1341,340323356Bladder--812073154747329511,1311,340323356MSI-High---1183154747321,2871,6911,340323356RCC---894747329511,1361,340323356TNBCOthers0473334817181,4631,2651,5861,8892,701754831AdjuvantKey. % of total US salesNSCLC1%24%50%63%62%50%46%34.9%33%30%28%28%Melanoma99%63%23%12%10%9%8%7.5%8%8%8%8%H&N0%7%9%5%5%6%8%7.5%7.5%8%8%8%Bladder0%0%3%5%5%6%8%7.5%7.5%8%8%8%MSI-High3%5%6%8%10.1%11.1%8%8%8%RCC1%6%8%7.5%7.5%8%8%8%TNBC3%12.5%13.5%18%18%18%Others0%6%14%12%11%18%13%12.5%12.5%15%18%18%AdjuvantKey. ex-US sales by indicationNSCLC3,2264,5225,4795,6725,7355,6571,2311,363Melanoma7709048528259291,161290321H&N194464742871217241RCC1744648741,451362401Others7836037228251,5562,471797882AdjuvantKey. % of total ex-US salesNSCLC68%75%74%69%59%48%43%43%Melanoma16%15%11%10%10%10%10%10%H&N3%6%8%8%8%RCC2%6%9%13%13%13%Others16%10%10%10%10%16%21%28%28%",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "6c39839bbcdc95dc",
      "text": "BMY reported total I/O franchise sales by indication in 2Q18 hence we assumed the same for Opdivo. Actual number could be different. Source: Company data, Morgan Stanley Research",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "3a2a956c32db309b",
      "text": "Exhibit 6: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "c82ac33e988b21bc",
      "text": "SMAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Feb-25Mar-25Apr-25May-25Jun-25Jul-25Bavencio (Pfizer/Merck KGaA)Annualized (Mar, Jun, Sep, Dec normalized)&#36;191&#36;203&#36;157&#36;160&#36;163&#36;157&#36;156&#36;156&#36;136&#36;136&#36;137&#36;126YoY growth-28%-24%-39%-38%-39%-39%-37%-35%-41%-40%-39%-36%MoM growth-2%6%-22%2%2%-4%-1%0%-12%0%0%-8%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;16&#36;21&#36;13&#36;13&#36;17&#36;13&#36;13&#36;16&#36;11&#36;11&#36;14&#36;11MoM growth-2%33%-38%2%27%-23%-1%25%-30%0%25%-26%Imfinzi (Astrazeneca)Annualized (Mar, Jun, Sep, Dec normalized)&#36;2,536&#36;2,751&#36;2,521&#36;2,748&#36;2,780&#36;2,769&#36;2,912&#36;3,138&#36;2,967&#36;3,179&#36;3,399&#36;3,328YoY growth18%25%18%26%21%31%34%34%32%33%44%42%MoM growth8%8%-8%9%1%0%5%8%-5%7%7%-2%IMS Monthly sales (4-4-5 weeks)&#36;211&#36;287&#36;210&#36;229&#36;290&#36;231&#36;243&#36;327&#36;247&#36;265&#36;354&#36;277MoM growth8%36%-27%9%26%-26%5%35%-24%7%34%-22%Keytruda (Merck)Annualized (Mar, Jun, Sep, Dec normalized)&#36;16,739&#36;17,151&#36;17,237&#36;16,962&#36;17,516&#36;17,493&#36;17,072&#36;17,371&#36;17,989&#36;17,990&#36;17,658&#36;17,216YoY growth14%18%16%16%15%15%12%10%8%5%10%6%MoM growth3%2%1%-2%3%0%-2%2%4%0%-2%-3%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;1,395&#36;1,787&#36;1,436&#36;1,413&#36;1,825&#36;1,458&#36;1,423&#36;1,810&#36;1,499&#36;1,499&#36;1,839&#36;1,435MoM growth3%28%-20%-2%29%-20%-2%27%-17%0%23%-22%Libtayo (Sanofi/Regeneron)Annualized (Mar, Jun, Sep, Dec normalized)&#36;3&#36;4&#36;3&#36;3&#36;3&#36;3$2&#36;4&#36;5&#36;7&#36;5&#36;4YoY growth-99%-98%-99%-99%-99%-99%-9%-99%-98%-98%-98%-20%MoM growth-40%39%-33%-14%30%-2%-25%63%20%34%-26%-11%IMS Monthly sales (4-4-5 weeks)&#36;0&#36;0&#36;0&#36;0$0$0$0$0$0&#36;1&#36;1$0MoM growth-40%74%-46%-14%63%-22%-25%104%-4%34%-8%-29%Total Opdivo (Bristol Myers)Annualized (Mar, Jun, Sep, Dec normalized)&#36;5,261&#36;5,331&#36;5,405&#36;5,181&#36;5,316&#36;5,413&#36;5,522&#36;5,640&#36;5,751&#36;5,648&#36;5,675&#36;5,743YoY growth5%-2%14%9%-11%20%18%14%16%8%9%17%MoM growth7%1%1%-4%3%2%2%2%2%-2%0%1%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;438&#36;555&#36;450&#36;432&#36;554&#36;451&#36;460&#36;588&#36;479&#36;471&#36;591&#36;479MoM growth7%27%-19%-4%28%-19%2%28%-18%-2%26%-19%Tecentriq (Roche)Annualized (Mar, Jun, Sep, Dec normalized)&#36;1,832&#36;1,824&#36;1,840&#36;1,759&#36;1,993&#36;1,622&#36;1,633&#36;1,864&#36;1,606&#36;1,656&#36;1,947&#36;1,570YoY growth-5%-16%5%-1%-10%-5%-6%-6%-7%-12%-2%-7%MoM growth9%0%1%-4%13%-19%1%14%-14%3%18%-19%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;153&#36;190&#36;153&#36;147&#36;208&#36;135&#36;136&#36;194&#36;134&#36;138&#36;203&#36;131MoM growth9%24%-19%-4%42%-35%1%43%-31%3%47%-35%Opdualg (Bristol Myers)Annualized (Mar, Jun, Sep, Dec normalized)&#36;836&#36;815&#36;880&#36;832&#36;877&#36;900&#36;895&#36;924&#36;951&#36;908&#36;936&#36;957YoY growth34%33%30%21%19%23%23%16%19%9%20%17%MoM growth2%-3%8%-5%5%3%-1%3%3%-4%3%2%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;70&#36;85&#36;73&#36;69&#36;91&#36;75&#36;75&#36;96&#36;79&#36;76&#36;98&#36;80MoM growth2%22%-14%-5%32%-18%-1%29%-18%-4%29%-18%Yervoy (Bristol Myers)Annualized (Mar, Jun, Sep, Dec normalized)&#36;1,544&#36;1,533&#36;1,651&#36;1,547&#36;1,587&#36;1,606&#36;1,576&#36;1,616&#36;1,642&#36;1,728&#36;1,709YoY growth11%16%24%20%19%19%16%10%8%7%22%13%MoM growth2%-1%8%-6%3%1%-2%3%2%1%4%-1%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;129&#36;160&#36;138&#36;129&#36;165&#36;134&#36;131&#36;168&#36;137&#36;138&#36;180&#36;142MoM growth2%24%-14%-6%28%-18%-2%28%-19%1%30%-21%Total I/OAnnualized (Mar, Jun, Sep, Dec normalized)&#36;28,106&#36;28,798&#36;28,815&#36;28,360&#36;29,358&#36;29,036&#36;28,822&#36;29,691&#36;29,964&#36;30,150&#36;30,548&#36;29,698YoY growth9%10%14%12%6%15%12%10%8%5%11%11%MoM growth5%2%0%-2%4%-1%-1%3%1%1%1%-3%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;2,342&#36;3,000&#36;2,401&#36;2,363&#36;3,058&#36;2,420&#36;2,402&#36;3,093&#36;2,497&#36;2,512&#36;3,182&#36;2,475MoM growth5%28%-20%-2%29%-21%-1%29%-19%1%27%-22%Padecv (Pfizer)Annualized (Mar, Jun, Sep, Dec normalized)&#36;8&#36;9&#36;8&#36;11&#36;8&#36;9&#36;10&#36;135&#36;1,672&#36;1,605&#36;1,617&#36;1,494YoY growth28%103%64%86%72%83%41%1855%22594%16675%22884%20940%MoM growth18%4%-4%35%-27%11%13%1198%1138%-4%1%-8%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;1&#36;1&#36;1&#36;1$1&#36;1&#36;1&#36;14&#36;139&#36;134&#36;168&#36;124MoM growth18%31%-23%35%-9%-11%13%1522%890%-4%26%-26%",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "0f1fca4000e4c2a9",
      "text": "Source: IQVIA Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4 or 5 week 'months.' The week starts in January, so the 5-week month falls at the end of each quarter: March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months. A reporting restriction has been implemented for a portion of the sales volumes for Yervoy in the mail channel within NSP since April-16, due to a contractual condition between a supplier and the manufacturer. A reporting restriction has been implemented for a portion of the sales volumes for Padecv in the mail, retail and non-retail channel within NSP since Jan-20, due to a contractual condition between a supplier and the manufacturer. Additional restrictions were placed in mail channel starting April-20 and in retail and non-retail channel starting Oct-20.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "651a64e805a7791f",
      "text": "Exhibit 7: I/O (except Padcev) drugs IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "6bb4db2725b2cbf1",
      "text": "Fot  t  t  t  t  t  t  t  t  t  t  e Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months. A reporting restriction has been implemented for a portion of the sales volumes for Yervoy in the mail channel within NSP since April-16, due to a contractual condition between a supplier and the manufacturer. A reporting restriction has been implemented for a portion of the sales volumes for Padcev in the mail, retail and non-retail channel within NSP since Jan-20, due to a contractual condition between a supplier and the manufacturer. Additional restrictions were placed in mail channel starting April-20 and in retail and non-retail channel starting Oct-20. Source: IQVIA",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5e0a470a399a9808",
      "text": "Exhibit 8: Alimta monthly sales trend. Keytruda + Alimta combo was approved on May 10, 2017 for treating patients in 1L NSCLC.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "d1148b8bf1d6fe8b",
      "text": "Exhibit 9: IQVIA sales estimates for Keytruda, Tecentriq and Opdivo have largely been within single digit % of reported sales",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "8a7192f6b5bd58f1",
      "text": "Exhibit 11: IQVIA monthly and annualized sales. For annualized sales, we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "ad8b3ebba3785278",
      "text": "Aug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Mar-25Apr-25May-25Jun-25Jul-25ALK/ROS1 InhibitorsAlecensa (Roche)Annualized (Mar, Jun, Sep, Dec normalized)&#36;576&#36;587&#36;601&#36;596&#36;597&#36;663&#36;678&#36;653&#36;658&#36;649&#36;656&#36;685YoY growth23%28%28%29%22%33%32%25%27%20%23%23%MoM growth3%2%2%-1%0%11%2%-4%1%-1%1%4%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;48&#36;61&#36;50&#36;50&#36;62&#36;55&#36;57&#36;68&#36;55&#36;54&#36;68&#36;57MoM growth3%27%-18%-1%25%-11%2%20%-19%-1%26%-16%Alunbrig (Takeda)Annualized (Mar, Jun, Sep, Dec normalized)&#36;87&#36;88&#36;83&#36;86&#36;93&#36;91&#36;112&#36;102&#36;114&#36;108&#36;119&#36;102YoY growth29%20%29%24%30%28%43%40%37%40%54%23%MoM growth4%1%-6%4%8%-2%22%-9%12%-5%10%-14%Monthly sales (not normalized)&#36;7&#36;9&#36;7&#36;7&#36;10&#36;8&#36;9&#36;11&#36;9&#36;9&#36;12&#36;8MoM growth4%26%-25%4%35%-22%22%14%-10%-5%37%-31%Lorbrena (Pfizer)Annualized (Mar, Jun, Sep, Dec normalized)&#36;272&#36;272&#36;286&#36;313&#36;299&#36;329&#36;338&#36;342&#36;348&#36;363&#36;381&#36;397YoY growth40%48%45%65%54%53%48%45%49%54%71%66%MoM growth13%0%5%9%-4%10%3%1%2%4%5%4%Monthly sales (not normalized)&#36;23&#36;28&#36;24&#36;26&#36;31&#36;27&#36;28&#36;36&#36;29&#36;30&#36;40&#36;33MoM growth13%25%-16%9%19%-12%3%26%-19%4%31%-17%Rozlytrek (Roche)Annualized (Mar, Jun, Sep, Dec normalized)&#36;45&#36;45&#36;45&#36;48&#36;44&#36;54&#36;51&#36;50&#36;50&#36;47&#36;48&#36;54YoY growth4%2%3%23%9%15%13%7%-5%-1%16%18%MoM growth0%0%0%7%-8%21%-4%-4%0%-6%3%12%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;4&#36;5&#36;4&#36;4&#36;5&#36;4 &#36;5&#36;4&#36;4&#36 ;5&#36;4&#36;4MoM growth0%25%-20%7%15%-3%-4%20%-20%-6%28%-10%Xalkori (Pfizer)Annualized (Mar, Jun, Sep, Dec normalized)&#36;81&#36;83&#36;82&#36;76&#36;84&#36;90&#36;86&#36;79&#36;81&#36;78&#36;82&#36;81YoY growth-4%2%0%-10%-6%3%-11%-7%-6%-4%-3%7%MoM growth7%2%-1%-7%10%7%-4%-8%3%-4%5%-1%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;7&#36;9&#36;7&#36;6&#36;9&#36;7&#36;7&#36;8&#36;7&#36;7&#36;9&#36;7MoM growth7%28%-21%-7%37%-14%-4%15%-18%-4%31%-21%Zykadia (Novartis)Annualized (Mar, Jun, Sep, Dec normalized)&#36;7&#36;8&#36;8&#36;8&#36;7&#36;8&#36;7&#36;7&#36;7&#36;7 &#36;7&#36;6YoY growth-5%4%-3%18%-3%-7%-4%-11%-18%20%0%-11%MoM growth7%14%-7%-3%-11%20%-12%-3%-5%8%1%-15%Monthly sales (not normalized)&#36;1&#36;1&#36;1&#36;1 &#36;1&#36;1 &#36;1 &#36;1 &#36;1 &#36 ;1 &#36;1 &#36;1MoM growth7%43%-25%-3%11%-4%-12%21%-24%8%27%-32%",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "d3a68dd7b2e8e59b",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4 or 5 week 'months.' The weeks start in January, so the 5 week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "198c3c6b7cce2189",
      "text": "**Exhibit 12:** ALK/ROS1 inhibitors IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c7e7a5dc420cbe86",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months'. The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "095d4b460307b422",
      "text": "Exhibit 13: ALK+ inhibitor weekly TRx share",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "e043ae1ad0bd45b9",
      "text": "PFE Franchise includes Xalkori and Lorbrena\nSource: IQVIA",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "d4cb52da61faf17d",
      "text": "Exhibit 14: ALK+ inhibitors weekly TRx YOY",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "83df912a15d0ea8f",
      "text": "PFE Franchise includes Xalkori and Lorbrena Source:IQVIA",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "b64bf83009ab5875",
      "text": "Exhibit 15: Recent ALK+ oral drug launches",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "e49f7f78e8579b70",
      "text": "Exhibit 16: Androgen and gonadotropin-releasing hormone inhibitor drugs with their combinations, route and approved indications",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "9d92dea098ba8a63",
      "text": "Drug nameCombination if anyRouteMOAIndicationErleada (JNJ)-OralAndrogen ReceptorCastration-Resistant Prostate Cancer (non-metastatic)Xtandi (PFE)-OralAndrogen ReceptorCastration-Resistant Prostate CancerZytiga (JNJ)-OralAndrogen ReceptorCastration-Resistant Prostate Carcinoma (metastatic), Castration-Sensitive Prostate Cancer (metastatic high-risk)Nubeqa (BAYN)-OralAndrogen ReceptorCastration-resistant prostate cancer (non-metastatic)Orgovyx (MYOV)-OralGnRH Receptoradvanced prostate cancer",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "04bb9c8f1ef2c378",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "d1dbdfcf5c01e7f9",
      "text": "Exhibit 17: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "e07aa1be8b35a258",
      "text": "SMAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25Androgen + GnRH InhibitorsErleada (Johnson &amp;amp; Johnson)Annualized (Mar, Jun, Sep, Dec normalized)$1,565$1,576$1,577$1,564$1,585$1,769$1,822$1,941$1,946$2,022$2,149$2,057YoY growth36%30%32%29%23%40%40%39%41%44%50%40%MoM growth6%1%0%-1%1%12%3%7%0%4%6%-4%IMS Monthly sales (not normalized; 4-4-5 weeks)$130$164$131$130$165$147$152$202$162$169$224$171MoM growth6%26%-20%-1%27%-11%3%33%-20%4%33%-23%Nubeqa (Bayer)Annualized (Mar, Jun, Sep, Dec normalized)$1,347$1,383$1,482$1,470$1,546$1,736$1,780$1,995$2,081$2,233$2,404$2,476YoY growth76%72%79%76%67%86%77%86%79%88%102%96%MoM growth7%3%7%-1%5%12%3%12%4%7%8%3%IMS Monthly sales (not normalized; 4-4-5 weeks)$112$144$124$122$161$145$148$208$173$186$250$206MoM growth7%28%-14%-1%31%-10%3%40%-17%7%35%-18%Orgovyx (Myovant)Annualized (Mar, Jun, Sep, Dec normalized)$651$647$697$718$793$832$940$1,029$1,108$1,154$1,266$1,256YoY growth111%97%102%109%110%130%116%123%111%115%126%104%MoM growth6%-1%8%3%10%5%13%10%8%4%10%-1%IMS Monthly sales (not normalized; 4-4-5 weeks)$54$67$58$60$83$69$78$107$92$96$132$105MoM growth6%24%-14%3%38%-16%13%37%-14%4%37%-21%Xtandi (Pfizer)Annualized (Mar, Jun, Sep, Dec normalized)$2,479$2,519$2,546$2,520$2,641$2,993$3,175$3,300$3,293$3,286$3,427$3,300YoY growth39%35%41%32%25%50%46%43%56%50%48%37%MoM growth3%2%1%-1%5%13%6%4%0%0%4%-4%IMS Monthly sales (not normalized; 4-4-5 weeks)$207$262$212$210$275$249$265$344$274$274$357$275MoM growth3%27%-19%-1%31%-9%6%30%-20%0%30%-23%Zytiga (Johnson &amp;amp; Johnson)Annualized (Mar, Jun, Sep, Dec normalized)$43$45$41$42$42$42$40$39$37$36$25$25YoY growth-21%-18%-24%-16%-23%-9%-13%-15%-15%-19%-44%-37%MoM growth7%5%-8%2%-1%1%-6%-2%-4%-4%-29%-1%IMS Monthly sales (not normalized; 4-4-5 weeks)$4$5$3$4$4$3$3$4$3$3$3$2MoM growth7%31%-26%2%23%-19%-6%23%-23%-4%-12%-21%",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "1525e423863e67d2",
      "text": "Fotot: QIA sales data (NSP) is captured weekly, and grouped into 4 or 5 week months. The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "0993bca760bdad0a",
      "text": "Exhibit 18: Androgen and GnRH inhibitor and drug IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4- week basis to better compare with the other months. See footnote.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "0cd0ac2129a61631",
      "text": "Fot  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "c70062763c287098",
      "text": "Exhibit 20: Weekly TRx YOY",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "7556efc2db761d3b",
      "text": "Exhibit 21: Oral drug launch comparison",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "553870f070064c2e",
      "text": "Note Xtandi data was restricted from week 10-87. Source:IQVIA",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "93724c3016fe4d8c",
      "text": "Exhibit 22: Weekly TRx share",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "78c5822ff7147443",
      "text": "Exhibit 23: Xtandi IQVIA sales vs reported (by Astellas) sales",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "af87ab4fe4f13064",
      "text": "Exhibit 25: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "2e65dd8567a26af9",
      "text": "SMAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25BTK InhibitorsBrukinsa (BeiGene)Annualized (Mar, Jun, Sep, Dec normalized)&#36;1,562&#36;1,707&#36;1,677&#36;1,819&#36;1,840&#36;1,926&#36;2,100&#36;2,165&#36;2,130&#36;2,158&#36;2,252&#36;2,232YoY growth87%92%85%91%72%89%71%73%54%50%36%56%MoM growth9%9%-2%8%1%5%9%3%-2%1%4%-1%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;130&#36;178&#36;140&#36;152&#36;192&#36;161&#36;175&#36;225&#36;178&#36;180&#36;235&#36;186MoM growth9%37%-21%8%26%-16%9%29%-21%1%30%-21%Calquence (Astrazeneca)Annualized (Mar, Jun, Sep, Dec normalized)&#36;2,209&#36;2,276&#36;2,197&#36;2,258&#36;2,470&#36;2,355&#36;2,707&#36;2,847&#36;2,754&#36;2,741&#36;2,972&#36;2,828YoY growth26%28%29%26%19%39%40%45%31%34%62%42%MoM growth11%3%-3%3%9%-5%15%5%-3%0%8%-5%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;184&#36;237&#36;183&#36;188&#36;257&#36;196&#36;226&#36;297&#36;230&#36;228&#36;310&#36;236MoM growth11%29%-23%3%37%-24%15%31%-23%0%36%-24%Imbruvica (Abbvie)Annualized (Mar, Jun, Sep, Dec normalized)&#36;2,500&#36;2,413&#36;2,278&#36;2,349&#36;2,461&#36;2,453&#36;2,573&#36;2,659&#36;2,447&#36;2,472&#36;2,457&#36;2,352YoY growth-7%-5%-10%-2%-16%4%-1%1%12%3%-3%-2%MoM growth4%-4%-6%3%5%0%5%3%-8%1%-1%-4%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;208&#36;251&#36;190&#36;196&#36;256&#36;204&#36;214&#36;277&#36;204&#36;206&#36;256&#36;196MoM growth4%21%-24%3%31%-20%5%29%-26%1%24%-23%Jaypirca (Eli Lilly)Annualized (Mar, Jun, Sep, Dec normalized)&#36;275&#36;283&#36;285&#36;294&#36;300&#36;321&#36;348&#36;367&#36;397&#36;389&#36;422&#36;448YoY growth244%205%171%139%141%100%104%96%90%76%87%76%MoM growth8%3%1%3%2%7%8%6%8%-2%8%6%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;23&#36;30&#36;24&#36;24&#36;31&#36;27&#36;29&#36;38&#36;33&#36;32&#36;44&#36;37YoY growth244%205%171%139%141%100%104%96%90%76%87%76%MoM growth8%29%-19%3%28%-14%8%32%-13%-2%35%-15%Venclexta (Abbvie/Roche)Annualized (Mar, Jun, Sep, Dec normalized)&#36;1,223&#36;1,286&#36;1,200&#36;1,242&#36;1,330&#36;1,312&#36;1,350&#36;1,372&#36;1,315&#36;1,333&#36;1,439&#36;1,348YoY growth17%18%19%17%18%28%25%26%13%18%23%13%MoM growth2%5%-7%3%7%-1%3%2%-4%1%8%-6%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;102&#36;134&#36;100&#36;103&#36;139&#36;109&#36;112&#36;143&#36;110&#36;111&#36;150&#36;112MoM growth2%31%-25%3%34%-21%3%27%-23%1%35%-25%",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "7be7140205d44314",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months'. The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "26543b0ebbc3c96d",
      "text": "**Exhibit 26:** IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "fda937dff5bb48ff",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "fa30cb01cc6013b5",
      "text": "Exhibit 27: Imbruvica weekly TRx and YOY",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "afdbbe8024b45138",
      "text": "Exhibit 28: Calquence weekly TRx and YOY",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "0cc09d2a01fe96e6",
      "text": "Exhibit 29: Venclexta weekly TRx and YOY",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "582a00dd59528846",
      "text": "Exhibit 30: Brukinsa weekly TRx and YOY",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "7ff6346e603f7729",
      "text": "Exhibit 31: Venclecta monthly sales",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "e605742416af5c78",
      "text": "Exhibit 32: CLL TRx market share",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "97bbf031b5950bc1",
      "text": "Exhibit 33: BTK Inhibitor oral TRx market share",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "4f6ccc94a5664571",
      "text": "Exhibit 34: BTK Inhibitor oral NRx market share",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "2462790ce309da41",
      "text": "Exhibit 35: CLL oral drug launch TRx comparison",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "448ec4ad2a4b5e29",
      "text": "Exhibit 36: Imbruvica, Calquence, Vencletta and Jaypirca IQVIA sales vs reported sales.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "2031a2204f4f4063",
      "text": "Exhibit 37: CDK 4/6 drugs (except Piquay and Tuksya) with their combinations, route and approved indications",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "3d17a9f8f7467540",
      "text": "Drug nameCombination if anyRouteMOAIndicationIbrance (PFE)aromatase inhibitor or fulvestrantOralCDK 4/6HR+/HER2-Breast Cancer (advanced or metastatic; + aromatase inhibitor or fulvestrant)Kisqali (NVS)aromatase inhibitor or fulvestrantOralCDK 4/6HR+/HER2-Breast Cancer (advanced or metastatic; + aromatase inhibitor or fulvestrant)Piquay (NVS)fulvestrantOralPI3KHR+/HER2-Breast cancer (advanced or metastatic & PIK3CA-mutated; + fulvestrant)Verzenio (LLY)aromatase inhibitor or fulvestrantOralCDK 4/6HR+/HER2-Breast Cancer (advanced or metastatic; +/- aromatase inhibitor or fulvestrant)Tuksya (SGEN)Herceptin and XelodaOralTKIHER2+ Breast cancer (advanced or metastatic)",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "fbda9ff1500e2a5d",
      "text": "TKI: tyrosine kinase inhibitor",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "770a3e94c4d5514c",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "4fdcfafe1082c493",
      "text": "Exhibit 38: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "a55f80c53e03c619",
      "text": "SMCDK 4/6 & PI3KAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25May-25Jun-25Jul-25Ibrance (Pfizer)Annualized (Mar, Jun, Sep, Dec normalized)&#36;2,913&#36;2,940&#36;2,978&#36;2,810&#36;3,010&#36;2,931&#36;3,123&#36;3,119&#36;3,034&#36;3,019&#36;3,092&#36;3,049YoY growth-7%-8%-1%-8%-4%-6%-1%-2%1%1%5%7%MoM growth3%1%1%-6%7%-3%7%0%-3%-1%2%-1%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;243&#36;306&#36;248&#36;234&#36;314&#36;244&#36;260&#36;325&#36;253&#36;252&#36;322&#36;254MoM growth3%26%-19%-6%34%-22%7%25%-22%-1%28%-21%Kisqali (Novartis)Annualized (Mar, Jun, Sep, Dec normalized)&#36;1,679&#36;1,730&#36;1,777&#36;1,899&#36;2,136&#36;2,416&#36;2,613&#36;2,820&#36;2,955&#36;3,055&#36;3,251&#36;3,308YoY growth70%64%65%73%73%92%90%94%96%100%109%115%MoM growth9%3%3%7%12%13%8%8%5%3%6%2%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;140&#36;180&#36;148&#36;158&#36;222&#36;201&#36;218&#36;294&#36;246&#36;255&#36;339&#36;276MoM growth9%29%-18%7%41%-9%8%35%-16%3%33%-19%Verzenio (Eli Lilly)Annualized (Mar, Jun, Sep, Dec normalized)&#36;3,665&#36;3,825&#36;3,803&#36;3,784&#36;3,904&#36;3,745&#36;4,030&#36;3,875&#36;3,828&#36;3,762&#36;3,885&#36;3,773YoY growth32%32%32%30%20%26%20%13%11%11%11%13%MoM growth10%4%-1%0%3%-4%8%-4%-1%-2%3%-3%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;305&#36;398&#36;317&#36;315&#36;407&#36;312&#36;336&#36;404&#36;319&#36;314&#36;405&#36;314MoM growth10%30%-20%0%29%-23%8%20%-21%-2%29%-22%Total CDK 4/6Annualized (Mar, Jun, Sep, Dec normalized)&#36;8,257&#36;8,494&#36;8,558&#36;8,493&#36;9,050&#36;9,092&#36;9,766&#36;9,813&#36;9,817&#36;9,835&#36;10,229&#36;10,130YoY growth20%19%23%20%19%24%24%22%23%25%28%32%MoM growth7%3%1%-1%7%0%7%0%0%0%4%-1%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;688&#36;885&#36;713&#36;708&#36;943&#36;758&#36;814&#36;1,022&#36;818&#36;820&#36;1,065&#36;844MoM growth7%29%-19%-1%33%-20%7%26%-20%0%30%-21%Piquay (Novartis)Annualized (Mar, Jun, Sep, Dec normalized)&#36;143&#36;141&#36;151&#36;133&#36;134&#36;129&#36;135&#36;129&#36;123&#36;128&#36;131&#36;133YoY growth-47%-43%-41%-46%-45%-45%-44%-38%-39%-28%-16%-12%MoM growth-6%-1%7%-12%1%-4%5%-4%-4%4%2%2%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;12&#36;15&#36;13&#36;11&#36;14&#36;11&#36;11&#36;13&#36;10&#36;11&#36;14&#36;11MoM growth-6%24%-14%-12%26%-23%5%20%-24%4%28%-19%Tukysa (Pfizer)Annualized (Mar, Jun, Sep, Dec normalized)&#36;9&#36;9&#36;10&#36;9&#36;12&#36;10&#36;8&#36;15&#36;342&#36;294&#36;292&#36;300YoY growth49%47%53%67%73%45%14%73%4194%3497%3193%3231%MoM growth-2%1%17%-16%35%-19%-14%78%2243%-14%-1%3%Annualized (Mar, Jun, Sep, Dec normalized)&#36;1&#36;1&#36;1&#36;1 &#36;1&#36;1&#36;2&#36;28&#36;24&#36;30&#36;25MoM growth-2%26%-6%-16%68%-35%-14%123%1774%-14%24%-18%",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "6a82903c17eed61e",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "aa6ec5fbab2c6b80",
      "text": "Exhibit 39: CDK 4/6 & PI3K IQVIA monthly sales trends. Kisqali March data negligible. We normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "e3aec7cfac45cefe",
      "text": "Fot  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "f00c4916c4bb426d",
      "text": "Exhibit 41: CDK 4/6 & PI3K absolute weekly TRx trend",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "f76a0c3e1325bb16",
      "text": "Exhibit 42: CDK 4/6 weekly TRx YOY",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "24393c2575ae850a",
      "text": "Exhibit 43: Ibrance and Kisqali TRx as % of total aromatase inhibitors (Femara + letrozole, Arimidex+anastrozole, Aromasin+exemestane)",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "963336b75f20e84a",
      "text": "Ibrance and Kisqali are indicated for use in conjunction with all aromatase inhibitors. We include Femara, Arimidex and Aromasin and their generics. We exclude Faslodex since it is a physician-administered IM injection so its Rx is understated by IQVIA. Source:IQVIA",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "ab0bd20c8d9daebc",
      "text": "Exhibit44: CDK 4/6 & PI3K launch comparison",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "b6a74fd9717408da",
      "text": "Exhibit 45: Ibrance and Verzenio IQVIA sales vs reported sales",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "31f5510ce9ad30ae",
      "text": "Bars (M)10.1620.1620.1640.1610.1620.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.1610.1620.1630.1640.1610.1630.1640.16",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "256bb4fe6f9f4739",
      "text": "**Exhibit 47:** IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote. Breyanzi, Kymriah and Yescarta are sold through REMS hence, IQVIA does not capture their sales.",
      "page": 27,
      "section": null
    },
    {
      "passage_id": "04dce2c317d92a31",
      "text": "Aug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25CD 3 x CD 20Columvi (Roche)Annualized (Mar, Jun, Sep, Dec normalized)&#36;38&#36;44&#36;39&#36;43&#36;43&#36;2&#36;1&#36;1&#36;1&#36;1#0&#36;0YoY growth108%57%-11%-6%-10%-97%-99%-98%-99%-99%-100%-99%MoM growth-5%15%-11%9%0%-96%-39%17%-49%44%-97%1704%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;3&#36;5&#36;3&#36;4&#36;4&#36;0&#36;0&#36;0&#36;0#0&#36;0&#36;0MoM growth-5%43%-28%9%25%-97%-39%46%-59%44%-96%1343%Epk初ly (GMAB/ABBV)Annualized (Mar, Jun, Sep, Dec normalized)&#36;1&#36;0&#36;0&#36;0&#36;0#1&#36;1&#36;2&#36;1&#36;1&#36;1&#36;1YoY growth-20%6%25%200%449%163%67%-33%-4%MoM growth50%-100%#DIV/0!#DIV/0!3728%97%20%46%-40%-5%-4%-17%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;0&#36;0&#36;0&#36;0#0&#36;0&#36;0&#36;0&#36;0&#36;0&#36;0MoM growth50%-100%#DIV/0!#DIV/0!4685%58%20%83%-52%-5%20%-33%",
      "page": 27,
      "section": null
    },
    {
      "passage_id": "e9fffab56f8e26e5",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 27,
      "section": null
    },
    {
      "passage_id": "f35a7c255fa91361",
      "text": "**Exhibit 48:** CD3 X CD20 drug IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 27,
      "section": null
    },
    {
      "passage_id": "abfa28a4829577e7",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 27,
      "section": null
    },
    {
      "passage_id": "6581008d715f3083",
      "text": "Exhibit 49: Epkinly IQVIA sales vs ABBV's reported profit",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "7c8aba295b357b66",
      "text": "Sales (SM)3Q:234Q:231Q:242Q:243Q:244Q:241Q:252Q:25EpkinlyActual&#36;14&#36;12&#36;12&#36;14&#36;16&#36;18&#36;21&#36;22IMS&#36;0&#36;0&#36;0&#36;0#0&#36;0&#36;0&#36;0% diff.NM24717%9465%6277%9685%35329%5992%8528%",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "6642e555e666fdd9",
      "text": "Source: Company data, IQVIA, Morgan Stanley Research",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "ebd2e41153e56097",
      "text": "Exhibit 50: CDK 19 & 79 drug with its combinations, route and approved indications. Breyanzi, Kymriah and Yescarta are sold through REMS",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "5a912ccd3b3b87cb",
      "text": "Drug nameCombination if anyRouteMOAIndicationBlincyto (AMGN)lisocabtagene maraleucelIVCD19acute lymphoblastic leukemia (ALL)Breyanzi (BMY)lisocabtagene maraleucelIVCD19large B-cell lymphomaKymriah (NVS)tisagenlecleucelIVCD19acute lymphoblastic leukemia (ALL), large B-cell lymphomaMonjuv (MYOV)tafasitamab-cxixIVCD19large B-cell lymphomaPolivy (ROG)polatuzumab vedotin-piiqIVCD79blarge B-cell lymphomaYescata (GILD)(axicabtagene ciloleucelIVCD19large B-cell lymphoma; follicular lymphoma",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "adb9d35be2e8b66f",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "924a83a1aafe2fc5",
      "text": "Exhibit 51: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote. Breyanzi, Kymriah and Yescarta are sold through REMS hence,IQVIA does not capture their sales.",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "b94f3e96da055299",
      "text": "SMAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25CD19/CD79Blincyto (Amgen)Annualized (Mar, Jun, Sep, Dec normalized)&#36;872&#36;1,031&#36;955&#36;971&#36;984&#36;1,098&#36;1,020&#36;1,098&#36;981&#36;1,037&#36;1,007&#36;939YoY growth63%88%74%61%71%76%87%85%54%64%79%48%MoM growth38%18%-7%2%1%12%-7%8%-11%6%-3%-7%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;33&#36;33&#36;33&#36;33 &#36;33&#36;33&#36;33&#36 ;33&#36;33&#36;33&#36;33&#36;33MoM growth0%0%0%0%0%0 %0%0%0%0%00%Monjuvl (Incyte/Morphosys)Annualized (Mar, Jun, Sep, Dec normalized)&#36;76&#36;77&#36;79&#36;79&#36;85&#36;74&#36;79&#36;73&#36;76&#36;77&#36;84&#36;84YoY growth-13%-13%-1%-6%-1%-11%-4%-16%-1%30%-3%7%MoM growth-3%1%3%-1%7%-12%6%-7%5%1%9%0%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;6&#36;8&#36;7&#36;7&#36;7&#36;8&#36;6&#36;6&#36;6&#36;9&#36;7&#36;7MoM growth-3%26%-17%0%0%16%-16%0%-16%1%36%-20%Polivy (Roche)Annualized (Mar, Jun, Sep, Dec normalized)&#36;622&#36;692&#36;642&#36;654&#36;691&#36;684&#36;664&#36;696&#36;733&#36;767&#36;736&#36;750YoY growth37%55%39%39%46%37%33%31%24%25%28%20%MoM growth-1%11%-7%2%6%-1%-3%5%5%5%-4%2%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;52&#36;72&#36;53&#36;55&#36;72&#36;57&#36;56&#36;73&#36;61&#36;64&#36;77&#36;63MoM growth-1%39%-26%2%32%-21%-3%31%-16%5%20%-18%",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "17a184536898dfbb",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "f018d730fa5c8538",
      "text": "**Exhibit 52:** CD 19 & 79 drug IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 29,
      "section": null
    },
    {
      "passage_id": "cd923b783149fa53",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 29,
      "section": null
    },
    {
      "passage_id": "01418b83f2591445",
      "text": "Exhibit 53: Blincvto IQVIA sales vs reported sales",
      "page": 29,
      "section": null
    },
    {
      "passage_id": "48c6267ecca39362",
      "text": "Source: Company data, IQVIA, Morgan Stanley Research",
      "page": 29,
      "section": null
    },
    {
      "passage_id": "f4effca0d3cd7b1d",
      "text": "Exhibit 54: CD 38 drug with its combinations, route and approved indications",
      "page": 29,
      "section": null
    },
    {
      "passage_id": "96de48aa6fac8105",
      "text": "Drug nameCombination if anyRouteMOAIndicationDarzalex (JNJ)lenalidomide, pomalidomide,bortezomib, melphalan, predison,dexamethasoneIVCD38Multiple Myeloma (+/- bortezomib & melphalan & prednisone, orlenalidomide/pomalidomide/bortezomib & dexamethasone)Darzalex Faspro (JNJ)lenalidomide, bortezomib, melphalan,predison, dexamethasoneSub-QCD38Multiple Myeloma (+/- bortezomib & melphalan & prednisone, or lenalidomide &dexamethasone, or bortezomib & dexamethasone)Sarclisa (SNY)pomalidomide and dexamethasoneIVCD38Multiple myeloma (+ pomalidomide and dexamethasone)",
      "page": 29,
      "section": null
    },
    {
      "passage_id": "4d7805ec37472bb5",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 29,
      "section": null
    },
    {
      "passage_id": "7ca66d37707163dd",
      "text": "**Exhibit 55:** IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "71aef85157ed15cf",
      "text": "SMCD 38Aug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25Darzelax Franchise (Johnson & Johnson)Annualized (Mar, Jun, Sep, Dec normalized)&#36;6,525&#36;6,525&#36;6,532&#36;6,767&#36;7,008&#36;6,767&#36;7,078&#36;7,501&#36;7,572&#36;7,633&#36;7,974&#36;7,738YoY growth25%20%26%25%20%33%29%23%25%21%29%26%MoM growth6%0%0%4%4%-3%5%6%1%1%4%-3%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;544&#36;708&#36;544&#36;564&#36;730&#36;564&#36;590&#36;781&#36;631&#36;636&#36;831&#36;645MoM growth6%30%-23%4%29%-23%5%32%-19%1%31%-22%Sarclesia (Sanofi)Annualized (Mar, Jun, Sep, Dec normalized)&#36;153&#36;166&#36;156&#36;166&#36;176&#36;181&#36;188&#36;209&#36;182&#36;186&#36;201&#36;201YoY growth30%23%31%36%23%49%38%29%29%28%38%37%MoM growth4%8%-6%6%6%3%4%11%-13%2%8%0%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;13&#36;17&#36;13&#36;14&#36;18&#36;15&#36;16&#36;22&#36;15&#36;16&#36;21&#36;17MoM growth4%36%-25%6%33%-18%4%39%-30%2%35%-20%",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "58ce9d955ce34629",
      "text": "Darzelax franchise includes Darzelax and Darzelax Faspro.",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "6d2290d9d3608056",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5week 'months'. The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "b67ddc3ab973bb1c",
      "text": "**Exhibit 56:** CD 38 drug IQVIA monthly sales trends. We normalize sales in March, June,September, and December to a 4-week basis to better compare with the other months.See footnote.",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "140f0dd482efa105",
      "text": "Darzelax franchise includes Darzelax and Darzelax Faspro.",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "1ac1eab1861830f6",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months'. The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "45a9336c51fcbc81",
      "text": "Exhibit 57: Darzelax franchise (including Darzelax Faspro) IQVIA sales vs reported sales",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "68f9d171b2f55c72",
      "text": "Sales (SM)Darzelax40.1510.1620.1630.1640.1610.1120.1730.1740.1110.1820.1830.1840.1810.1920.1930.1940.1910.2020.2030.2040.2010.2120.2130.2140.2110.2220.2230.2240.2210.2320.2330.2340.2310.2420.2430.2440.2410.2520.25Actual82091019669124915182018212820083418264829883768323835283668402844484638455896289618770846189578963812181798132813081498165814481418164817981298127IMS51793091049122914891869219922682548266830983798332836383788419846384658957895589688794885689028967815281218179812781308141816581298176814481428164% diff.78%9%-9%2%2%8%-3%-2%-5%-4%0%-3%-3%-2%-4%-4%-5%0%6%-1%-3%-2%-4%-1%-3%-2%-3%-4%-5%-3%-7%-4%-4%-5%-2%-4%-4%",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "cc1fc007475deb2f",
      "text": "Source: Company data, IQVIA, Morgan Stanley Research",
      "page": 30,
      "section": null
    },
    {
      "passage_id": "316e366650d17f94",
      "text": "Exhibit 58: DLL 3 inhibitor drugs with their combinations, route and approved indications",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "014c51351121853e",
      "text": "Drug nameCombination if anyRouteMOAIndicationImdelitra (AMGN)-IVdelta-like ligand 3ES-SCLC",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "e81fe249c096b348",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "d694f323b8a74d9f",
      "text": "Exhibit 59: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "f23ee0a212ad7ad2",
      "text": "$MDLL 3Aug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25Imdelitra (AMGN)Annualized (Mar, Jun, Sep, Dec normalized)&#36;139&#36;177&#36;227&#36;244&#36;259&#36;285&#36;306&#36;364&#36;379&#36;394&#36;432&#36;471YoY growthMoM growth55%27%28%8%6%10%7%19%4%4%10%9%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;12&#36;18&#36;19&#36;20&#36;27&#36;24&#36;25&#36;38&#36;32&#36;33&#36;45&#36;39MoM growth55%59%2%8%32%-12%7%49%-17%4%37%-13%",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "8d56a0d7ecd65dd3",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "342aae3b99677928",
      "text": "**Exhibit 60:** IQVIA monthly sales trends. We normalize sales in March, June, September,and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "fc4c4fcf09a2f070",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "b809df825ba4655c",
      "text": "Exhibit 61: EGFR exon 20 inhibitor drugs with their combinations, route and approved indications",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "1f5804d5c31edc89",
      "text": "Drug nameCombination if anyRouteMOAIndicationRybreatn (JNJ)-IVEGFRNSCLC",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "1a0f8386eefca609",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 31,
      "section": null
    },
    {
      "passage_id": "efd635b9b13a4413",
      "text": "**Exhibit 62:** IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "610d163bdacb2884",
      "text": "SMEGFR exon-20Aug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25Rybrevant (Johnson & Johnson)Annualized (Mar, Jun, Sep, Dec normalized)&#36;231&#36;267&#36;305&#36;332&#36;344&#36;370&#36;377&#36;390&#36;385&#36;401&#36;423&#36;416YoY growth315%370%473%370%331%267%216%164%105%125%117%82%MoM growth1%16%14%9%4%8%2%4%-1%4%5%-2%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;19&#36;28&#36;25&#36;28&#36;36&#36;31&#36;31&#36;41&#36;32&#36;33&#36;44&#36;35MoM growth1%45%-9%9%29%-14%2%29%-21%4%32%-21%",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "7f0094557ff33941",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "417966b1a73906ac",
      "text": "**Exhibit 63:** IQVIA monthly sales trends. We normalize sales in March, June, September,and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "1082c1ba99f6e835",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "9d50466be6c5175f",
      "text": "Exhibit 64: FLT-3 inhibitor drugs with their combinations, route and approved indications",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "73e670eac1cb245f",
      "text": "Drug nameCombination if anyRouteMOAIndicationVanflyta (Daiichi)-OralFLT3AMLXospata (Astellas)-OralFLT3AML",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "daa4527c49c03cb7",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 32,
      "section": null
    },
    {
      "passage_id": "6ac0f488410d1ff6",
      "text": "**Exhibit 65:** IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "c5514c8dce23140b",
      "text": "SMFLT-3 InhibitorsAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25Vanflyta (Daiichi)Annualized (Mar, Jun, Sep, Dec normalized)&#36;28&#36;28&#36;31&#36;28&#36;34&#36;35&#36;40&#36;42&#36;60&#36;46&#36;54&#36;43YoY growth-2%556%437%267%146%-33%170%84%224%76%98%49%MoM growth-4%0%12%-8%21%3%14%3%44%-24%17%-20%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;2&#36;3&#36;3&#36;2&#36;4&#36;3&#36;3&#36;4&#36;5&#36;4&#36;4&#36;4MoM growth-4%25%-11%-8%51%-18%14%29%15%-24%17%-20%Xospata (Astellas)Annualized (Mar, Jun, Sep, Dec normalized)&#36;154&#36;165&#36;159&#36;155&#36;166&#36;174&#36;172&#36;168&#36;168&#36;173&#36;213&#36;176YoY growth17%28%24%22%23%24%17%10%0%13%30%13%MoM growth-1%7%-4%-2%7%5%-1%-3%0%3%23%-17%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;13&#36;17&#36;13&#36;13&#36;17&#36;14&#36;14&#36;17&#36;14&#36;14 &#36;18&#36;15MoM growth-1%34%-23%-2%33%-16%-1%22%-20%3%23%-17%",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "47f61817572436f1",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "8d6209b70ac6370b",
      "text": "**Exhibit 66:** IQVIA monthly sales trends. We normalize sales in March, June, September,and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "ff6187685aa79248",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "c644549649e9bb3f",
      "text": "Exhibit 67: FRa inhibitor drugs with their combinations, route and approved indications",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "ea784ca5421ad832",
      "text": "Drug nameCombination if anyRouteMOAIndicationElahere (Abbvie)-OralFRaepithelial ovarian, fallopian tube, or primary peritoneal cancer",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "38c13aa5d1e666c9",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 33,
      "section": null
    },
    {
      "passage_id": "7f24e3471831e45f",
      "text": "**Exhibit 68:** IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 34,
      "section": null
    },
    {
      "passage_id": "9dae36c09b006d1d",
      "text": "&#36;MFRaAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25Elahere (Abbvie)Annualized (Mar, Jun, Sep, Dec normalized)&#36;197&#36;202&#36;209&#36;223&#36;213&#36;265&#36;241&#36;102&#36;3&#36;3&#36;5&#36;4YoY growth13%19%17%24%-3%40%32%-48%-99%-99%-97%-98%MoM growth-1%2%4%7%-5%24%-9%-58%-97%1%89%-24%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;16&#36;21&#36;17&#36;19&#36;22&#36;22&#36;20&#36;11&#36;0&#36;0&#36;1&#36;0MoM growth-1%28%-17%7%19%0%-9%-47%-98%1%136%-40%",
      "page": 34,
      "section": null
    },
    {
      "passage_id": "7d6df6b20bdd52d4",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 34,
      "section": null
    },
    {
      "passage_id": "a79a3ef8c0f1c925",
      "text": "**Exhibit 69:** IQVIA monthly sales trends. We normalize sales in March, June, September,and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 34,
      "section": null
    },
    {
      "passage_id": "5335c72c782844eb",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 34,
      "section": null
    },
    {
      "passage_id": "4c09e5965c7e5853",
      "text": "Exhibit 70: Elahere IQVIA sales vs reported sales",
      "page": 34,
      "section": null
    },
    {
      "passage_id": "7dceebfdfe7b98da",
      "text": "Sales (&#36;M)4Q-221Q-232Q-233Q-234Q-231Q-242Q-243Q-244Q-241Q-252Q-25ElahereActual&#36;3&#36;30&#36;77&#36;105&#36;113&#36;64&#36;128&#36;139&#36;146&#36;165&#36;138IMS&#36;0&#36;31&#36;46&#36;53&#36;52&#36;53&#36;54&#36;59&#36;50&#36;1% diff.NM8708%148%131%115%24%141%156%150%231%13498%",
      "page": 34,
      "section": null
    },
    {
      "passage_id": "949c7cab2fb3a495",
      "text": "Source: Company data, IQVIA, Morgan Stanley Research",
      "page": 34,
      "section": null
    },
    {
      "passage_id": "c9b0f729d03cd8c0",
      "text": "Exhibit 71: HER2 inhibitor drugs with their combinations, route and approved indications",
      "page": 34,
      "section": null
    },
    {
      "passage_id": "f44e642fa58078cc",
      "text": "Drug nameCombination if anyRouteMOAIndicationEnhertu (Daiichi)-IVHER2Breast cancer, NSCLC, Gastric or gastroesophageal junction adenocarcinoma, Solid tumors",
      "page": 34,
      "section": null
    },
    {
      "passage_id": "a391efb39ba43bc3",
      "text": "Exhibit 72: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 35,
      "section": null
    },
    {
      "passage_id": "6d572e5708bc4d13",
      "text": "$MAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25HER2Enhertu (Dalichi)Annualized (Mar, Jun, Sep, Dec normalized)$2,416$1,932$2,008$1,959$2,071$2,073$2,222$2,255$2,286$2,299$2,255$2,359YoY growth55%24%27%28%27%30%32%31%30%26%27%31%MoM growth35%-20%4%-2%6%0%7%2%1%1%-2%5%IMS Monthly sales (not normalized; 4-4-5 weeks)$158$201$167$163$216$173$185$235$190$192$235$197MoM growth5%28%-17%-2%32%-20%7%27%-19%1%23%-16%",
      "page": 35,
      "section": null
    },
    {
      "passage_id": "1f894f3ad2579565",
      "text": "Fot  i Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months. Source: IQVIA",
      "page": 35,
      "section": null
    },
    {
      "passage_id": "11ec3669a5628a1a",
      "text": "Exhibit 73: IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4- week basis to better compare with the other months. See footnote.",
      "page": 35,
      "section": null
    },
    {
      "passage_id": "709d6fa824c989a0",
      "text": "Fotoote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week months. The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 35,
      "section": null
    },
    {
      "passage_id": "a1c1993cb7b6e841",
      "text": "Exhibit 74: Kinase inhibitor drugs with their combinations, route and approved indications",
      "page": 35,
      "section": null
    },
    {
      "passage_id": "c28530a2549e79ad",
      "text": "Drug nameCombination if anyRouteMOAIndicationBalversa (JNJ)-OralFGFR, VEGFR, PDGFRUrothelial Carcinoma (locally advanced or metastatic)Cabometyx (EXEL)-OralMET, VEGFR, AXLRCC (advanced), HCCGavreto (ROG/BPMC)-OralRETRET+ NSCLC (metastatic)Inlyta (PFE)Keytruda (MRK), Bavencio (PFE)OralVEGFRRCC (advanced; + Bavencio or Keytruda)Inrebi (BMY)OralOralJAK2, FLT3Myelofibrosis (intermediate-2 or high-risk primary or secondary)Lenvima (Eisai)Keytruda (MRK), Affinitor (NVS)OralVEGFRThyroid Cancer (locally recurrent or metastatic), RCC (advanced; + Affinitor), HCC (unresectable), Endometrial carcinoma (+ Keytruda)Nexavar (BAYN)-OralBRAF, VEGFR, PDGFRHCC (unresectable), RCC (advanced), Thyroid Carcinoma (locally recurrent or metastatic)Retevmo (LLY)-OralRETRET+ NSCLC (metastatic), RET+ Thyroid cancer (advanced or metastatic)Sutent (PFE)-OralVEGFR, PDGFRGIST, RCC (advanced, adjuvant), pNET (unresectable locally advanced or metastatic)Vitrakvi (BAYN)-OralTRKSolid tumors",
      "page": 35,
      "section": null
    },
    {
      "passage_id": "d20a1cec586b3a59",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 35,
      "section": null
    },
    {
      "passage_id": "a137222dbd0ec64f",
      "text": "Exhibit 75: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 36,
      "section": null
    },
    {
      "passage_id": "a9c95fb078b9bf3d",
      "text": "SMKinase InhibitorsAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25Augtyro (Bristol Myers)Annualized (Mar, Jun, Sep, Dec normalized)&#36;34&#36;39&#36;40&#36;40&#36;44&#36;56&#36;55&#36;62&#36;65&#36;70&#36;73&#36;69YoY growth1348%430%245%193%215%222%170%179%MoM growth37%16%3%-1%10%28%-14%4%8%4%-6%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;3&#36;4&#36;3&#36;3&#36;5&#36;5&#36;5&#36;7&#36;5&#36;6&#36;8&#36;6MoM growth37%45%-17%-1%38%2%-3%42%-17%8%30%-24%Balversa (Johnson & Johnson)Annualized (Mar, Jun, Sep, Dec normalized)&#36;40&#36;47&#36;44&#36;52&#36;48&#36;53&#36;54&#36;54&#36;65&#36;54&#36;71&#36;70YoY growth19%32%17%54%4%13%13%-3%35%8%41%55%MoM growth-11%17%-8%20%-9%11%13%-1%21%-17%32%-1%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;3&#36;5&#36;4&#36;4&#36;5&#36;4&#36;5&#36;6&#36;5&#36;4&#36;7&#36;6YoY growth19%32%17%54%4%13%13%-3%35%8%41%55%MoM growth-11%46%-26%20%14%-12%-12%24%-3%-17%65%-21%Cabometyx (Exelixis)Annualized (Mar, Jun, Sep, Dec normalized)&#36;1.558&#36;1.604&#36;1.598&#36;1.579&#36;1.663&#36;1.652&#36;1.719&#36;1.815&#36;1.765&#36;1.772&#36;1.827&#36;1.868YoY growth18%21%22%16%19%21%25%28%22%19%25%24%MoM growth3%3%0%-1%5%-1%4%6%-3%0%3%2%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;130&#36;167&#36;133&#36;132&#36;173&#36;138&#36;143&#36;189&#36;147&#36;148&#36;190&#36;156MoM growth3%29%-20%-1%32%-21%4%32%-22%0%29%-18%Sutent (Pfizer)Annualized (Mar, Jun, Sep, Dec normalized)&#36;9&#36;10&#36;8&#36;8&#36;12&#36;9&#36;12&#36;6&#36;9&#36;10&#36;8&#36;7YoY growth-38%-9%-30%-28%7%-27%-3%-39%3%21%-13%-26%MoM growth-10%9%-18%6%45%-23%28%-46%35%10%-12%-14%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;1&#36;1&#36;1&#36;1 &#36;1&#36;1&#36;1&#36;1&#36;1&#36;1&#36;1&#36;1MoM growth-10%36%-35%6%82%-38%-23%-33%8%10%10%-31%Lenvima (Eisai)Annualized (Mar, Jun, Sep, Dec normalized)&#36;1.235&#36;1.248&#36;1.254&#36;1.266&#36;1.302&#36;1.301&#36;1.354&#36;1.399&#36;1.409&#36;1.340&#36;1.439&#36;1.426YoY growth9%9%11%15%9%13%13%18%16%16%22%17%MoM growth2%1%0%1%3%0%4%3%1%-5%7%-1%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;103&#36;130&#36;105&#36;106&#36;136&#36;108&#36;113&#36;146&#36;117&#36;112&#36;150&#36;119MoM growth2%26%-20%1%29%-20%4%29%-19%-5%34%-21%Nexavar (Bayer)Annualized (Mar, Jun, Sep, Dec normalized)&#36;3&#36;8&#36;5&#36;5&#36;5&#36;4&#36;3&#36;3&#36;3&#36;5&#36;3&#36;2YoY growth-68%-28%-21%-48%-45%-59%-60%-72%-45%-44%-64%-60%MoM growth-34%131%-36%5%-12%-19%-8%-2%-7%50%-38%-29%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;0&#36;1&#36;0&#36;0&#36;0&#36;0 &#36;0&#36;0&#36;0&#36;0&#36;0&#36;0MoM growth-34%188%-49%5%9%-36%8%23%-26%50%-23%-44%Retevmo (Eli Lilly)Annualized (Mar, Jun, Sep, Dec normalized)&#36;204&#36;217&#36;221&#36;200&#36;231&#36;245&#36;242&#36;258&#36;247&#36;260&#36;265&#36;263YoY growth48%41%46%33%41%35%23%36%26%34%35%32%MoM growth3%6%2%-9%15%6%1%6%-4%5%2%-1%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;17&#36;23&#36;18&#36;17&#36;24&#36;20&#36;27&#36;21&#36;22&#36;28&#36;22&#36;2MoM growth3%33%-19%-9%44%-15%-1%33%-23%5%28%-21%Inlyta (Pfizer)Annualized (Mar, Jun, Sep, Dec normalized)&#36;590&#36;592&#36;596&#36;601&#36;591&#36;604&#36;612&#36;578&#36;578&#36;554&#36;596&#36;578YoY growth-6%-8%-4%-4%-14%1%-1%-6%-3%-3%3%6%MoM growth9%0%1%1%-2%2%1%-6%0%-4%8%-3%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;49&#36;62&#36;50&#36;50&#36;62&#36;55&#36;61&#36;60&#36;44&#36;46&#36;62&#36;46MoM growth9%25%-19%1%23%-18%-1%18%-20%-4%35%-22%Vitrakvi (Bayer)Annualized (Mar, Jun, Sep, Dec normalized)&#36;92&#36;91&#36;89&#36;81&#36;88&#36;102&#36;98&#36;97&#36;102&#36;103&#36;106&#36;113YoY growth19%17%14%5%7%17%23%11%28%27%17%25%MoM growth2%-2%-2%-9%8%16%-4%-1%4%2%3%7%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;8&#36;9&#36;7&#36;7&#36;9&#36;8&#36;8&#36;10&#36;8&#36;9&#36;11&#36;9MoM growth2%23%-21%-9%35%-7%4%24%-16%2%28%-15%Imrebi (Bristol Myers)Annualized (Mar, Jun, Sep, Dec normalized)&#36;52&#36;49&#36;51&#36;52&#36;49&#36;54&#36;50&#36;51&#36;50&#36;60&#36;55&#36;52YoY growth-12%-26%-7%-8%-12%-12%-8%-3%-3%14%18%-1%MoM growth0%-6%4%3%-6%10%0%4%-3%19%-8%-5%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;4&#36;5&#36;4&#36;4&#36;5&#36;4 &#36;4&#36;5&#36;4&#36;5&#36;6&#36;4MoM growth0%17%-17%3%17%-12%-8%29%-22%19%15%-24%Gavreto (Blueprint)Annualized (Mar, Jun, Sep, Dec normalized)&#36;26&#36;24&#36;20&#36;24&#36;26&#36;24&#36;32&#36;32&#36;27&#36;31&#36;33&#36;33YoY growth17%12%-18%0%4%-8%2%26%3%26%35%16%MoM growth-9%-8%-16%21%9%-8%3%1%-15%14%7%-2%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;2&#36;2&#36;2&#36;2 &#36;3&#36;2&#36;3&#36;3&#36;2&#36;3&#36;3&#36;3MoM growth-9%15%-33%21%36%-26%3%26%-32%14%34%-21%",
      "page": 36,
      "section": null
    },
    {
      "passage_id": "e669e48beef1b085",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months'. The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 36,
      "section": null
    },
    {
      "passage_id": "c3b7fbde2dd4c400",
      "text": "**Exhibit 76:** Kinase inhibitor cancer drug IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 37,
      "section": null
    },
    {
      "passage_id": "5867712aaac20181",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 37,
      "section": null
    },
    {
      "passage_id": "2c863406491dd074",
      "text": "Exhibit 77: KRAS inhibitor drugs with their combinations, route and approved indications",
      "page": 37,
      "section": null
    },
    {
      "passage_id": "8b71714477e7fd57",
      "text": "Drug nameCombination if anyRouteMOAIndicationLumakras (AMGN)-OralKRASNSCLC",
      "page": 37,
      "section": null
    },
    {
      "passage_id": "162877f1f904b573",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 37,
      "section": null
    },
    {
      "passage_id": "38a4decba13bf0f9",
      "text": "Exhibit 78: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 38,
      "section": null
    },
    {
      "passage_id": "bc5e0c59b438d29c",
      "text": "$MAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25May-25Jun-25Jul-25KRASKrazati (Mirati)Annualized (Mar, Jun, Sep, Dec normalized)$19$19$114$150$159$195$217$210$211$212$219YoY growth1368%1298%4629%5996%4755%3794%5085%4454%3868%3968%1367%MoM growth-2%3%490%32%6%23%12%-3%1%1%-3%IMS Monthly sales (not normalized; 4-4-5 weeks)$2$2$9$12$17$16$18$22$18$18$23MoM growth-2%29%372%32%32%-2%12%21%-20%1%29%Lumakras (Amgen)Annualized (Mar, Jun, Sep, Dec normalized)$174$169$160$170$176$206$212$195$197$198$209YoY growth10%-1%16%-2%3%12%9%3%6%15%27%MoM growth4%-3%-5%6%3%17%3%-8%1%1%6%IMS Monthly sales (not normalized; 4-4-5 weeks)$15$18$13$14$18$17$18$20$16$16$22MoM growth4%21%-24%6%29%-6%3%15%-19%1%32%",
      "page": 38,
      "section": null
    },
    {
      "passage_id": "c1753ff4e0ab917b",
      "text": "Fotot: QVAs sales data (NSP) is captured weekly, and grouped into 4- or 5-week months. The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months. Source: IQVIA",
      "page": 38,
      "section": null
    },
    {
      "passage_id": "5ff9017a5e3ed575",
      "text": "Exhibit 79: IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4- week basis to better compare with the other months. See footnote.",
      "page": 38,
      "section": null
    },
    {
      "passage_id": "50edd4471e4d46d5",
      "text": "Fotot: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week months. The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 38,
      "section": null
    },
    {
      "passage_id": "657c42beb25ea993",
      "text": "PARP data are unreliable as all the companies are not reporting prescribing data from IQVIA. Beyond data not reported that skews the analysis, indications differ (by line of treatment) and Zejula is the only one that does not require a companion diagnostic test—Lynparza in 4L+ for gBRCA+, Rubraca in 3L+ tBRCA+, and Zejula in maintenance for all- comers.",
      "page": 38,
      "section": null
    },
    {
      "passage_id": "718e0790d7e75b28",
      "text": "Exhibit 80: PARP inhibitor drugs with their combinations, route and approved indications",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "86df855d768eac1a",
      "text": "Drug nameCombination if anyRouteMOAIndicationLynparza (AZN)bevacizumabOralPARPOvarian cancer, Breast cancer, Pancreatic cancer, Prostate cancerRubraca (CLVS)-OralPARPOvarian cancerZejula (GSK)-OralPARPOvarian cancer",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "c3c91151dcabdde3",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "8e596aebcb532b26",
      "text": "**Exhibit 81**: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote: Data skewed and not representative of actual figures due to manufacturer data blocks.",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "448f855505d55c03",
      "text": "SMAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25PARP InhibitorsLynparza (Astrazeneca)Annualized (Mar, Jun, Sep, Dec normalized)&#36;1,139&#36;1,137&#36;1,147&#36;1,140&#36;1,176&#36;1,234&#36;1,293&#36;1,269&#36;1,266&#36;1,272&#36;1,350&#36;1,319YoY growth11%11%16%17%12%23%21%17%17%19%24%19%MoM growth3%0%1%-1%3%5%5%-2%0%0%6%-2%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;95&#36;118&#36;96&#36;95&#36;123&#36;103&#36;108&#36;132&#36;106&#36;106&#36;141&#36;110MoM growth3%25%-19%-1%29%-16%5%23%-20%0%33%-22%Rubraca (Clovis)Annualized (Mar, Jun, Sep, Dec normalized)&#36;42&#36;42&#36;38&#36;43&#36;37&#36;38&#36;38&#36;37&#36;35&#36;30&#36;32&#36;31YoY growth-3%-4%-10%9%-13%-13%-15%-10%-13%-24%-17%-20%MoM growth7%1%-10%13%-12%0%1%-4%-6%-13%4%-2%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;3&#36;4&#36;3&#36;4&#36;4&#36;3&#36;3&#36;4&#36;3&#36;3 &#36;3&#36;3MoM growth7%26%-28%13%10%-20%1%20%-24%-13%31%-21%Talzenna (PFE)Annualized (Mar, Jun, Sep, Dec normalized)&#36;86&#36;87&#36;84&#36;93&#36;97&#36;107&#36;112&#36;128&#36;140&#36;143&#36;149&#36;143YoY growth153%134%100%98%105%96%69%105%87%98%88%64%MoM growth-2%1%-3%10%4%11%4%14%10%3%4%-4%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;7&#36;9&#36;7&#36;8&#36;10&#36;9&#36;9&#36;13&#36;12&#36;12&#36;16&#36;12MoM growth-2%27%-23%10%30%-12%4%43%-12%3%30%-23%Zejula (Glaxo)Annualized (Mar, Jun, Sep, Dec normalized)&#36;399&#36;420&#36;380&#36;399&#36;394&#36;409&#36;406&#36;413&#36;431&#36;419&#36;414&#36;398YoY growth11%3%-8%7%-1%4%0%3%8%6%3%2%MoM growth2%5%-9%5%-1%4%-1%2%4%-3%-1%-4%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;33&#36;44&#36;32&#36;33&#36;41&#36;34&#36;34&#36;43&#36;36&#36;35&#36;43&#36;33MoM growth2%32%-28%5%23%-17%-1%27%-16%-3%24%-23%",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "dcc0215cbdfa9e37",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "bc6c4f746f22b1fe",
      "text": "Data skewed and not representative of actual figures due to manufacturer data blocks.",
      "page": 39,
      "section": null
    },
    {
      "passage_id": "eed4292d6dfd2281",
      "text": "**Exhibit 82:** PARP inhibitors IQVIA monthly sales trends. Data skewed and not representative of actual figures due to manufacturer data blocks. We normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "6b1104d38aede62f",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months. Data skewed and not representative of actual figures due to manufacturer data blocks.",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "e165f55927a4059f",
      "text": "Exhibit 83: Lyncpara and Talzenna IQVIA sales vs reported sales",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "3f86546d5f78d21d",
      "text": "Sales (MN) Lyncpara10-1720-1730-1740-1710-1920-1930-1940-1910-1920-1930-1940-2010-2020-2030-2040-2010-2120-2130-2140-2110-2220-2230-2240-2210-2320-2330-2340-2310-2420-2430-2440-2410-2520-25Actual527523537554566583584512519543570594597520952245245525352695270529452705312531453315268531153225352526853195347537853125378IMS505651953555156156757551015113512951475167517351905205521352185225523552455265526052635269527152765273528752985305531453435354% diff.335%27.9%89%55%31%37%26%49%18%26%32%32%18%21%18%19%19%23%20%25%10%18%21%26%0%15%17%29%0%7%14%20%-9%7%TalzennaActualIMS% diff.",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "26b6ba77826ec98c",
      "text": "Source: Company data, IQVIA, Morgan Stanley Research",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "c2db20faacea32cd",
      "text": "Exhibit 84: Proteasome inhibitor drugs with their combinations, route and approved indications",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "9ba7cb13919f4942",
      "text": "Drug nameCombination if anyRouteMOAIndicationKyprolis (AMGN)lenalidomide, dexamethasoneIVProteasomeMultiple MyelomaNinlaro (Takeda)lenalidomide, dexamethasoneOralProteasomeMultiple MyelomaVelcade (Takeda)-IV, SQProteasomeMultiple Myeloma",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "83d3fb7b778c0a57",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 40,
      "section": null
    },
    {
      "passage_id": "b5423242a197efbe",
      "text": "**Exhibit 85:** IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "4c6494b9336a09db",
      "text": "$MProteasome inhibitorsAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25Kyprolis (Amgen)Annualized (Mar, Jun, Sep, Dec normalized)&#36;884&#36;946&#36;845&#36;877&#36;950&#36;771&#36;875&#36;1,036&#36;788&#36;843&#36;988&#36;788YoY growth4%-2%6%4%10%-8%1%6%-6%-6%13%-8%MoM growth4%7%-11%4%8%-19%14%18%-24%7%17%-20%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;74&#36;98&#36;70&#36;73&#36;99&#36;64&#36;73&#36;108&#36;66&#36;70&#36;103&#36;66MoM growth4%34%-28%4%35%-35%14%48%-39%7%46%-36%Ninlaro (Takeda)Annualized (Mar, Jun, Sep, Dec normalized)&#36;209&#36;205&#36;201&#36;297&#36;348&#36;232&#36;236&#36;229&#36;229&#36;230&#36;245&#36;230YoY growth-8%-15%-19%37%43%5%1%0%0%9%10%7%MoM growth-3%-2%-2%47%17%-33%2%-3%0%0%6%-6%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;3&#36;3&#36;2&#36;4&#36;5&#36;2&#36;2&#36;3&#36;2&#36;2&#36;3 &#36;3MoM growth-2%7%-18%58%42%-58%4%31%-20%-2%50%-26%Velcade (Takeda)Annualized (Mar, Jun, Sep, Dec normalized)&#36;31&#36;26&#36;27&#36;42&#36;48&#36;25&#36;27&#36;28&#36;28&#36;27&#36;33&#36;30YoY growth-28%-39%-36%14%42%-24%-17%-20%0%-14%10%-5%MoM growth-2%-15%2%58%14%-47%4%5%0%-2%20%-8%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;3&#36;3&#36;2&#36;4&#36;5&#36;2&#36;2&#36;3&#36;2&#36;2&#36;3 &#36;3MoM growth-2%7%-18%58%42%-58%4%31%-20%-2%50%-26%",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "58f26a8a74d60565",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months'. The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "8af871172b5934da",
      "text": "**Exhibit 86:** Proteasome inhibitor drug IQVIA monthly sales trends. IQVIA restated Velcade data starting April 2019. We normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "39d5c9880a346b1c",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months'. The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "0201610e9b61d2d0",
      "text": "Exhibit 87: Kyprolis IQVIA sales vs reported sales",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "65a5c403d7af3e94",
      "text": "Euro 100KyprolisOct 312018Oct 312017Oct 312016Oct 312015Oct 312014Oct 312013Oct 312012Oct 312011Oct 312010Oct 312009Oct 312008Oct 312007Oct 312006Oct 312005Oct 312004Oct 312003Oct 312002Oct 312001Oct 312000Oct 311999Oct 311998Oct 311997Oct 311996Oct 311995Oct 311994Oct 311993Oct 311992Oct 311991Oct 311990Oct 311989Oct 311988Oct 311987Oct 311986Oct 311985Oct 311984Oct 311983Oct 311982Oct 311981Oct 311980Oct 311979Oct 311978Oct 311977Oct 311976Oct 311975Oct 311974Oct 311973Oct 311972Oct 311971Oct 311970Oct 311969Oct 311968Oct 311967Oct 311966Oct 311965Oct 311964Oct 311963Oct 311962Oct 311961Oct 311960Oct 311959Oct 311958Oct 311957Oct 311956Oct 311955Oct 311954Oct 311953Oct 311952Oct 311951Oct 311950Oct 311949Oct 311948Oct 311947Oct 311946Oct 311945Oct 311944Oct 311943Oct 311942Oct 311941Oct 311940Oct 311939Oct 311938Oct 311937Oct 311936Oct 311935Oct 311934Oct 311933Oct 311932Oct 311931Oct 311930Oct 311929Oct 311928Oct 311927Oct 311926Oct 311925Oct 311924Oct 311923Oct 311922Oct 311921Oct 311920Oct 311919Oct 311918Oct 311917Oct 311916Oct 311915Oct 311914Oct 311913Oct 311912Oct 311911Oct 311910Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905Oct 311904Oct 311903Oct 311902Oct 311901Oct 311900Oct 311909Oct 311908Oct 311907Oct 311906Oct 311905",
      "page": 41,
      "section": null
    },
    {
      "passage_id": "bea78cc3bc0eaabf",
      "text": "Exhibit 88: SLAMF7 drug with its combinations, route and approved indications",
      "page": 42,
      "section": null
    },
    {
      "passage_id": "c0cd77a4a2990d30",
      "text": "Drug nameCombination if anyRouteMOAIndicationEmpliciti (BMY)lenalidomide, pomalidomide, dexamethasoneIVSLAMF7Multiple Myeloma (+ lenalidomide/pomalidomide &amp;amp; dexamethasone)",
      "page": 42,
      "section": null
    },
    {
      "passage_id": "9491be84fdac54fe",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 42,
      "section": null
    },
    {
      "passage_id": "8245ae3732c324be",
      "text": "Exhibit 89: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 42,
      "section": null
    },
    {
      "passage_id": "9d19198975956ce1",
      "text": "$MAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25SLAMF7Empliciti (Bristol Myers)Annualized (Mar, Jun, Sep, Dec normalized)$153$154$153$156$153$153$146$164$148$142$151$147YoY growth-2%-3%-6%0%-4%0%-2%6%-1%-7%1%-12%MoM growth-8%0%0%2%-2%0%-4%12%-10%-4%7%-3%IMS Monthly sales (not normalized; 4-4-5 weeks)$13$16$13$13$16$13$12$17$12$12$16$12MoM growth-8%25%-20%2%22%-20%-4%40%-28%-4%33%-22%",
      "page": 42,
      "section": null
    },
    {
      "passage_id": "27d07ee5097ff883",
      "text": "Fotot: QIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months. The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 42,
      "section": null
    },
    {
      "passage_id": "7c30f81e8ef05c87",
      "text": "Exhibit 90: SLAMF7 drug IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4- week basis to better compare with the other months. See footnote.",
      "page": 42,
      "section": null
    },
    {
      "passage_id": "a60161076c499245",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 42,
      "section": null
    },
    {
      "passage_id": "6e773fa7e2943373",
      "text": "Exhibit 91: TROP-2 drugs with their combinations, route and approved indications",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "f523ca074fa51739",
      "text": "Drug nameCombination if anyRouteMOAIndicationTrodelvy (GILD)-IVTrop-2Metastatic triple-negative breast cancer (TNBC)",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "a43dfab4eed337ee",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "e220f7b70ae47e2e",
      "text": "Exhibit 92: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "63c05304fc80b3fb",
      "text": "SMAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25TROP-2Trodelvy (Gilead)Annualized (Mar, Jun, Sep, Dec normalized)$876$879$865$831$857$827$827$848$832$824$857$853YoY growth12%12%10%4%-1%1%2%-1%-2%-7%1%4%MoM growth7%0%-2%-4%3%-4%0%2%-2%-1%4%0%IMS Monthly sales (not normalized; 4-4-5 weeks)$73$92$72$69$89$69$69$88$69$69$89$71MoM growth7%25%-21%-4%29%-23%0%28%-22%-1%30%-20%",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "6f7c40ae7d9f77a9",
      "text": "Fotot: QVAs s data (NSP) is captured weekly, and grouped into 4- or 5-week months. The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "a49188978766be30",
      "text": "Exhibit 93: TROP- 2 drug IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4- week basis to better compare with the other months. See footnote.",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "4c93d7c693603f9b",
      "text": "Fotot: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week months. The weeks start in January, so the 5-week month falls at the end of each quarter. March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "a55f0a3f00fe87ff",
      "text": "Exhibit 94: Trodelvy IQVIA sales vs reported sales",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "5db440c1ba0c6d97",
      "text": "Sales ($M)2Q.203Q.204Q.201Q.212Q.213Q.214Q.211Q.222Q.223Q.224Q.221Q.232Q.233Q.234Q.231Q.242Q.243Q.244Q.241Q.252Q.25TrodelvyActual$20$53$49$72$89$101$109$119$120$139$147$162$189$201$226$206$224$226$247$181$224IMS$19$49$64$72$88$96$109$120$126$137$154$169$197$209$225$227$237$234$231$227$228% diff.7%8%-24%0%1%5%0%0%-5%1%-5%-4%-4%-4%1%-9%-6%-3%7%-20%-2%",
      "page": 43,
      "section": null
    },
    {
      "passage_id": "1579ca91ea18c49a",
      "text": "Exhibit 95: Thalidomide analogue drugs with their combinations, route and approved indications",
      "page": 44,
      "section": null
    },
    {
      "passage_id": "97f6373172b6183e",
      "text": "Drug nameCombination if anyRouteMOAIndicationPomalyst (BMY)dexamethasoneOralThalidomideMultiple Myeloma (+ dexamethasone)Revlimid (BMY)dexamethasone, RituxanOralThalidomideMultiple Myeloma (+ dexamethasone), Transfusion-Dependent Anemia due to MDS, MCL, Follicular Lymphoma (+ Rituxam), Marginal Zone Lymphoma (+ Rituxan)Thalomid (BMY)dexamethasoneOralThalidomideMultiple Myeloma (+ dexamethasone), acute and maintenance therapy for cutaneous manifestations of ENL",
      "page": 44,
      "section": null
    },
    {
      "passage_id": "05cd462010c6361e",
      "text": "MDS: Myelodysplastic Syndrome, MCL: Mantle Cell Lymphoma, ENL: erythema nodosum leprosum)",
      "page": 44,
      "section": null
    },
    {
      "passage_id": "95a9baeae575abc6",
      "text": "Source: FDA.gov, Morgan Stanley Research",
      "page": 44,
      "section": null
    },
    {
      "passage_id": "b264b35a9521e216",
      "text": "**A reporting restriction has been implemented in the mail channel for a portion of the** **sales and prescription volumes for Pomalyst, Revlimid and Thalomid starting April** **2021.**",
      "page": 44,
      "section": null
    },
    {
      "passage_id": "d4c7612263a6b366",
      "text": "Exhibit 96: IQVIA monthly and annualized sales. For annualized sales we normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 44,
      "section": null
    },
    {
      "passage_id": "52d7de693e119c04",
      "text": "SMAug-24Sep-24Oct-24Nov-24Dec-24Jan-25Mar-25Apr-25Apr-25May-25Jun-25Jul-25Thalidomide analoguesPomalyst (Bristol Myers)Annualized (Mar, Jun, Sep, Dec normalized)&#36;1,906&#36;1,885&#36;1,919&#36;3,049&#36;3,170&#36;2,584&#36;2,942&#36;3,223&#36;3,008&#36;3,073&#36;3,926&#36;2,981YoY growth28%26%20%100%97%52%63%75%64%67%109%62%MoM growth4%-1%2%59%4%-18%14%10%-7%2%28%-24%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;159&#36;196&#36;160&#36;254&#36;330&#36;215&#36;245&#36;336&#36;251&#36;256&#36;327&#36;248MoM growth4%24%-19%59%30%-35%14%37%-25%2%28%-24%Revlimid (Bristol Myers)Annualized (Mar, Jun, Sep, Dec normalized)&#36;2,441&#36;2,470&#36;2,496&#36;5,564&#36;5,236&#36;4,136&#36;4,392&#36;4,353&#36;4,177&#36;3,988&#36;5,371&#36;3,150YoY growth6%10%3%148%129%78%64%54%57%45%113%22%MoM growth-5%1%1%123%-6%-21%6%-1%-4%-5%35%-41%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;203&#36;257&#36;208&#36;464&#36;545&#36;345&#36;366&#36;453&#36;348&#36;332&#36;448&#36;262MoM growth-5%26%-19%123%18%-37%6%24%-23%-5%35%-41%Thalomid (Bristol Myers)Annualized (Mar, Jun, Sep, Dec normalized)&#36;13&#36;13&#36;13&#36;26&#36;28&#36;22&#36;25&#36;26&#36;25&#36;24&#36;32&#36;23YoY growth-10%-7%-4%121%131%88%137%105%89%106%140%68%MoM growth-4%-5%2%104%5%-22%14%5%-4%-5%35%-27%IMS Monthly sales (not normalized; 4-4-5 weeks)&#36;1&#36;1&#36;1&#36;2&#36;3&#36;2&#36;2&#36;3&#36;2#2&#36;3&#36;2MoM growth-4%19%-18%104%32%-38%14%31%-24%-5%35%-27%",
      "page": 44,
      "section": null
    },
    {
      "passage_id": "9dda57defe64afc7",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December.Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 44,
      "section": null
    },
    {
      "passage_id": "b19d35df21ea2672",
      "text": "**Exhibit 97:** Thalidomide analogue drug IQVIA monthly sales trends. We normalize sales in March, June, September, and December to a 4-week basis to better compare with the other months. See footnote.",
      "page": 45,
      "section": null
    },
    {
      "passage_id": "b8c5b8d9b8e2046f",
      "text": "Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week 'months.' The weeks start in January, so the 5-week month falls at the end of each quarter: March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 45,
      "section": null
    },
    {
      "passage_id": "d8cd0c2074b79c0e",
      "text": "Exhibit 98: Revlimid IQVIA sales vs reported sales",
      "page": 45,
      "section": null
    },
    {
      "passage_id": "09c9b35d9b5d7e0f",
      "text": "Sales (M)10-1120-1130-1140-1110-1220-1230-1240-1210-1320-1330-1340-1310-1420-1430-1440-1410-1520-15RevlimidActual$911$873$895$866$937$1,030$1,153$1,180$1,234$1,350$1,361$1,473$1,447$1,558$1,667$1,729$1,886IMS$290$252$257$257$258$337$333$333$372$300$447$463$452$465$501$512$544% diff205%247%240%237%275%251%247%258%225%257%254%218%220%247%220%237%215%",
      "page": 45,
      "section": null
    },
    {
      "passage_id": "ef56f15ac88c37b6",
      "text": "Source: IQVIA, Company reported",
      "page": 45,
      "section": null
    },
    {
      "passage_id": "3fa42b59dce007e0",
      "text": "Exhibit 99: Oncology biosimilars U.S. approval/launch time-line",
      "page": 46,
      "section": null
    },
    {
      "passage_id": "147ab31ddbd2cef5",
      "text": "BrandBiosimilarActive ingredientCompanyApproved onLaunch actual/expectedNeulastaFulphilapegfilgrastim-jmdViatris/BioconJun 4, 2018Jul 9, 2018 est.NeulastaUdenycapegfilgrastim-cbqvCoherusNov 2, 2018Jan 3, 2019NeulastaZiextenzopegfilgrastim-bmezNovartisNov 5, 2019Nov-19 estNeulastaNyvepriapegfilgrastim-apgfPfizerJun 11, 2020Jan-21 estNeulastaFylnetrapegfilgrastim-pbbkAmnealMay 27, 20221H23 est.NeulastaStimufendpegfilgrastim-fpgkFresenius KabiSep 2, 2022Mar-23 est.NeupogenZarxiofilgrastim-sndzNovartisMar 6, 2015Sep 3, 2015NeupogenNivestymfilgrastim-aafiPfizerJul 20, 2018Oct 1, 2018NeupogenReleukofilgrastim-ayowAmnealMar 1, 2022Nov 23, 2022AvastinMvasibevacizumab-awwbAmgen/AbbvieSep 14, 2017Jul 18, 2019AvastinZirabevbevacizumab-bvzrPfizerJun 28, 2019Dec 31, 2019AvastinAlymsysbevacizumab-malyAmnealApr 13, 2022Oct 3, 2022HerceptinOgivritrastuzumab-dkstViatris/BioconDec 1, 2017Dec 2, 2019HerceptinOntruzanttrastuzumab-dttbOrganon/Samsung BioepisJan 18, 2019Apr 15, 2020HerceptinTrazimeratrastuzumab-qyypPfizerMar 11, 2019Feb 19, 2020HerceptinKanjintitrastuzumab-annsAmgen/AbbvieJun 13, 2019Jul 18, 2019RituxanRuxiencerituximab-pvrrPfizerJul 23, 2019Jan-20 estRituxanRiabnirituximab-arrxAmgen/AbbvieDec 17, 2020Jan-21 estEpogenRetacritepoetin alfa-epbxPfizerMay 15, 2018Nov 12, 2018XgevaConexencedenosumabFresenius KabiMar 26, 20252H25XgevaWyostdenosumab-bbdzSandozMar 5, 2024Jun 2, 2025XgevaXbrykdenosumabSamsung BioepisFeb 13, 2025TBDXgevaOsenveltdenosumab-bmwoCelltrionMar 3, 2025Jun-25",
      "page": 46,
      "section": null
    },
    {
      "passage_id": "79cf39894518ca0a",
      "text": "Source: Company data, FDA, Morgan Stanley Research",
      "page": 46,
      "section": null
    },
    {
      "passage_id": "db4e94b28f43ce2e",
      "text": "Exhibit 100: Biosimilar Neulasta monthly sales share vs branded Neulasta",
      "page": 46,
      "section": null
    },
    {
      "passage_id": "6e40ef5c827a03d3",
      "text": "Exhibit 101: Biosimilar Neulasta 52-week TRx share. Neulasta is Sub-Q",
      "page": 47,
      "section": null
    },
    {
      "passage_id": "31332418eb3b0f61",
      "text": "Exhibit 102: Biosimilar Avastin monthly sales share vs branded Avastin",
      "page": 47,
      "section": null
    },
    {
      "passage_id": "8c6753349e6197e1",
      "text": "Exhibit 103: Biosimilar Herceptin monthly sales share vs branded Herceptin",
      "page": 47,
      "section": null
    },
    {
      "passage_id": "0f6f8f4b71568aa9",
      "text": "Exhibit 104: Biosimilar Rituxan monthly sales share vs branded Rituxan",
      "page": 48,
      "section": null
    },
    {
      "passage_id": "534170e43ed47527",
      "text": "Exhibit 105: Biosimilar Neupogen monthly sales share vs branded Neupogen",
      "page": 48,
      "section": null
    },
    {
      "passage_id": "909fd48c020ddbb0",
      "text": "Exhibit 106: Biosimilar Neupogen 52-week TRx share. Neupogen is administered as an IV as well as Sub-Q",
      "page": 48,
      "section": null
    },
    {
      "passage_id": "58e6dfa19d53f6f3",
      "text": "Exhibit 107: Biosimilar Epogen monthly sales share vs branded Epogen",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "c3345ab404eec8c4",
      "text": "Exhibit 108: Biosimilar Epogen 52-week TRx share. Epogen is administered as an IV as well as Sub-Q",
      "page": 49,
      "section": null
    },
    {
      "passage_id": "a256b5a7b42dbbb2",
      "text": "ChannelsNPA (National Prescription Audit) Monthly and WeeklyNSP (National Sales Perspectives)Chain Pharmacies**Independent Pharmacies**Mass Merchandisers (grouped w/Chain Pharmacies)**Foodstores w/Pharmacies**Mail Service Providers**Long-Term Care**HMOs*Non-federal Hospitals*Federal Facilities*Clinics*Home Healthcare*Miscellaneous - Prisons, Universities, Veterinarians*",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "14d09cc25c462185",
      "text": "Monthly TRx (NPA) and Sales (NSP) channel sources",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "7963887d39a23cd6",
      "text": "**EUTRx** represents the total number of dispensed tablets associated with each prescription that is dispensed.",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "6627f1531c62b9cc",
      "text": "**NPA**: \"National estimates of prescriptions, or the rate at which drugs move out of the pharmacy and into the hands of a consumer via formal dispensed prescriptions\"",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "8da32b0285a12666",
      "text": "**NSP**: \"National sales estimates of product packages into retail drugstores, hospitals, clinics, and other nonretail type outlets\"",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "10454212df3049dd",
      "text": "**NSP units**: \"Total amount of packages sold of a particular drug to the dispensing outlet/chain/hospital.\"",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "7215bf0d9a4f79e6",
      "text": "**NSP Price**: \"Is based on a number of sources, depending upon Class of Trade (Channel). It generally represents a best estimation of Net price without the impact of proprietary",
      "page": 50,
      "section": null
    },
    {
      "passage_id": "448e363a0baf6af1",
      "text": "rebating by the manufacturer. Equation = Sales \\(\\) /\\(Units\"",
      "page": 51,
      "section": null
    },
    {
      "passage_id": "c5096af556bbfa2b",
      "text": "NSP Sales \\(\\) :\\(Total amount of the sales into the dispensing outlets, chain, and health care providers from the manufacturers and distribution centers expressed in US dollars.\"",
      "page": 51,
      "section": null
    },
    {
      "passage_id": "0498d64b41f90c80",
      "text": "IQVIA sales data (NSP) is captured weekly, and grouped into 4 or 5 week 'months.' The weeks start in January, so the 5 week month falls at the end of each quarter: March, June, September, and December. Periodically, an extra week is added in November to ensure that DDD reporting months do not deviate too far from calendar months.",
      "page": 51,
      "section": null
    },
    {
      "passage_id": "8cb150abd0017371",
      "text": "Brief from IQVIA on NSP Price: Note that NSP reflects significant Class Of Trade discounts and is often well below Gross Price even though it does not reflect rebates manufacturers pay to payers. \"Our NSP Sales \\(\\)'s\\(represent a trade price or transaction price. It is the actual cost that was charged to acquire the pharmaceutical products as seen on the purchase invoice. NSP is a projected database. What that means is IQVIA collects the data from the sample (which for NSP represents about 88%) and using IQVIA methodology, the data is projected to 100% of the universe. The prices reflected in IQVIA National Sales Perspectives\" are the prices outlets (i.e. pharmacies, hospitals, clinics) pay for the products, whether purchased directly from a manufacturer or indirectly via a wholesaler or chain warehouse. Invoice line item discounts are included. Prompt- payment discounts and bottom- line invoice discounts are not included. Rebates, typically paid by the manufacturer directly to a customer, insurer, or PBM (Pharmacy Benefits Manager), are not reflected.\"",
      "page": 51,
      "section": null
    },
    {
      "passage_id": "1b514f95be0c57e4",
      "text": "Morgan Stanley is acting as financial advisor to Merck in relation to a definitive agreement to acquire Verona Pharma plc as announced on July 9, 2025. The transaction is subject to approval under the Hart- Scott- Rodino Antitrust Improvements Act, approval of Verona Pharma shareholders, sanction by the High Court of Justice of England and Wales and other customary conditions. This report and the information provided herein is not intended to (i) provide voting advice, (ii) serve as an endorsement of the proposed transaction, or (iii) result in the procurement, withholding or revocation of a proxy or any other action by a security holder. Merck has agreed to pay fees to Morgan Stanley for its financial services. Please refer to the notes at the end of this report.",
      "page": 51,
      "section": null
    },
    {
      "passage_id": "a76f9bbc23c2df6d",
      "text": "The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, Morgan Stanley includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.",
      "page": 52,
      "section": null
    },
    {
      "passage_id": "d3b6c8fb8036e652",
      "text": "For mportant dislures, stck price chrt and qity rating histories regarding companie that are the subject of this report, please see the Morgan Stanley Research Disclosre Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.",
      "page": 52,
      "section": null
    },
    {
      "passage_id": "aa7569177bbc4bb2",
      "text": "For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303- 2495; Hong Kong +852 2848- 5999; Latin America +1 718 754- 5444 (U.S.); London +44 (0)20- 7425- 8169; Singapore +65 6834- 6860; Sydney +61 (0)2- 9770- 1505; Tokyo +81 (0)3- 6836- 9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.",
      "page": 52,
      "section": null
    },
    {
      "passage_id": "a3c9319e323f0062",
      "text": "Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflict policies. A Portuguese version of the policy can be found at www.morganstanley.com.br",
      "page": 52,
      "section": null
    },
    {
      "passage_id": "78baa31abd91bb13",
      "text": "As of July 31, 2025, Morgan Stanley beneficially owned \\(1\\%\\) or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: 4D Molecular Therapeutics Inc, Abbvie Inc, Acadia Pharmaceuticals Inc, Akero Therapeutics Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Arctis Biotherapeutics, Inc, argenx SE, Arrowhead Pharmaceuticals Inc, Arvinas Inc, Ascendis Pharma A/S, Axsome Therapeutics, Bicycle Therapeutics Plc, Biogen Inc, Biomarin Pharmaceutical Inc, Bristol Myers Squibb Co, C4 Therapeutics, Cabaletta Bio Inc, Centessa Pharmaceuticals, Inc, Certara Inc, CG Oncology, Cytokinetics Inc, Denali Therapeutics Inc, Dyne Therapeutics Inc, Eli Lilly & Co, Exelixis Inc, Galapagos NV, Gennab A/S, Gilead Sciences Inc, Halozyme Therapeutics, Inc, Incyte Corp, Intellia Therapeutics Inc, Ionis Pharmaceuticals Inc, Johnson & Johnson, Merck & Co, Inc, Mirum Pharmaceuticals, Moderna Inc, Neurocrine Biosciences Inc, Nurx Therapeutics Inc, Organon & Co, Pfizer Inc, ProKidney Corp, Recursion Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Regenxbio Inc, Rocket Pharmaceuticals Inc, Royalty Pharma Plc, Sarepta Therapeutics Inc, Schrodinger Inc, Silence Therapeutics Plc, Structure Therapeutics Inc, Trevi Therapeutics Inc, Tscan Therapeutics Inc, Vertex Pharmaceuticals, Viking Therapeutics Inc, Vir Biotechnology Inc, Zentalis Pharmaceuticals Inc.",
      "page": 52,
      "section": null
    },
    {
      "passage_id": "a2f33b9c107cc80c",
      "text": "Within the last 12 months, Morgan Stanley managed or co- managed a public offering (or 144A offering) of securities of Aardvark Therapeutics Inc, Abbvie Inc, ABSCI CORP, Akero Therapeutics Inc, Ascendis Pharma A/S, Bicara Therapeutics, BioAge Labs Inc, Biogen Inc, Biohaven Ltd, CG Oncology, Cricntics Pharmaceuticals, Dyne Therapeutics Inc, Eli Lilly & Co, Gilead Sciences Inc, Ionis Pharmaceuticals Inc, Kymera Therapeutics Inc, Pfizer Inc, Pharvaris NV, Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, Sana Biotechnology, Inc, Trevi Therapeutics Inc, Vertex Pharmaceuticals, Zenas Biopharma Inc.",
      "page": 52,
      "section": null
    },
    {
      "passage_id": "5cfb6fe7b5878ed6",
      "text": "Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Aardvark Therapeutics Inc, Abbvie Inc, ABSCI CORP, Akero Therapeutics Inc, Amicus, Ascendis Pharma A/S, Bicara Therapeutics, BioAge Labs Inc, Biogen Inc, Biohaven Ltd, Bristol Myers Squibb Co, CG Oncology, Contineum Therapeutics, Cricntics Pharmaceuticals, Dyne Therapeutics Inc, Eli Lilly & Co, Gilead Sciences Inc, Ionis Pharmaceuticals Inc, Kymera Therapeutics Inc, Pfizer Inc, Pharvaris NV, Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, Royalty Pharma Plc, Sana Biotechnology, Inc, Sarepta Therapeutics Inc, Trevi Therapeutics Inc, Zenas Biopharma Inc.",
      "page": 52,
      "section": null
    },
    {
      "passage_id": "863914e918183dec",
      "text": "In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Aardvark Therapeutics Inc, Abbvie Inc, Abivax, ABSCI CORP, Acadia Pharmaceuticals Inc, Adagene Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc, Alcor, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Akero Therapeutics Inc,",
      "page": 52,
      "section": null
    },
    {
      "passage_id": "f2e519b9d091c50d",
      "text": "Within the last 12 months, Morgan Stanley has either provided or is providing non- investment banking, securities- related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Abbvie Inc., Amgen Inc., BeOn Medicines, Biogen Inc, BioNTech SE, Bristol Myers Squibb Co, Certara Inc, Cytokinetics Inc, Eli Lilly & Co., Genmab A/S, Gilead Sciences Inc, Incyte Corp, Johnson & Johnson, Merck & Co., Inc., Moderna Inc, Organon & Co., Pfizer Inc, Royalty Pharma Plc, Vertex Pharmaceuticals.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "6ae3be05b4c9ac2b",
      "text": "An employee, director or consultant of Morgan Stanley is a director of Merck & Co., Inc. This person is not a research analyst or a member of a research analyst's household. Morgan Stanley & Co. LLC makes a market in the securities of 4D Molecular Therapeutics Inc, Aardvark Therapeutics Inc, ABSCI CORP, Alector Inc, Amgen Inc, Amicus Therapeutics Inc, Arcellix Inc, Arcus Biosciences Inc, Arctis Biotherapeutics, Inc., Arrowhead Pharmaceuticals Inc, Arvinas Inc, Bicycle Therapeutics Plc, Biohaven Ltd, C4 Therapeutics, Celldex Therapeutics Inc, Centessa Pharmaceuticals, Inc, Certara Inc, CG Oncology, Cricntics Pharmaceuticals, Cullinan Therapeutics, Cytokinetics Inc, Denali Therapeutics Inc, Disc Medicine Inc, Dyne Therapeutics Inc, Erasca, Inc, Immunocore Holdings Ltd, Insmed Inc, Intellia Therapeutics Inc, IO Biotech, Ionis Pharmaceuticals Inc, Kymera Therapeutics Inc, Kyverna Therapeutics, Mirum Pharmaceuticals, Nurix Therapeutics Inc, Prime Medicine Inc, ProKidney Corp, PTC Therapeutics, Regenbio Inc, Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, Schrodinger Inc, Silence Therapeutics Plc, Ultragenyx Pharmaceutical Inc, United Therapeutics Corp, Vir Biotechnology Inc, Y- mABs Therapeutics Inc, Zentalis Pharmaceuticals Inc.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "4bec9779a5496f39",
      "text": "The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "8f0808914fbaae99",
      "text": "Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "657b125bc8f6f067",
      "text": "Morgan Stanley uses a relative rating system using terms such as Overweight, Equal- weight, Not- Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal- weight, Not- Rated and Underweight are not the equivalent of buy, hold and Sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "54a5e9bd98c539bf",
      "text": "(as of July 31, 2025)",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "8c06d74ef2f63268",
      "text": "The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm. For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal- weight, Not- Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal- weight, Not- Rated and Underweight are not the equivalent of buy, hold, and Sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal- weight and Not- Rated to hold and Underweight to sell recommendations, respectively.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "cb427cac3df8cf24",
      "text": "Coverage UniverseInvestment Banking Clients (IBC)Other Material Investment Services Clients (MISC)Stock Rating CategoryCount% of TotalCount% of Total IBC% of Rating CategoryCount% of Total Other MISCOverweight/Buy149540%37845%25%70141%Equal-weight/Hold160743%37445%23%76645%Not-Rated/Hold50%00%0%20%Underweight/Sell58816%8310%14%23614%Total3,6958351705",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "cdd369661fe166f0",
      "text": "Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the \\(\\%\\) of total' column may not add up to exactly 100 percent.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "66b8a5c2bf344883",
      "text": "Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12- 18 months.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "014132ce1ab76cf9",
      "text": "Equal- weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12- 18 months.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "95bef98a430c9f20",
      "text": "Not- Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk- adjusted basis, over the next 12- 18 months.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "0593fd0ada64eb0f",
      "text": "Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk- adjusted basis, over the next 12- 18 months.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "ee6ce4b6619b933c",
      "text": "Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "80c5c11382052fd1",
      "text": "Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12- 18 months to be attractive vs. the relevant broad market benchmark, as indicated below.",
      "page": 53,
      "section": null
    },
    {
      "passage_id": "6fc987c12de49dc6",
      "text": "In- Line (): The analyst expects the performance of his or her industry coverage universe over the next 12- 18 months to be in line with the relevant broad market benchmark, as indicated below. Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12- 18 months with caution vs. the relevant broad market benchmark, as indicated below. Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub- regional index or MSCI AC Asia Pacific ex Japan Index.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "f5f0ab124de1718e",
      "text": "A member of Research who had or could have had access to the research prior to completion owns securities (or related derivatives) in the Eli Lilly & Co. This person is not a research analyst or a member of research analyst's household.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "a5bb6eff5c9a2b50",
      "text": "Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "fc42dc5b1a9d2424",
      "text": "Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd- Frank Wall Street Reform and Consumer Protection Act.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "b2bc13161e834442",
      "text": "Morgan Stanley produces an equity research product called a \"Tactical Idea.\" Views contained in a \"Tactical Idea\" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "237c9ef1e6821050",
      "text": "Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third- party vendors or distributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "4c8783684a0b7daa",
      "text": "Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html).",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "a34f91999a1195f9",
      "text": "If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research. Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "940483efcb14471f",
      "text": "The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts, strategists or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "79a175de22a50309",
      "text": "The Important Regulatory Disclosures on Subject Companies' section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "71fa2f7b5b83583d",
      "text": "With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "9f5fc54b0b7781f5",
      "text": "Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre- approved by authorized members of Research management.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "cda3fe2e45b382d8",
      "text": "Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "2be9dff294651c15",
      "text": "To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited (MSTL). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non- customer reader within the scope of Article",
      "page": 54,
      "section": null
    },
    {
      "passage_id": "6305806ad24650bc",
      "text": "7- 1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.",
      "page": 55,
      "section": null
    },
    {
      "passage_id": "030b053aa783d130",
      "text": "Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.",
      "page": 55,
      "section": null
    },
    {
      "passage_id": "03e45d8337af6dc7",
      "text": "The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.",
      "page": 55,
      "section": null
    },
    {
      "passage_id": "bc41bf250a762495",
      "text": "The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.",
      "page": 55,
      "section": null
    },
    {
      "passage_id": "ace52a9d465e4328",
      "text": "As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.",
      "page": 55,
      "section": null
    },
    {
      "passage_id": "7997af776e405af4",
      "text": "The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.",
      "page": 55,
      "section": null
    },
    {
      "passage_id": "d4d9376031828e04",
      "text": "Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley. Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/101, or any other similar framework. The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products. Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.",
      "page": 55,
      "section": null
    },
    {
      "passage_id": "2cf4574f5c26c7d8",
      "text": "Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.",
      "page": 55,
      "section": null
    },
    {
      "passage_id": "320401a55c6a7686",
      "text": "PRICE\\* (08/28/2025)",
      "page": 55,
      "section": null
    },
    {
      "passage_id": "9692793262b5c56b",
      "text": "Terence C Flynn, Ph.D.Abbvie Inc. (ABBV.N)O (05/11/2020)&#36;207.92Bristol Myers Squibb Co (BMY.N)U (04/06/2022)&#36;46.88Eli Lilly & Co. (LLY.N)O (09/03/2020)&#36;731.96Johnson & Johnson (JNJ.N)E (09/07/2021)&#36;175.45Merck & Co., Inc. (MRK.N)E (09/07/2021)&#36;83.21Organon & Co. (OGN.N)E (06/11/2021)&#36;9.18Pfizer Inc (PFE.N)E (07/30/2019)&#36;24.60Royalty Pharma Plc (RPRX.O)O (05/16/2025)&#36;35.62",
      "page": 56,
      "section": null
    },
    {
      "passage_id": "37bdc26691d5e705",
      "text": "Stock Ratings are subject to change. Please see latest research for each company.",
      "page": 56,
      "section": null
    },
    {
      "passage_id": "dff85987cdbfbcd6",
      "text": "* Historical prices are not split adjusted.",
      "page": 56,
      "section": null
    },
    {
      "passage_id": "e037c3e904ac763c",
      "text": "COMPANY (TICKER)RATING (AS OF)PRICE* (08/28/2025)Judah C. Frommer, CFA4D Molecular Therapeutics Inc (FDMTO)U (11/21/2024)&#36;6.18Abivax (ABVX.O)O (07/23/2025)&#36;81.64Apellis Pharmaceuticals Inc (APLS.O)E (11/21/2024)&#36;28.05Arcelix Inc (ACLX.O)O (03/07/2024)&#36;70.25Arcutis Biotherapeutics, Inc. (ARQT.O)O (07/02/2025)&#36;15.49Bicara Therapeutics (BCAX.O)O (10/08/2024)&#36;11.91Celldex Therapeutics Inc (CLDX.O)O (03/20/2025)&#36;22.38Compass Pathways PLC (CMPS.O)O (08/08/2025)&#36;4.81enGene Holdings Inc. (ENGN.O)O (03/08/2024)&#36;4.75Galapagos NV (GLPG.O)U (02/13/2025)&#36;32.41Genmab A/S (GMAB.O)E (07/02/2025)&#36;25.11Incyte Corp (INCY.O)E (07/02/2025)&#36;83.70Kymera Therapeutics Inc (KYMR.O)O (07/02/2025)&#36;41.75Mural Oncology (MURA.O)E (03/25/2025)&#36;2.07ProKidney Corp (PROK.O)E (11/10/2022)&#36;2.50PTC Therapeutics (PTCT.O)O (03/06/2025)&#36;49.79Regenxbio Inc (RGNX.O)O (11/15/2024)&#36;9.01Trevi Therapeutics Inc (TRVI.O)O (08/21/2025)&#36;7.21Zenas Biopharma Inc (ZBIO.O)O (07/02/2025)&#36;16.26Maxwell SkorAdagene Inc. (ADAG.O)E (01/30/2025)&#36;2.22Amicus Therapeutics Inc. (FOLD.O)O (07/16/2025)&#36;7.65Ascendis Pharma A/S (ASND.O)O (05/05/2025)&#36;193.90Atea Pharmaceuticals Inc (AVIR.O)E (08/12/2024)&#36;3.47Bicycle Therapeutics Plc (BCYC.O)E (02/14/2022)&#36;7.08Crinetics Pharmaceuticals (CRNX.O)O (01/16/2024)&#36;30.65Cytokinetics Inc (CYTK.O)O (02/13/2025)&#36;37.35Inspired Inc (INSM.O)E (08/12/2025)&#36;134.97Pharvaris N.V. (PHVS.O)O (08/15/2023)&#36;22.84Sana Biotechnology, Inc (SANA.O)O (03/01/2021)&#36;3.01Tscan Therapeutics Inc (TCRX.O)O (03/13/2025)&#36;1.82Ultragenyx Pharmaceutical Inc (RARE.O)O (03/27/2019)&#36;30.30Michael E UlzAardvark Therapeutics Inc. (AARD.O)O (03/10/2025)&#36;8.49Akero Therapeutics Inc (AKRO.O)O (01/27/2023)&#36;46.94Alnylam Pharmaceuticals Inc (ALNY.O)E (09/09/2022)&#36;452.33Arrowhead Pharmaceuticals Inc (ARWR.O)E (09/09/2022)&#36;22.34BioAge Labs Inc (BIOA.O)U (12/09/2024)&#36;4.80Cabaletta Bio Inc (CABA.O)O (01/27/2023)&#36;1.50",
      "page": 56,
      "section": null
    },
    {
      "passage_id": "61ea7a8de3199cdd",
      "text": "Dyne Therapeutics Inc (DYN.O)O (04/30/2024)$13.75Fractyl Health Inc (GUTS.O)O (02/27/2024)$0.99IO Biotech (IOBT.O)O (11/30/2021)$1.58Ionis Pharmaceuticals Inc (IONS.O)O (07/30/2025)$42.62Kyverna Therapeutics (KYTX.O)O (03/04/2024)$3.70Mirum Pharmaceuticals (MIRM.O)O (11/13/2023)$75.53Rhythm Pharmaceuticals Inc (RYTM.O)O (12/19/2023)$104.23Rocket Pharmaceuticals Inc (RCKT.O)E (05/27/2025)$3.35Sarepta Therapeutics Inc (SRPT.O)E (06/16/2025)$18.34Silence Therapeutics Plc (SLN.O)O (05/08/2023)$5.10Tenaya Therapeutics Inc (TNYA.O)O (08/24/2021)$1.13Viking Therapeutics Inc (VKTX.O)O (06/27/2024)$27.58Vir Biotechnology Inc (VIR.O)O (01/08/2025)$5.04Y-mABs Therapeutics Inc. (YMAB.O)E (08/05/2025)$8.54Zentalis Pharmaceuticals Inc (ZNTL.O)E (06/18/2024)$1.76",
      "page": 57,
      "section": null
    },
    {
      "passage_id": "d9155f59e9b675f6",
      "text": "ABSCI CORP (ABSI.O)O (07/03/2024)$2.47Acadia Pharmaceuticals Inc (ACAD.O)E (08/06/2024)$26.23Alector Inc (ALEC.O)U (11/26/2024)$2.39argenx SE (ARGX.O)O (07/02/2025)$704.07Axsome Therapeutics (AXSM.O)O (04/29/2024)$121.75BeOne Medicines (ONC.O)O (12/02/2024)$297.96Biomarin Pharmaceutical Inc (BMRN.O)O (07/02/2025)$57.68Centessa Pharmaceuticals, Inc (CNTA.O)O (09/19/2024)$16.56Certara Inc (CERT.O)E (01/05/2021)$10.87CG Oncology (CGON.O)O (02/19/2024)$26.72Contineum Therapeutics (CTNM.O)O (04/30/2024)$10.05Cullinan Therapeutics (CGEM.O)O (03/06/2025)$7.61Denali Therapeutics Inc (DNLI.O)O (03/06/2025)$15.65Disc Medicine Inc (IRON.O)O (11/04/2024)$59.66Erasca, Inc. (ERAS.O)E (08/17/2025)$1.57Exelixis Inc. (EXEL.O)O (01/26/2025)$37.90Halozyme Therapeutics, Inc (HALO.O)O (08/05/2025)$72.81Immunocore Holdings Ltd (IMCR.O)E (12/12/2024)$32.24Neurocrine Biosciences Inc (NBIX.O)O (03/06/2025)$138.94Recursion Pharmaceuticals Inc (RXRX.O)E (05/22/2023)$4.87Schrodinger Inc. (SDGR.O)E (11/19/2021)$19.76",
      "page": 57,
      "section": null
    },
    {
      "passage_id": "00bcb9ba8c98b44e",
      "text": "Alumis Inc. (ALMS.O)O (05/30/2025)$4.70Amgen Inc. (AMGN.O)E (10/16/2023)$285.61Arcus Biosciences Inc. (RCUS.N)O (10/11/2022)$10.61Arvinas Inc (ARVN.O)E (04/06/2022)$7.76Biogen Inc (BIIB.O)E (10/31/2024)$132.65Biohaven Ltd (BHVN.N)O (07/24/2024)$15.52BioNTech SE (BNTX.O)O (09/23/2024)$101.93C4 Therapeutics (CCCC.O)E (11/06/2023)$2.55CRISPR Therapeutics AG (CRSP.O)U (10/11/2022)$53.05Gilead Sciences Inc. (GILD.O)O (01/10/2025)$112.56Intellia Therapeutics Inc (NTLA.O)E (01/26/2025)$11.60Legend Biotech Corp (LEGN.O)O (01/31/2022)$34.37Moderna Inc (MRNA.O)E (12/16/2020)$24.47Nurix Therapeutics Inc. (NRIX.O)E (10/11/2022)$9.41Prime Medicine Inc (PRME.O)E (11/14/2022)$3.44Regeneron Pharmaceuticals Inc. (REGN.O)O (09/09/2022)$579.61Structure Therapeutics Inc (GPCR.O)O (09/22/2024)$19.14",
      "page": 57,
      "section": null
    },
    {
      "passage_id": "1021041cb0ead27e",
      "text": "United Therapeutics Corp (UTHR.O) E (07/11/2024) \\$307.24",
      "page": 58,
      "section": null
    },
    {
      "passage_id": "d59ff38595c5cbd8",
      "text": "Vertex Pharmaceuticals (VRTX.O) E (05/03/2022) \\$392.05",
      "page": 58,
      "section": null
    },
    {
      "passage_id": "43cbbca83ffcd4d2",
      "text": "Stock Ratings are subject to change. Please see latest research for each company.",
      "page": 58,
      "section": null
    },
    {
      "passage_id": "92ba3b24de5ff33c",
      "text": "* Historical prices are not split adjusted.",
      "page": 58,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "5dc8f59a60c48918",
      "name": "ADGM Branch",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "394218ab3d61ca43",
      "name": "Aardvark Therapeutics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f443b8b74e05708c",
      "name": "Aardvark Therapeutics Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4a4bef43c7bfa9f1",
      "name": "Abbvie Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ed49291dd8535b70",
      "name": "Abu Dhabi",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7a8acf40cea751b9",
      "name": "Acadia Pharmaceuticals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6a2ad8c9a1d57a63",
      "name": "Acadia Pharmaceuticals Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ad3baf6ab633d43b",
      "name": "Adagene Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5116c8ebe3678cc0",
      "name": "Akero Therapeutics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f3b6b3f250f42fb9",
      "name": "Akero Therapeutics Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e970e25f5b33fddb",
      "name": "Alector Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ce2ccb36242da64f",
      "name": "Alnylam Pharmaceuticals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "65911636744ff4ec",
      "name": "Alnylam Pharmaceuticals Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9612cce96a083c31",
      "name": "Alumis Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a9935cd77e910646",
      "name": "America Index",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "aa4b9a172f427744",
      "name": "Amgen Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6823ccc624fd5def",
      "name": "Amicus Therapeutics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6fb1a9d53df3c6c4",
      "name": "Amicus Therapeutics Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e8600890357193e9",
      "name": "Analyst Industry",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "264f4569dd91d68d",
      "name": "Analyst Stock",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jan-21",
              "Feb-21",
              "Mar-21",
              "Apr-21",
              "May-21",
              "Jun-21",
              "Jul-21",
              "Aug-21",
              "Sep-21",
              "Oct-21",
              "Nov-21",
              "Dec-21",
              "Jan-22",
              "Feb-22",
              "Mar-22",
              "Apr-22",
              "May-22",
              "Jun-22",
              "Jul-22",
              "Aug-22",
              "Sep-22",
              "Oct-22",
              "Nov-22",
              "Dec-22",
              "Jan-23",
              "Feb-23",
              "Mar-23",
              "Apr-23",
              "May-23",
              "Jun-23",
              "Jul-23",
              "Aug-23",
              "Sep-23",
              "Oct-23",
              "Nov-23",
              "Dec-23",
              "Jan-24",
              "Feb-24",
              "Mar-24",
              "Apr-24",
              "May-24",
              "Jun-24",
              "Jul-24",
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "USD",
            "range": {
              "min": 4000,
              "max": 16000
            }
          },
          "y2": {
            "unit": "%",
            "range": {
              "min": -60,
              "max": 40
            }
          }
        },
        "series": [
          {
            "name": "Total sales",
            "unit": "USD",
            "values": [
              6000,
              5000,
              8000,
              6000,
              5000,
              8000,
              6000,
              5000,
              8000,
              6000,
              5000,
              6000,
              7000,
              6000,
              8000,
              7000,
              6000,
              8000,
              7000,
              6000,
              8000,
              7000,
              6000,
              8000,
              9000,
              8000,
              10000,
              9000,
              8000,
              10000,
              9000,
              8000,
              10000,
              9000,
              8000,
              10000,
              11000,
              10000,
              12000,
              11000,
              10000,
              12000,
              11000,
              10000,
              12000,
              11000,
              10000,
              12000,
              13000,
              12000,
              13000,
              12000,
              13000,
              11000
            ]
          },
          {
            "name": "YoY",
            "unit": "%",
            "values": [
              -10,
              -20,
              10,
              -10,
              -20,
              10,
              -10,
              -20,
              10,
              -10,
              -20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20,
              20
            ]
          }
        ],
        "figure_id": "f34b7b78e7e7be70",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 3,
        "axes": null,
        "series": [],
        "figure_id": "b50aecefb6f30a98",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 10,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Sep-14",
              "Feb-15",
              "Jul-15",
              "Dec-15",
              "May-16",
              "Oct-16",
              "Mar-17",
              "Aug-17",
              "Jan-18",
              "Jun-18",
              "Nov-18",
              "Apr-19",
              "Sep-19",
              "Feb-20",
              "Jul-20",
              "Dec-20",
              "May-21",
              "Oct-21",
              "Mar-22",
              "Aug-22",
              "Jan-23",
              "Jun-23",
              "Nov-23",
              "Apr-24",
              "Sep-24",
              "Feb-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "SM",
            "range": {
              "min": 0,
              "max": 1600
            }
          }
        },
        "series": [
          {
            "name": "Keytruda (MRK)",
            "unit": "SM",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Opdivo (BMY)",
            "unit": "SM",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Imfinzi (AZN)",
            "unit": "SM",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Yervoy (BMY)",
            "unit": "SM",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Tecentriq (ROG)",
            "unit": "SM",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Opdualag (BMY)",
            "unit": "SM",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Bavencio (MRK.D)",
            "unit": "SM",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Libtayo (REGN/SM)",
            "unit": "SM",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "f247eff0ca4f4049",
        "provenance": {
          "page": 10
        }
      },
      {
        "type": "line",
        "title": "Monthly IMS sales ($M) - Alimta (LLY)",
        "page": 10,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jan-15",
              "Apr-15",
              "Jul-15",
              "Oct-15",
              "Jan-16",
              "Apr-16",
              "Jul-16",
              "Oct-16",
              "Jan-17",
              "Apr-17",
              "Jul-17",
              "Oct-17",
              "Jan-18",
              "Apr-18",
              "Jul-18",
              "Oct-18",
              "Jan-19",
              "Apr-19",
              "Jul-19",
              "Oct-19",
              "Jan-20",
              "Apr-20",
              "Jul-20",
              "Oct-20",
              "Jan-21",
              "Apr-21",
              "Jul-21",
              "Oct-21",
              "Jan-22",
              "Apr-22",
              "Jul-22",
              "Oct-22",
              "Jan-23",
              "Apr-23",
              "Jul-23",
              "Oct-23",
              "Jan-24",
              "Apr-24",
              "Jul-24",
              "Oct-24",
              "Jan-25",
              "Apr-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "$M",
            "range": {
              "min": 0,
              "max": 140
            }
          }
        },
        "series": [
          {
            "name": "Monthly IMS sales",
            "unit": "$M",
            "values": [
              85,
              90,
              88,
              117,
              85,
              95,
              102,
              80,
              70,
              80,
              95,
              70,
              75,
              80,
              85,
              90,
              98,
              110,
              90,
              98,
              95,
              102,
              90,
              95,
              110,
              100,
              110,
              80,
              110,
              95,
              90,
              80,
              10,
              8,
              6,
              5,
              4,
              3,
              2,
              1,
              1,
              1,
              1,
              1
            ]
          }
        ],
        "figure_id": "5f7866abdc18e574",
        "provenance": {
          "page": 10
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 13,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 70
            }
          }
        },
        "series": [
          {
            "name": "Alecensa",
            "unit": "%",
            "values": [
              57,
              59,
              59,
              58,
              59,
              54,
              60,
              59,
              61,
              57,
              59,
              54,
              59,
              57,
              59,
              52,
              57,
              54,
              56,
              53,
              57,
              56
            ]
          },
          {
            "name": "Rozytrek",
            "unit": "%",
            "values": [
              5,
              4,
              6,
              4,
              5,
              3,
              5,
              4,
              6,
              4,
              5,
              6,
              4,
              7,
              5,
              4,
              6,
              3,
              5,
              4,
              6,
              5
            ]
          },
          {
            "name": "PFE Franchise",
            "unit": "%",
            "values": [
              30,
              30,
              31,
              30,
              31,
              30,
              30,
              29,
              31,
              30,
              33,
              29,
              31,
              30,
              32,
              30,
              34,
              31,
              33,
              32,
              35,
              33
            ]
          },
          {
            "name": "Zykadia",
            "unit": "%",
            "values": [
              2,
              1,
              2,
              1,
              2,
              1,
              2,
              1,
              2,
              1,
              2,
              1,
              2,
              1,
              2,
              1,
              2,
              1,
              2,
              1,
              3,
              1
            ]
          },
          {
            "name": "Alunbrig",
            "unit": "%",
            "values": [
              4,
              5,
              4,
              5,
              4,
              6,
              4,
              5,
              4,
              5,
              4,
              5,
              4,
              5,
              4,
              5,
              4,
              5,
              4,
              5,
              4,
              5
            ]
          }
        ],
        "figure_id": "367c23314798c7d3",
        "provenance": {
          "page": 13
        }
      },
      {
        "type": "line",
        "title": "Weekly YOY",
        "page": 14,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -100,
              "max": 400
            }
          }
        },
        "series": [
          {
            "name": "Alecensa",
            "unit": "%",
            "values": [
              10,
              -5,
              10,
              -10,
              -5,
              -20,
              -10,
              -5,
              5,
              10,
              5,
              10,
              5,
              10,
              5,
              10,
              -5,
              -10
            ]
          },
          {
            "name": "PFE Franchise",
            "unit": "%",
            "values": [
              20,
              25,
              30,
              15,
              40,
              20,
              10,
              20,
              10,
              20,
              15,
              20,
              20,
              20,
              30,
              20,
              20,
              20
            ]
          },
          {
            "name": "Zykadia",
            "unit": "%",
            "values": [
              130,
              20,
              200,
              370,
              200,
              150,
              -60,
              -20,
              -50,
              -10,
              -60,
              -20,
              -50,
              200,
              -40,
              350,
              -60,
              -46
            ]
          },
          {
            "name": "Alunbrig",
            "unit": "%",
            "values": [
              10,
              20,
              10,
              -10,
              10,
              -10,
              100,
              220,
              100,
              320,
              50,
              60,
              70,
              50,
              150,
              50,
              60,
              45
            ]
          },
          {
            "name": "Total Market",
            "unit": "%",
            "values": [
              20,
              25,
              30,
              20,
              40,
              30,
              20,
              20,
              20,
              30,
              20,
              20,
              20,
              30,
              20,
              30,
              20,
              18
            ]
          }
        ],
        "figure_id": "50b0d10d1e69e520",
        "provenance": {
          "page": 14
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 14,
        "axes": {
          "x": {
            "type": "linear",
            "labels": "Weeks since launch"
          },
          "y": {
            "unit": "TRx",
            "range": {
              "min": 0,
              "max": 700
            }
          }
        },
        "series": [
          {
            "name": "Alecensa (Roche)",
            "unit": "TRx",
            "values": [
              {
                "x": 0,
                "y": 0
              },
              {
                "x": 25,
                "y": 70
              },
              {
                "x": 50,
                "y": 100
              },
              {
                "x": 75,
                "y": 150
              },
              {
                "x": 100,
                "y": 200
              },
              {
                "x": 125,
                "y": 250
              },
              {
                "x": 150,
                "y": 300
              },
              {
                "x": 175,
                "y": 350
              },
              {
                "x": 200,
                "y": 400
              },
              {
                "x": 225,
                "y": 420
              },
              {
                "x": 250,
                "y": 450
              },
              {
                "x": 275,
                "y": 480
              },
              {
                "x": 300,
                "y": 500
              },
              {
                "x": 325,
                "y": 520
              },
              {
                "x": 350,
                "y": 550
              },
              {
                "x": 375,
                "y": 580
              },
              {
                "x": 400,
                "y": 550
              },
              {
                "x": 425,
                "y": 500
              },
              {
                "x": 440,
                "y": 520
              }
            ]
          },
          {
            "name": "Rozlytrek (Roche)",
            "unit": "TRx",
            "values": [
              {
                "x": 0,
                "y": 0
              },
              {
                "x": 25,
                "y": 10
              },
              {
                "x": 50,
                "y": 20
              },
              {
                "x": 75,
                "y": 30
              },
              {
                "x": 100,
                "y": 40
              },
              {
                "x": 125,
                "y": 50
              },
              {
                "x": 150,
                "y": 60
              },
              {
                "x": 175,
                "y": 65
              },
              {
                "x": 200,
                "y": 70
              },
              {
                "x": 225,
                "y": 75
              },
              {
                "x": 250,
                "y": 80
              },
              {
                "x": 275,
                "y": 70
              },
              {
                "x": 300,
                "y": 60
              },
              {
                "x": 325,
                "y": 50
              },
              {
                "x": 350,
                "y": 40
              }
            ]
          },
          {
            "name": "Lorbrena (Pfizer)",
            "unit": "TRx",
            "values": [
              {
                "x": 0,
                "y": 0
              },
              {
                "x": 25,
                "y": 30
              },
              {
                "x": 50,
                "y": 50
              },
              {
                "x": 75,
                "y": 70
              },
              {
                "x": 100,
                "y": 90
              },
              {
                "x": 125,
                "y": 110
              },
              {
                "x": 150,
                "y": 120
              },
              {
                "x": 175,
                "y": 130
              },
              {
                "x": 200,
                "y": 140
              },
              {
                "x": 225,
                "y": 150
              },
              {
                "x": 250,
                "y": 160
              },
              {
                "x": 275,
                "y": 180
              },
              {
                "x": 300,
                "y": 220
              },
              {
                "x": 325,
                "y": 280
              },
              {
                "x": 350,
                "y": 350
              }
            ]
          },
          {
            "name": "Alunbrig (Takeda)",
            "unit": "TRx",
            "values": [
              {
                "x": 0,
                "y": 0
              },
              {
                "x": 25,
                "y": 5
              },
              {
                "x": 50,
                "y": 10
              },
              {
                "x": 75,
                "y": 15
              },
              {
                "x": 100,
                "y": 20
              },
              {
                "x": 125,
                "y": 25
              },
              {
                "x": 150,
                "y": 30
              },
              {
                "x": 175,
                "y": 35
              },
              {
                "x": 200,
                "y": 40
              },
              {
                "x": 225,
                "y": 45
              },
              {
                "x": 250,
                "y": 50
              },
              {
                "x": 275,
                "y": 55
              },
              {
                "x": 300,
                "y": 60
              },
              {
                "x": 325,
                "y": 50
              },
              {
                "x": 350,
                "y": 40
              },
              {
                "x": 375,
                "y": 50
              },
              {
                "x": 400,
                "y": 60
              },
              {
                "x": 425,
                "y": 70
              },
              {
                "x": 440,
                "y": 65
              }
            ]
          }
        ],
        "figure_id": "3162fcc1c68c1812",
        "provenance": {
          "page": 14
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 17,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -80,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "Xtandi",
            "unit": "%",
            "values": [
              15,
              20,
              10,
              20,
              15,
              25,
              20,
              30,
              10,
              35,
              20,
              25,
              25,
              20,
              25,
              35,
              30,
              34
            ]
          },
          {
            "name": "Zytiga",
            "unit": "%",
            "values": [
              -25,
              -15,
              -35,
              -30,
              -40,
              -10,
              0,
              -50,
              -20,
              -5,
              -30,
              10,
              -20,
              -30,
              -60,
              -70,
              -50,
              -33
            ]
          },
          {
            "name": "Erleada",
            "unit": "%",
            "values": [
              10,
              15,
              0,
              20,
              55,
              15,
              25,
              40,
              0,
              20,
              10,
              20,
              25,
              15,
              20,
              25,
              20,
              30
            ]
          },
          {
            "name": "Nubeqa",
            "unit": "%",
            "values": [
              50,
              70,
              40,
              60,
              40,
              70,
              40,
              60,
              40,
              50,
              40,
              60,
              50,
              60,
              50,
              80,
              70,
              86
            ]
          },
          {
            "name": "Total Market",
            "unit": "%",
            "values": [
              5,
              10,
              5,
              15,
              10,
              20,
              10,
              20,
              5,
              15,
              10,
              15,
              20,
              15,
              10,
              20,
              25,
              26
            ]
          }
        ],
        "figure_id": "70e826c08caf6426",
        "provenance": {
          "page": 17
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 17,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 60
            }
          }
        },
        "series": [
          {
            "name": "Xtandi",
            "unit": "%",
            "values": [
              25.0,
              24.5,
              25.0,
              24.0,
              24.5,
              24.0,
              25.0,
              26.0,
              25.5,
              25.0,
              25.5,
              25.0,
              26.0,
              25.5,
              25.0,
              25.5,
              25.0,
              26.0
            ]
          },
          {
            "name": "Zytiga",
            "unit": "%",
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          {
            "name": "Gx Zytiga",
            "unit": "%",
            "values": [
              47.5,
              47.0,
              48.0,
              49.0,
              47.0,
              47.0,
              48.0,
              46.0,
              45.0,
              44.0,
              43.5,
              44.0,
              43.0,
              42.0,
              42.5,
              41.5,
              40.0,
              41.0
            ]
          },
          {
            "name": "Erleada",
            "unit": "%",
            "values": [
              9.0,
              9.0,
              9.5,
              9.0,
              9.0,
              9.0,
              9.5,
              9.0,
              9.0,
              9.0,
              9.0,
              9.0,
              9.0,
              9.0,
              9.0,
              9.0,
              9.0,
              9.0
            ]
          },
          {
            "name": "Nubeqa",
            "unit": "%",
            "values": [
              9.0,
              9.5,
              9.0,
              9.0,
              9.5,
              9.0,
              9.0,
              9.5,
              10.0,
              10.0,
              10.5,
              10.5,
              10.5,
              11.0,
              11.0,
              11.5,
              12.0,
              12.0
            ]
          },
          {
            "name": "Orgovyx",
            "unit": "%",
            "values": [
              9.5,
              10.0,
              10.0,
              10.0,
              10.0,
              10.0,
              10.0,
              10.0,
              10.5,
              11.0,
              11.0,
              11.5,
              11.5,
              12.0,
              12.0,
              12.5,
              12.0,
              12.0
            ]
          }
        ],
        "figure_id": "a823971479b8371e",
        "provenance": {
          "page": 17
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 20,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "left": {
              "unit": "TRx",
              "range": {
                "min": 0,
                "max": 3000
              }
            },
            "right": {
              "unit": "%",
              "range": {
                "min": -60,
                "max": 120
              }
            }
          }
        },
        "series": [
          {
            "name": "Weekly TRx",
            "unit": "TRx",
            "values": [
              2350,
              2150,
              2250,
              1850,
              2500,
              1700,
              1900,
              2300,
              2650,
              2050,
              2400,
              2150,
              2350,
              2100,
              2300,
              1800,
              2100,
              2600
            ]
          },
          {
            "name": "Weekly YOY growth",
            "unit": "%",
            "values": [
              -10,
              -20,
              -15,
              -30,
              10,
              -35,
              -15,
              -5,
              10,
              100,
              -10,
              -5,
              -15,
              -5,
              -10,
              -25,
              -5,
              15
            ]
          }
        ],
        "figure_id": "ca03a302b30e6f1d",
        "provenance": {
          "page": 20
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 21,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "left": {
              "unit": "TRx",
              "range": {
                "min": 0,
                "max": 3000
              }
            },
            "right": {
              "unit": "%",
              "range": {
                "min": -50,
                "max": 250
              }
            }
          }
        },
        "series": [
          {
            "name": "Weekly TRx",
            "unit": "TRx",
            "values": [
              1950,
              1550,
              1900,
              1700,
              1750,
              2350,
              1800,
              1950,
              1900,
              2450,
              2650,
              2350,
              2750,
              2300,
              2050,
              2150,
              2600,
              2400
            ]
          },
          {
            "name": "Weekly YOY growth",
            "unit": "%",
            "values": [
              40,
              25,
              15,
              10,
              20,
              55,
              20,
              35,
              25,
              230,
              40,
              30,
              45,
              30,
              -10,
              20,
              40,
              35
            ]
          }
        ],
        "figure_id": "e939a2094eb16854",
        "provenance": {
          "page": 21
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 21,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "left": {
              "unit": "Weekly TRx",
              "range": {
                "min": 700,
                "max": 1900
              }
            },
            "right": {
              "unit": "Weekly YOY",
              "range": {
                "min": -40,
                "max": 100
              }
            }
          }
        },
        "series": [
          {
            "name": "Weekly TRx",
            "unit": null,
            "values": [
              1400,
              1480,
              1350,
              1450,
              1580,
              1450,
              1250,
              1500,
              1550,
              1480,
              1600,
              1300,
              1450,
              1350,
              1180,
              1050,
              1400,
              1650
            ]
          },
          {
            "name": "Weekly YOY growth",
            "unit": "%",
            "values": [
              30,
              10,
              20,
              0,
              25,
              35,
              20,
              10,
              20,
              85,
              10,
              -10,
              0,
              10,
              -5,
              -20,
              -15,
              10
            ]
          }
        ],
        "figure_id": "487484c5841a7fa9",
        "provenance": {
          "page": 21
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 21,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "left": {
              "unit": "TRx",
              "range": {
                "min": 0,
                "max": 1400
              }
            },
            "right": {
              "unit": "%",
              "range": {
                "min": -100,
                "max": 700
              }
            }
          }
        },
        "series": [
          {
            "name": "Weekly TRx",
            "unit": "TRx",
            "values": [
              650,
              880,
              780,
              800,
              650,
              900,
              780,
              980,
              700,
              900,
              850,
              1050,
              1030,
              1080,
              980,
              1050,
              980,
              950,
              980,
              800,
              1150,
              800,
              1080,
              950,
              1200,
              1050,
              1180,
              1100
            ]
          },
          {
            "name": "Weekly YOY growth",
            "unit": "%",
            "values": [
              100,
              130,
              100,
              120,
              100,
              150,
              100,
              120,
              80,
              100,
              80,
              60,
              80,
              60,
              50,
              60,
              50,
              60,
              50,
              60,
              50,
              60,
              50,
              60,
              50,
              60,
              50,
              60
            ]
          }
        ],
        "figure_id": "caa93dd1049204b8",
        "provenance": {
          "page": 21
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 22,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Mar-16",
              "May-16",
              "Jul-16",
              "Sep-16",
              "Nov-16",
              "Jan-17",
              "Mar-17",
              "May-17",
              "Jul-17",
              "Sep-17",
              "Nov-17",
              "Jan-18",
              "Mar-18",
              "May-18",
              "Jul-18",
              "Sep-18",
              "Nov-18",
              "Jan-19",
              "Mar-19",
              "May-19",
              "Jul-19",
              "Sep-19",
              "Nov-19",
              "Jan-20",
              "Mar-20",
              "May-20",
              "Jul-20",
              "Sep-20",
              "Nov-20",
              "Jan-21",
              "Mar-21",
              "May-21",
              "Jul-21",
              "Sep-21",
              "Nov-21",
              "Jan-22",
              "Mar-22",
              "May-22",
              "Jul-22",
              "Sep-22",
              "Nov-22",
              "Jan-23",
              "Mar-23",
              "May-23",
              "Jul-23",
              "Sep-23",
              "Nov-23",
              "Jan-24",
              "Mar-24",
              "May-24",
              "Jul-24",
              "Sep-24",
              "Nov-24",
              "Jan-25",
              "Mar-25",
              "May-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "USD million",
            "range": {
              "min": 0,
              "max": 140
            }
          }
        },
        "series": [
          {
            "name": "Venclexta (ABBV)",
            "unit": "USD million",
            "values": [
              0.5,
              1,
              1.5,
              2,
              3,
              4,
              5,
              6,
              7,
              8,
              9,
              10,
              12,
              15,
              18,
              22,
              28,
              32,
              38,
              42,
              45,
              48,
              52,
              58,
              60,
              55,
              62,
              65,
              68,
              70,
              72,
              75,
              78,
              80,
              82,
              85,
              88,
              90,
              92,
              95,
              98,
              100,
              102,
              105,
              108,
              110,
              112,
              115,
              118,
              120,
              115,
              118,
              120,
              118,
              115,
              118
            ]
          }
        ],
        "figure_id": "281810c3f507a4e6",
        "provenance": {
          "page": 22
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 22,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 50
            }
          }
        },
        "series": [
          {
            "name": "Brukinsa (Beigene)",
            "unit": "%",
            "values": [
              15.0,
              16.0,
              14.5,
              15.5,
              16.5,
              17.5,
              16.0,
              17.0,
              14.0,
              16.0,
              17.0,
              15.0,
              17.5,
              16.0,
              18.0,
              17.0,
              18.0,
              18.0
            ]
          },
          {
            "name": "Imbruvica (ABBV)",
            "unit": "%",
            "values": [
              44.0,
              47.0,
              43.0,
              42.0,
              44.0,
              44.0,
              40.0,
              44.0,
              40.0,
              42.0,
              39.0,
              40.0,
              38.0,
              39.0,
              37.0,
              40.0,
              35.0,
              40.0
            ]
          },
          {
            "name": "Calquence (AZN)",
            "unit": "%",
            "values": [
              36.0,
              35.0,
              35.0,
              37.0,
              38.0,
              41.0,
              39.0,
              37.0,
              44.0,
              36.0,
              42.0,
              38.0,
              41.0,
              35.0,
              43.0,
              38.0,
              43.0,
              38.0
            ]
          },
          {
            "name": "Jaypirca (LLY)",
            "unit": "%",
            "values": [
              3.0,
              2.5,
              3.0,
              3.5,
              3.0,
              3.0,
              4.0,
              3.0,
              3.0,
              3.0,
              3.0,
              3.5,
              4.0,
              3.0,
              4.0,
              3.5,
              4.5,
              4.0
            ]
          }
        ],
        "figure_id": "d08356df4b11b8d8",
        "provenance": {
          "page": 22
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 23,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 50
            }
          }
        },
        "series": [
          {
            "name": "Brukinsa (Beigene)",
            "unit": "%",
            "values": [
              16.5,
              19.5,
              19.5,
              14.5,
              17.5,
              21,
              14,
              20.5,
              17.5,
              21,
              18,
              19.5,
              17.5,
              22,
              17,
              22.5,
              20,
              18
            ]
          },
          {
            "name": "Imbruvica (ABBV)",
            "unit": "%",
            "values": [
              40.5,
              33,
              39,
              37,
              34.5,
              40,
              34.5,
              40,
              35,
              33,
              36,
              32.5,
              35.5,
              38.5,
              30,
              34,
              30,
              35
            ]
          },
          {
            "name": "Calquence (AZN)",
            "unit": "%",
            "values": [
              39,
              41,
              38,
              42.5,
              37,
              39,
              44,
              40,
              42,
              43,
              45,
              42,
              45,
              38,
              44,
              39,
              42,
              42
            ]
          },
          {
            "name": "Jaypirca (LLY)",
            "unit": "%",
            "values": [
              3,
              4.5,
              3.5,
              4.5,
              2.5,
              4.5,
              3.5,
              4,
              3.5,
              4.5,
              4,
              4.5,
              5.5,
              4.5,
              4,
              5,
              6.5,
              4
            ]
          }
        ],
        "figure_id": "1e34dde6e0672a46",
        "provenance": {
          "page": 23
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 23,
        "axes": {
          "x": {
            "type": "value",
            "labels": "Weeks since launch"
          },
          "y": {
            "unit": "TRx",
            "range": {
              "min": 0,
              "max": 5500
            }
          }
        },
        "series": [
          {
            "name": "Imbruvica (ABBV)",
            "unit": "TRx",
            "values": []
          },
          {
            "name": "Calquence (AZN)",
            "unit": "TRx",
            "values": []
          },
          {
            "name": "Jaypirca (LLY)",
            "unit": "TRx",
            "values": []
          },
          {
            "name": "Venclexta (ABBV/Roche)",
            "unit": "TRx",
            "values": []
          },
          {
            "name": "Brukinsa (BeiGene)",
            "unit": "TRx",
            "values": []
          }
        ],
        "figure_id": "b0ce9cd0c6842826",
        "provenance": {
          "page": 23
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 26,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "TRx",
            "range": {
              "min": 0,
              "max": 5000
            }
          }
        },
        "series": [
          {
            "name": "Ibrance",
            "unit": "TRx",
            "values": [
              2700,
              2900,
              2700,
              2800,
              2600,
              2900,
              2800,
              2900,
              3000,
              2800,
              2900,
              3000,
              3100,
              2900,
              3100,
              2800,
              3000,
              3100
            ]
          },
          {
            "name": "Kisqali",
            "unit": "TRx",
            "values": [
              1700,
              1800,
              1900,
              2000,
              1800,
              1700,
              2000,
              2200,
              2500,
              2600,
              2700,
              2800,
              2900,
              2700,
              2800,
              3400,
              3200,
              3200
            ]
          },
          {
            "name": "Piqray",
            "unit": "TRx",
            "values": [
              100,
              100,
              100,
              100,
              100,
              100,
              100,
              100,
              100,
              100,
              100,
              100,
              100,
              100,
              100,
              100,
              100,
              100
            ]
          },
          {
            "name": "Verzenio",
            "unit": "TRx",
            "values": [
              3700,
              4300,
              4100,
              4300,
              3500,
              4500,
              3400,
              4200,
              3800,
              4200,
              4000,
              4200,
              4300,
              3800,
              4400,
              3900,
              4000,
              4300
            ]
          }
        ],
        "figure_id": "46aa63ba1712ff5b",
        "provenance": {
          "page": 26
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 26,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -60,
              "max": 140
            }
          }
        },
        "series": [
          {
            "name": "Ibrance",
            "unit": "%",
            "values": [
              -18,
              -10,
              -15,
              -18,
              -10,
              -35,
              -10,
              -25,
              -5,
              -10,
              -5,
              0,
              -5,
              -10,
              -5,
              0,
              10,
              15
            ]
          },
          {
            "name": "Kisqali Franchise",
            "unit": "%",
            "values": [
              70,
              55,
              60,
              30,
              85,
              60,
              80,
              50,
              90,
              60,
              100,
              90,
              95,
              85,
              100,
              90,
              95,
              88
            ]
          },
          {
            "name": "Verzenio",
            "unit": "%",
            "values": [
              10,
              20,
              10,
              15,
              40,
              15,
              5,
              15,
              10,
              20,
              10,
              5,
              10,
              5,
              10,
              5,
              10,
              4
            ]
          },
          {
            "name": "Total Market",
            "unit": "%",
            "values": [
              10,
              10,
              5,
              10,
              20,
              20,
              5,
              30,
              15,
              15,
              10,
              15,
              15,
              10,
              15,
              20,
              25,
              22
            ]
          }
        ],
        "figure_id": "505954c8d31f6a4e",
        "provenance": {
          "page": 26
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 26,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 4
            }
          }
        },
        "series": [
          {
            "name": "Ibrance",
            "unit": "%",
            "values": [
              2.2,
              2.3,
              2.1,
              2.2,
              2.1,
              2.1,
              2.1,
              1.9,
              2.2,
              2.2,
              2.3,
              2.1,
              2.2,
              2.3,
              2.0,
              2.2,
              2.3,
              2.3
            ]
          },
          {
            "name": "Kisqali",
            "unit": "%",
            "values": [
              1.3,
              1.4,
              1.3,
              1.1,
              1.5,
              1.4,
              1.6,
              1.8,
              1.9,
              1.9,
              2.0,
              1.9,
              2.1,
              2.2,
              2.0,
              2.3,
              2.2,
              2.4
            ]
          },
          {
            "name": "Verzenio",
            "unit": "%",
            "values": [
              3.2,
              3.4,
              3.1,
              3.3,
              3.0,
              3.2,
              2.6,
              2.9,
              3.1,
              3.0,
              2.9,
              3.1,
              3.0,
              3.1,
              3.0,
              3.0,
              2.9,
              3.2
            ]
          }
        ],
        "figure_id": "7c118c19006babcf",
        "provenance": {
          "page": 26
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 28,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jun-23",
              "Jul-23",
              "Aug-23",
              "Sep-23",
              "Oct-23",
              "Nov-23",
              "Dec-23",
              "Jan-24",
              "Feb-24",
              "Mar-24",
              "Apr-24",
              "May-24",
              "Jun-24",
              "Jul-24",
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "$'000",
            "range": {
              "min": 0,
              "max": 6000
            }
          }
        },
        "series": [
          {
            "name": "Columvi (Roche)",
            "unit": "$'000",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              50,
              100,
              100,
              100,
              150,
              150,
              100,
              100,
              150,
              150,
              150,
              150,
              150,
              150,
              150,
              150,
              150,
              150,
              150
            ]
          },
          {
            "name": "Epkinly (GMAB/ABBV)",
            "unit": "$'000",
            "values": [
              0,
              100,
              500,
              1500,
              3700,
              3800,
              3900,
              5000,
              5900,
              5600,
              5900,
              5800,
              3500,
              3200,
              3500,
              3200,
              3500,
              3600,
              3500,
              200,
              150,
              100,
              100,
              100,
              100,
              100
            ]
          }
        ],
        "figure_id": "681c3f721fe7dca0",
        "provenance": {
          "page": 28
        }
      },
      {
        "type": "table",
        "title": null,
        "page": 30,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Q1 19",
              "Q2 19",
              "Q3 19",
              "Q4 19",
              "Q1 20",
              "Q2 20",
              "Q3 20",
              "Q4 20",
              "Q1 21",
              "Q2 21",
              "Q3 21",
              "Q4 21",
              "Q1 22",
              "Q2 22",
              "Q3 22",
              "Q4 22",
              "Q1 23",
              "Q2 23",
              "Q3 23",
              "Q4 23",
              "Q1 24",
              "Q2 24",
              "Q3 24",
              "Q4 24",
              "Q1 25",
              "Q2 25",
              "Q3 25",
              "Q4 25",
              "Q1 26",
              "Q2 26",
              "Q3 26",
              "Q4 26",
              "Q1 27",
              "Q2 27",
              "Q3 27",
              "Q4 27",
              "Q1 28",
              "Q2 28",
              "Q3 28",
              "Q4 28"
            ]
          },
          "y": {
            "unit": null,
            "range": null
          }
        },
        "series": [
          {
            "name": "Revenue",
            "unit": null,
            "values": [
              11,
              11,
              12,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11,
              11
            ]
          },
          {
            "name": "EBITDA",
            "unit": null,
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "Adj. EBITDA",
            "unit": null,
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          }
        ],
        "figure_id": "7380f5c5e0c83fe7",
        "provenance": {
          "page": 30
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 32,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "May-24",
              "Jun-24",
              "Jul-24",
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "$'000",
            "range": {
              "min": 0,
              "max": 45000
            }
          }
        },
        "series": [
          {
            "name": "Imdelltra (AMGN)",
            "unit": "$'000",
            "values": [
              1000,
              4000,
              7000,
              10000,
              14000,
              19000,
              20500,
              21500,
              23500,
              26000,
              30000,
              31500,
              32500,
              35000,
              39000
            ]
          }
        ],
        "figure_id": "2cedf81b650cf52a",
        "provenance": {
          "page": 32
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 33,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "May-21",
              "Jun-21",
              "Jul-21",
              "Aug-21",
              "Sep-21",
              "Oct-21",
              "Nov-21",
              "Dec-21",
              "Jan-22",
              "Feb-22",
              "Mar-22",
              "Apr-22",
              "May-22",
              "Jun-22",
              "Jul-22",
              "Aug-22",
              "Sep-22",
              "Oct-22",
              "Nov-22",
              "Dec-22",
              "Jan-23",
              "Feb-23",
              "Mar-23",
              "Apr-23",
              "May-23",
              "Jun-23",
              "Jul-23",
              "Aug-23",
              "Sep-23",
              "Oct-23",
              "Nov-23",
              "Dec-23",
              "Jan-24",
              "Feb-24",
              "Mar-24",
              "Apr-24",
              "May-24",
              "Jun-24",
              "Jul-24",
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "million USD",
            "range": {
              "min": 0,
              "max": 40
            }
          }
        },
        "series": [
          {
            "name": "Rybrevant (JNJ)",
            "unit": "million USD",
            "values": [
              0.5,
              1.5,
              3.5,
              4.0,
              4.0,
              4.0,
              4.0,
              4.0,
              3.5,
              3.5,
              3.5,
              3.5,
              3.5,
              4.0,
              4.0,
              4.0,
              4.0,
              4.0,
              4.0,
              4.0,
              4.5,
              5.0,
              5.5,
              5.0,
              5.0,
              5.0,
              5.0,
              5.0,
              5.0,
              5.0,
              5.0,
              5.0,
              7.0,
              10.0,
              15.0,
              16.0,
              19.0,
              20.0,
              22.0,
              25.0,
              28.0,
              30.0,
              32.0,
              33.0,
              34.0,
              35.0,
              35.5,
              35.0,
              35.0
            ]
          }
        ],
        "figure_id": "73463315d41d4dad",
        "provenance": {
          "page": 33
        }
      },
      {
        "type": "line",
        "title": "Monthly IMS sales ($M)",
        "page": 34,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Nov-18",
              "Jan-19",
              "Mar-19",
              "May-19",
              "Jul-19",
              "Sep-19",
              "Nov-19",
              "Jan-20",
              "Mar-20",
              "May-20",
              "Jul-20",
              "Sep-20",
              "Nov-20",
              "Jan-21",
              "Mar-21",
              "May-21",
              "Jul-21",
              "Sep-21",
              "Nov-21",
              "Jan-22",
              "Mar-22",
              "May-22",
              "Jul-22",
              "Sep-22",
              "Nov-22",
              "Jan-23",
              "Mar-23",
              "May-23",
              "Jul-23",
              "Sep-23",
              "Nov-23",
              "Jan-24",
              "Mar-24",
              "May-24",
              "Jul-24",
              "Sep-24",
              "Nov-24",
              "Jan-25",
              "Mar-25",
              "May-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "$M",
            "range": {
              "min": 0,
              "max": 20
            }
          }
        },
        "series": [
          {
            "name": "Xospata (Astellas)",
            "unit": "$M",
            "values": [
              1.5,
              2.5,
              2.8,
              3.2,
              3.8,
              4.5,
              5.0,
              5.5,
              6.0,
              6.5,
              6.2,
              6.8,
              7.2,
              7.8,
              8.5,
              8.8,
              9.2,
              9.5,
              9.0,
              9.5,
              10.0,
              10.5,
              10.8,
              11.0,
              11.5,
              12.2,
              11.0,
              10.8,
              11.0,
              11.5,
              12.0,
              13.0,
              13.8,
              13.0,
              12.8,
              13.5,
              14.0,
              14.5,
              17.8,
              14.5
            ]
          },
          {
            "name": "Vanflyta (Daiichi)",
            "unit": "$M",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              1.0,
              2.5,
              1.5,
              2.0,
              4.2,
              1.5,
              2.0,
              2.5,
              2.8,
              3.2,
              3.8,
              4.8,
              3.5
            ]
          }
        ],
        "figure_id": "6777a8a99493498d",
        "provenance": {
          "page": 34
        }
      },
      {
        "type": "line",
        "title": "Elahere (ABBV)",
        "page": 35,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Mar-23",
              "Apr-23",
              "May-23",
              "Jun-23",
              "Jul-23",
              "Aug-23",
              "Sep-23",
              "Oct-23",
              "Nov-23",
              "Dec-23",
              "Jan-24",
              "Feb-24",
              "Mar-24",
              "Apr-24",
              "May-24",
              "Jun-24",
              "Jul-24",
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "$M",
            "range": {
              "min": 0,
              "max": 25
            }
          }
        },
        "series": [
          {
            "name": "Monthly IMS sales",
            "unit": "$M",
            "values": [
              0.5,
              1.5,
              15,
              12,
              13.5,
              14.5,
              14.8,
              15,
              15,
              18.5,
              15.5,
              16.5,
              15.5,
              16.5,
              13.5,
              16.5,
              16.8,
              17,
              17.5,
              18.5,
              17.5,
              18.5,
              22,
              20.5,
              7,
              0.5,
              0.5,
              0.5,
              0.5
            ]
          }
        ],
        "figure_id": "166ae5a9f1e438f1",
        "provenance": {
          "page": 35
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 36,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Dec-19",
              "Jan-20",
              "Feb-20",
              "Mar-20",
              "Apr-20",
              "May-20",
              "Jun-20",
              "Jul-20",
              "Aug-20",
              "Sep-20",
              "Oct-20",
              "Nov-20",
              "Dec-20",
              "Jan-21",
              "Feb-21",
              "Mar-21",
              "Apr-21",
              "May-21",
              "Jun-21",
              "Jul-21",
              "Aug-21",
              "Sep-21",
              "Oct-21",
              "Nov-21",
              "Dec-21",
              "Jan-22",
              "Feb-22",
              "Mar-22",
              "Apr-22",
              "May-22",
              "Jun-22",
              "Jul-22",
              "Aug-22",
              "Sep-22",
              "Oct-22",
              "Nov-22",
              "Dec-22",
              "Jan-23",
              "Feb-23",
              "Mar-23",
              "Apr-23",
              "May-23",
              "Jun-23",
              "Jul-23"
            ]
          },
          "y": {
            "unit": "$M",
            "range": {
              "min": 0,
              "max": 250
            }
          }
        },
        "series": [
          {
            "name": "Enhertu (Daiichi)",
            "unit": "$M",
            "values": [
              5,
              8,
              10,
              12,
              15,
              18,
              20,
              22,
              25,
              28,
              30,
              32,
              35,
              38,
              40,
              45,
              50,
              55,
              60,
              65,
              70,
              75,
              80,
              85,
              90,
              95,
              100,
              105,
              110,
              115,
              120,
              125,
              130,
              135,
              140,
              145,
              150,
              155,
              160,
              165,
              170,
              175,
              180,
              185
            ]
          }
        ],
        "figure_id": "5037240412c84323",
        "provenance": {
          "page": 36
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 39,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jun-21",
              "Jul-21",
              "Aug-21",
              "Sep-21",
              "Oct-21",
              "Nov-21",
              "Dec-21",
              "Jan-22",
              "Feb-22",
              "Mar-22",
              "Apr-22",
              "May-22",
              "Jun-22",
              "Jul-22",
              "Aug-22",
              "Sep-22",
              "Oct-22",
              "Nov-22",
              "Dec-22",
              "Jan-23",
              "Feb-23",
              "Mar-23",
              "Apr-23",
              "May-23",
              "Jun-23",
              "Jul-23",
              "Aug-23",
              "Sep-23",
              "Oct-23",
              "Nov-23",
              "Dec-23",
              "Jan-24",
              "Feb-24",
              "Mar-24",
              "Apr-24",
              "May-24",
              "Jun-24",
              "Jul-24",
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "USD million",
            "range": {
              "min": 0,
              "max": 20
            }
          }
        },
        "series": [
          {
            "name": "Lumakras (AMGN)",
            "unit": "USD million",
            "values": [
              4,
              6,
              8,
              9.5,
              10,
              10,
              10.5,
              12,
              13,
              12.5,
              12,
              13,
              13.5,
              13,
              12.5,
              13,
              14,
              16,
              12,
              13,
              14,
              13.5,
              13,
              14.5,
              16,
              15,
              14,
              14.5,
              13.5,
              13,
              14,
              14.5,
              15,
              16,
              17,
              17.5,
              18,
              17,
              16,
              16.5,
              17,
              17.5,
              18,
              17.5,
              17,
              16.5,
              16,
              15
            ]
          },
          {
            "name": "Krazati (AMGN)",
            "unit": "USD million",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0.5,
              1,
              0.5,
              0.5,
              0.5,
              0.5,
              0.5,
              0.5,
              0.5,
              0.5,
              0.5,
              1,
              1.5,
              2,
              12,
              15,
              16,
              17,
              18,
              17.5,
              18,
              17.5,
              18,
              18.5,
              18,
              17.5,
              17,
              16.5,
              16
            ]
          }
        ],
        "figure_id": "2e345e78604b9b29",
        "provenance": {
          "page": 39
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 42,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Jan-15",
              "Apr-15",
              "Jul-15",
              "Oct-15",
              "Jan-16",
              "Apr-16",
              "Jul-16",
              "Oct-16",
              "Jan-17",
              "Apr-17",
              "Jul-17",
              "Oct-17",
              "Jan-18",
              "Apr-18",
              "Jul-18",
              "Oct-18",
              "Jan-19",
              "Apr-19",
              "Jul-19",
              "Oct-19",
              "Jan-20",
              "Apr-20",
              "Jul-20",
              "Oct-20",
              "Jan-21",
              "Apr-21",
              "Jul-21",
              "Oct-21",
              "Jan-22",
              "Apr-22",
              "Jul-22",
              "Oct-22",
              "Jan-23",
              "Apr-23",
              "Jul-23",
              "Oct-23",
              "Jan-24",
              "Apr-24",
              "Jul-24",
              "Oct-24",
              "Jan-25",
              "Apr-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "$M",
            "range": {
              "min": 0,
              "max": 400
            }
          }
        },
        "series": [
          {
            "name": "Kyprolis (AMGN)",
            "unit": "$M",
            "values": [
              100,
              110,
              120,
              130,
              140,
              150,
              160,
              170,
              180,
              190,
              200,
              210,
              220,
              230,
              240,
              250,
              260,
              270,
              280,
              290,
              300,
              310,
              320,
              330,
              340,
              350,
              360,
              370,
              380,
              390,
              300,
              200,
              100,
              50,
              30,
              20,
              15,
              10,
              8,
              6,
              5,
              4,
              3
            ]
          },
          {
            "name": "Ninlaro (Takeda)",
            "unit": "$M",
            "values": [
              50,
              60,
              70,
              80,
              90,
              100,
              110,
              120,
              130,
              140,
              150,
              160,
              170,
              180,
              190,
              200,
              210,
              220,
              230,
              240,
              250,
              260,
              270,
              280,
              290,
              300,
              310,
              320,
              330,
              340,
              350,
              360,
              370,
              380,
              390,
              400,
              390,
              380,
              370,
              360,
              350,
              340,
              330
            ]
          },
          {
            "name": "Velcade (Takeda)",
            "unit": "$M",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Gx Velcade",
            "unit": "$M",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "13d81d1f6bf2943f",
        "provenance": {
          "page": 42
        }
      },
      {
        "type": "line",
        "title": "Monthly IMS sales ($M)",
        "page": 43,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Dec-15",
              "May-16",
              "Oct-16",
              "Mar-17",
              "Aug-17",
              "Jan-18",
              "Jun-18",
              "Nov-18",
              "Apr-19",
              "Sep-19",
              "Feb-20",
              "Jul-20",
              "Dec-20",
              "May-21",
              "Oct-21",
              "Mar-22",
              "Aug-22",
              "Jan-23",
              "Jun-23",
              "Nov-23",
              "Apr-24",
              "Sep-24",
              "Feb-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "$M",
            "range": {
              "min": 0,
              "max": 25
            }
          }
        },
        "series": [
          {
            "name": "Empliciti (BMY)",
            "unit": "$M",
            "values": [
              1.5,
              8.5,
              10.5,
              11.5,
              12.0,
              11.5,
              12.5,
              13.0,
              18.0,
              20.5,
              18.5,
              17.5,
              19.5,
              16.0,
              14.5,
              15.0,
              14.5,
              13.0,
              14.0,
              13.5,
              12.5,
              13.5,
              12.5,
              12.0
            ]
          }
        ],
        "figure_id": "1dd65b3cb874911c",
        "provenance": {
          "page": 43
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 44,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Apr-20",
              "Jul-20",
              "Oct-20",
              "Jan-21",
              "Apr-21",
              "Jul-21",
              "Oct-21",
              "Jan-22",
              "Apr-22",
              "Jul-22",
              "Oct-22",
              "Jan-23",
              "Apr-23",
              "Jul-23",
              "Oct-23",
              "Jan-24",
              "Apr-24",
              "Jul-24",
              "Oct-24",
              "Jan-25",
              "Apr-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "$M",
            "range": {
              "min": 0,
              "max": 80
            }
          }
        },
        "series": [
          {
            "name": "Trodelvy (GILD)",
            "unit": "$M",
            "values": [
              0,
              10,
              20,
              22,
              25,
              28,
              32,
              35,
              38,
              42,
              48,
              55,
              60,
              65,
              70,
              72,
              75,
              70,
              72,
              70,
              70,
              72
            ]
          }
        ],
        "figure_id": "e99e385bf5dd5001",
        "provenance": {
          "page": 44
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 46,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jan-15",
              "Apr-15",
              "Jul-15",
              "Oct-15",
              "Jan-16",
              "Apr-16",
              "Jul-16",
              "Oct-16",
              "Jan-17",
              "Apr-17",
              "Jul-17",
              "Oct-17",
              "Jan-18",
              "Apr-18",
              "Jul-18",
              "Oct-18",
              "Jan-19",
              "Apr-19",
              "Jul-19",
              "Oct-19",
              "Jan-20",
              "Apr-20",
              "Jul-20",
              "Oct-20",
              "Jan-21",
              "Apr-21",
              "Jul-21",
              "Oct-21",
              "Jan-22",
              "Apr-22",
              "Jul-22",
              "Oct-22",
              "Jan-23",
              "Apr-23",
              "Jul-23",
              "Oct-23",
              "Jan-24",
              "Apr-24",
              "Jul-24",
              "Oct-24",
              "Jan-25",
              "Apr-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "Monthly IMS sales ($M)",
            "range": {
              "min": 0,
              "max": 600
            }
          }
        },
        "series": [
          {
            "name": "Revlimid (BMY)",
            "unit": "$M",
            "values": [
              80,
              85,
              80,
              80,
              85,
              90,
              95,
              100,
              105,
              110,
              115,
              120,
              130,
              140,
              150,
              160,
              170,
              180,
              185,
              190,
              195,
              200,
              190,
              180,
              140,
              150,
              160,
              170,
              180,
              190,
              160,
              140,
              360,
              400,
              450,
              500,
              520,
              480,
              450,
              400,
              350,
              370,
              380,
              350,
              450,
              300
            ]
          },
          {
            "name": "Pomalyst (BMY)",
            "unit": "$M",
            "values": [
              20,
              25,
              25,
              30,
              30,
              35,
              35,
              40,
              40,
              45,
              45,
              50,
              50,
              55,
              55,
              60,
              60,
              65,
              65,
              70,
              70,
              75,
              75,
              80,
              80,
              85,
              85,
              90,
              90,
              95,
              100,
              100,
              110,
              120,
              130,
              140,
              150,
              160,
              170,
              180,
              190,
              200,
              210,
              220,
              230,
              240
            ]
          },
          {
            "name": "Gs Revlimid",
            "unit": "$M",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              30,
              40,
              50,
              60,
              70,
              80,
              90,
              100,
              120,
              140,
              160,
              180,
              200,
              210
            ]
          },
          {
            "name": "Thalomid (BMY)",
            "unit": "$M",
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null
            ]
          }
        ],
        "figure_id": "c65480b4272707f0",
        "provenance": {
          "page": 46
        }
      },
      {
        "type": "line",
        "title": "IQVIA Monthly Sales share",
        "page": 47,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jun-18",
              "Nov-18",
              "Apr-19",
              "Sep-19",
              "Feb-20",
              "Jul-20",
              "Dec-20",
              "May-21",
              "Oct-21",
              "Mar-22",
              "Aug-22",
              "Jan-23",
              "Jun-23",
              "Nov-23",
              "Apr-24",
              "Sep-24",
              "Feb-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "Neulasta (AMGN)",
            "unit": "%",
            "values": [
              100,
              95,
              85,
              78,
              75,
              73,
              70,
              67,
              65,
              64,
              63,
              62,
              60,
              62,
              45,
              42,
              48,
              35
            ]
          },
          {
            "name": "Stimufend (Fresenius Kabi)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Fulphila (BIOCON)",
            "unit": "%",
            "values": [
              0,
              2,
              5,
              8,
              10,
              12,
              13,
              14,
              15,
              16,
              17,
              18,
              19,
              20,
              25,
              35,
              25,
              28
            ]
          },
          {
            "name": "Udenyca (Accord)",
            "unit": "%",
            "values": [
              0,
              5,
              10,
              18,
              19,
              18,
              17,
              16,
              15,
              14,
              13,
              12,
              15,
              18,
              30,
              20,
              38,
              30
            ]
          },
          {
            "name": "Fylnetra (AMRX)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Ziextenzo (NVS)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Nyvepriya (PFE)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "08e18adc81cd2a61",
        "provenance": {
          "page": 47
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 48,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 60
            }
          }
        },
        "series": [
          {
            "name": "Neulasta (AMGN)",
            "unit": "%",
            "values": [
              35,
              39,
              36,
              39,
              44,
              38,
              40,
              48,
              41,
              35,
              38,
              37,
              34,
              36,
              29,
              34,
              32,
              32
            ]
          },
          {
            "name": "Udenyca (Coherus)",
            "unit": "%",
            "values": [
              10,
              9,
              7,
              5,
              3,
              1,
              2,
              1,
              3,
              5,
              6,
              7,
              8,
              9,
              11,
              9,
              13,
              9
            ]
          },
          {
            "name": "Fulphila (VTRS)",
            "unit": "%",
            "values": [
              12,
              11,
              10,
              11,
              12,
              13,
              14,
              15,
              17,
              19,
              18,
              17,
              18,
              19,
              18,
              19,
              21,
              19
            ]
          },
          {
            "name": "Ziextenzo (SDZ)",
            "unit": "%",
            "values": [
              7,
              8,
              8,
              7,
              6,
              5,
              7,
              6,
              5,
              4,
              5,
              6,
              5,
              4,
              5,
              3,
              4,
              4
            ]
          },
          {
            "name": "Nyvepria (PFE)",
            "unit": "%",
            "values": [
              38,
              36,
              34,
              37,
              35,
              39,
              33,
              30,
              31,
              34,
              30,
              32,
              31,
              33,
              38,
              34,
              35,
              37
            ]
          }
        ],
        "figure_id": "1ae752414218f2e5",
        "provenance": {
          "page": 48
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 48,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct-18",
              "Jan-19",
              "Apr-19",
              "Jul-19",
              "Oct-19",
              "Jan-20",
              "Apr-20",
              "Jul-20",
              "Oct-20",
              "Jan-21",
              "Apr-21",
              "Jul-21",
              "Oct-21",
              "Jan-22",
              "Apr-22",
              "Jul-22",
              "Oct-22",
              "Jan-23",
              "Apr-23",
              "Jul-23",
              "Oct-23",
              "Jan-24",
              "Apr-24",
              "Jul-24",
              "Oct-24",
              "Jan-25",
              "Apr-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "Avastin (ROG)",
            "unit": "%",
            "values": [
              100,
              100,
              100,
              98,
              90,
              80,
              72,
              62,
              50,
              45,
              40,
              35,
              30,
              28,
              26,
              25,
              27,
              26,
              25,
              23,
              20,
              18,
              18,
              19,
              15,
              16,
              17
            ]
          },
          {
            "name": "Mvasi (AMGN)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              2,
              10,
              20,
              30,
              40,
              45,
              43,
              42,
              40,
              41,
              40,
              42,
              40,
              42,
              43,
              42,
              40,
              40,
              45,
              55,
              50,
              48,
              45,
              43
            ]
          },
          {
            "name": "Zirabev (PFE)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              5,
              10,
              15,
              20,
              25,
              30,
              32,
              35,
              30,
              32,
              30,
              28,
              25,
              20,
              18,
              20,
              22,
              25,
              28
            ]
          },
          {
            "name": "Alymsys (AMRX)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              2,
              5,
              7,
              8,
              9,
              10,
              8,
              7,
              6,
              5
            ]
          }
        ],
        "figure_id": "b1cb74043dfe8244",
        "provenance": {
          "page": 48
        }
      },
      {
        "type": "line",
        "title": "IQVIA Monthly Sales share",
        "page": 49,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct-18",
              "Jan-19",
              "Apr-19",
              "Jul-19",
              "Oct-19",
              "Jan-20",
              "Apr-20",
              "Jul-20",
              "Oct-20",
              "Jan-21",
              "Apr-21",
              "Jul-21",
              "Oct-21",
              "Jan-22",
              "Apr-22",
              "Jul-22",
              "Oct-22",
              "Jan-23",
              "Apr-23",
              "Jul-23",
              "Oct-23",
              "Jan-24",
              "Apr-24",
              "Jul-24",
              "Oct-24",
              "Jan-25",
              "Apr-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "Rituxan (ROG)",
            "unit": "%",
            "values": [
              100,
              100,
              100,
              100,
              100,
              85,
              95,
              80,
              85,
              75,
              65,
              60,
              55,
              50,
              48,
              49,
              47,
              46,
              45,
              44,
              43,
              42,
              41,
              40,
              39,
              39,
              39,
              39
            ]
          },
          {
            "name": "Truxima (TEVA)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              15,
              5,
              10,
              15,
              20,
              22,
              25,
              28,
              40,
              20,
              22,
              20,
              23,
              25,
              26,
              25,
              24,
              25,
              26,
              27,
              27,
              28,
              28
            ]
          },
          {
            "name": "Ruxience (PFE)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              5,
              10,
              15,
              20,
              25,
              28,
              27,
              28,
              27,
              28,
              27,
              28,
              27,
              28,
              27,
              28,
              27,
              28,
              28
            ]
          },
          {
            "name": "Riabni (AMGN)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              1,
              2,
              3,
              4,
              5,
              6,
              7,
              8,
              9,
              10,
              9,
              8,
              7
            ]
          }
        ],
        "figure_id": "0d3df26c42ac4931",
        "provenance": {
          "page": 49
        }
      },
      {
        "type": "line",
        "title": "IQVIA Monthly Sales share",
        "page": 49,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jul-15",
              "Oct-15",
              "Jan-16",
              "Apr-16",
              "Jul-16",
              "Oct-16",
              "Jan-17",
              "Apr-17",
              "Jul-17",
              "Oct-17",
              "Jan-18",
              "Apr-18",
              "Jul-18",
              "Oct-18",
              "Jan-19",
              "Apr-19",
              "Jul-19",
              "Oct-19",
              "Jan-20",
              "Apr-20",
              "Jul-20",
              "Oct-20",
              "Jan-21",
              "Apr-21",
              "Jul-21",
              "Oct-21",
              "Jan-22",
              "Apr-22",
              "Jul-22",
              "Oct-22",
              "Jan-23",
              "Apr-23",
              "Jul-23",
              "Oct-23",
              "Jan-24",
              "Apr-24",
              "Jul-24",
              "Oct-24",
              "Jan-25",
              "Apr-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "Neupogen (AMGN)",
            "unit": "%",
            "values": [
              99.5,
              98,
              95,
              90,
              85,
              80,
              75,
              70,
              65,
              60,
              55,
              50,
              45,
              40,
              35,
              30,
              25,
              20,
              18,
              16,
              14,
              12,
              10,
              8,
              7,
              6,
              5,
              4,
              3,
              2,
              2,
              2,
              2,
              2,
              2,
              2,
              2,
              2,
              2,
              2,
              2
            ]
          },
          {
            "name": "Nivestym (PFE)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Releuko (AMRX)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Zarxio (NVS)",
            "unit": "%",
            "values": [
              0.5,
              2,
              5,
              10,
              15,
              20,
              25,
              30,
              35,
              40,
              45,
              50,
              55,
              60,
              65,
              70,
              75,
              80,
              82,
              84,
              86,
              88,
              90,
              92,
              93,
              94,
              95,
              96,
              97,
              98,
              98,
              98,
              98,
              98,
              98,
              98,
              98,
              98,
              98,
              98,
              98
            ]
          }
        ],
        "figure_id": "64f4bcb31426918c",
        "provenance": {
          "page": 49
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 49,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 60
            }
          }
        },
        "series": [
          {
            "name": "Zarxio (SDZ)",
            "unit": "%",
            "values": [
              23,
              21,
              22,
              20,
              23,
              24,
              20,
              27,
              23,
              18,
              20,
              22,
              19,
              16,
              20,
              17,
              19,
              21
            ]
          },
          {
            "name": "Neupogen (AMGN)",
            "unit": "%",
            "values": [
              32,
              34,
              32,
              35,
              33,
              37,
              30,
              37,
              34,
              36,
              37,
              35,
              37,
              36,
              40,
              35,
              41,
              39
            ]
          },
          {
            "name": "Nivestym (PFE)",
            "unit": "%",
            "values": [
              44,
              42,
              45,
              40,
              42,
              49,
              42,
              35,
              47,
              42,
              40,
              44,
              38,
              45,
              38,
              42,
              39,
              39
            ]
          }
        ],
        "figure_id": "a06d2a4e0779fdd5",
        "provenance": {
          "page": 49
        }
      },
      {
        "type": "line",
        "title": "IQVIA Monthly Sales share",
        "page": 50,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Apr-18",
              "Jul-18",
              "Oct-18",
              "Jan-19",
              "Apr-19",
              "Jul-19",
              "Oct-19",
              "Jan-20",
              "Apr-20",
              "Jul-20",
              "Oct-20",
              "Jan-21",
              "Apr-21",
              "Jul-21",
              "Oct-21",
              "Jan-22",
              "Apr-22",
              "Jul-22",
              "Oct-22",
              "Jan-23",
              "Apr-23",
              "Jul-23",
              "Oct-23",
              "Jan-24",
              "Apr-24",
              "Jul-24",
              "Oct-24",
              "Jan-25",
              "Apr-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "Epogen (AMGM)",
            "unit": "%",
            "values": [
              99,
              97,
              95,
              93,
              91,
              89,
              87,
              85,
              80,
              82,
              75,
              77,
              70,
              75,
              72,
              70,
              75,
              82,
              79,
              55,
              62,
              40,
              50,
              45,
              40,
              38,
              35,
              32,
              45,
              35
            ]
          },
          {
            "name": "Retacrit (PFE)",
            "unit": "%",
            "values": [
              1,
              3,
              5,
              7,
              9,
              11,
              13,
              15,
              20,
              18,
              25,
              23,
              30,
              25,
              28,
              30,
              25,
              18,
              21,
              45,
              38,
              60,
              50,
              55,
              60,
              62,
              65,
              68,
              55,
              65
            ]
          }
        ],
        "figure_id": "662679aa29172863",
        "provenance": {
          "page": 50
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 50,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "8/30/24",
              "9/20/24",
              "10/11/24",
              "11/1/24",
              "11/22/24",
              "12/13/24",
              "1/3/25",
              "1/24/25",
              "2/14/25",
              "3/7/25",
              "3/28/25",
              "4/18/25",
              "5/9/25",
              "5/30/25",
              "6/20/25",
              "7/11/25",
              "8/1/25",
              "8/22/25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 80
            }
          }
        },
        "series": [
          {
            "name": "Epogen (AMGN)",
            "unit": "%",
            "values": [
              47,
              44,
              46,
              43,
              44,
              42,
              45,
              46,
              42,
              45,
              43,
              60,
              72,
              68,
              52,
              45,
              40,
              39
            ]
          },
          {
            "name": "Retacrit (PFE)",
            "unit": "%",
            "values": [
              53,
              56,
              54,
              57,
              56,
              58,
              55,
              54,
              58,
              55,
              57,
              40,
              28,
              32,
              48,
              55,
              60,
              61
            ]
          }
        ],
        "figure_id": "e525ea42c77d9b3c",
        "provenance": {
          "page": 50
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "a7124aff48e5eb97",
        "value": 430.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "company's disclosures as available. In 2Q25, lung cancer comprised \\(\\sim 28\\%\\) (MS est.) \\((\\sim \\$ 430\\mathrm{nm})\\) of US Opdivo sales and in range of \\(25\\% - 30\\% (\\sim \\$ 1,306\\mathrm{nm}\\) bas",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5b9c483b1e10d055",
        "value": 1306.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "\\%\\) (MS est.) \\((\\sim \\$ 430\\mathrm{nm})\\) of US Opdivo sales and in range of \\(25\\% - 30\\% (\\sim \\$ 1,306\\mathrm{nm}\\) based on assumption of \\(27.5\\%\\) of US Keytruda sales. BTK Inhibitors: Abbvie'",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ef023727e7b736d2",
        "value": 55.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "bRituxan (Exhibit 104): Pfizer's Ruxience was launched on January 23, 2020 and had sales of \\(\\sim \\$ 55\\mathrm{nm}\\) and had share of \\(\\sim 26\\%\\) in July. The label lack's rheumatoid arthritis (RA)",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b9cb8e0cf51b85f0",
        "value": 68.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "een approved for RA on June 6, 2022. Avastin (Exhibit 102): In July, Amgen's Mvasi recorded \\(\\sim \\$ 68\\mathrm{nm}\\) sales \\(\\sim 47\\%\\) share). Pfizer's Zirabev was launched on December 31, 2019 and",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5908a95046442bcb",
        "value": 32.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "im 47\\%\\) share). Pfizer's Zirabev was launched on December 31, 2019 and generated sales of \\(\\sim \\$ 32\\mathrm{nm}\\) ( \\(\\sim 22\\%\\) share). Amneal's Alymsys, which was approved in April 2022, launch",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "3078f5eb52ab6763",
        "value": 19.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "( \\(\\sim 6\\%\\) share) in July. bHerceptin (Exhibit 103): In July, Amgen's Kanjinti recorded \\(\\sim \\$ 19\\mathrm{nm}\\) bHerceptin (Exhibit 103): In July, Amgen's Kanjinti recorded \\(\\sim \\$ 19\\mathrm{n",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1d1ab6a18dc7fde8",
        "value": 19.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ded \\(\\sim \\$ 19\\mathrm{nm}\\) bHerceptin (Exhibit 103): In July, Amgen's Kanjinti recorded \\(\\sim \\$ 19\\mathrm{nm}\\) # MAJOR PHARMACEUTICALS North America Industry View In- Line BIOTECHNOLOGY North Am",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ca8bef86953d3792",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "sales (\\~7% share). Biocon's Ogivri was launched on December 2, 2019 and generated sales of \\~\\$21mn (\\~8% shar",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "cf2d3a6364142198",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "s (\\~7% share). Biocon's Ogivri was launched on December 2, 2019 and generated sales of \\~\\$21mn (\\~8% share); Pfizer's Trazimera was launched on February 19, 2020 and generated sales of \\~\\$18mn (\\~6",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "169e7ecbbd547a43",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "~8% share); Pfizer's Trazimera was launched on February 19, 2020 and generated sales of \\~\\$18mn (\\~6%); Organon/Samsung Bioepis's Ontruzant was launched on April 15, 2020, and IQVIA had sales of \\~\\$",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "dde4eee7ea4513ad",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ganon/Samsung Bioepis's Ontruzant was launched on April 15, 2020, and IQVIA had sales of \\~\\$2mn (\\~1%). Other charts include bNeulasta (Exhibit 100 & Exhibit 101), bNeupogen (Exhibit 105 & Exhibit 10",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "0f1426ef94c6e9bb",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "& Exhibit 106) and bEpogen (Exhibit 107 & Exhibit 108). AstraZeneca/Merck's Lynparza sales were - 2% sequentially in July vs +6% in June and 0% in May (Exhibit 81). YoY Lynparza grew +19% in July vs +",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "82d9bde47b05ca1e",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(Exhibit 107 & Exhibit 108). AstraZeneca/Merck's Lynparza sales were - 2% sequentially in July vs +6% in June and 0% in May (Exhibit 81). YoY Lynparza grew +19% in July vs +24% in June and +19% in May",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "88435c053c110ada",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Exhibit 108). AstraZeneca/Merck's Lynparza sales were - 2% sequentially in July vs +6% in June and 0% in May (Exhibit 81). YoY Lynparza grew +19% in July vs +24% in June and +19% in May. Lynparza rece",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "7b9ba9d159aa2085",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "a sales were - 2% sequentially in July vs +6% in June and 0% in May (Exhibit 81). YoY Lynparza grew +19% in July vs +24% in June and +19% in May. Lynparza received additional approval as a first- line",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "d3676e23f4a4a96a",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "% sequentially in July vs +6% in June and 0% in May (Exhibit 81). YoY Lynparza grew +19% in July vs +24% in June and +19% in May. Lynparza received additional approval as a first- line maintenance the",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "a9912444bf094af0",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "July vs +6% in June and 0% in May (Exhibit 81). YoY Lynparza grew +19% in July vs +24% in June and +19% in May. Lynparza received additional approval as a first- line maintenance therapy in combinatio",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "92bcb055c4148792",
        "value": 21.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "sales (\\~7% share). Biocon's Ogivri was launched on December 2, 2019 and generated sales of \\~\\$21mn (\\~8% share); Pfizer's Trazimera was launched on February 19, 2020 and generated sales of \\~\\$18m",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "62e48ae3cee02029",
        "value": 18.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "\\$21mn (\\~8% share); Pfizer's Trazimera was launched on February 19, 2020 and generated sales of \\~\\$18mn (\\~6%); Organon/Samsung Bioepis's Ontruzant was launched on April 15, 2020, and IQVIA had sale",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "5789859600715ac9",
        "value": 2.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "~6%); Organon/Samsung Bioepis's Ontruzant was launched on April 15, 2020, and IQVIA had sales of \\~\\$2mn (\\~1%). Other charts include bNeulasta (Exhibit 100 & Exhibit 101), bNeupogen (Exhibit 105 & Ex",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "82207e6582b5fa0b",
        "value": -0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>IMMUNO ONCOLOGY</td><td></td><td></td><td></td></tr><tr><td>Bavencio (PFE/MRK.DE)</td><td>-40%</td><td></td><td>-36%</td></tr><tr><td>Imfinzi (AZN)</td><td>33%</td><td>44%</td><td>42%</td></",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "393def6a5bbac2d0",
        "value": -0.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "OGY</td><td></td><td></td><td></td></tr><tr><td>Bavencio (PFE/MRK.DE)</td><td>-40%</td><td></td><td>-36%</td></tr><tr><td>Imfinzi (AZN)</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>Keytruda (M",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "8add13f7eadc00b7",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Bavencio (PFE/MRK.DE)</td><td>-40%</td><td></td><td>-36%</td></tr><tr><td>Imfinzi (AZN)</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>Keytruda (MRK)</td><td>5%</td><td>10%</td><td>6%</td></",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "dcea2f31b1bf6aa9",
        "value": 0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(PFE/MRK.DE)</td><td>-40%</td><td></td><td>-36%</td></tr><tr><td>Imfinzi (AZN)</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>Keytruda (MRK)</td><td>5%</td><td>10%</td><td>6%</td></tr><tr><td>Li",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "af286020a3b51595",
        "value": 0.42,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>-40%</td><td></td><td>-36%</td></tr><tr><td>Imfinzi (AZN)</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>Keytruda (MRK)</td><td>5%</td><td>10%</td><td>6%</td></tr><tr><td>Libtayo (REGN",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "78966e9f830192c4",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>Imfinzi (AZN)</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>Keytruda (MRK)</td><td>5%</td><td>10%</td><td>6%</td></tr><tr><td>Libtayo (REGN/SNY)</td><td>-98%</td><td>-98%</td><td>-20%",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "50ab8d4e88130b48",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "mfinzi (AZN)</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>Keytruda (MRK)</td><td>5%</td><td>10%</td><td>6%</td></tr><tr><td>Libtayo (REGN/SNY)</td><td>-98%</td><td>-98%</td><td>-20%</td></tr><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2fad65006cac612c",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>Keytruda (MRK)</td><td>5%</td><td>10%</td><td>6%</td></tr><tr><td>Libtayo (REGN/SNY)</td><td>-98%</td><td>-98%</td><td>-20%</td></tr><tr><td>Opdiv",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "080fe9f752893ddb",
        "value": -0.98,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>Keytruda (MRK)</td><td>5%</td><td>10%</td><td>6%</td></tr><tr><td>Libtayo (REGN/SNY)</td><td>-98%</td><td>-98%</td><td>-20%</td></tr><tr><td>Opdivo (BMY)</td><td>8%</td><td>9%</td><td>17%</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "58336a2d24f1d95a",
        "value": -0.98,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "da (MRK)</td><td>5%</td><td>10%</td><td>6%</td></tr><tr><td>Libtayo (REGN/SNY)</td><td>-98%</td><td>-98%</td><td>-20%</td></tr><tr><td>Opdivo (BMY)</td><td>8%</td><td>9%</td><td>17%</td></tr><tr><td>O",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "b737f06648ef084c",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>5%</td><td>10%</td><td>6%</td></tr><tr><td>Libtayo (REGN/SNY)</td><td>-98%</td><td>-98%</td><td>-20%</td></tr><tr><td>Opdivo (BMY)</td><td>8%</td><td>9%</td><td>17%</td></tr><tr><td>Opdualag (BMY)",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "de4665cf97ff7cde",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Libtayo (REGN/SNY)</td><td>-98%</td><td>-98%</td><td>-20%</td></tr><tr><td>Opdivo (BMY)</td><td>8%</td><td>9%</td><td>17%</td></tr><tr><td>Opdualag (BMY)</td><td>9%</td><td>20%</td><td>17%</td></t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "08b42494304ba17b",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(REGN/SNY)</td><td>-98%</td><td>-98%</td><td>-20%</td></tr><tr><td>Opdivo (BMY)</td><td>8%</td><td>9%</td><td>17%</td></tr><tr><td>Opdualag (BMY)</td><td>9%</td><td>20%</td><td>17%</td></tr><tr><td>Te",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "fc226f24fe18c1b7",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-98%</td><td>-98%</td><td>-20%</td></tr><tr><td>Opdivo (BMY)</td><td>8%</td><td>9%</td><td>17%</td></tr><tr><td>Opdualag (BMY)</td><td>9%</td><td>20%</td><td>17%</td></tr><tr><td>Tecentriq (R",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "3ac60e7cfb9db7c9",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>Opdivo (BMY)</td><td>8%</td><td>9%</td><td>17%</td></tr><tr><td>Opdualag (BMY)</td><td>9%</td><td>20%</td><td>17%</td></tr><tr><td>Tecentriq (ROG)</td><td>-12%</td><td>-2%</td><td>-7%</td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e361a6b43e269058",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>Opdivo (BMY)</td><td>8%</td><td>9%</td><td>17%</td></tr><tr><td>Opdualag (BMY)</td><td>9%</td><td>20%</td><td>17%</td></tr><tr><td>Tecentriq (ROG)</td><td>-12%</td><td>-2%</td><td>-7%</td></tr><tr><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "22c33a5326653c06",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Y)</td><td>8%</td><td>9%</td><td>17%</td></tr><tr><td>Opdualag (BMY)</td><td>9%</td><td>20%</td><td>17%</td></tr><tr><td>Tecentriq (ROG)</td><td>-12%</td><td>-2%</td><td>-7%</td></tr><tr><td>Yervoy (B",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a9ba71b8131bb694",
        "value": -0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Opdualag (BMY)</td><td>9%</td><td>20%</td><td>17%</td></tr><tr><td>Tecentriq (ROG)</td><td>-12%</td><td>-2%</td><td>-7%</td></tr><tr><td>Yervoy (BMY)</td><td>7%</td><td>22%</td><td>13%</td></",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c9c777730ec0c239",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "alag (BMY)</td><td>9%</td><td>20%</td><td>17%</td></tr><tr><td>Tecentriq (ROG)</td><td>-12%</td><td>-2%</td><td>-7%</td></tr><tr><td>Yervoy (BMY)</td><td>7%</td><td>22%</td><td>13%</td></tr><tr><td>Pe",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "1f27b75a9d339c40",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>9%</td><td>20%</td><td>17%</td></tr><tr><td>Tecentriq (ROG)</td><td>-12%</td><td>-2%</td><td>-7%</td></tr><tr><td>Yervoy (BMY)</td><td>7%</td><td>22%</td><td>13%</td></tr><tr><td>Pedgev (PFE)</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "8ded59cc4cb0323c",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Tecentriq (ROG)</td><td>-12%</td><td>-2%</td><td>-7%</td></tr><tr><td>Yervoy (BMY)</td><td>7%</td><td>22%</td><td>13%</td></tr><tr><td>Pedgev (PFE)</td><td>16675%</td><td>22884%</td><td>20940",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a1ef7fd71d8e3bf7",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "centriq (ROG)</td><td>-12%</td><td>-2%</td><td>-7%</td></tr><tr><td>Yervoy (BMY)</td><td>7%</td><td>22%</td><td>13%</td></tr><tr><td>Pedgev (PFE)</td><td>16675%</td><td>22884%</td><td>20940%</td></tr>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "7da182ed00f6db49",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>-12%</td><td>-2%</td><td>-7%</td></tr><tr><td>Yervoy (BMY)</td><td>7%</td><td>22%</td><td>13%</td></tr><tr><td>Pedgev (PFE)</td><td>16675%</td><td>22884%</td><td>20940%</td></tr><tr><td>ANDR",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d87d304479b4caac",
        "value": 166.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Yervoy (BMY)</td><td>7%</td><td>22%</td><td>13%</td></tr><tr><td>Pedgev (PFE)</td><td>16675%</td><td>22884%</td><td>20940%</td></tr><tr><td>ANDROGEN + GNRH</td><td></td><td></td><td></td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "6221108a83d52d1b",
        "value": 228.84,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ervoy (BMY)</td><td>7%</td><td>22%</td><td>13%</td></tr><tr><td>Pedgev (PFE)</td><td>16675%</td><td>22884%</td><td>20940%</td></tr><tr><td>ANDROGEN + GNRH</td><td></td><td></td><td></td></tr><tr><td>I",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "68735e7f94a65aee",
        "value": 209.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>7%</td><td>22%</td><td>13%</td></tr><tr><td>Pedgev (PFE)</td><td>16675%</td><td>22884%</td><td>20940%</td></tr><tr><td>ANDROGEN + GNRH</td><td></td><td></td><td></td></tr><tr><td>INHIBITORS</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c0c309c583dde1b8",
        "value": 0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td></tr><tr><td>INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Erleada (JNJ)</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>Nubeqa (BAYN)</td><td>88%</td><td>102%</td><td>96%</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e18e2c870da703e9",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Erleada (JNJ)</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>Nubeqa (BAYN)</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "18b9321777a3daf8",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "NHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Erleada (JNJ)</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>Nubeqa (BAYN)</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>Orgovyx (MY",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "024338bc449e66aa",
        "value": 0.88,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Erleada (JNJ)</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>Nubeqa (BAYN)</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>Orgovyx (MYOV)</td><td>115%</td><td>126%</td><td>104%<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "7871e32515a3cec3",
        "value": 1.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rleada (JNJ)</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>Nubeqa (BAYN)</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>Orgovyx (MYOV)</td><td>115%</td><td>126%</td><td>104%</td></tr><tr",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "8548e47ec5e7413b",
        "value": 0.96,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>Nubeqa (BAYN)</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>Orgovyx (MYOV)</td><td>115%</td><td>126%</td><td>104%</td></tr><tr><td>Xtandi (",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "9fa18e1443043b52",
        "value": 1.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Nubeqa (BAYN)</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>Orgovyx (MYOV)</td><td>115%</td><td>126%</td><td>104%</td></tr><tr><td>Xtandi (PFE)</td><td>50%</td><td>48%</td><td>37%</td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "9727c939d98e05e7",
        "value": 1.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "qa (BAYN)</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>Orgovyx (MYOV)</td><td>115%</td><td>126%</td><td>104%</td></tr><tr><td>Xtandi (PFE)</td><td>50%</td><td>48%</td><td>37%</td></tr><tr><td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "6d60f51e28efeaa0",
        "value": 1.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>Orgovyx (MYOV)</td><td>115%</td><td>126%</td><td>104%</td></tr><tr><td>Xtandi (PFE)</td><td>50%</td><td>48%</td><td>37%</td></tr><tr><td>Zytiga (JNJ)",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4a23886f7fe4edb2",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>Orgovyx (MYOV)</td><td>115%</td><td>126%</td><td>104%</td></tr><tr><td>Xtandi (PFE)</td><td>50%</td><td>48%</td><td>37%</td></tr><tr><td>Zytiga (JNJ)</td><td>-19%</td><td>-44%</td><td>-37%</td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "0688e9606c7a61c7",
        "value": 0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "vyx (MYOV)</td><td>115%</td><td>126%</td><td>104%</td></tr><tr><td>Xtandi (PFE)</td><td>50%</td><td>48%</td><td>37%</td></tr><tr><td>Zytiga (JNJ)</td><td>-19%</td><td>-44%</td><td>-37%</td></tr><tr><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "aeccd44fdd99de27",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>115%</td><td>126%</td><td>104%</td></tr><tr><td>Xtandi (PFE)</td><td>50%</td><td>48%</td><td>37%</td></tr><tr><td>Zytiga (JNJ)</td><td>-19%</td><td>-44%</td><td>-37%</td></tr><tr><td>ALK/ROS1 I",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c4f7e778619ba298",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>Xtandi (PFE)</td><td>50%</td><td>48%</td><td>37%</td></tr><tr><td>Zytiga (JNJ)</td><td>-19%</td><td>-44%</td><td>-37%</td></tr><tr><td>ALK/ROS1 INHIBITORS</td><td></td><td></td><td></td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "6f6665832b9dc966",
        "value": -0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Xtandi (PFE)</td><td>50%</td><td>48%</td><td>37%</td></tr><tr><td>Zytiga (JNJ)</td><td>-19%</td><td>-44%</td><td>-37%</td></tr><tr><td>ALK/ROS1 INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>A",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a63b6311e58ea53f",
        "value": -0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>50%</td><td>48%</td><td>37%</td></tr><tr><td>Zytiga (JNJ)</td><td>-19%</td><td>-44%</td><td>-37%</td></tr><tr><td>ALK/ROS1 INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Alecensa (ROG)",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a51913090e9d1236",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>ALK/ROS1 INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Alecensa (ROG)</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>Alunbrig (Takeda)</td><td>40%</td><td>54%</td><td>23%</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "330d2b7e3db18786",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">ALK/ROS1 INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Alecensa (ROG)</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>Alunbrig (Takeda)</td><td>40%</td><td>54%</td><td>23%</td></tr><tr>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "40d09024f1f5eeec",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "HIBITORS</td><td></td><td></td><td></td></tr><tr><td>Alecensa (ROG)</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>Alunbrig (Takeda)</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>Lorbrena",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "8aaf3e7e617e24c7",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>Alecensa (ROG)</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>Alunbrig (Takeda)</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>Lorbrena (PFE)</td><td>54%</td><td>71%</td><td>66%</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "bd5d0f6034146a93",
        "value": 0.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "sa (ROG)</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>Alunbrig (Takeda)</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>Lorbrena (PFE)</td><td>54%</td><td>71%</td><td>66%</td></tr><tr><td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "dece59fe730ff0db",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>Alunbrig (Takeda)</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>Lorbrena (PFE)</td><td>54%</td><td>71%</td><td>66%</td></tr><tr><td>Rozlytrek (",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "0d312a404a9a2749",
        "value": 0.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>Alunbrig (Takeda)</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>Lorbrena (PFE)</td><td>54%</td><td>71%</td><td>66%</td></tr><tr><td>Rozlytrek (ROG)</td><td>-1%</td><td>16%</td><td>18%</td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "848eb8e498db7547",
        "value": 0.71,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ig (Takeda)</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>Lorbrena (PFE)</td><td>54%</td><td>71%</td><td>66%</td></tr><tr><td>Rozlytrek (ROG)</td><td>-1%</td><td>16%</td><td>18%</td></tr><tr><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "347624d40ce20281",
        "value": 0.66,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>Lorbrena (PFE)</td><td>54%</td><td>71%</td><td>66%</td></tr><tr><td>Rozlytrek (ROG)</td><td>-1%</td><td>16%</td><td>18%</td></tr><tr><td>Xalkori (P",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "94923f9835752931",
        "value": -0.99,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Morgan Stanley | RESEARCH UPDATE <table><tr><td>Elahere (Abbvie)</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>HER2</td><td></td><td></td><td></td></tr><tr><td>Enhertu",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "0d7704e1efe242d9",
        "value": -0.97,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Morgan Stanley | RESEARCH UPDATE <table><tr><td>Elahere (Abbvie)</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>HER2</td><td></td><td></td><td></td></tr><tr><td>Enhertu (Daiichi)</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9cfda6c1390da4a9",
        "value": -0.98,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "organ Stanley | RESEARCH UPDATE <table><tr><td>Elahere (Abbvie)</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>HER2</td><td></td><td></td><td></td></tr><tr><td>Enhertu (Daiichi)</td><td>26%</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a615eb4ed6d1607a",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-98%</td></tr><tr><td>HER2</td><td></td><td></td><td></td></tr><tr><td>Enhertu (Daiichi)</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>KINASE INHIBITORS</td><td></td><td></td><td></td></tr><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ff4cef3ba8afedaf",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>HER2</td><td></td><td></td><td></td></tr><tr><td>Enhertu (Daiichi)</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>KINASE INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Augty",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c6eb4235d37b2e3e",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">HER2</td><td></td><td></td><td></td></tr><tr><td>Enhertu (Daiichi)</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>KINASE INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Augtyro (BMY)</td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "0b0caed3494bb3b0",
        "value": 2.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>KINASE INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Augtyro (BMY)</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>Balversa (JNJ)</td><td>8%</td><td>41%</td><td>55%</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "61f1e3a75c5910bf",
        "value": 1.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>KINASE INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Augtyro (BMY)</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>Balversa (JNJ)</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "5bef7008b7ae49ba",
        "value": 1.79,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "IBITORS</td><td></td><td></td><td></td></tr><tr><td>Augtyro (BMY)</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>Balversa (JNJ)</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>Cabometyx (",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "2f23b73a35caa60c",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>Augtyro (BMY)</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>Balversa (JNJ)</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>Cabometyx (EXEL)</td><td>19%</td><td>25%</td><td>24%</td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b33611536a2be9a9",
        "value": 0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "yro (BMY)</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>Balversa (JNJ)</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>Cabometyx (EXEL)</td><td>19%</td><td>25%</td><td>24%</td></tr><tr><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ce40af74b921a3dd",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>Balversa (JNJ)</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>Cabometyx (EXEL)</td><td>19%</td><td>25%</td><td>24%</td></tr><tr><td>Inlyta (P",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b45f0fd21ac8ba44",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>Balversa (JNJ)</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>Cabometyx (EXEL)</td><td>19%</td><td>25%</td><td>24%</td></tr><tr><td>Inlyta (PFE)</td><td>-3%</td><td>3%</td><td>6%</td></tr",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9fda2081b543c568",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ersa (JNJ)</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>Cabometyx (EXEL)</td><td>19%</td><td>25%</td><td>24%</td></tr><tr><td>Inlyta (PFE)</td><td>-3%</td><td>3%</td><td>6%</td></tr><tr><td>Sut",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d58b153da0582e5b",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>Cabometyx (EXEL)</td><td>19%</td><td>25%</td><td>24%</td></tr><tr><td>Inlyta (PFE)</td><td>-3%</td><td>3%</td><td>6%</td></tr><tr><td>Sutent (PFE)</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c6c5cf831455da08",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Cabometyx (EXEL)</td><td>19%</td><td>25%</td><td>24%</td></tr><tr><td>Inlyta (PFE)</td><td>-3%</td><td>3%</td><td>6%</td></tr><tr><td>Sutent (PFE)</td><td>21%</td><td>-13%</td><td>-26%</td></",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "7f6c24fcc087e464",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ometyx (EXEL)</td><td>19%</td><td>25%</td><td>24%</td></tr><tr><td>Inlyta (PFE)</td><td>-3%</td><td>3%</td><td>6%</td></tr><tr><td>Sutent (PFE)</td><td>21%</td><td>-13%</td><td>-26%</td></tr><tr><td>N",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "84b6df37155dca43",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "L)</td><td>19%</td><td>25%</td><td>24%</td></tr><tr><td>Inlyta (PFE)</td><td>-3%</td><td>3%</td><td>6%</td></tr><tr><td>Sutent (PFE)</td><td>21%</td><td>-13%</td><td>-26%</td></tr><tr><td>Nexavar (BAY",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f0e02c9d35503584",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Inlyta (PFE)</td><td>-3%</td><td>3%</td><td>6%</td></tr><tr><td>Sutent (PFE)</td><td>21%</td><td>-13%</td><td>-26%</td></tr><tr><td>Nexavar (BAYN)</td><td>-44%</td><td>-64%</td><td>-60%",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "345758adf232684f",
        "value": -0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Inlyta (PFE)</td><td>-3%</td><td>3%</td><td>6%</td></tr><tr><td>Sutent (PFE)</td><td>21%</td><td>-13%</td><td>-26%</td></tr><tr><td>Nexavar (BAYN)</td><td>-44%</td><td>-64%</td><td>-60%</td></tr><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "18520bff5ca94311",
        "value": -0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "E)</td><td>-3%</td><td>3%</td><td>6%</td></tr><tr><td>Sutent (PFE)</td><td>21%</td><td>-13%</td><td>-26%</td></tr><tr><td>Nexavar (BAYN)</td><td>-44%</td><td>-64%</td><td>-60%</td></tr><tr><td>Retevmo",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e80c1c9b661bcae0",
        "value": -0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Sutent (PFE)</td><td>21%</td><td>-13%</td><td>-26%</td></tr><tr><td>Nexavar (BAYN)</td><td>-44%</td><td>-64%</td><td>-60%</td></tr><tr><td>Retevmo (LLY)</td><td>34%</td><td>35%</td><td>32%</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "33a7bfbebc7c2058",
        "value": -0.64,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nt (PFE)</td><td>21%</td><td>-13%</td><td>-26%</td></tr><tr><td>Nexavar (BAYN)</td><td>-44%</td><td>-64%</td><td>-60%</td></tr><tr><td>Retevmo (LLY)</td><td>34%</td><td>35%</td><td>32%</td></tr><tr><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fe8cbb3a05d71f14",
        "value": -0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>21%</td><td>-13%</td><td>-26%</td></tr><tr><td>Nexavar (BAYN)</td><td>-44%</td><td>-64%</td><td>-60%</td></tr><tr><td>Retevmo (LLY)</td><td>34%</td><td>35%</td><td>32%</td></tr><tr><td>Lenvima (Ei",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "6a406f6265d6d145",
        "value": 0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>Nexavar (BAYN)</td><td>-44%</td><td>-64%</td><td>-60%</td></tr><tr><td>Retevmo (LLY)</td><td>34%</td><td>35%</td><td>32%</td></tr><tr><td>Lenvima (Eisai)</td><td>16%</td><td>22%</td><td>17%</td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "aa2673286bb030db",
        "value": 0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ar (BAYN)</td><td>-44%</td><td>-64%</td><td>-60%</td></tr><tr><td>Retevmo (LLY)</td><td>34%</td><td>35%</td><td>32%</td></tr><tr><td>Lenvima (Eisai)</td><td>16%</td><td>22%</td><td>17%</td></tr><tr><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "1ef57b95ad87abaf",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>-44%</td><td>-64%</td><td>-60%</td></tr><tr><td>Retevmo (LLY)</td><td>34%</td><td>35%</td><td>32%</td></tr><tr><td>Lenvima (Eisai)</td><td>16%</td><td>22%</td><td>17%</td></tr><tr><td>Vitrakvi (",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "afc8817c4ab648a1",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Retevmo (LLY)</td><td>34%</td><td>35%</td><td>32%</td></tr><tr><td>Lenvima (Eisai)</td><td>16%</td><td>22%</td><td>17%</td></tr><tr><td>Vitrakvi (BAYN)</td><td>27%</td><td>17%</td><td>25%</td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9f7964e9f1f7adae",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "evmo (LLY)</td><td>34%</td><td>35%</td><td>32%</td></tr><tr><td>Lenvima (Eisai)</td><td>16%</td><td>22%</td><td>17%</td></tr><tr><td>Vitrakvi (BAYN)</td><td>27%</td><td>17%</td><td>25%</td></tr><tr><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b96a4ce53496f3e4",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>34%</td><td>35%</td><td>32%</td></tr><tr><td>Lenvima (Eisai)</td><td>16%</td><td>22%</td><td>17%</td></tr><tr><td>Vitrakvi (BAYN)</td><td>27%</td><td>17%</td><td>25%</td></tr><tr><td>Inrebi (BM",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "0a9372b5a70ed763",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>Lenvima (Eisai)</td><td>16%</td><td>22%</td><td>17%</td></tr><tr><td>Vitrakvi (BAYN)</td><td>27%</td><td>17%</td><td>25%</td></tr><tr><td>Inrebi (BMY)</td><td>14%</td><td>18%</td><td>-1%</td></",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "5cc093a17e5bdbc0",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ma (Eisai)</td><td>16%</td><td>22%</td><td>17%</td></tr><tr><td>Vitrakvi (BAYN)</td><td>27%</td><td>17%</td><td>25%</td></tr><tr><td>Inrebi (BMY)</td><td>14%</td><td>18%</td><td>-1%</td></tr><tr><td>G",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "708429871bf27ec3",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>16%</td><td>22%</td><td>17%</td></tr><tr><td>Vitrakvi (BAYN)</td><td>27%</td><td>17%</td><td>25%</td></tr><tr><td>Inrebi (BMY)</td><td>14%</td><td>18%</td><td>-1%</td></tr><tr><td>Gavreto (BPMC",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3ca5614351ecd4c6",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>Vitrakvi (BAYN)</td><td>27%</td><td>17%</td><td>25%</td></tr><tr><td>Inrebi (BMY)</td><td>14%</td><td>18%</td><td>-1%</td></tr><tr><td>Gavreto (BPMC)</td><td>26%</td><td>35%</td><td>16%</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "bc086d5e494e1823",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "trakvi (BAYN)</td><td>27%</td><td>17%</td><td>25%</td></tr><tr><td>Inrebi (BMY)</td><td>14%</td><td>18%</td><td>-1%</td></tr><tr><td>Gavreto (BPMC)</td><td>26%</td><td>35%</td><td>16%</td></tr><tr><td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fe7377c29aee207a",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>27%</td><td>17%</td><td>25%</td></tr><tr><td>Inrebi (BMY)</td><td>14%</td><td>18%</td><td>-1%</td></tr><tr><td>Gavreto (BPMC)</td><td>26%</td><td>35%</td><td>16%</td></tr><tr><td>KRAS</td><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "2eaa44a1d01372d5",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Inrebi (BMY)</td><td>14%</td><td>18%</td><td>-1%</td></tr><tr><td>Gavreto (BPMC)</td><td>26%</td><td>35%</td><td>16%</td></tr><tr><td>KRAS</td><td></td><td></td><td></td></tr><tr><td>Krazat",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "dac6879e88db670b",
        "value": 0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nrebi (BMY)</td><td>14%</td><td>18%</td><td>-1%</td></tr><tr><td>Gavreto (BPMC)</td><td>26%</td><td>35%</td><td>16%</td></tr><tr><td>KRAS</td><td></td><td></td><td></td></tr><tr><td>Krazati (Mirati)</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ea2af2ecd2c43095",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>14%</td><td>18%</td><td>-1%</td></tr><tr><td>Gavreto (BPMC)</td><td>26%</td><td>35%</td><td>16%</td></tr><tr><td>KRAS</td><td></td><td></td><td></td></tr><tr><td>Krazati (Mirati)</td><td>3968%",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "07b0d64c4541244e",
        "value": 39.68,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>16%</td></tr><tr><td>KRAS</td><td></td><td></td><td></td></tr><tr><td>Krazati (Mirati)</td><td>3968%</td><td>1367%</td><td>1013%</td></tr><tr><td>Lumakras (Amgen)</td><td>15%</td><td>27%</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "307a1eff5548fe9d",
        "value": 13.67,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>KRAS</td><td></td><td></td><td></td></tr><tr><td>Krazati (Mirati)</td><td>3968%</td><td>1367%</td><td>1013%</td></tr><tr><td>Lumakras (Amgen)</td><td>15%</td><td>27%</td><td>15%</td></tr><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "004637c326a683e3",
        "value": 10.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "AS</td><td></td><td></td><td></td></tr><tr><td>Krazati (Mirati)</td><td>3968%</td><td>1367%</td><td>1013%</td></tr><tr><td>Lumakras (Amgen)</td><td>15%</td><td>27%</td><td>15%</td></tr><tr><td>PARP IN",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3bafa3a9df585028",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "razati (Mirati)</td><td>3968%</td><td>1367%</td><td>1013%</td></tr><tr><td>Lumakras (Amgen)</td><td>15%</td><td>27%</td><td>15%</td></tr><tr><td>PARP INHIBITORS</td><td></td><td></td><td></td></tr><tr",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a295a998e68ef5ea",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ti)</td><td>3968%</td><td>1367%</td><td>1013%</td></tr><tr><td>Lumakras (Amgen)</td><td>15%</td><td>27%</td><td>15%</td></tr><tr><td>PARP INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Lynparz",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "62340c22a9713da3",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3968%</td><td>1367%</td><td>1013%</td></tr><tr><td>Lumakras (Amgen)</td><td>15%</td><td>27%</td><td>15%</td></tr><tr><td>PARP INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Lynparza (AZN)</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "34753464aa25f232",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td>PARP INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Lynparza (AZN)</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>Rubraca (CLVS)</td><td>-24%</td><td>-17%</td><td>-20%</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "474c9cdd8e737128",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>PARP INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Lynparza (AZN)</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>Rubraca (CLVS)</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b33397ec280205a2",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "HIBITORS</td><td></td><td></td><td></td></tr><tr><td>Lynparza (AZN)</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>Rubraca (CLVS)</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>Talzenna",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "51839b6b2fae2deb",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Lynparza (AZN)</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>Rubraca (CLVS)</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>Talzenna (PFE)</td><td>98%</td><td>88%</td><td>64%</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "37a482ed922991c4",
        "value": -0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "arza (AZN)</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>Rubraca (CLVS)</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>Talzenna (PFE)</td><td>98%</td><td>88%</td><td>64%</td></tr><tr><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "64d5dd76520ea693",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<table><tr><td>Tecentriq (ROG)</td><td>3%</td><td>18%</td><td>-19%</td></tr><tr><td>Yervoy (BMY)</td><td>1%</td><td>4%</td><td>-1%</td></tr><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "e21c43b748a12d28",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<table><tr><td>Tecentriq (ROG)</td><td>3%</td><td>18%</td><td>-19%</td></tr><tr><td>Yervoy (BMY)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Pedge",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "5fea0017ff3559e3",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<table><tr><td>Tecentriq (ROG)</td><td>3%</td><td>18%</td><td>-19%</td></tr><tr><td>Yervoy (BMY)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Pedgev (PFE)</td><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "3890a30fe8d86fe5",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e><tr><td>Tecentriq (ROG)</td><td>3%</td><td>18%</td><td>-19%</td></tr><tr><td>Yervoy (BMY)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Pedgev (PFE)</td><td>-4%</td><td>1%</td><td>-8%</td></tr>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "61812d74c936ebdc",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ecentriq (ROG)</td><td>3%</td><td>18%</td><td>-19%</td></tr><tr><td>Yervoy (BMY)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Pedgev (PFE)</td><td>-4%</td><td>1%</td><td>-8%</td></tr><tr><td col",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "e093bf15f66873b5",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "OG)</td><td>3%</td><td>18%</td><td>-19%</td></tr><tr><td>Yervoy (BMY)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Pedgev (PFE)</td><td>-4%</td><td>1%</td><td>-8%</td></tr><tr><td colspan=\"4\">AN",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "d0aa3d1d294d07cd",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Yervoy (BMY)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Pedgev (PFE)</td><td>-4%</td><td>1%</td><td>-8%</td></tr><tr><td colspan=\"4\">ANDROGEN + GNRH</td></tr><tr><td colspan=\"4\"",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "8adae53a37740ca2",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Yervoy (BMY)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Pedgev (PFE)</td><td>-4%</td><td>1%</td><td>-8%</td></tr><tr><td colspan=\"4\">ANDROGEN + GNRH</td></tr><tr><td colspan=\"4\">INHIBITORS<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b44c1b9d7fb996b2",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "BMY)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Pedgev (PFE)</td><td>-4%</td><td>1%</td><td>-8%</td></tr><tr><td colspan=\"4\">ANDROGEN + GNRH</td></tr><tr><td colspan=\"4\">INHIBITORS</td></tr><t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "dc675d9032547ee6",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "=\"4\">ANDROGEN + GNRH</td></tr><tr><td colspan=\"4\">INHIBITORS</td></tr><tr><td>Erleada (JNJ)</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>Nubeqa (BAYN)</td><td>7%</td><td>8%</td><td>3%</td></tr><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "535bfe935d6223a5",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "EN + GNRH</td></tr><tr><td colspan=\"4\">INHIBITORS</td></tr><tr><td>Erleada (JNJ)</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>Nubeqa (BAYN)</td><td>7%</td><td>8%</td><td>3%</td></tr><tr><td>Orgo",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b6c9b5d4794745f8",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td colspan=\"4\">INHIBITORS</td></tr><tr><td>Erleada (JNJ)</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>Nubeqa (BAYN)</td><td>7%</td><td>8%</td><td>3%</td></tr><tr><td>Orgovyx (MYOV)<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "da9fd2d155e1054e",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>Erleada (JNJ)</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>Nubeqa (BAYN)</td><td>7%</td><td>8%</td><td>3%</td></tr><tr><td>Orgovyx (MYOV)</td><td>4%</td><td>10%</td><td>-1%</td></tr",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "358d08f6b7b1aaf3",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>Erleada (JNJ)</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>Nubeqa (BAYN)</td><td>7%</td><td>8%</td><td>3%</td></tr><tr><td>Orgovyx (MYOV)</td><td>4%</td><td>10%</td><td>-1%</td></tr><tr><td>Xt",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "7a9e45ef319293ee",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "JNJ)</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>Nubeqa (BAYN)</td><td>7%</td><td>8%</td><td>3%</td></tr><tr><td>Orgovyx (MYOV)</td><td>4%</td><td>10%</td><td>-1%</td></tr><tr><td>Xtandi (PFE)<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c9820ef3df66309c",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>Nubeqa (BAYN)</td><td>7%</td><td>8%</td><td>3%</td></tr><tr><td>Orgovyx (MYOV)</td><td>4%</td><td>10%</td><td>-1%</td></tr><tr><td>Xtandi (PFE)</td><td>0%</td><td>4%</td><td>-4%</td></tr>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "3f9516e52ab872ac",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>Nubeqa (BAYN)</td><td>7%</td><td>8%</td><td>3%</td></tr><tr><td>Orgovyx (MYOV)</td><td>4%</td><td>10%</td><td>-1%</td></tr><tr><td>Xtandi (PFE)</td><td>0%</td><td>4%</td><td>-4%</td></tr><tr><td>Zyt",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "4a494e52996133e1",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "YN)</td><td>7%</td><td>8%</td><td>3%</td></tr><tr><td>Orgovyx (MYOV)</td><td>4%</td><td>10%</td><td>-1%</td></tr><tr><td>Xtandi (PFE)</td><td>0%</td><td>4%</td><td>-4%</td></tr><tr><td>Zytiga (JNJ)</t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "0ec711d4b5933e59",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>Orgovyx (MYOV)</td><td>4%</td><td>10%</td><td>-1%</td></tr><tr><td>Xtandi (PFE)</td><td>0%</td><td>4%</td><td>-4%</td></tr><tr><td>Zytiga (JNJ)</td><td>-4%</td><td>-29%</td><td>-1%</td></t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c1b7c370998f7be8",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Orgovyx (MYOV)</td><td>4%</td><td>10%</td><td>-1%</td></tr><tr><td>Xtandi (PFE)</td><td>0%</td><td>4%</td><td>-4%</td></tr><tr><td>Zytiga (JNJ)</td><td>-4%</td><td>-29%</td><td>-1%</td></tr><tr><td c",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "857901f7cd31b22a",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "YOV)</td><td>4%</td><td>10%</td><td>-1%</td></tr><tr><td>Xtandi (PFE)</td><td>0%</td><td>4%</td><td>-4%</td></tr><tr><td>Zytiga (JNJ)</td><td>-4%</td><td>-29%</td><td>-1%</td></tr><tr><td colspan=\"4\">",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "5650440416026d6f",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Xtandi (PFE)</td><td>0%</td><td>4%</td><td>-4%</td></tr><tr><td>Zytiga (JNJ)</td><td>-4%</td><td>-29%</td><td>-1%</td></tr><tr><td colspan=\"4\">ALK/ROS1 INHIBITORS</td></tr><tr><td>Alece",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "20240b0c77c39278",
        "value": -0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Xtandi (PFE)</td><td>0%</td><td>4%</td><td>-4%</td></tr><tr><td>Zytiga (JNJ)</td><td>-4%</td><td>-29%</td><td>-1%</td></tr><tr><td colspan=\"4\">ALK/ROS1 INHIBITORS</td></tr><tr><td>Alecensa (ROG)</t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "61485c6c35dc36eb",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "E)</td><td>0%</td><td>4%</td><td>-4%</td></tr><tr><td>Zytiga (JNJ)</td><td>-4%</td><td>-29%</td><td>-1%</td></tr><tr><td colspan=\"4\">ALK/ROS1 INHIBITORS</td></tr><tr><td>Alecensa (ROG)</td><td>-1%</td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "7c56b84269d73b2e",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-1%</td></tr><tr><td colspan=\"4\">ALK/ROS1 INHIBITORS</td></tr><tr><td>Alecensa (ROG)</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>Alunbrig (Takeda)</td><td>-5%</td><td>10%</td><td>-14%</t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "8d59f09bee6969d4",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td colspan=\"4\">ALK/ROS1 INHIBITORS</td></tr><tr><td>Alecensa (ROG)</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>Alunbrig (Takeda)</td><td>-5%</td><td>10%</td><td>-14%</td></tr><tr><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "f09ba967335932e3",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td colspan=\"4\">ALK/ROS1 INHIBITORS</td></tr><tr><td>Alecensa (ROG)</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>Alunbrig (Takeda)</td><td>-5%</td><td>10%</td><td>-14%</td></tr><tr><td>Lorbrena",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "972b1a0df558365b",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>Alecensa (ROG)</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>Alunbrig (Takeda)</td><td>-5%</td><td>10%</td><td>-14%</td></tr><tr><td>Lorbrena (PFE)</td><td>4%</td><td>5%</td><td>4%</td></",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "44df586557a470c2",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ensa (ROG)</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>Alunbrig (Takeda)</td><td>-5%</td><td>10%</td><td>-14%</td></tr><tr><td>Lorbrena (PFE)</td><td>4%</td><td>5%</td><td>4%</td></tr><tr><td>R",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "42b8240add4f4798",
        "value": -0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>Alunbrig (Takeda)</td><td>-5%</td><td>10%</td><td>-14%</td></tr><tr><td>Lorbrena (PFE)</td><td>4%</td><td>5%</td><td>4%</td></tr><tr><td>Rozlytrek (RO",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ddc386f07e9609e4",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>Alunbrig (Takeda)</td><td>-5%</td><td>10%</td><td>-14%</td></tr><tr><td>Lorbrena (PFE)</td><td>4%</td><td>5%</td><td>4%</td></tr><tr><td>Rozlytrek (ROG)</td><td>-6%</td><td>3%</td><td>12%</td></t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "7a004d97eeab53a8",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ig (Takeda)</td><td>-5%</td><td>10%</td><td>-14%</td></tr><tr><td>Lorbrena (PFE)</td><td>4%</td><td>5%</td><td>4%</td></tr><tr><td>Rozlytrek (ROG)</td><td>-6%</td><td>3%</td><td>12%</td></tr><tr><td>X",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "25735c451b81300f",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-5%</td><td>10%</td><td>-14%</td></tr><tr><td>Lorbrena (PFE)</td><td>4%</td><td>5%</td><td>4%</td></tr><tr><td>Rozlytrek (ROG)</td><td>-6%</td><td>3%</td><td>12%</td></tr><tr><td>Xalkori (PFE",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "6eaf57202bd54049",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Lorbrena (PFE)</td><td>4%</td><td>5%</td><td>4%</td></tr><tr><td>Rozlytrek (ROG)</td><td>-6%</td><td>3%</td><td>12%</td></tr><tr><td>Xalkori (PFE)</td><td>-4%</td><td>5%</td><td>-1%</td></t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "47839ad96f1db703",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "orbrena (PFE)</td><td>4%</td><td>5%</td><td>4%</td></tr><tr><td>Rozlytrek (ROG)</td><td>-6%</td><td>3%</td><td>12%</td></tr><tr><td>Xalkori (PFE)</td><td>-4%</td><td>5%</td><td>-1%</td></tr><tr><td>Zy",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "882337ad0b649135",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "E)</td><td>4%</td><td>5%</td><td>4%</td></tr><tr><td>Rozlytrek (ROG)</td><td>-6%</td><td>3%</td><td>12%</td></tr><tr><td>Xalkori (PFE)</td><td>-4%</td><td>5%</td><td>-1%</td></tr><tr><td>Zykadia (NVS)",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "1ac27b9bf35b37df",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>Rozlytrek (ROG)</td><td>-6%</td><td>3%</td><td>12%</td></tr><tr><td>Xalkori (PFE)</td><td>-4%</td><td>5%</td><td>-1%</td></tr><tr><td>Zykadia (NVS)</td><td>8%</td><td>1%</td><td>-15%</td></t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "450b139dbdac71b3",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "zlytrek (ROG)</td><td>-6%</td><td>3%</td><td>12%</td></tr><tr><td>Xalkori (PFE)</td><td>-4%</td><td>5%</td><td>-1%</td></tr><tr><td>Zykadia (NVS)</td><td>8%</td><td>1%</td><td>-15%</td></tr><tr><td co",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "8f613410a8d75a14",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "G)</td><td>-6%</td><td>3%</td><td>12%</td></tr><tr><td>Xalkori (PFE)</td><td>-4%</td><td>5%</td><td>-1%</td></tr><tr><td>Zykadia (NVS)</td><td>8%</td><td>1%</td><td>-15%</td></tr><tr><td colspan=\"4\">B",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "dfb0283d1de708d1",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>Xalkori (PFE)</td><td>-4%</td><td>5%</td><td>-1%</td></tr><tr><td>Zykadia (NVS)</td><td>8%</td><td>1%</td><td>-15%</td></tr><tr><td colspan=\"4\">BTK INHIBITORS</td></tr><tr><td>Brukinsa (ON",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ad3c8b15907048f8",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Xalkori (PFE)</td><td>-4%</td><td>5%</td><td>-1%</td></tr><tr><td>Zykadia (NVS)</td><td>8%</td><td>1%</td><td>-15%</td></tr><tr><td colspan=\"4\">BTK INHIBITORS</td></tr><tr><td>Brukinsa (ONC)</td><td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "93f91434ae0cb843",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "FE)</td><td>-4%</td><td>5%</td><td>-1%</td></tr><tr><td>Zykadia (NVS)</td><td>8%</td><td>1%</td><td>-15%</td></tr><tr><td colspan=\"4\">BTK INHIBITORS</td></tr><tr><td>Brukinsa (ONC)</td><td>1%</td><td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "842dcd5342016883",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1%</td><td>-15%</td></tr><tr><td colspan=\"4\">BTK INHIBITORS</td></tr><tr><td>Brukinsa (ONC)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Calquence (AZN)</td><td>0%</td><td>8%</td><td>-5%</td></t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "864fc74802ab6d25",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-15%</td></tr><tr><td colspan=\"4\">BTK INHIBITORS</td></tr><tr><td>Brukinsa (ONC)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Calquence (AZN)</td><td>0%</td><td>8%</td><td>-5%</td></tr><tr><td>I",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "33cde81ead52897f",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td colspan=\"4\">BTK INHIBITORS</td></tr><tr><td>Brukinsa (ONC)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Calquence (AZN)</td><td>0%</td><td>8%</td><td>-5%</td></tr><tr><td>Imbruvica (A",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "061796b767079205",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>Brukinsa (ONC)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Calquence (AZN)</td><td>0%</td><td>8%</td><td>-5%</td></tr><tr><td>Imbruvica (ABBV/JNJ)</td><td>1%</td><td>-1%</td><td>-4%</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "05a5e8e3d569d82f",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rukinsa (ONC)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Calquence (AZN)</td><td>0%</td><td>8%</td><td>-5%</td></tr><tr><td>Imbruvica (ABBV/JNJ)</td><td>1%</td><td>-1%</td><td>-4%</td></tr><tr",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "0c3cc13d5374a6a4",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "C)</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>Calquence (AZN)</td><td>0%</td><td>8%</td><td>-5%</td></tr><tr><td>Imbruvica (ABBV/JNJ)</td><td>1%</td><td>-1%</td><td>-4%</td></tr><tr><td>Vencle",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "9e1931c5398514b3",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Calquence (AZN)</td><td>0%</td><td>8%</td><td>-5%</td></tr><tr><td>Imbruvica (ABBV/JNJ)</td><td>1%</td><td>-1%</td><td>-4%</td></tr><tr><td>Venclexta (ABBV/ROG)</td><td>1%</td><td>8%</td><td>-6%</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "5a68990122af68d1",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ce (AZN)</td><td>0%</td><td>8%</td><td>-5%</td></tr><tr><td>Imbruvica (ABBV/JNJ)</td><td>1%</td><td>-1%</td><td>-4%</td></tr><tr><td>Venclexta (ABBV/ROG)</td><td>1%</td><td>8%</td><td>-6%</td></tr><tr",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "0ff7660bdc437615",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<table><tr><td>Nexavar (BAYN)</td><td>50%</td><td>-38%</td><td>-29%</td></tr><tr><td>Retevmo (LLY)</td><td>5%</td><td>2%</td><td>-1%</td></tr",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "6ba2fab83126c880",
        "value": -0.38,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<table><tr><td>Nexavar (BAYN)</td><td>50%</td><td>-38%</td><td>-29%</td></tr><tr><td>Retevmo (LLY)</td><td>5%</td><td>2%</td><td>-1%</td></tr><tr><td>Lenv",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "be0ea6754ff51493",
        "value": -0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<table><tr><td>Nexavar (BAYN)</td><td>50%</td><td>-38%</td><td>-29%</td></tr><tr><td>Retevmo (LLY)</td><td>5%</td><td>2%</td><td>-1%</td></tr><tr><td>Lenvima (Eisai)</",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e640f1187df7dfec",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>Nexavar (BAYN)</td><td>50%</td><td>-38%</td><td>-29%</td></tr><tr><td>Retevmo (LLY)</td><td>5%</td><td>2%</td><td>-1%</td></tr><tr><td>Lenvima (Eisai)</td><td>-5%</td><td>7%</td><td>-1%</td></",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "385f3bacd95b90ff",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "avar (BAYN)</td><td>50%</td><td>-38%</td><td>-29%</td></tr><tr><td>Retevmo (LLY)</td><td>5%</td><td>2%</td><td>-1%</td></tr><tr><td>Lenvima (Eisai)</td><td>-5%</td><td>7%</td><td>-1%</td></tr><tr><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "d41c9dea087657f7",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>50%</td><td>-38%</td><td>-29%</td></tr><tr><td>Retevmo (LLY)</td><td>5%</td><td>2%</td><td>-1%</td></tr><tr><td>Lenvima (Eisai)</td><td>-5%</td><td>7%</td><td>-1%</td></tr><tr><td>Vitravki (B",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "67a0e10b55144031",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Retevmo (LLY)</td><td>5%</td><td>2%</td><td>-1%</td></tr><tr><td>Lenvima (Eisai)</td><td>-5%</td><td>7%</td><td>-1%</td></tr><tr><td>Vitravki (BAYN)</td><td>2%</td><td>3%</td><td>7%</td></t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "7fc79f626edf4050",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "etevmo (LLY)</td><td>5%</td><td>2%</td><td>-1%</td></tr><tr><td>Lenvima (Eisai)</td><td>-5%</td><td>7%</td><td>-1%</td></tr><tr><td>Vitravki (BAYN)</td><td>2%</td><td>3%</td><td>7%</td></tr><tr><td>In",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e60c6b001fc9808c",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>5%</td><td>2%</td><td>-1%</td></tr><tr><td>Lenvima (Eisai)</td><td>-5%</td><td>7%</td><td>-1%</td></tr><tr><td>Vitravki (BAYN)</td><td>2%</td><td>3%</td><td>7%</td></tr><tr><td>Inrebi (BMY)<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "d7e8630b30b4ba96",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>Lenvima (Eisai)</td><td>-5%</td><td>7%</td><td>-1%</td></tr><tr><td>Vitravki (BAYN)</td><td>2%</td><td>3%</td><td>7%</td></tr><tr><td>Inrebi (BMY)</td><td>19%</td><td>-8%</td><td>-5%</td></tr>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c6d5b4f3955ef18f",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "vima (Eisai)</td><td>-5%</td><td>7%</td><td>-1%</td></tr><tr><td>Vitravki (BAYN)</td><td>2%</td><td>3%</td><td>7%</td></tr><tr><td>Inrebi (BMY)</td><td>19%</td><td>-8%</td><td>-5%</td></tr><tr><td>Gav",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "cb3048100ecc0e68",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>-5%</td><td>7%</td><td>-1%</td></tr><tr><td>Vitravki (BAYN)</td><td>2%</td><td>3%</td><td>7%</td></tr><tr><td>Inrebi (BMY)</td><td>19%</td><td>-8%</td><td>-5%</td></tr><tr><td>Gavreto (BPMC)",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "5582a36b593a64a3",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>Vitravki (BAYN)</td><td>2%</td><td>3%</td><td>7%</td></tr><tr><td>Inrebi (BMY)</td><td>19%</td><td>-8%</td><td>-5%</td></tr><tr><td>Gavreto (BPMC)</td><td>14%</td><td>7%</td><td>-2%</td><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "1097d14888bda1e8",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Vitravki (BAYN)</td><td>2%</td><td>3%</td><td>7%</td></tr><tr><td>Inrebi (BMY)</td><td>19%</td><td>-8%</td><td>-5%</td></tr><tr><td>Gavreto (BPMC)</td><td>14%</td><td>7%</td><td>-2%</td></tr><tr><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "1500115016dce1ff",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "AYN)</td><td>2%</td><td>3%</td><td>7%</td></tr><tr><td>Inrebi (BMY)</td><td>19%</td><td>-8%</td><td>-5%</td></tr><tr><td>Gavreto (BPMC)</td><td>14%</td><td>7%</td><td>-2%</td></tr><tr><td>KRAS</td><td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "d4beed704c100d5e",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Inrebi (BMY)</td><td>19%</td><td>-8%</td><td>-5%</td></tr><tr><td>Gavreto (BPMC)</td><td>14%</td><td>7%</td><td>-2%</td></tr><tr><td>KRAS</td><td></td><td></td><td></td></tr><tr><td>Krazati",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "4c3451e5045096cd",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nrebi (BMY)</td><td>19%</td><td>-8%</td><td>-5%</td></tr><tr><td>Gavreto (BPMC)</td><td>14%</td><td>7%</td><td>-2%</td></tr><tr><td>KRAS</td><td></td><td></td><td></td></tr><tr><td>Krazati (Mirati)</t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "9a8c47c5d0096e72",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>19%</td><td>-8%</td><td>-5%</td></tr><tr><td>Gavreto (BPMC)</td><td>14%</td><td>7%</td><td>-2%</td></tr><tr><td>KRAS</td><td></td><td></td><td></td></tr><tr><td>Krazati (Mirati)</td><td>1%</t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "a1be7730a5aa0dad",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-2%</td></tr><tr><td>KRAS</td><td></td><td></td><td></td></tr><tr><td>Krazati (Mirati)</td><td>1%</td><td>3%</td><td>-3%</td></tr><tr><td>Lumakras (Amgen)</td><td>1%</td><td>6%</td><td>-8%</td></",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "ab45f6186d2df6e5",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>KRAS</td><td></td><td></td><td></td></tr><tr><td>Krazati (Mirati)</td><td>1%</td><td>3%</td><td>-3%</td></tr><tr><td>Lumakras (Amgen)</td><td>1%</td><td>6%</td><td>-8%</td></tr><tr><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "25ef0dfadee53062",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>KRAS</td><td></td><td></td><td></td></tr><tr><td>Krazati (Mirati)</td><td>1%</td><td>3%</td><td>-3%</td></tr><tr><td>Lumakras (Amgen)</td><td>1%</td><td>6%</td><td>-8%</td></tr><tr><td>PARP INHIBI",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f2ed525a12239c8d",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>Krazati (Mirati)</td><td>1%</td><td>3%</td><td>-3%</td></tr><tr><td>Lumakras (Amgen)</td><td>1%</td><td>6%</td><td>-8%</td></tr><tr><td>PARP INHIBITORS</td><td></td><td></td><td></td></tr><tr><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b479f2c5ae15ee09",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ati (Mirati)</td><td>1%</td><td>3%</td><td>-3%</td></tr><tr><td>Lumakras (Amgen)</td><td>1%</td><td>6%</td><td>-8%</td></tr><tr><td>PARP INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Lynparza",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "13ace884e2b9b6be",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>1%</td><td>3%</td><td>-3%</td></tr><tr><td>Lumakras (Amgen)</td><td>1%</td><td>6%</td><td>-8%</td></tr><tr><td>PARP INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Lynparza (AZN)</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "efddc6a697c1e700",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td>PARP INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Lynparza (AZN)</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>Rubraca (CLVS)</td><td>-13%</td><td>4%</td><td>-2%</td></",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c444acc7120305c5",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>PARP INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Lynparza (AZN)</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>Rubraca (CLVS)</td><td>-13%</td><td>4%</td><td>-2%</td></tr><tr><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "a5769aeeb0ab987e",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Lynparza (AZN)</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>Rubraca (CLVS)</td><td>-13%</td><td>4%</td><td>-2%</td></tr><tr><td>Talzenna (P",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "76a0fad810fef9d2",
        "value": -0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Lynparza (AZN)</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>Rubraca (CLVS)</td><td>-13%</td><td>4%</td><td>-2%</td></tr><tr><td>Talzenna (PFE)</td><td>3%</td><td>4%</td><td>-4%</td></",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "adede9508728b94a",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nparza (AZN)</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>Rubraca (CLVS)</td><td>-13%</td><td>4%</td><td>-2%</td></tr><tr><td>Talzenna (PFE)</td><td>3%</td><td>4%</td><td>-4%</td></tr><tr><td>Ze",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f5b7c84c418a13a7",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>Rubraca (CLVS)</td><td>-13%</td><td>4%</td><td>-2%</td></tr><tr><td>Talzenna (PFE)</td><td>3%</td><td>4%</td><td>-4%</td></tr><tr><td>Zejula (GSK)<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "dadc6a7f620c5ffb",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Rubraca (CLVS)</td><td>-13%</td><td>4%</td><td>-2%</td></tr><tr><td>Talzenna (PFE)</td><td>3%</td><td>4%</td><td>-4%</td></tr><tr><td>Zejula (GSK)</td><td>-3%</td><td>-1%</td><td>-4%</td></tr",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "9154953380c11f36",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "braca (CLVS)</td><td>-13%</td><td>4%</td><td>-2%</td></tr><tr><td>Talzenna (PFE)</td><td>3%</td><td>4%</td><td>-4%</td></tr><tr><td>Zejula (GSK)</td><td>-3%</td><td>-1%</td><td>-4%</td></tr><tr><td>PR",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "ee5aad3b960575a3",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>-13%</td><td>4%</td><td>-2%</td></tr><tr><td>Talzenna (PFE)</td><td>3%</td><td>4%</td><td>-4%</td></tr><tr><td>Zejula (GSK)</td><td>-3%</td><td>-1%</td><td>-4%</td></tr><tr><td>PROTEASOME</t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "602f038bc1d767a7",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>Talzenna (PFE)</td><td>3%</td><td>4%</td><td>-4%</td></tr><tr><td>Zejula (GSK)</td><td>-3%</td><td>-1%</td><td>-4%</td></tr><tr><td>PROTEASOME</td><td></td><td></td><td></td></tr><tr><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f3a21e5e5c1039b3",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Talzenna (PFE)</td><td>3%</td><td>4%</td><td>-4%</td></tr><tr><td>Zejula (GSK)</td><td>-3%</td><td>-1%</td><td>-4%</td></tr><tr><td>PROTEASOME</td><td></td><td></td><td></td></tr><tr><td>INHIBITORS</",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "d023ae2d994cdca8",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "FE)</td><td>3%</td><td>4%</td><td>-4%</td></tr><tr><td>Zejula (GSK)</td><td>-3%</td><td>-1%</td><td>-4%</td></tr><tr><td>PROTEASOME</td><td></td><td></td><td></td></tr><tr><td>INHIBITORS</td><td></td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e174fd448092e421",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td></tr><tr><td>INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Kyprolis (AMGN)</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>Ninlaro (Takeda)</td><td>0%</td><td>6%</td><td>-6%</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "338e085f8204b4d9",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>INHIBITORS</td><td></td><td></td><td></td></tr><tr><td>Kyprolis (AMGN)</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>Ninlaro (Takeda)</td><td>0%</td><td>6%</td><td>-6%</td></tr><tr><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "dc50c3e7b803d408",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "HIBITORS</td><td></td><td></td><td></td></tr><tr><td>Kyprolis (AMGN)</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>Ninlaro (Takeda)</td><td>0%</td><td>6%</td><td>-6%</td></tr><tr><td>Velcade (T",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e5f78220b33f0bd6",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>Kyprolis (AMGN)</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>Ninlaro (Takeda)</td><td>0%</td><td>6%</td><td>-6%</td></tr><tr><td>Velcade (Takeda)</td><td>-2%</td><td>20%</td><td>-8%</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "af35cff2dc502106",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "lis (AMGN)</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>Ninlaro (Takeda)</td><td>0%</td><td>6%</td><td>-6%</td></tr><tr><td>Velcade (Takeda)</td><td>-2%</td><td>20%</td><td>-8%</td></tr><tr><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "eed08b54652b3982",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>Ninlaro (Takeda)</td><td>0%</td><td>6%</td><td>-6%</td></tr><tr><td>Velcade (Takeda)</td><td>-2%</td><td>20%</td><td>-8%</td></tr><tr><td>SLAMF7</t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b3c7b12df4d6d81a",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>Ninlaro (Takeda)</td><td>0%</td><td>6%</td><td>-6%</td></tr><tr><td>Velcade (Takeda)</td><td>-2%</td><td>20%</td><td>-8%</td></tr><tr><td>SLAMF7</td><td></td><td></td><td></td></tr><tr><td>Empl",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "1e0d8f49f1ef5b0e",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ro (Takeda)</td><td>0%</td><td>6%</td><td>-6%</td></tr><tr><td>Velcade (Takeda)</td><td>-2%</td><td>20%</td><td>-8%</td></tr><tr><td>SLAMF7</td><td></td><td></td><td></td></tr><tr><td>Empliciti (BMY)<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c31d66142045be3f",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>0%</td><td>6%</td><td>-6%</td></tr><tr><td>Velcade (Takeda)</td><td>-2%</td><td>20%</td><td>-8%</td></tr><tr><td>SLAMF7</td><td></td><td></td><td></td></tr><tr><td>Empliciti (BMY)</td><td>-4%<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "1afa2b463698091d",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-8%</td></tr><tr><td>SLAMF7</td><td></td><td></td><td></td></tr><tr><td>Empliciti (BMY)</td><td>-4%</td><td>7%</td><td>-3%</td></tr><tr><td>THALIDOMIDE</td><td></td><td></td><td></td></tr><tr><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "8cedc93bdef7f806",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>SLAMF7</td><td></td><td></td><td></td></tr><tr><td>Empliciti (BMY)</td><td>-4%</td><td>7%</td><td>-3%</td></tr><tr><td>THALIDOMIDE</td><td></td><td></td><td></td></tr><tr><td>ANALOGUES</t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "22bf58bfdcd9a82b",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>SLAMF7</td><td></td><td></td><td></td></tr><tr><td>Empliciti (BMY)</td><td>-4%</td><td>7%</td><td>-3%</td></tr><tr><td>THALIDOMIDE</td><td></td><td></td><td></td></tr><tr><td>ANALOGUES</td><td></td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "89f6f616a07f10ab",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td></tr><tr><td>ANALOGUES</td><td></td><td></td><td></td></tr><tr><td>Pomalyst (BMY)</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>Revlimid (BMY)</td><td>-5%</td><td>35%</td><td>-41%</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "0416cd49e18bd0c1",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>ANALOGUES</td><td></td><td></td><td></td></tr><tr><td>Pomalyst (BMY)</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>Revlimid (BMY)</td><td>-5%</td><td>35%</td><td>-41%</td></tr><tr><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "dd8a5fbdcdd09eb0",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>NSCLC</td><td>26%</td><td>42%</td><td>50%</td><td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "1c1094e1483b01bd",
        "value": 0.42,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>NSCLC</td><td>26%</td><td>42%</td><td>50%</td><td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%</td><td>26%<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "25f2baba32ab2b69",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>NSCLC</td><td>26%</td><td>42%</td><td>50%</td><td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%</td><td>26%</td><td>28%<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "3372feabe928c9a9",
        "value": 0.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td><td></td><td></td><td></td></tr><tr><td>NSCLC</td><td>26%</td><td>42%</td><td>50%</td><td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%</td><td>26%</td><td>28%</td><td>28%<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "141b8387fbea5958",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td></tr><tr><td>NSCLC</td><td>26%</td><td>42%</td><td>50%</td><td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%</td><td>26%</td><td>28%</td><td>28%</td><td></td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "50b20df56bcfb63c",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td></td></tr><tr><td>NSCLC</td><td>26%</td><td>42%</td><td>50%</td><td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%</td><td>26%</td><td>28%</td><td>28%</td><td></td></tr><tr><t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "620057567fc5f22f",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>NSCLC</td><td>26%</td><td>42%</td><td>50%</td><td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%</td><td>26%</td><td>28%</td><td>28%</td><td></td></tr><tr><td>Melanoma</",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "cda1a68d68cb2a2d",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>NSCLC</td><td>26%</td><td>42%</td><td>50%</td><td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%</td><td>26%</td><td>28%</td><td>28%</td><td></td></tr><tr><td>Melanoma</td><td>73%</",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "694903af8cd4c1d1",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>26%</td><td>42%</td><td>50%</td><td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%</td><td>26%</td><td>28%</td><td>28%</td><td></td></tr><tr><td>Melanoma</td><td>73%</td><td>49%</",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "39b39e84e2fcfe1a",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>42%</td><td>50%</td><td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%</td><td>26%</td><td>28%</td><td>28%</td><td></td></tr><tr><td>Melanoma</td><td>73%</td><td>49%</td><td>15%</",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "d0a72594a0655968",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>50%</td><td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%</td><td>26%</td><td>28%</td><td>28%</td><td></td></tr><tr><td>Melanoma</td><td>73%</td><td>49%</td><td>15%</td><td>27%</",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "59fe8da3dfb2a69f",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>36%</td><td>23%</td><td>20%</td><td>24%</td><td>24%</td><td>25%</td><td>26%</td><td>28%</td><td>28%</td><td></td></tr><tr><td>Melanoma</td><td>73%</td><td>49%</td><td>15%</td><td>27%</td><td>30%</",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "f04da468faa71f6f",
        "value": 0.73,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>24%</td><td>25%</td><td>26%</td><td>28%</td><td>28%</td><td></td></tr><tr><td>Melanoma</td><td>73%</td><td>49%</td><td>15%</td><td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b7f9d519b9dbd692",
        "value": 0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>25%</td><td>26%</td><td>28%</td><td>28%</td><td></td></tr><tr><td>Melanoma</td><td>73%</td><td>49%</td><td>15%</td><td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%</td><td>22%<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "d24edf1e4c4d4a84",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>26%</td><td>28%</td><td>28%</td><td></td></tr><tr><td>Melanoma</td><td>73%</td><td>49%</td><td>15%</td><td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%</td><td>22%</td><td>22%<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "47ef66c9bef9f948",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>28%</td><td>28%</td><td></td></tr><tr><td>Melanoma</td><td>73%</td><td>49%</td><td>15%</td><td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%</td><td>22%</td><td>22%</td><td>22%<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b97a54a4d3c0c398",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>28%</td><td></td></tr><tr><td>Melanoma</td><td>73%</td><td>49%</td><td>15%</td><td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%</td><td>22%</td><td>22%</td><td>22%</td><td></td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "4f85754edf3dead0",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td></tr><tr><td>Melanoma</td><td>73%</td><td>49%</td><td>15%</td><td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%</td><td>22%</td><td>22%</td><td>22%</td><td></td></tr><tr><t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "29217050d27cbf7a",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Melanoma</td><td>73%</td><td>49%</td><td>15%</td><td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%</td><td>22%</td><td>22%</td><td>22%</td><td></td></tr><tr><td>RCC</td><t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "59f4724d97dc65cb",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "elanoma</td><td>73%</td><td>49%</td><td>15%</td><td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%</td><td>22%</td><td>22%</td><td>22%</td><td></td></tr><tr><td>RCC</td><td>1%</td><td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b1c60f1f3b708c5f",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>73%</td><td>49%</td><td>15%</td><td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%</td><td>22%</td><td>22%</td><td>22%</td><td></td></tr><tr><td>RCC</td><td>1%</td><td>8%</td><td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "65028f499006f1ac",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>49%</td><td>15%</td><td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%</td><td>22%</td><td>22%</td><td>22%</td><td></td></tr><tr><td>RCC</td><td>1%</td><td>8%</td><td>18%</td><td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "8128db031ea581bf",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>15%</td><td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%</td><td>22%</td><td>22%</td><td>22%</td><td></td></tr><tr><td>RCC</td><td>1%</td><td>8%</td><td>18%</td><td>20%</td><td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "62fbc31d356e01d8",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>27%</td><td>30%</td><td>31%</td><td>28%</td><td>24%</td><td>21%</td><td>22%</td><td>22%</td><td>22%</td><td></td></tr><tr><td>RCC</td><td>1%</td><td>8%</td><td>18%</td><td>20%</td><td>24%</td><td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "1579ba80a221903f",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>24%</td><td>21%</td><td>22%</td><td>22%</td><td>22%</td><td></td></tr><tr><td>RCC</td><td>1%</td><td>8%</td><td>18%</td><td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "12c8bc16b092ca1b",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4%</td><td>21%</td><td>22%</td><td>22%</td><td>22%</td><td></td></tr><tr><td>RCC</td><td>1%</td><td>8%</td><td>18%</td><td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</td><td>23%</",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "7ccb05c37f85f9b9",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "21%</td><td>22%</td><td>22%</td><td>22%</td><td></td></tr><tr><td>RCC</td><td>1%</td><td>8%</td><td>18%</td><td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</td><td>23%</td><td>23%<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "2733ee20d0ae4144",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "22%</td><td>22%</td><td>22%</td><td></td></tr><tr><td>RCC</td><td>1%</td><td>8%</td><td>18%</td><td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</td><td>23%</td><td>23%</td><td>23%<",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "780eb05f2a084e2a",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "22%</td><td>22%</td><td></td></tr><tr><td>RCC</td><td>1%</td><td>8%</td><td>18%</td><td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</td><td>23%</td><td>23%</td><td>23%</td><td></td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "469458baf9b9bf1c",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "22%</td><td></td></tr><tr><td>RCC</td><td>1%</td><td>8%</td><td>18%</td><td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</td><td>23%</td><td>23%</td><td>23%</td><td></td></tr><tr><t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "9ce85b59a99f1af6",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>RCC</td><td>1%</td><td>8%</td><td>18%</td><td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</td><td>23%</td><td>23%</td><td>23%</td><td></td></tr><tr><td>SCCHN</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "79d3015f149be616",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>RCC</td><td>1%</td><td>8%</td><td>18%</td><td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</td><td>23%</td><td>23%</td><td>23%</td><td></td></tr><tr><td>SCCHN</td><td></td><td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "060fb8e3e4a513fe",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>1%</td><td>8%</td><td>18%</td><td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</td><td>23%</td><td>23%</td><td>23%</td><td></td></tr><tr><td>SCCHN</td><td></td><td></td><td></",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "dfdec8bb56921b5b",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>8%</td><td>18%</td><td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</td><td>23%</td><td>23%</td><td>23%</td><td></td></tr><tr><td>SCCHN</td><td></td><td></td><td></td><td>5%</t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "ad64917c6af8c834",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>18%</td><td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</td><td>23%</td><td>23%</td><td>23%</td><td></td></tr><tr><td>SCCHN</td><td></td><td></td><td></td><td>5%</td><td>5%</td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "3ef254b7bffbc531",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>20%</td><td>24%</td><td>25%</td><td>24%</td><td>24%</td><td>22%</td><td>23%</td><td>23%</td><td>23%</td><td></td></tr><tr><td>SCCHN</td><td></td><td></td><td></td><td>5%</td><td>5%</td><td>4%</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "8c694738eeeaf328",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>23%</td><td>23%</td><td>23%</td><td></td></tr><tr><td>SCCHN</td><td></td><td></td><td></td><td>5%</td><td>5%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td><td>3%</td><td>0%</td><td>0%</td><td><",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "ee10c0cd3c63906f",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>23%</td><td>23%</td><td></td></tr><tr><td>SCCHN</td><td></td><td></td><td></td><td>5%</td><td>5%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td><td>3%</td><td>0%</td><td>0%</td><td></td></tr><t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "bd6a292cc072323e",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>23%</td><td></td></tr><tr><td>SCCHN</td><td></td><td></td><td></td><td>5%</td><td>5%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td><td>3%</td><td>0%</td><td>0%</td><td></td></tr><tr><td>Upper",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b00022f97b8d232e",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td></td></tr><tr><td>SCCHN</td><td></td><td></td><td></td><td>5%</td><td>5%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td><td>3%</td><td>0%</td><td>0%</td><td></td></tr><tr><td>Upper GI-Bladder",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "a59f7d20a561ce62",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>SCCHN</td><td></td><td></td><td></td><td>5%</td><td>5%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td><td>3%</td><td>0%</td><td>0%</td><td></td></tr><tr><td>Upper GI-Bladder</td><td></",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "154ccfdc9ece7711",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>SCCHN</td><td></td><td></td><td></td><td>5%</td><td>5%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td><td>3%</td><td>0%</td><td>0%</td><td></td></tr><tr><td>Upper GI-Bladder</td><td></td><td></td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "3c6cf92ac68edfd1",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td></td><td>5%</td><td>5%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td><td>3%</td><td>0%</td><td>0%</td><td></td></tr><tr><td>Upper GI-Bladder</td><td></td><td></td><td></td><",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "8d9cfe3645b48866",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td><td></td><td>5%</td><td>5%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td><td>3%</td><td>0%</td><td>0%</td><td></td></tr><tr><td>Upper GI-Bladder</td><td></td><td></td><td></td><td></td><td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "96f79f5bd6a7f500",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td>5%</td><td>5%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td><td>3%</td><td>0%</td><td>0%</td><td></td></tr><tr><td>Upper GI-Bladder</td><td></td><td></td><td></td><td></td><td></td><td><",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "2ba5da82a2a94ae1",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td></tr><tr><td>Upper GI-Bladder</td><td></td><td></td><td></td><td></td><td></td><td></td><td>4%</td><td>12%</td><td>24%</td><td>26%</td><td>27%</td><td>27%</td><td></td></tr><tr><td>Others</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "8467e40495d8e7f6",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>Upper GI-Bladder</td><td></td><td></td><td></td><td></td><td></td><td></td><td>4%</td><td>12%</td><td>24%</td><td>26%</td><td>27%</td><td>27%</td><td></td></tr><tr><td>Others</td><td>0%</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "e45b79b99e32db08",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "per GI-Bladder</td><td></td><td></td><td></td><td></td><td></td><td></td><td>4%</td><td>12%</td><td>24%</td><td>26%</td><td>27%</td><td>27%</td><td></td></tr><tr><td>Others</td><td>0%</td><td>2%</td><",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b0334605a3d9e107",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "er</td><td></td><td></td><td></td><td></td><td></td><td></td><td>4%</td><td>12%</td><td>24%</td><td>26%</td><td>27%</td><td>27%</td><td></td></tr><tr><td>Others</td><td>0%</td><td>2%</td><td>16%</td><",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "df6ea2890d41723c",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td></td><td></td><td></td><td></td><td></td><td>4%</td><td>12%</td><td>24%</td><td>26%</td><td>27%</td><td>27%</td><td></td></tr><tr><td>Others</td><td>0%</td><td>2%</td><td>16%</td><td>12%</td><",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "f402fca2d43e9ca2",
        "value": -0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;136</td><td>&#36;136</td><td>&#36;137</td><td>&#36;126</td></tr><tr><td>YoY growth</td><td>-28%</td><td>-24%</td><td>-39%</td><td>-38%</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "ac4db114028ee9ee",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;136</td><td>&#36;137</td><td>&#36;126</td></tr><tr><td>YoY growth</td><td>-28%</td><td>-24%</td><td>-39%</td><td>-38%</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td><td>-41%</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "ac26b183435f4f35",
        "value": -0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "136</td><td>&#36;137</td><td>&#36;126</td></tr><tr><td>YoY growth</td><td>-28%</td><td>-24%</td><td>-39%</td><td>-38%</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td><td>-41%</td><td>-40%</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "b061391fe8beaeba",
        "value": -0.38,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "#36;137</td><td>&#36;126</td></tr><tr><td>YoY growth</td><td>-28%</td><td>-24%</td><td>-39%</td><td>-38%</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td><td>-41%</td><td>-40%</td><td>-39%</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "dcbfed944e454ada",
        "value": -0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;126</td></tr><tr><td>YoY growth</td><td>-28%</td><td>-24%</td><td>-39%</td><td>-38%</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td><td>-41%</td><td>-40%</td><td>-39%</td><td>-36%</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "200505994999fc4a",
        "value": -0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>YoY growth</td><td>-28%</td><td>-24%</td><td>-39%</td><td>-38%</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td><td>-41%</td><td>-40%</td><td>-39%</td><td>-36%</td></tr><tr><td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "9ceca7c19f837a00",
        "value": -0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>YoY growth</td><td>-28%</td><td>-24%</td><td>-39%</td><td>-38%</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td><td>-41%</td><td>-40%</td><td>-39%</td><td>-36%</td></tr><tr><td>MoM growth</t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "25cbd98b8fc99396",
        "value": -0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-28%</td><td>-24%</td><td>-39%</td><td>-38%</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td><td>-41%</td><td>-40%</td><td>-39%</td><td>-36%</td></tr><tr><td>MoM growth</td><td>-2%</td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c6d84066c1adcc69",
        "value": -0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-24%</td><td>-39%</td><td>-38%</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td><td>-41%</td><td>-40%</td><td>-39%</td><td>-36%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>6%</td><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "340842201885448e",
        "value": -0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-39%</td><td>-38%</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td><td>-41%</td><td>-40%</td><td>-39%</td><td>-36%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>6%</td><td>-22%</td><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "488ff41e408bf8ca",
        "value": -0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-38%</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td><td>-41%</td><td>-40%</td><td>-39%</td><td>-36%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>6%</td><td>-22%</td><td>2%</td><td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "5eaa2610a7d8e2d7",
        "value": -0.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-39%</td><td>-39%</td><td>-37%</td><td>-35%</td><td>-41%</td><td>-40%</td><td>-39%</td><td>-36%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>6%</td><td>-22%</td><td>2%</td><td>2%</td><td>-",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f567551828141066",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-35%</td><td>-41%</td><td>-40%</td><td>-39%</td><td>-36%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>6%</td><td>-22%</td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "5fa611719925fef7",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-41%</td><td>-40%</td><td>-39%</td><td>-36%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>6%</td><td>-22%</td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</td><td>0%</td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "37a5b79baeeea0a6",
        "value": -0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>-40%</td><td>-39%</td><td>-36%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>6%</td><td>-22%</td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</td><td>0%</td><td>0%</td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "8089086aaeab270c",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>-39%</td><td>-36%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>6%</td><td>-22%</td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</td><td>0%</td><td>0%</td><td>-8%</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "3f42c259673f2ade",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "39%</td><td>-36%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>6%</td><td>-22%</td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</td><td>0%</td><td>0%</td><td>-8%</td></tr><tr><t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "1502997eb8585d90",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">-36%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>6%</td><td>-22%</td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</td><td>0%</td><td>0%</td><td>-8%</td></tr><tr><td>IMS Month",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "aaf98cabe357f5be",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>MoM growth</td><td>-2%</td><td>6%</td><td>-22%</td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</td><td>0%</td><td>0%</td><td>-8%</td></tr><tr><td>IMS Monthly sales (no",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "19572168797ea0e0",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "oM growth</td><td>-2%</td><td>6%</td><td>-22%</td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</td><td>0%</td><td>0%</td><td>-8%</td></tr><tr><td>IMS Monthly sales (not normalized",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "e1bd44f609091a49",
        "value": -0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-2%</td><td>6%</td><td>-22%</td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</td><td>0%</td><td>0%</td><td>-8%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 wee",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c073415dafcdd9e1",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>6%</td><td>-22%</td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</td><td>0%</td><td>0%</td><td>-8%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "cd83b8c8c8a89544",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>-22%</td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</td><td>0%</td><td>0%</td><td>-8%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;16</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "0a0d2dec8f14634b",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>2%</td><td>2%</td><td>-4%</td><td>-1%</td><td>0%</td><td>-12%</td><td>0%</td><td>0%</td><td>-8%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;16</td><td>&#36;21",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "fb5c0acbcbc15f9f",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;11</td><td>&#36;11</td><td>&#36;14</td><td>&#36;11</td></tr><tr><td>MoM growth</td><td>-2%</td><td>33%</td><td>-38%</td><td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "6ba7e7eb2fb59ddc",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";11</td><td>&#36;11</td><td>&#36;14</td><td>&#36;11</td></tr><tr><td>MoM growth</td><td>-2%</td><td>33%</td><td>-38%</td><td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30%</td><td>0%",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "5c13b9b5a44b0698",
        "value": -0.38,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;11</td><td>&#36;14</td><td>&#36;11</td></tr><tr><td>MoM growth</td><td>-2%</td><td>33%</td><td>-38%</td><td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30%</td><td>0%</td><td>25%",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "fae62da634b9c58f",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;14</td><td>&#36;11</td></tr><tr><td>MoM growth</td><td>-2%</td><td>33%</td><td>-38%</td><td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30%</td><td>0%</td><td>25%</td><td>-26%",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "9c0250aba4828d6f",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;11</td></tr><tr><td>MoM growth</td><td>-2%</td><td>33%</td><td>-38%</td><td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30%</td><td>0%</td><td>25%</td><td>-26%</td></tr><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f2a2293052cbedfd",
        "value": -0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";11</td></tr><tr><td>MoM growth</td><td>-2%</td><td>33%</td><td>-38%</td><td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30%</td><td>0%</td><td>25%</td><td>-26%</td></tr><tr><td>Imfin",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "784e1767f049a979",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>-2%</td><td>33%</td><td>-38%</td><td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30%</td><td>0%</td><td>25%</td><td>-26%</td></tr><tr><td>Imfinzi (Astrazene",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "84424acce916252b",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>-2%</td><td>33%</td><td>-38%</td><td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30%</td><td>0%</td><td>25%</td><td>-26%</td></tr><tr><td>Imfinzi (Astrazeneca)</td><td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "7f4a3436c6c8747d",
        "value": -0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-2%</td><td>33%</td><td>-38%</td><td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30%</td><td>0%</td><td>25%</td><td>-26%</td></tr><tr><td>Imfinzi (Astrazeneca)</td><td></td><td></t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "0d8887588087c5aa",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>33%</td><td>-38%</td><td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30%</td><td>0%</td><td>25%</td><td>-26%</td></tr><tr><td>Imfinzi (Astrazeneca)</td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "43d72516c1c5efeb",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-38%</td><td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30%</td><td>0%</td><td>25%</td><td>-26%</td></tr><tr><td>Imfinzi (Astrazeneca)</td><td></td><td></td><td></td><td></td><td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "977251c644473cca",
        "value": -0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>2%</td><td>27%</td><td>-23%</td><td>-1%</td><td>25%</td><td>-30%</td><td>0%</td><td>25%</td><td>-26%</td></tr><tr><td>Imfinzi (Astrazeneca)</td><td></td><td></td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "1576d966fa816b6f",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";2,967</td><td>&#36;3,179</td><td>&#36;3,399</td><td>&#36;3,328</td></tr><tr><td>YoY growth</td><td>18%</td><td>25%</td><td>18%</td><td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "316478ab8753ec43",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;3,179</td><td>&#36;3,399</td><td>&#36;3,328</td></tr><tr><td>YoY growth</td><td>18%</td><td>25%</td><td>18%</td><td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%</td><td>33%<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "d2e2d24c71c0e001",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9</td><td>&#36;3,399</td><td>&#36;3,328</td></tr><tr><td>YoY growth</td><td>18%</td><td>25%</td><td>18%</td><td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%</td><td>33%</td><td>44%<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "4ee1be8390146584",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;3,399</td><td>&#36;3,328</td></tr><tr><td>YoY growth</td><td>18%</td><td>25%</td><td>18%</td><td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%</td><td>33%</td><td>44%</td><td>42%<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "3a18b5e872f4da8e",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;3,328</td></tr><tr><td>YoY growth</td><td>18%</td><td>25%</td><td>18%</td><td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%</td><td>33%</td><td>44%</td><td>42%</td></tr><tr",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "ff645e81f7bc94dd",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "328</td></tr><tr><td>YoY growth</td><td>18%</td><td>25%</td><td>18%</td><td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "72713d3419d261f6",
        "value": 0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>18%</td><td>25%</td><td>18%</td><td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "eab47a9f0a5cf9ab",
        "value": 0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>18%</td><td>25%</td><td>18%</td><td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>MoM growth</td><td>8%</td><td>8%",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "3f8d0ab067980002",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>18%</td><td>25%</td><td>18%</td><td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>MoM growth</td><td>8%</td><td>8%</td><td>-8",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "409caad7ca0141eb",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>25%</td><td>18%</td><td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>MoM growth</td><td>8%</td><td>8%</td><td>-8%</td><td>9%",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c81556e795f879ef",
        "value": 0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>18%</td><td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>MoM growth</td><td>8%</td><td>8%</td><td>-8%</td><td>9%</td><td>1%<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "e7091dfb21f700c8",
        "value": 0.42,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>26%</td><td>21%</td><td>31%</td><td>34%</td><td>34%</td><td>32%</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>MoM growth</td><td>8%</td><td>8%</td><td>-8%</td><td>9%</td><td>1%</td><td>0%</",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "9abb42ccada9c130",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "34%</td><td>34%</td><td>32%</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>MoM growth</td><td>8%</td><td>8%</td><td>-8%</td><td>9%</td><td>1%</td><td>0%</td><td>5%</td><td>8%</td><td>-5%</td><td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "e75628535336322c",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">34%</td><td>32%</td><td>33%</td><td>44%</td><td>42%</td></tr><tr><td>MoM growth</td><td>8%</td><td>8%</td><td>-8%</td><td>9%</td><td>1%</td><td>0%</td><td>5%</td><td>8%</td><td>-5%</td><td>7%</td><td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "aad6b137e9abfb3f",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;658</td><td>&#36;649</td><td>&#36;656</td><td>&#36;685</td></tr><tr><td>YoY growth</td><td>23%</td><td>28%</td><td>28%</td><td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "bd9cfe95ec6cbd66",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>&#36;649</td><td>&#36;656</td><td>&#36;685</td></tr><tr><td>YoY growth</td><td>23%</td><td>28%</td><td>28%</td><td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%</td><td>20%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "76102f37b0338b98",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;649</td><td>&#36;656</td><td>&#36;685</td></tr><tr><td>YoY growth</td><td>23%</td><td>28%</td><td>28%</td><td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%</td><td>20%</td><td>23%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "17672146bbdece34",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;656</td><td>&#36;685</td></tr><tr><td>YoY growth</td><td>23%</td><td>28%</td><td>28%</td><td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%</td><td>20%</td><td>23%</td><td>23%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "611b902d93ebdafd",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&#36;685</td></tr><tr><td>YoY growth</td><td>23%</td><td>28%</td><td>28%</td><td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%</td><td>20%</td><td>23%</td><td>23%</td></tr><tr",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "be40dddc5de5a8fd",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "685</td></tr><tr><td>YoY growth</td><td>23%</td><td>28%</td><td>28%</td><td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "7e56c2be653c385e",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>23%</td><td>28%</td><td>28%</td><td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "711bf8da1a8fa7c7",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>23%</td><td>28%</td><td>28%</td><td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>MoM growth</td><td>3%</td><td>2%",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "3698d708dbadaa70",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>23%</td><td>28%</td><td>28%</td><td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>MoM growth</td><td>3%</td><td>2%</td><td>2%",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "eafd6ecb0a2941de",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>28%</td><td>28%</td><td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>MoM growth</td><td>3%</td><td>2%</td><td>2%</td><td>-1%",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "81e402d4d1095a59",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>28%</td><td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>MoM growth</td><td>3%</td><td>2%</td><td>2%</td><td>-1%</td><td>0%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "de712216f3b1d83b",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>29%</td><td>22%</td><td>33%</td><td>32%</td><td>25%</td><td>27%</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>MoM growth</td><td>3%</td><td>2%</td><td>2%</td><td>-1%</td><td>0%</td><td>11%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "24c6d0bba8f08010",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "32%</td><td>25%</td><td>27%</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>MoM growth</td><td>3%</td><td>2%</td><td>2%</td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><t",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "430febb10f29dc55",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">25%</td><td>27%</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>MoM growth</td><td>3%</td><td>2%</td><td>2%</td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><td>-1%</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "038740a4c511cdd5",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>27%</td><td>20%</td><td>23%</td><td>23%</td></tr><tr><td>MoM growth</td><td>3%</td><td>2%</td><td>2%</td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><td>-1%</td><td>1%</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "cd4fdab0e8929a05",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>20%</td><td>23%</td><td>23%</td></tr><tr><td>MoM growth</td><td>3%</td><td>2%</td><td>2%</td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><td>-1%</td><td>1%</td><td>4%</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "8b612cd5f0b922fc",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>23%</td><td>23%</td></tr><tr><td>MoM growth</td><td>3%</td><td>2%</td><td>2%</td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "1e587000956ccb69",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>23%</td></tr><tr><td>MoM growth</td><td>3%</td><td>2%</td><td>2%</td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>IMS Monthly",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "0314dcbb1502f368",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>MoM growth</td><td>3%</td><td>2%</td><td>2%</td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>IMS Monthly sales (not ",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "512c51c9ecb8e1c2",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>MoM growth</td><td>3%</td><td>2%</td><td>2%</td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>IMS Monthly sales (not normalized;",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "93a6454259856f8f",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>3%</td><td>2%</td><td>2%</td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "14a63df69e2e0f74",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>2%</td><td>2%</td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "619d7c0413df14ad",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>2%</td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;48</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "ad302f4469ca046f",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-1%</td><td>0%</td><td>11%</td><td>2%</td><td>-4%</td><td>1%</td><td>-1%</td><td>1%</td><td>4%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;48</td><td>&#36;61<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "1532f7a632cb463b",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;55</td><td>&#36;54</td><td>&#36;68</td><td>&#36;57</td></tr><tr><td>MoM growth</td><td>3%</td><td>27%</td><td>-18%</td><td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "b2ca64009edd5a01",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;55</td><td>&#36;54</td><td>&#36;68</td><td>&#36;57</td></tr><tr><td>MoM growth</td><td>3%</td><td>27%</td><td>-18%</td><td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%</td><td>-1",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "6328a8cca894e7e8",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">&#36;54</td><td>&#36;68</td><td>&#36;57</td></tr><tr><td>MoM growth</td><td>3%</td><td>27%</td><td>-18%</td><td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%</td><td>-1%</td><td>26",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "d4f02e311399aa5d",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;68</td><td>&#36;57</td></tr><tr><td>MoM growth</td><td>3%</td><td>27%</td><td>-18%</td><td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%</td><td>-1%</td><td>26%</td><td>-16",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "4e2fb52df8e58fa6",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;57</td></tr><tr><td>MoM growth</td><td>3%</td><td>27%</td><td>-18%</td><td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%</td><td>-1%</td><td>26%</td><td>-16%</td></tr><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "3d3c17358edca248",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";57</td></tr><tr><td>MoM growth</td><td>3%</td><td>27%</td><td>-18%</td><td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%</td><td>-1%</td><td>26%</td><td>-16%</td></tr><tr><td>Alunb",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "1fad4d488de42133",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>3%</td><td>27%</td><td>-18%</td><td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%</td><td>-1%</td><td>26%</td><td>-16%</td></tr><tr><td>Alunbrig (Takeda)<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "25b6d724858a14f8",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>3%</td><td>27%</td><td>-18%</td><td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%</td><td>-1%</td><td>26%</td><td>-16%</td></tr><tr><td>Alunbrig (Takeda)</td><td></td",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "6bf2a516079da0b1",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>3%</td><td>27%</td><td>-18%</td><td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%</td><td>-1%</td><td>26%</td><td>-16%</td></tr><tr><td>Alunbrig (Takeda)</td><td></td><td></td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "65bdb65e6af32e39",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>27%</td><td>-18%</td><td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%</td><td>-1%</td><td>26%</td><td>-16%</td></tr><tr><td>Alunbrig (Takeda)</td><td></td><td></td><td></td><td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "033300a1cdb4647f",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-18%</td><td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%</td><td>-1%</td><td>26%</td><td>-16%</td></tr><tr><td>Alunbrig (Takeda)</td><td></td><td></td><td></td><td></td><td></td",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "e6379b742fb27889",
        "value": -0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-1%</td><td>25%</td><td>-11%</td><td>2%</td><td>20%</td><td>-19%</td><td>-1%</td><td>26%</td><td>-16%</td></tr><tr><td>Alunbrig (Takeda)</td><td></td><td></td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "2a2d0a315fccfb8f",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;114</td><td>&#36;108</td><td>&#36;119</td><td>&#36;102</td></tr><tr><td>YoY growth</td><td>29%</td><td>20%</td><td>29%</td><td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "f40f697d70ab7083",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>&#36;108</td><td>&#36;119</td><td>&#36;102</td></tr><tr><td>YoY growth</td><td>29%</td><td>20%</td><td>29%</td><td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%</td><td>40%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "2b231abcd0438f84",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;108</td><td>&#36;119</td><td>&#36;102</td></tr><tr><td>YoY growth</td><td>29%</td><td>20%</td><td>29%</td><td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%</td><td>40%</td><td>54%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "bfe83d8d5b61de71",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;119</td><td>&#36;102</td></tr><tr><td>YoY growth</td><td>29%</td><td>20%</td><td>29%</td><td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%</td><td>40%</td><td>54%</td><td>23%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "a780ba3071fb1db9",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&#36;102</td></tr><tr><td>YoY growth</td><td>29%</td><td>20%</td><td>29%</td><td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%</td><td>40%</td><td>54%</td><td>23%</td></tr><tr",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "ada8986f5bb7ab62",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "102</td></tr><tr><td>YoY growth</td><td>29%</td><td>20%</td><td>29%</td><td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "215a007351a90f2b",
        "value": 0.43,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>29%</td><td>20%</td><td>29%</td><td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "7c47c1393287276a",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>29%</td><td>20%</td><td>29%</td><td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>MoM growth</td><td>4%</td><td>1%",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "cad13856b9b19e69",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>29%</td><td>20%</td><td>29%</td><td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>MoM growth</td><td>4%</td><td>1%</td><td>-6",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "b63dea6447a4af4b",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>20%</td><td>29%</td><td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>MoM growth</td><td>4%</td><td>1%</td><td>-6%</td><td>4%",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "3350535ad1778459",
        "value": 0.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>29%</td><td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>MoM growth</td><td>4%</td><td>1%</td><td>-6%</td><td>4%</td><td>8%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "0c3c44ff97529d8b",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>24%</td><td>30%</td><td>28%</td><td>43%</td><td>40%</td><td>37%</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>MoM growth</td><td>4%</td><td>1%</td><td>-6%</td><td>4%</td><td>8%</td><td>-2%<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "c5866220cb58c701",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "43%</td><td>40%</td><td>37%</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>MoM growth</td><td>4%</td><td>1%</td><td>-6%</td><td>4%</td><td>8%</td><td>-2%</td><td>22%</td><td>-9%</td><td>12%</td>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "788ae69da1c1ebf8",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">40%</td><td>37%</td><td>40%</td><td>54%</td><td>23%</td></tr><tr><td>MoM growth</td><td>4%</td><td>1%</td><td>-6%</td><td>4%</td><td>8%</td><td>-2%</td><td>22%</td><td>-9%</td><td>12%</td><td>-5%</td",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "9fd2a9a828bec348",
        "value": 0.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "941</td><td>$1,946</td><td>$2,022</td><td>$2,149</td><td>$2,057</td></tr><tr><td>YoY growth</td><td>36%</td><td>30%</td><td>32%</td><td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "7d53d5021c52d282",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$1,946</td><td>$2,022</td><td>$2,149</td><td>$2,057</td></tr><tr><td>YoY growth</td><td>36%</td><td>30%</td><td>32%</td><td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%</td><td>44%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "408dbe6e7406ab45",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>$2,022</td><td>$2,149</td><td>$2,057</td></tr><tr><td>YoY growth</td><td>36%</td><td>30%</td><td>32%</td><td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%</td><td>44%</td><td>50%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "df7fc9483f4ab3ed",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>$2,149</td><td>$2,057</td></tr><tr><td>YoY growth</td><td>36%</td><td>30%</td><td>32%</td><td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%</td><td>44%</td><td>50%</td><td>40%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "a1d93e6bc81a054f",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>$2,057</td></tr><tr><td>YoY growth</td><td>36%</td><td>30%</td><td>32%</td><td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%</td><td>44%</td><td>50%</td><td>40%</td></tr><tr",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "12a221eafd7d830a",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "057</td></tr><tr><td>YoY growth</td><td>36%</td><td>30%</td><td>32%</td><td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "b7f30a01bb0c2d52",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>36%</td><td>30%</td><td>32%</td><td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "3e5a489db3f1de5e",
        "value": 0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>36%</td><td>30%</td><td>32%</td><td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>MoM growth</td><td>6%</td><td>1%",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "ea70f0bfae0c259a",
        "value": 0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>36%</td><td>30%</td><td>32%</td><td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>MoM growth</td><td>6%</td><td>1%</td><td>0%",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "40e4195b329f8dc0",
        "value": 0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>30%</td><td>32%</td><td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>MoM growth</td><td>6%</td><td>1%</td><td>0%</td><td>-1%",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "bfcf7b3c1b5beb75",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>32%</td><td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>MoM growth</td><td>6%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "5bef723dbb5a1e26",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>29%</td><td>23%</td><td>40%</td><td>40%</td><td>39%</td><td>41%</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>MoM growth</td><td>6%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "7b1f9451700a7ef5",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "40%</td><td>39%</td><td>41%</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>MoM growth</td><td>6%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "d8a147e36bc8b421",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">39%</td><td>41%</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>MoM growth</td><td>6%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td>4%</td><td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "937376766581dd9a",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>41%</td><td>44%</td><td>50%</td><td>40%</td></tr><tr><td>MoM growth</td><td>6%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td>4%</td><td>6%</td><td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "852596430b5e82a0",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>44%</td><td>50%</td><td>40%</td></tr><tr><td>MoM growth</td><td>6%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td>4%</td><td>6%</td><td>-4%</td></",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "3ae6fcceed355afb",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>50%</td><td>40%</td></tr><tr><td>MoM growth</td><td>6%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>I",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "bfcfa7586d2fa496",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>40%</td></tr><tr><td>MoM growth</td><td>6%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>IMS Monthly ",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "ad4abaa87c3c4e89",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>MoM growth</td><td>6%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>IMS Monthly sales (not n",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "a8a2463594ac81ac",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>MoM growth</td><td>6%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>IMS Monthly sales (not normalized; ",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "f83a20a0b2b248bf",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "h</td><td>6%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "4a38dbbe5fa5d405",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>1%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "fda29dd52129fa5b",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>0%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$130</td><td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "5d79e4ae251f45f0",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>-1%</td><td>1%</td><td>12%</td><td>3%</td><td>7%</td><td>0%</td><td>4%</td><td>6%</td><td>-4%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$130</td><td>$164</td><",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "d22df7e420321082",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>$202</td><td>$162</td><td>$169</td><td>$224</td><td>$171</td></tr><tr><td>MoM growth</td><td>6%</td><td>26%</td><td>-20%</td><td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "6322957165218525",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>$162</td><td>$169</td><td>$224</td><td>$171</td></tr><tr><td>MoM growth</td><td>6%</td><td>26%</td><td>-20%</td><td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%</td><td>4%",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "09935c4d3dbc798e",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2</td><td>$169</td><td>$224</td><td>$171</td></tr><tr><td>MoM growth</td><td>6%</td><td>26%</td><td>-20%</td><td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%</td><td>4%</td><td>33%",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "d3f918c6a2185eb2",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9</td><td>$224</td><td>$171</td></tr><tr><td>MoM growth</td><td>6%</td><td>26%</td><td>-20%</td><td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%</td><td>4%</td><td>33%</td><td>-23%",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "de93fdbed06cf596",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "24</td><td>$171</td></tr><tr><td>MoM growth</td><td>6%</td><td>26%</td><td>-20%</td><td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%</td><td>4%</td><td>33%</td><td>-23%</td></tr><t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "d61c47726fccc6a5",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "171</td></tr><tr><td>MoM growth</td><td>6%</td><td>26%</td><td>-20%</td><td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%</td><td>4%</td><td>33%</td><td>-23%</td></tr><tr><td>Nubeqa",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "3dbb27ad9be8c5e5",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>6%</td><td>26%</td><td>-20%</td><td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%</td><td>4%</td><td>33%</td><td>-23%</td></tr><tr><td>Nubeqa (Bayer)</td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "35b6d5bd24188ecb",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>6%</td><td>26%</td><td>-20%</td><td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%</td><td>4%</td><td>33%</td><td>-23%</td></tr><tr><td>Nubeqa (Bayer)</td><td></td><td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "1beb69fdb5bdd100",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>6%</td><td>26%</td><td>-20%</td><td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%</td><td>4%</td><td>33%</td><td>-23%</td></tr><tr><td>Nubeqa (Bayer)</td><td></td><td></td><td><",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "a981a709bea3e36d",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>26%</td><td>-20%</td><td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%</td><td>4%</td><td>33%</td><td>-23%</td></tr><tr><td>Nubeqa (Bayer)</td><td></td><td></td><td></td><td></td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "4eba5198e5bd3c36",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-20%</td><td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%</td><td>4%</td><td>33%</td><td>-23%</td></tr><tr><td>Nubeqa (Bayer)</td><td></td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "845040e77c282a90",
        "value": -0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-1%</td><td>27%</td><td>-11%</td><td>3%</td><td>33%</td><td>-20%</td><td>4%</td><td>33%</td><td>-23%</td></tr><tr><td>Nubeqa (Bayer)</td><td></td><td></td><td></td><td></td><td></td><td></td><td><",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "cbefd9ed961458ef",
        "value": 0.76,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "995</td><td>$2,081</td><td>$2,233</td><td>$2,404</td><td>$2,476</td></tr><tr><td>YoY growth</td><td>76%</td><td>72%</td><td>79%</td><td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "d057242ceb66b852",
        "value": 0.72,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$2,081</td><td>$2,233</td><td>$2,404</td><td>$2,476</td></tr><tr><td>YoY growth</td><td>76%</td><td>72%</td><td>79%</td><td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%</td><td>88%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "d2df740b79b5891f",
        "value": 0.79,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>$2,233</td><td>$2,404</td><td>$2,476</td></tr><tr><td>YoY growth</td><td>76%</td><td>72%</td><td>79%</td><td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%</td><td>88%</td><td>102%",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "db6f3ef0d986851e",
        "value": 0.76,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>$2,404</td><td>$2,476</td></tr><tr><td>YoY growth</td><td>76%</td><td>72%</td><td>79%</td><td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%</td><td>88%</td><td>102%</td><td>96%",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "dcb6a24a43f37d21",
        "value": 0.67,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>$2,476</td></tr><tr><td>YoY growth</td><td>76%</td><td>72%</td><td>79%</td><td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%</td><td>88%</td><td>102%</td><td>96%</td></tr><t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "be0a2b337d9cbe4a",
        "value": 0.86,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "476</td></tr><tr><td>YoY growth</td><td>76%</td><td>72%</td><td>79%</td><td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>MoM gr",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "d9380def43d5969b",
        "value": 0.77,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>76%</td><td>72%</td><td>79%</td><td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>MoM growth</td><td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "4ca16042286131ba",
        "value": 0.86,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>76%</td><td>72%</td><td>79%</td><td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>MoM growth</td><td>7%</td><td>3",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "4d0a308cae125d94",
        "value": 0.79,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>76%</td><td>72%</td><td>79%</td><td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>MoM growth</td><td>7%</td><td>3%</td><td>7",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "84649998e4ee064d",
        "value": 0.88,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>72%</td><td>79%</td><td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>MoM growth</td><td>7%</td><td>3%</td><td>7%</td><td>-1",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "24ca53627ab757e1",
        "value": 1.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>79%</td><td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>MoM growth</td><td>7%</td><td>3%</td><td>7%</td><td>-1%</td><td>5%",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "93717f1609e9fded",
        "value": 0.96,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>76%</td><td>67%</td><td>86%</td><td>77%</td><td>86%</td><td>79%</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>MoM growth</td><td>7%</td><td>3%</td><td>7%</td><td>-1%</td><td>5%</td><td>12%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "29ce7b05790bb0bc",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7%</td><td>86%</td><td>79%</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>MoM growth</td><td>7%</td><td>3%</td><td>7%</td><td>-1%</td><td>5%</td><td>12%</td><td>3%</td><td>12%</td><td>4%</td><t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "3dea3d07a191c171",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "86%</td><td>79%</td><td>88%</td><td>102%</td><td>96%</td></tr><tr><td>MoM growth</td><td>7%</td><td>3%</td><td>7%</td><td>-1%</td><td>5%</td><td>12%</td><td>3%</td><td>12%</td><td>4%</td><td>7%</td><t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "0c06ea675b81d591",
        "value": 0.87,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";2,130</td><td>&#36;2,158</td><td>&#36;2,252</td><td>&#36;2,232</td></tr><tr><td>YoY growth</td><td>87%</td><td>92%</td><td>85%</td><td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "3741008237ed4490",
        "value": 0.92,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;2,158</td><td>&#36;2,252</td><td>&#36;2,232</td></tr><tr><td>YoY growth</td><td>87%</td><td>92%</td><td>85%</td><td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%</td><td>50%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "29aac167a655a465",
        "value": 0.85,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8</td><td>&#36;2,252</td><td>&#36;2,232</td></tr><tr><td>YoY growth</td><td>87%</td><td>92%</td><td>85%</td><td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%</td><td>50%</td><td>36%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "5ce31ccfd10cbebf",
        "value": 0.91,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;2,252</td><td>&#36;2,232</td></tr><tr><td>YoY growth</td><td>87%</td><td>92%</td><td>85%</td><td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%</td><td>50%</td><td>36%</td><td>56%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "d055ff76ebabd7f2",
        "value": 0.72,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;2,232</td></tr><tr><td>YoY growth</td><td>87%</td><td>92%</td><td>85%</td><td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%</td><td>50%</td><td>36%</td><td>56%</td></tr><tr",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "f157bb17183f46d3",
        "value": 0.89,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "232</td></tr><tr><td>YoY growth</td><td>87%</td><td>92%</td><td>85%</td><td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%</td><td>50%</td><td>36%</td><td>56%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "7646a4ee4172b0b1",
        "value": 0.71,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>87%</td><td>92%</td><td>85%</td><td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%</td><td>50%</td><td>36%</td><td>56%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "633b395c986bd949",
        "value": 0.73,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>87%</td><td>92%</td><td>85%</td><td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%</td><td>50%</td><td>36%</td><td>56%</td></tr><tr><td>MoM growth</td><td>9%</td><td>9%",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "1a8cd771105741c0",
        "value": 0.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>87%</td><td>92%</td><td>85%</td><td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%</td><td>50%</td><td>36%</td><td>56%</td></tr><tr><td>MoM growth</td><td>9%</td><td>9%</td><td>-2",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "3d5cee518d2a700f",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>92%</td><td>85%</td><td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%</td><td>50%</td><td>36%</td><td>56%</td></tr><tr><td>MoM growth</td><td>9%</td><td>9%</td><td>-2%</td><td>8%",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "f0c1decd1f4e5f8c",
        "value": 0.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>85%</td><td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%</td><td>50%</td><td>36%</td><td>56%</td></tr><tr><td>MoM growth</td><td>9%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "0a7e3c7da85e02ba",
        "value": 0.56,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>91%</td><td>72%</td><td>89%</td><td>71%</td><td>73%</td><td>54%</td><td>50%</td><td>36%</td><td>56%</td></tr><tr><td>MoM growth</td><td>9%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "37804a7557a79e8a",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "71%</td><td>73%</td><td>54%</td><td>50%</td><td>36%</td><td>56%</td></tr><tr><td>MoM growth</td><td>9%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "cc3d8fd8cc68ea0e",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">73%</td><td>54%</td><td>50%</td><td>36%</td><td>56%</td></tr><tr><td>MoM growth</td><td>9%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td>1%</td><td",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "bcbb524a10ccfab5",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>54%</td><td>50%</td><td>36%</td><td>56%</td></tr><tr><td>MoM growth</td><td>9%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td>1%</td><td>4%</td><td",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "0cde056dab1b95f6",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>50%</td><td>36%</td><td>56%</td></tr><tr><td>MoM growth</td><td>9%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td>1%</td><td>4%</td><td>-1%</td></t",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "81a5d47a95577b93",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>36%</td><td>56%</td></tr><tr><td>MoM growth</td><td>9%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>I",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "e197eefb15b7ae36",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>56%</td></tr><tr><td>MoM growth</td><td>9%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>IMS Monthly ",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "ec02871dcfd1e265",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>MoM growth</td><td>9%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not ",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "26ea4a3fe3db7cb6",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>MoM growth</td><td>9%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not normalized;",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "e6d6d506851c6f71",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "th</td><td>9%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 week",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "70148901d0240edd",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>9%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "9fc2e72355c506f2",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>-2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;130</td",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "b0f5d1623299bd0b",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2%</td><td>8%</td><td>1%</td><td>5%</td><td>9%</td><td>3%</td><td>-2%</td><td>1%</td><td>4%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;130</td><td>&#36;1",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "c5df1090930a2501",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;178</td><td>&#36;180</td><td>&#36;235</td><td>&#36;186</td></tr><tr><td>MoM growth</td><td>9%</td><td>37%</td><td>-21%</td><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "4fc5945cd41dd4c5",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8</td><td>&#36;180</td><td>&#36;235</td><td>&#36;186</td></tr><tr><td>MoM growth</td><td>9%</td><td>37%</td><td>-21%</td><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%</td><td>1%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "c4764a783ae98049",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;180</td><td>&#36;235</td><td>&#36;186</td></tr><tr><td>MoM growth</td><td>9%</td><td>37%</td><td>-21%</td><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%</td><td>1%</td><td>30%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "2a64fe8d56c65806",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;235</td><td>&#36;186</td></tr><tr><td>MoM growth</td><td>9%</td><td>37%</td><td>-21%</td><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%</td><td>1%</td><td>30%</td><td>-21%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "1efecb91b9ece00f",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;186</td></tr><tr><td>MoM growth</td><td>9%</td><td>37%</td><td>-21%</td><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%</td><td>1%</td><td>30%</td><td>-21%</td></tr><t",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "69d3c2b68430c605",
        "value": -0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";186</td></tr><tr><td>MoM growth</td><td>9%</td><td>37%</td><td>-21%</td><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%</td><td>1%</td><td>30%</td><td>-21%</td></tr><tr><td>Calque",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "7987f26b4c01fbd4",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>MoM growth</td><td>9%</td><td>37%</td><td>-21%</td><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%</td><td>1%</td><td>30%</td><td>-21%</td></tr><tr><td>Calquence (Astrazen",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "cd8969cb0cb135f0",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "M growth</td><td>9%</td><td>37%</td><td>-21%</td><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%</td><td>1%</td><td>30%</td><td>-21%</td></tr><tr><td>Calquence (Astrazeneca)</td><t",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "c07a90bc0fb4bb63",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>9%</td><td>37%</td><td>-21%</td><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%</td><td>1%</td><td>30%</td><td>-21%</td></tr><tr><td>Calquence (Astrazeneca)</td><td></td><td><",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "5ec646eb0832b924",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>37%</td><td>-21%</td><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%</td><td>1%</td><td>30%</td><td>-21%</td></tr><tr><td>Calquence (Astrazeneca)</td><td></td><td></td><td></td>",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "6831484089cc06dc",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-21%</td><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%</td><td>1%</td><td>30%</td><td>-21%</td></tr><tr><td>Calquence (Astrazeneca)</td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "2f38f0325732fa7f",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>8%</td><td>26%</td><td>-16%</td><td>9%</td><td>29%</td><td>-21%</td><td>1%</td><td>30%</td><td>-21%</td></tr><tr><td>Calquence (Astrazeneca)</td><td></td><td></td><td></td><td></td><td></td><td><",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "d070f3398b7c8c32",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";2,754</td><td>&#36;2,741</td><td>&#36;2,972</td><td>&#36;2,828</td></tr><tr><td>YoY growth</td><td>26%</td><td>28%</td><td>29%</td><td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "9ea80801aa0c7c88",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;2,741</td><td>&#36;2,972</td><td>&#36;2,828</td></tr><tr><td>YoY growth</td><td>26%</td><td>28%</td><td>29%</td><td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%</td><td>34%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "8553abaad029c6b0",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1</td><td>&#36;2,972</td><td>&#36;2,828</td></tr><tr><td>YoY growth</td><td>26%</td><td>28%</td><td>29%</td><td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%</td><td>34%</td><td>62%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "fcf99e87696379a3",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;2,972</td><td>&#36;2,828</td></tr><tr><td>YoY growth</td><td>26%</td><td>28%</td><td>29%</td><td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%</td><td>34%</td><td>62%</td><td>42%<",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "96c18e457433332f",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;2,828</td></tr><tr><td>YoY growth</td><td>26%</td><td>28%</td><td>29%</td><td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%</td><td>34%</td><td>62%</td><td>42%</td></tr><tr",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "3a8a92bdc10690b3",
        "value": 0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "828</td></tr><tr><td>YoY growth</td><td>26%</td><td>28%</td><td>29%</td><td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%</td><td>34%</td><td>62%</td><td>42%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "c8b4c274b99e45e7",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>26%</td><td>28%</td><td>29%</td><td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%</td><td>34%</td><td>62%</td><td>42%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "98e73e01ec551062",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>26%</td><td>28%</td><td>29%</td><td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%</td><td>34%</td><td>62%</td><td>42%</td></tr><tr><td>MoM growth</td><td>11%</td><td>3",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "3902dd856476206e",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>26%</td><td>28%</td><td>29%</td><td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%</td><td>34%</td><td>62%</td><td>42%</td></tr><tr><td>MoM growth</td><td>11%</td><td>3%</td><td>-",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "faec9c76e229c507",
        "value": 0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>28%</td><td>29%</td><td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%</td><td>34%</td><td>62%</td><td>42%</td></tr><tr><td>MoM growth</td><td>11%</td><td>3%</td><td>-3%</td><td>3",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "611a7f728e539f5a",
        "value": 0.62,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>29%</td><td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%</td><td>34%</td><td>62%</td><td>42%</td></tr><tr><td>MoM growth</td><td>11%</td><td>3%</td><td>-3%</td><td>3%</td><td>9%",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "083bcffecbaa4a65",
        "value": 0.42,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>26%</td><td>19%</td><td>39%</td><td>40%</td><td>45%</td><td>31%</td><td>34%</td><td>62%</td><td>42%</td></tr><tr><td>MoM growth</td><td>11%</td><td>3%</td><td>-3%</td><td>3%</td><td>9%</td><td>-5%",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "1f617d587e165e84",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "40%</td><td>45%</td><td>31%</td><td>34%</td><td>62%</td><td>42%</td></tr><tr><td>MoM growth</td><td>11%</td><td>3%</td><td>-3%</td><td>3%</td><td>9%</td><td>-5%</td><td>15%</td><td>5%</td><td>-3%</td>",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "be36a204c3bdec3e",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "45%</td><td>31%</td><td>34%</td><td>62%</td><td>42%</td></tr><tr><td>MoM growth</td><td>11%</td><td>3%</td><td>-3%</td><td>3%</td><td>9%</td><td>-5%</td><td>15%</td><td>5%</td><td>-3%</td><td>0%</td><",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "e36906f2d3e35427",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";3,034</td><td>&#36;3,019</td><td>&#36;3,092</td><td>&#36;3,049</td></tr><tr><td>YoY growth</td><td>-7%</td><td>-8%</td><td>-1%</td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "174275e6823c1f76",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;3,019</td><td>&#36;3,092</td><td>&#36;3,049</td></tr><tr><td>YoY growth</td><td>-7%</td><td>-8%</td><td>-1%</td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</td><td>1%</t",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "be7853f8d2b6a6a1",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9</td><td>&#36;3,092</td><td>&#36;3,049</td></tr><tr><td>YoY growth</td><td>-7%</td><td>-8%</td><td>-1%</td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</td><td>1%</td><td>5%</td",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "db21062c50028428",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;3,092</td><td>&#36;3,049</td></tr><tr><td>YoY growth</td><td>-7%</td><td>-8%</td><td>-1%</td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</td><td>1%</td><td>5%</td><td>7%</td>",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "e73efb08e5b0ebf3",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;3,049</td></tr><tr><td>YoY growth</td><td>-7%</td><td>-8%</td><td>-1%</td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</td><td>1%</td><td>5%</td><td>7%</td></tr><tr><td",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "2a2b5549602e6542",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "049</td></tr><tr><td>YoY growth</td><td>-7%</td><td>-8%</td><td>-1%</td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</td><td>1%</td><td>5%</td><td>7%</td></tr><tr><td>MoM growth<",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "4217c9dbcafbce0f",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>-7%</td><td>-8%</td><td>-1%</td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</td><td>1%</td><td>5%</td><td>7%</td></tr><tr><td>MoM growth</td><td>3%</",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "7bfba736999508da",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>-7%</td><td>-8%</td><td>-1%</td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</td><td>1%</td><td>5%</td><td>7%</td></tr><tr><td>MoM growth</td><td>3%</td><td>1%</td",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "09933aea749f4c2d",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-7%</td><td>-8%</td><td>-1%</td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</td><td>1%</td><td>5%</td><td>7%</td></tr><tr><td>MoM growth</td><td>3%</td><td>1%</td><td>1%</td",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "a1b948816a473f54",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-8%</td><td>-1%</td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</td><td>1%</td><td>5%</td><td>7%</td></tr><tr><td>MoM growth</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</t",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "42733f65f4127591",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>-1%</td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</td><td>1%</td><td>5%</td><td>7%</td></tr><tr><td>MoM growth</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</t",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "a079ebf47f06891c",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-8%</td><td>-4%</td><td>-6%</td><td>-1%</td><td>-2%</td><td>1%</td><td>1%</td><td>5%</td><td>7%</td></tr><tr><td>MoM growth</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "ebeebdee4c771106",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-1%</td><td>-2%</td><td>1%</td><td>1%</td><td>5%</td><td>7%</td></tr><tr><td>MoM growth</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><t",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "148c2d1c9998b9fc",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-2%</td><td>1%</td><td>1%</td><td>5%</td><td>7%</td></tr><tr><td>MoM growth</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><td>-1%</td><",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "37398921579e0114",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>1%</td><td>1%</td><td>5%</td><td>7%</td></tr><tr><td>MoM growth</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><td>-1%</td><td>2%</td><",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "e02c020b3d72b2d7",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>1%</td><td>5%</td><td>7%</td></tr><tr><td>MoM growth</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><td>-1%</td><td>2%</td><td>-1%</td>",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "7680dd50b81f0bea",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>5%</td><td>7%</td></tr><tr><td>MoM growth</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><td>-1%</td><td>2%</td><td>-1%</td></tr><tr><td",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "19c806d7c9cb98ab",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>7%</td></tr><tr><td>MoM growth</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><td>-1%</td><td>2%</td><td>-1%</td></tr><tr><td>IMS Monthl",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "3a5b2c923d865e0e",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>MoM growth</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><td>-1%</td><td>2%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "3dc8745e8a47b327",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>MoM growth</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><td>-1%</td><td>2%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not normalized",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "1526fd7990cd635b",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "h</td><td>3%</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><td>-1%</td><td>2%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 wee",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "b12eb2ed88a034d9",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1%</td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><td>-1%</td><td>2%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "e5f994fc4ab587eb",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>1%</td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><td>-1%</td><td>2%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;243</td",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "8dd4d3a0fde19284",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-6%</td><td>7%</td><td>-3%</td><td>7%</td><td>0%</td><td>-3%</td><td>-1%</td><td>2%</td><td>-1%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;243</td><td>&#36;3",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "ba0f2a11a47fc310",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;253</td><td>&#36;252</td><td>&#36;322</td><td>&#36;254</td></tr><tr><td>MoM growth</td><td>3%</td><td>26%</td><td>-19%</td><td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "4a5ce1c2f4da24f7",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3</td><td>&#36;252</td><td>&#36;322</td><td>&#36;254</td></tr><tr><td>MoM growth</td><td>3%</td><td>26%</td><td>-19%</td><td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%</td><td>-1",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "01fc8c7c370d2379",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;252</td><td>&#36;322</td><td>&#36;254</td></tr><tr><td>MoM growth</td><td>3%</td><td>26%</td><td>-19%</td><td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%</td><td>-1%</td><td>28",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "b4acd748919bc103",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;322</td><td>&#36;254</td></tr><tr><td>MoM growth</td><td>3%</td><td>26%</td><td>-19%</td><td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%</td><td>-1%</td><td>28%</td><td>-21",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "ee7b23955ef1eac1",
        "value": 0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&#36;254</td></tr><tr><td>MoM growth</td><td>3%</td><td>26%</td><td>-19%</td><td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%</td><td>-1%</td><td>28%</td><td>-21%</td></tr><",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "03c70bdd8b3f1241",
        "value": -0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "254</td></tr><tr><td>MoM growth</td><td>3%</td><td>26%</td><td>-19%</td><td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%</td><td>-1%</td><td>28%</td><td>-21%</td></tr><tr><td>Kisqa",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "663b4c2c30bf1e4b",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>3%</td><td>26%</td><td>-19%</td><td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%</td><td>-1%</td><td>28%</td><td>-21%</td></tr><tr><td>Kisqali (Novartis)",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "a313444d1e1fd809",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>3%</td><td>26%</td><td>-19%</td><td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%</td><td>-1%</td><td>28%</td><td>-21%</td></tr><tr><td>Kisqali (Novartis)</td><td></t",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "2c47432718960d95",
        "value": -0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>3%</td><td>26%</td><td>-19%</td><td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%</td><td>-1%</td><td>28%</td><td>-21%</td></tr><tr><td>Kisqali (Novartis)</td><td></td><td></td>",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "bac3edf0327ba1b6",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>26%</td><td>-19%</td><td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%</td><td>-1%</td><td>28%</td><td>-21%</td></tr><tr><td>Kisqali (Novartis)</td><td></td><td></td><td></td><td>",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "16055a6a576bea50",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-19%</td><td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%</td><td>-1%</td><td>28%</td><td>-21%</td></tr><tr><td>Kisqali (Novartis)</td><td></td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "e64e2f264e8e9123",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-6%</td><td>34%</td><td>-22%</td><td>7%</td><td>25%</td><td>-22%</td><td>-1%</td><td>28%</td><td>-21%</td></tr><tr><td>Kisqali (Novartis)</td><td></td><td></td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "ba75fc3d4d770a38",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";2,955</td><td>&#36;3,055</td><td>&#36;3,251</td><td>&#36;3,308</td></tr><tr><td>YoY growth</td><td>70%</td><td>64%</td><td>65%</td><td>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%<",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "197292fa619a1e60",
        "value": 0.64,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;3,055</td><td>&#36;3,251</td><td>&#36;3,308</td></tr><tr><td>YoY growth</td><td>70%</td><td>64%</td><td>65%</td><td>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%</td><td>100%",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "e828b06cbebb1dbf",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5</td><td>&#36;3,251</td><td>&#36;3,308</td></tr><tr><td>YoY growth</td><td>70%</td><td>64%</td><td>65%</td><td>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%</td><td>100%</td><td>109",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "02c1a2460bdd05fa",
        "value": 0.73,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;3,251</td><td>&#36;3,308</td></tr><tr><td>YoY growth</td><td>70%</td><td>64%</td><td>65%</td><td>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%</td><td>100%</td><td>109%</td><td>11",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "d782dfd5b6c3a931",
        "value": 0.73,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;3,308</td></tr><tr><td>YoY growth</td><td>70%</td><td>64%</td><td>65%</td><td>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%</td><td>100%</td><td>109%</td><td>115%</td></tr>",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "087a8d3e58ec25c0",
        "value": 0.92,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "308</td></tr><tr><td>YoY growth</td><td>70%</td><td>64%</td><td>65%</td><td>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%</td><td>100%</td><td>109%</td><td>115%</td></tr><tr><td>MoM ",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "65e5c393f7d82bd0",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>70%</td><td>64%</td><td>65%</td><td>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%</td><td>100%</td><td>109%</td><td>115%</td></tr><tr><td>MoM growth</td><",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "c725d511210cc0f3",
        "value": 0.94,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>70%</td><td>64%</td><td>65%</td><td>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%</td><td>100%</td><td>109%</td><td>115%</td></tr><tr><td>MoM growth</td><td>9%</td><td",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "fc49b82be9ffbf5a",
        "value": 0.96,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>70%</td><td>64%</td><td>65%</td><td>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%</td><td>100%</td><td>109%</td><td>115%</td></tr><tr><td>MoM growth</td><td>9%</td><td>3%</td><td",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "a8a759bbdc8db6b2",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>64%</td><td>65%</td><td>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%</td><td>100%</td><td>109%</td><td>115%</td></tr><tr><td>MoM growth</td><td>9%</td><td>3%</td><td>3%</td><td>",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "0616840de7ba21e2",
        "value": 1.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>65%</td><td>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%</td><td>100%</td><td>109%</td><td>115%</td></tr><tr><td>MoM growth</td><td>9%</td><td>3%</td><td>3%</td><td>7%</td><td>12",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "99eb49d3eea41f09",
        "value": 1.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>73%</td><td>73%</td><td>92%</td><td>90%</td><td>94%</td><td>96%</td><td>100%</td><td>109%</td><td>115%</td></tr><tr><td>MoM growth</td><td>9%</td><td>3%</td><td>3%</td><td>7%</td><td>12%</td><td>13%",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "685e0f6396ab1467",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>94%</td><td>96%</td><td>100%</td><td>109%</td><td>115%</td></tr><tr><td>MoM growth</td><td>9%</td><td>3%</td><td>3%</td><td>7%</td><td>12%</td><td>13%</td><td>8%</td><td>8%</td><td>5%</td><td",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "e3ebff9635e14c76",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>96%</td><td>100%</td><td>109%</td><td>115%</td></tr><tr><td>MoM growth</td><td>9%</td><td>3%</td><td>3%</td><td>7%</td><td>12%</td><td>13%</td><td>8%</td><td>8%</td><td>5%</td><td>3%</td><td",
        "provenance": {
          "page": 23
        }
      },
      {
        "num_id": "aefefecced96aa5f",
        "value": 1.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">&#36;1</td><td>&#36;1</td><td>&#36;1</td><td>#0</td><td>&#36;0</td></tr><tr><td>YoY growth</td><td>108%</td><td>57%</td><td>-11%</td><td>-6%</td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><t",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "56b3726c9b4ee308",
        "value": 0.57,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;1</td><td>&#36;1</td><td>#0</td><td>&#36;0</td></tr><tr><td>YoY growth</td><td>108%</td><td>57%</td><td>-11%</td><td>-6%</td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><td>-99%</td><t",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "b7b2eac16e3e09de",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>&#36;1</td><td>#0</td><td>&#36;0</td></tr><tr><td>YoY growth</td><td>108%</td><td>57%</td><td>-11%</td><td>-6%</td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><td>-99%</td><td>-99%</td><",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "18e8d0ae819f9961",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>#0</td><td>&#36;0</td></tr><tr><td>YoY growth</td><td>108%</td><td>57%</td><td>-11%</td><td>-6%</td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><td>-99%</td><td>-99%</td><td>-100%</td>",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "adf45d47be3e97f9",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&#36;0</td></tr><tr><td>YoY growth</td><td>108%</td><td>57%</td><td>-11%</td><td>-6%</td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><td>-99%</td><td>-99%</td><td>-100%</td><td>-99%</td",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "3c8df5f08d7bf807",
        "value": -0.97,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>YoY growth</td><td>108%</td><td>57%</td><td>-11%</td><td>-6%</td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><td>-99%</td><td>-99%</td><td>-100%</td><td>-99%</td></tr><tr><td",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "f7c274a477e01cd6",
        "value": -0.99,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>YoY growth</td><td>108%</td><td>57%</td><td>-11%</td><td>-6%</td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><td>-99%</td><td>-99%</td><td>-100%</td><td>-99%</td></tr><tr><td>MoM growth</",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "a8d82c4b75cff531",
        "value": -0.98,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "th</td><td>108%</td><td>57%</td><td>-11%</td><td>-6%</td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><td>-99%</td><td>-99%</td><td>-100%</td><td>-99%</td></tr><tr><td>MoM growth</td><td>-5%</t",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "6e13cc42a29b5d12",
        "value": -0.99,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8%</td><td>57%</td><td>-11%</td><td>-6%</td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><td>-99%</td><td>-99%</td><td>-100%</td><td>-99%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>15%</td",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "e8f9b836015d496e",
        "value": -0.99,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>-11%</td><td>-6%</td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><td>-99%</td><td>-99%</td><td>-100%</td><td>-99%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>15%</td><td>-11%</td",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "4a65277c6625c422",
        "value": -1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>-6%</td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><td>-99%</td><td>-99%</td><td>-100%</td><td>-99%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>15%</td><td>-11%</td><td>9%</td><",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "a7efbf20a4f122ae",
        "value": -0.99,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-10%</td><td>-97%</td><td>-99%</td><td>-98%</td><td>-99%</td><td>-99%</td><td>-100%</td><td>-99%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>15%</td><td>-11%</td><td>9%</td><td>0%</td><td>",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "e02dc87baf6f400d",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>-98%</td><td>-99%</td><td>-99%</td><td>-100%</td><td>-99%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>15%</td><td>-11%</td><td>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "6c55c733d3cfdf8d",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-99%</td><td>-99%</td><td>-100%</td><td>-99%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>15%</td><td>-11%</td><td>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49%</td><td>44",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "557ea552827cd654",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-99%</td><td>-100%</td><td>-99%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>15%</td><td>-11%</td><td>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49%</td><td>44%</td><td>-9",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "35214a52af9c814e",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-100%</td><td>-99%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>15%</td><td>-11%</td><td>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49%</td><td>44%</td><td>-97%</td><td>17",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "c6714467d1c4de86",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>-99%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>15%</td><td>-11%</td><td>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49%</td><td>44%</td><td>-97%</td><td>1704%</td></t",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "e2f5f9c556b993c8",
        "value": -0.96,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-99%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>15%</td><td>-11%</td><td>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49%</td><td>44%</td><td>-97%</td><td>1704%</td></tr><tr><td>I",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "b06680cb9afdfc51",
        "value": -0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>MoM growth</td><td>-5%</td><td>15%</td><td>-11%</td><td>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49%</td><td>44%</td><td>-97%</td><td>1704%</td></tr><tr><td>IMS Monthly sa",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "2d9eaabb872b7866",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>-5%</td><td>15%</td><td>-11%</td><td>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49%</td><td>44%</td><td>-97%</td><td>1704%</td></tr><tr><td>IMS Monthly sales (not norm",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "ede1f4ee7298fa58",
        "value": -0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-5%</td><td>15%</td><td>-11%</td><td>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49%</td><td>44%</td><td>-97%</td><td>1704%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "1170de07c77ee39a",
        "value": 0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>15%</td><td>-11%</td><td>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49%</td><td>44%</td><td>-97%</td><td>1704%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td>",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "2d32db9c17616829",
        "value": -0.97,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-11%</td><td>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49%</td><td>44%</td><td>-97%</td><td>1704%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;3</",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "c68ffdf1c676bb71",
        "value": 17.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>9%</td><td>0%</td><td>-96%</td><td>-39%</td><td>17%</td><td>-49%</td><td>44%</td><td>-97%</td><td>1704%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;3</td><td>&#36;5",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "97480fa455fadf7c",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">&#36;0</td><td>&#36;0</td><td>#0</td><td>&#36;0</td><td>&#36;0</td></tr><tr><td>MoM growth</td><td>-5%</td><td>43%</td><td>-28%</td><td>9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-5",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "3341cd99966b4c8e",
        "value": 0.43,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;0</td><td>#0</td><td>&#36;0</td><td>&#36;0</td></tr><tr><td>MoM growth</td><td>-5%</td><td>43%</td><td>-28%</td><td>9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-59%</td><td>4",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "ea96eacd69381578",
        "value": -0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>#0</td><td>&#36;0</td><td>&#36;0</td></tr><tr><td>MoM growth</td><td>-5%</td><td>43%</td><td>-28%</td><td>9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-59%</td><td>44%</td><td>-",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "02d00b1d6c46f764",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;0</td><td>&#36;0</td></tr><tr><td>MoM growth</td><td>-5%</td><td>43%</td><td>-28%</td><td>9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-59%</td><td>44%</td><td>-96%</td><td>1",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "44baaa9b36f283fb",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>&#36;0</td></tr><tr><td>MoM growth</td><td>-5%</td><td>43%</td><td>-28%</td><td>9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-59%</td><td>44%</td><td>-96%</td><td>1343%</td></",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "0960ed06384de292",
        "value": -0.97,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;0</td></tr><tr><td>MoM growth</td><td>-5%</td><td>43%</td><td>-28%</td><td>9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-59%</td><td>44%</td><td>-96%</td><td>1343%</td></tr><tr><td>E",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "010e00d8a3b725cf",
        "value": -0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>-5%</td><td>43%</td><td>-28%</td><td>9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-59%</td><td>44%</td><td>-96%</td><td>1343%</td></tr><tr><td>Epk初ly (GMAB/A",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "382dc5b9c01c7f87",
        "value": 0.46,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rowth</td><td>-5%</td><td>43%</td><td>-28%</td><td>9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-59%</td><td>44%</td><td>-96%</td><td>1343%</td></tr><tr><td>Epk初ly (GMAB/ABBV)</td><td>",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "1674a21123dc9d60",
        "value": -0.59,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-5%</td><td>43%</td><td>-28%</td><td>9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-59%</td><td>44%</td><td>-96%</td><td>1343%</td></tr><tr><td>Epk初ly (GMAB/ABBV)</td><td></td><td></t",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "d3957133b291b4ef",
        "value": 0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">43%</td><td>-28%</td><td>9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-59%</td><td>44%</td><td>-96%</td><td>1343%</td></tr><tr><td>Epk初ly (GMAB/ABBV)</td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "06f46a5a0e08e687",
        "value": -0.96,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">-28%</td><td>9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-59%</td><td>44%</td><td>-96%</td><td>1343%</td></tr><tr><td>Epk初ly (GMAB/ABBV)</td><td></td><td></td><td></td><td></td><td><",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "59a657519cb8c178",
        "value": 13.43,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">9%</td><td>25%</td><td>-97%</td><td>-39%</td><td>46%</td><td>-59%</td><td>44%</td><td>-96%</td><td>1343%</td></tr><tr><td>Epk初ly (GMAB/ABBV)</td><td></td><td></td><td></td><td></td><td></td><td></td>",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "1f87bdf556dd4172",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;1</td><td>&#36;1</td><td>&#36;1</td></tr><tr><td>YoY growth</td><td></td><td></td><td></td><td>-20%</td><td>6%</td><td>25%</td><td>200%</td><td>449%</td><td>163%</td><td>67%</td><td>-33%</td><td>",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "2117b1eba20c7365",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;1</td><td>&#36;1</td></tr><tr><td>YoY growth</td><td></td><td></td><td></td><td>-20%</td><td>6%</td><td>25%</td><td>200%</td><td>449%</td><td>163%</td><td>67%</td><td>-33%</td><td>-4%</td></tr>",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "40c1553e933288d0",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>&#36;1</td></tr><tr><td>YoY growth</td><td></td><td></td><td></td><td>-20%</td><td>6%</td><td>25%</td><td>200%</td><td>449%</td><td>163%</td><td>67%</td><td>-33%</td><td>-4%</td></tr><tr><td>MoM",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "59c59af61d2767d7",
        "value": 2.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>YoY growth</td><td></td><td></td><td></td><td>-20%</td><td>6%</td><td>25%</td><td>200%</td><td>449%</td><td>163%</td><td>67%</td><td>-33%</td><td>-4%</td></tr><tr><td>MoM growth</td>",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "525a7d298c61b36b",
        "value": 4.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>YoY growth</td><td></td><td></td><td></td><td>-20%</td><td>6%</td><td>25%</td><td>200%</td><td>449%</td><td>163%</td><td>67%</td><td>-33%</td><td>-4%</td></tr><tr><td>MoM growth</td><td>50%</td><",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "22a5df48f8a2a0e6",
        "value": 1.63,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "th</td><td></td><td></td><td></td><td>-20%</td><td>6%</td><td>25%</td><td>200%</td><td>449%</td><td>163%</td><td>67%</td><td>-33%</td><td>-4%</td></tr><tr><td>MoM growth</td><td>50%</td><td>-100%</td>",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "426373286e564533",
        "value": 0.67,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td>-20%</td><td>6%</td><td>25%</td><td>200%</td><td>449%</td><td>163%</td><td>67%</td><td>-33%</td><td>-4%</td></tr><tr><td>MoM growth</td><td>50%</td><td>-100%</td><td>#DIV/0!</",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "15e74c0d858a766e",
        "value": -0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td></td><td>-20%</td><td>6%</td><td>25%</td><td>200%</td><td>449%</td><td>163%</td><td>67%</td><td>-33%</td><td>-4%</td></tr><tr><td>MoM growth</td><td>50%</td><td>-100%</td><td>#DIV/0!</td><td>#DIV/",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "2a4d09a2ac452a61",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-20%</td><td>6%</td><td>25%</td><td>200%</td><td>449%</td><td>163%</td><td>67%</td><td>-33%</td><td>-4%</td></tr><tr><td>MoM growth</td><td>50%</td><td>-100%</td><td>#DIV/0!</td><td>#DIV/0!</td><td>37",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "a750877dc4b2aab5",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>449%</td><td>163%</td><td>67%</td><td>-33%</td><td>-4%</td></tr><tr><td>MoM growth</td><td>50%</td><td>-100%</td><td>#DIV/0!</td><td>#DIV/0!</td><td>3728%</td><td>97%</td><td>20%</td><td>46%<",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "d4984931cca7c5c8",
        "value": -1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>163%</td><td>67%</td><td>-33%</td><td>-4%</td></tr><tr><td>MoM growth</td><td>50%</td><td>-100%</td><td>#DIV/0!</td><td>#DIV/0!</td><td>3728%</td><td>97%</td><td>20%</td><td>46%</td><td>-40%",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "4a2c0910f9094c8f",
        "value": 37.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-4%</td></tr><tr><td>MoM growth</td><td>50%</td><td>-100%</td><td>#DIV/0!</td><td>#DIV/0!</td><td>3728%</td><td>97%</td><td>20%</td><td>46%</td><td>-40%</td><td>-5%</td><td>-4%</td><td>-17%</td></tr",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "23cb3ea0e463fecf",
        "value": 0.97,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>MoM growth</td><td>50%</td><td>-100%</td><td>#DIV/0!</td><td>#DIV/0!</td><td>3728%</td><td>97%</td><td>20%</td><td>46%</td><td>-40%</td><td>-5%</td><td>-4%</td><td>-17%</td></tr><tr><td>IMS M",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "d14c2366378244ec",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>50%</td><td>-100%</td><td>#DIV/0!</td><td>#DIV/0!</td><td>3728%</td><td>97%</td><td>20%</td><td>46%</td><td>-40%</td><td>-5%</td><td>-4%</td><td>-17%</td></tr><tr><td>IMS Monthly sales ",
        "provenance": {
          "page": 27
        }
      },
      {
        "num_id": "77c2b65331faf0a1",
        "value": 247.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>#0</td><td>&#36;0</td><td>&#36;0</td><td>&#36;0</td></tr><tr><td>% diff.</td><td>NM</td><td>24717%</td><td>9465%</td><td>6277%</td><td>9685%</td><td>35329%</td><td>5992%</td><td>8528%</td></tr",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "c1d6e2a78a81582e",
        "value": 94.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;0</td><td>&#36;0</td><td>&#36;0</td></tr><tr><td>% diff.</td><td>NM</td><td>24717%</td><td>9465%</td><td>6277%</td><td>9685%</td><td>35329%</td><td>5992%</td><td>8528%</td></tr></table> Sourc",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "92a1fb2159fb3b49",
        "value": 62.77,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;0</td><td>&#36;0</td></tr><tr><td>% diff.</td><td>NM</td><td>24717%</td><td>9465%</td><td>6277%</td><td>9685%</td><td>35329%</td><td>5992%</td><td>8528%</td></tr></table> Source: Company dat",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "6a3dedd2b361c445",
        "value": 96.85,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>&#36;0</td></tr><tr><td>% diff.</td><td>NM</td><td>24717%</td><td>9465%</td><td>6277%</td><td>9685%</td><td>35329%</td><td>5992%</td><td>8528%</td></tr></table> Source: Company data, IQVIA, Morg",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "cef39d3600c265f2",
        "value": 353.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>% diff.</td><td>NM</td><td>24717%</td><td>9465%</td><td>6277%</td><td>9685%</td><td>35329%</td><td>5992%</td><td>8528%</td></tr></table> Source: Company data, IQVIA, Morgan Stanley Res",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "9d3b860e344d693c",
        "value": 59.92,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">% diff.</td><td>NM</td><td>24717%</td><td>9465%</td><td>6277%</td><td>9685%</td><td>35329%</td><td>5992%</td><td>8528%</td></tr></table> Source: Company data, IQVIA, Morgan Stanley Research # CD 19 &",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "c0ab6462f580dbdc",
        "value": 85.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>NM</td><td>24717%</td><td>9465%</td><td>6277%</td><td>9685%</td><td>35329%</td><td>5992%</td><td>8528%</td></tr></table> Source: Company data, IQVIA, Morgan Stanley Research # CD 19 & 79 Exhibit 50",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "864e71917cc30b63",
        "value": 0.63,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;981</td><td>&#36;1,037</td><td>&#36;1,007</td><td>&#36;939</td></tr><tr><td>YoY growth</td><td>63%</td><td>88%</td><td>74%</td><td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%<",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "c1622a26310cd923",
        "value": 0.88,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;1,037</td><td>&#36;1,007</td><td>&#36;939</td></tr><tr><td>YoY growth</td><td>63%</td><td>88%</td><td>74%</td><td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%</td><td>64%<",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "c8b2bcf5e653278a",
        "value": 0.74,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "037</td><td>&#36;1,007</td><td>&#36;939</td></tr><tr><td>YoY growth</td><td>63%</td><td>88%</td><td>74%</td><td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%</td><td>64%</td><td>79%<",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "846bd084b451604f",
        "value": 0.61,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;1,007</td><td>&#36;939</td></tr><tr><td>YoY growth</td><td>63%</td><td>88%</td><td>74%</td><td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%</td><td>64%</td><td>79%</td><td>48%<",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "fa3b1f333f4fd346",
        "value": 0.71,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&#36;939</td></tr><tr><td>YoY growth</td><td>63%</td><td>88%</td><td>74%</td><td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%</td><td>64%</td><td>79%</td><td>48%</td></tr><tr",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "0a082ed686adaa11",
        "value": 0.76,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "939</td></tr><tr><td>YoY growth</td><td>63%</td><td>88%</td><td>74%</td><td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%</td><td>64%</td><td>79%</td><td>48%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "60f45350700537ca",
        "value": 0.87,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>63%</td><td>88%</td><td>74%</td><td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%</td><td>64%</td><td>79%</td><td>48%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "6e66482d65c83999",
        "value": 0.85,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>63%</td><td>88%</td><td>74%</td><td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%</td><td>64%</td><td>79%</td><td>48%</td></tr><tr><td>MoM growth</td><td>38%</td><td>1",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "5287c13fe70202b8",
        "value": 0.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>63%</td><td>88%</td><td>74%</td><td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%</td><td>64%</td><td>79%</td><td>48%</td></tr><tr><td>MoM growth</td><td>38%</td><td>18%</td><td>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "a4aa856d20456acb",
        "value": 0.64,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>88%</td><td>74%</td><td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%</td><td>64%</td><td>79%</td><td>48%</td></tr><tr><td>MoM growth</td><td>38%</td><td>18%</td><td>-7%</td><td>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "4e11659bf868ea06",
        "value": 0.79,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>74%</td><td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%</td><td>64%</td><td>79%</td><td>48%</td></tr><tr><td>MoM growth</td><td>38%</td><td>18%</td><td>-7%</td><td>2%</td><td>1",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "1e569fd26d0bd52c",
        "value": 0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>61%</td><td>71%</td><td>76%</td><td>87%</td><td>85%</td><td>54%</td><td>64%</td><td>79%</td><td>48%</td></tr><tr><td>MoM growth</td><td>38%</td><td>18%</td><td>-7%</td><td>2%</td><td>1%</td><td>12",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "8fad3ff47d3c6481",
        "value": 0.38,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "87%</td><td>85%</td><td>54%</td><td>64%</td><td>79%</td><td>48%</td></tr><tr><td>MoM growth</td><td>38%</td><td>18%</td><td>-7%</td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</t",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "ae26320d6477626f",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "85%</td><td>54%</td><td>64%</td><td>79%</td><td>48%</td></tr><tr><td>MoM growth</td><td>38%</td><td>18%</td><td>-7%</td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</td><td>6%</td",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "8bd8648c45a819fb",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "54%</td><td>64%</td><td>79%</td><td>48%</td></tr><tr><td>MoM growth</td><td>38%</td><td>18%</td><td>-7%</td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</td><td>6%</td><td>-3%</td",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "8964bc05a947fbfe",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "64%</td><td>79%</td><td>48%</td></tr><tr><td>MoM growth</td><td>38%</td><td>18%</td><td>-7%</td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</td><td>6%</td><td>-3%</td><td>-7%</td",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "0a9b8b863d1b1a87",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">79%</td><td>48%</td></tr><tr><td>MoM growth</td><td>38%</td><td>18%</td><td>-7%</td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</td><td>6%</td><td>-3%</td><td>-7%</td></tr><tr><",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "017769390dbc7873",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>48%</td></tr><tr><td>MoM growth</td><td>38%</td><td>18%</td><td>-7%</td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</td><td>6%</td><td>-3%</td><td>-7%</td></tr><tr><td>IMS Mont",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "a4cb995dfd451657",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>MoM growth</td><td>38%</td><td>18%</td><td>-7%</td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</td><td>6%</td><td>-3%</td><td>-7%</td></tr><tr><td>IMS Monthly sales (n",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "9e48082df871d6bf",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "oM growth</td><td>38%</td><td>18%</td><td>-7%</td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</td><td>6%</td><td>-3%</td><td>-7%</td></tr><tr><td>IMS Monthly sales (not normalize",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "76e2ea5f65ed5686",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>38%</td><td>18%</td><td>-7%</td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</td><td>6%</td><td>-3%</td><td>-7%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 we",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "8facbd46d0b893aa",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>18%</td><td>-7%</td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</td><td>6%</td><td>-3%</td><td>-7%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "6b8318504ca35b82",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-7%</td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</td><td>6%</td><td>-3%</td><td>-7%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;33</td",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "59a3d473a557b91d",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>2%</td><td>1%</td><td>12%</td><td>-7%</td><td>8%</td><td>-11%</td><td>6%</td><td>-3%</td><td>-7%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;33</td><td>&#36;33",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "2fac0d9073fdaa63",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;33</td><td>&#36;33</td><td>&#36;33</td><td>&#36;33</td></tr><tr><td>MoM growth</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0 %</td><td>0%</td><td>0%</td><td>0%</td><td>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "7bcc3351bc30687c",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;33</td><td>&#36;33</td><td>&#36;33</td><td>&#36;33</td></tr><tr><td>MoM growth</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0 %</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "983d5d13f3541d4d",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;33</td><td>&#36;33</td><td>&#36;33</td></tr><tr><td>MoM growth</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0 %</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "a2404f2a5fe1fbf4",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&#36;33</td><td>&#36;33</td></tr><tr><td>MoM growth</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0 %</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td></tr>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "66f011b5082689c3",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";33</td><td>&#36;33</td></tr><tr><td>MoM growth</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0 %</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td></tr><tr><td>Mon",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "f406a93d3df85e2f",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">&#36;33</td></tr><tr><td>MoM growth</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0 %</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td></tr><tr><td>Monjuvl (Incyt",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "f932a74412967ce5",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>MoM growth</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0 %</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td></tr><tr><td>Monjuvl (Incyte/Morphosys)",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "bcbd37f2a6f72565",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>MoM growth</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0 %</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td></tr><tr><td>Monjuvl (Incyte/Morphosys)</td><td></",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "36a609528332382d",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "th</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0 %</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td></tr><tr><td>Monjuvl (Incyte/Morphosys)</td><td></td><td></td",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "d0a4799e47de9576",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0 %</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td></tr><tr><td>Monjuvl (Incyte/Morphosys)</td><td></td><td></td><td></td><",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "bfac195e8fa5ac9a",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">0%</td><td>0%</td><td>0%</td><td>0 %</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0</td><td>0%</td></tr><tr><td>Monjuvl (Incyte/Morphosys)</td><td></td><td></td><td></td><td></td><td></td><td>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "eb2462068957d354",
        "value": -0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;76</td><td>&#36;77</td><td>&#36;84</td><td>&#36;84</td></tr><tr><td>YoY growth</td><td>-13%</td><td>-13%</td><td>-1%</td><td>-6%</td><td>-1%</td><td>-11%</td><td>-4%</td><td>-16%</td><td>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "bf336e87114d4071",
        "value": -0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "76</td><td>&#36;77</td><td>&#36;84</td><td>&#36;84</td></tr><tr><td>YoY growth</td><td>-13%</td><td>-13%</td><td>-1%</td><td>-6%</td><td>-1%</td><td>-11%</td><td>-4%</td><td>-16%</td><td>-1%</td><td>3",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "3f020de4c7325dd0",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;77</td><td>&#36;84</td><td>&#36;84</td></tr><tr><td>YoY growth</td><td>-13%</td><td>-13%</td><td>-1%</td><td>-6%</td><td>-1%</td><td>-11%</td><td>-4%</td><td>-16%</td><td>-1%</td><td>30%</td><td>-3",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "0902ce8dd7129544",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;84</td><td>&#36;84</td></tr><tr><td>YoY growth</td><td>-13%</td><td>-13%</td><td>-1%</td><td>-6%</td><td>-1%</td><td>-11%</td><td>-4%</td><td>-16%</td><td>-1%</td><td>30%</td><td>-3%</td><td>7%",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "3e2b57828c2bf6e4",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>&#36;84</td></tr><tr><td>YoY growth</td><td>-13%</td><td>-13%</td><td>-1%</td><td>-6%</td><td>-1%</td><td>-11%</td><td>-4%</td><td>-16%</td><td>-1%</td><td>30%</td><td>-3%</td><td>7%</td></tr><t",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "441c9cf36d2f3c99",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4</td></tr><tr><td>YoY growth</td><td>-13%</td><td>-13%</td><td>-1%</td><td>-6%</td><td>-1%</td><td>-11%</td><td>-4%</td><td>-16%</td><td>-1%</td><td>30%</td><td>-3%</td><td>7%</td></tr><tr><td>MoM gr",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "bc098e3e385b507b",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>YoY growth</td><td>-13%</td><td>-13%</td><td>-1%</td><td>-6%</td><td>-1%</td><td>-11%</td><td>-4%</td><td>-16%</td><td>-1%</td><td>30%</td><td>-3%</td><td>7%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "3f890aff9f75e470",
        "value": -0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "owth</td><td>-13%</td><td>-13%</td><td>-1%</td><td>-6%</td><td>-1%</td><td>-11%</td><td>-4%</td><td>-16%</td><td>-1%</td><td>30%</td><td>-3%</td><td>7%</td></tr><tr><td>MoM growth</td><td>-3%</td><td>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "c5abfb52dadccdae",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";7,572</td><td>&#36;7,633</td><td>&#36;7,974</td><td>&#36;7,738</td></tr><tr><td>YoY growth</td><td>25%</td><td>20%</td><td>26%</td><td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "6dff8346baa46e19",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;7,633</td><td>&#36;7,974</td><td>&#36;7,738</td></tr><tr><td>YoY growth</td><td>25%</td><td>20%</td><td>26%</td><td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%</td><td>21%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "bc90d7f59b5588e7",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3</td><td>&#36;7,974</td><td>&#36;7,738</td></tr><tr><td>YoY growth</td><td>25%</td><td>20%</td><td>26%</td><td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%</td><td>21%</td><td>29%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "299921d9afbd8cdf",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;7,974</td><td>&#36;7,738</td></tr><tr><td>YoY growth</td><td>25%</td><td>20%</td><td>26%</td><td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%</td><td>21%</td><td>29%</td><td>26%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "96d69eeb5a1c9822",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;7,738</td></tr><tr><td>YoY growth</td><td>25%</td><td>20%</td><td>26%</td><td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%</td><td>21%</td><td>29%</td><td>26%</td></tr><tr",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "b1b7ab56ea67d593",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "738</td></tr><tr><td>YoY growth</td><td>25%</td><td>20%</td><td>26%</td><td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%</td><td>21%</td><td>29%</td><td>26%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "214e3989852d536c",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>25%</td><td>20%</td><td>26%</td><td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%</td><td>21%</td><td>29%</td><td>26%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "1a3d7e0e5356e5be",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>25%</td><td>20%</td><td>26%</td><td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%</td><td>21%</td><td>29%</td><td>26%</td></tr><tr><td>MoM growth</td><td>6%</td><td>0%",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "fe54830397ba40bd",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>25%</td><td>20%</td><td>26%</td><td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%</td><td>21%</td><td>29%</td><td>26%</td></tr><tr><td>MoM growth</td><td>6%</td><td>0%</td><td>0%",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "ad9f35adedb1f9de",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>20%</td><td>26%</td><td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%</td><td>21%</td><td>29%</td><td>26%</td></tr><tr><td>MoM growth</td><td>6%</td><td>0%</td><td>0%</td><td>4%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "7d0662f813d0df1b",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>26%</td><td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%</td><td>21%</td><td>29%</td><td>26%</td></tr><tr><td>MoM growth</td><td>6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "80299a06d9756585",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>25%</td><td>20%</td><td>33%</td><td>29%</td><td>23%</td><td>25%</td><td>21%</td><td>29%</td><td>26%</td></tr><tr><td>MoM growth</td><td>6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "a5617cf8fb0d2a8f",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "29%</td><td>23%</td><td>25%</td><td>21%</td><td>29%</td><td>26%</td></tr><tr><td>MoM growth</td><td>6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "6b5242790e1d8190",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">23%</td><td>25%</td><td>21%</td><td>29%</td><td>26%</td></tr><tr><td>MoM growth</td><td>6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>1%</td><td>",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "5a20c2504a03a963",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>25%</td><td>21%</td><td>29%</td><td>26%</td></tr><tr><td>MoM growth</td><td>6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>1%</td><td>4%</td><td>",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "36b4712b090727a1",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>21%</td><td>29%</td><td>26%</td></tr><tr><td>MoM growth</td><td>6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>1%</td><td>4%</td><td>-3%</td></t",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "80422a140a5af9e4",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>29%</td><td>26%</td></tr><tr><td>MoM growth</td><td>6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>1%</td><td>4%</td><td>-3%</td></tr><tr><td>I",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "8688c7140a0d7eae",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>26%</td></tr><tr><td>MoM growth</td><td>6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>1%</td><td>4%</td><td>-3%</td></tr><tr><td>IMS Monthly ",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "d542c8620644f643",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>MoM growth</td><td>6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>1%</td><td>4%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not n",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "cf64fb9aad02a2d1",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>MoM growth</td><td>6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>1%</td><td>4%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; ",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "86b017e9de8ff514",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "th</td><td>6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>1%</td><td>4%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "24b34db8e1bd7a87",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6%</td><td>0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>1%</td><td>4%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "3720c6b3f5ae6894",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>1%</td><td>4%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;544</td",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "897336d97b0fd460",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>4%</td><td>4%</td><td>-3%</td><td>5%</td><td>6%</td><td>1%</td><td>1%</td><td>4%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;544</td><td>&#36;7",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "5afc2c09f4f54f1c",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;631</td><td>&#36;636</td><td>&#36;831</td><td>&#36;645</td></tr><tr><td>MoM growth</td><td>6%</td><td>30%</td><td>-23%</td><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "9d0b9ebf605f923c",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1</td><td>&#36;636</td><td>&#36;831</td><td>&#36;645</td></tr><tr><td>MoM growth</td><td>6%</td><td>30%</td><td>-23%</td><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%</td><td>1%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "ca5ba47645f0cd65",
        "value": -0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;636</td><td>&#36;831</td><td>&#36;645</td></tr><tr><td>MoM growth</td><td>6%</td><td>30%</td><td>-23%</td><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%</td><td>1%</td><td>31%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "fbdbbd35576aa86c",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;831</td><td>&#36;645</td></tr><tr><td>MoM growth</td><td>6%</td><td>30%</td><td>-23%</td><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%</td><td>1%</td><td>31%</td><td>-22%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "f35f0d02b16c4ef6",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;645</td></tr><tr><td>MoM growth</td><td>6%</td><td>30%</td><td>-23%</td><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%</td><td>1%</td><td>31%</td><td>-22%</td></tr><t",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "064a4227696697b7",
        "value": -0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";645</td></tr><tr><td>MoM growth</td><td>6%</td><td>30%</td><td>-23%</td><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%</td><td>1%</td><td>31%</td><td>-22%</td></tr><tr><td>Sarcle",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "ab90188b23122fad",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>MoM growth</td><td>6%</td><td>30%</td><td>-23%</td><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%</td><td>1%</td><td>31%</td><td>-22%</td></tr><tr><td>Sarclesia (Sanofi)<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "2370dea728a2f98e",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "M growth</td><td>6%</td><td>30%</td><td>-23%</td><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%</td><td>1%</td><td>31%</td><td>-22%</td></tr><tr><td>Sarclesia (Sanofi)</td><td></t",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "34ede9f9be9a600f",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>6%</td><td>30%</td><td>-23%</td><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%</td><td>1%</td><td>31%</td><td>-22%</td></tr><tr><td>Sarclesia (Sanofi)</td><td></td><td></td><",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "0f0777719fc3f2a6",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>30%</td><td>-23%</td><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%</td><td>1%</td><td>31%</td><td>-22%</td></tr><tr><td>Sarclesia (Sanofi)</td><td></td><td></td><td></td><td><",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "12f0387a70f744f0",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-23%</td><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%</td><td>1%</td><td>31%</td><td>-22%</td></tr><tr><td>Sarclesia (Sanofi)</td><td></td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "fa44ae3fbbef2e1d",
        "value": -0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>4%</td><td>29%</td><td>-23%</td><td>5%</td><td>32%</td><td>-19%</td><td>1%</td><td>31%</td><td>-22%</td></tr><tr><td>Sarclesia (Sanofi)</td><td></td><td></td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "fcdc112d12e2f39b",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;182</td><td>&#36;186</td><td>&#36;201</td><td>&#36;201</td></tr><tr><td>YoY growth</td><td>30%</td><td>23%</td><td>31%</td><td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "7ae948badec1ea29",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>&#36;186</td><td>&#36;201</td><td>&#36;201</td></tr><tr><td>YoY growth</td><td>30%</td><td>23%</td><td>31%</td><td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%</td><td>28%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "d5066172d97cdb9d",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;186</td><td>&#36;201</td><td>&#36;201</td></tr><tr><td>YoY growth</td><td>30%</td><td>23%</td><td>31%</td><td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%</td><td>28%</td><td>38%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "8338193bdd026779",
        "value": 0.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;201</td><td>&#36;201</td></tr><tr><td>YoY growth</td><td>30%</td><td>23%</td><td>31%</td><td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%</td><td>28%</td><td>38%</td><td>37%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "62c429041fdafb09",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&#36;201</td></tr><tr><td>YoY growth</td><td>30%</td><td>23%</td><td>31%</td><td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%</td><td>28%</td><td>38%</td><td>37%</td></tr><tr",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "be195c3867079790",
        "value": 0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "201</td></tr><tr><td>YoY growth</td><td>30%</td><td>23%</td><td>31%</td><td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%</td><td>28%</td><td>38%</td><td>37%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "992f54a71c97cf72",
        "value": 0.38,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>30%</td><td>23%</td><td>31%</td><td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%</td><td>28%</td><td>38%</td><td>37%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "605067005d5e25b7",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>30%</td><td>23%</td><td>31%</td><td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%</td><td>28%</td><td>38%</td><td>37%</td></tr><tr><td>MoM growth</td><td>4%</td><td>8%",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "02c69781daab7400",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>30%</td><td>23%</td><td>31%</td><td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%</td><td>28%</td><td>38%</td><td>37%</td></tr><tr><td>MoM growth</td><td>4%</td><td>8%</td><td>-6",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "1513a2b60599703d",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>23%</td><td>31%</td><td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%</td><td>28%</td><td>38%</td><td>37%</td></tr><tr><td>MoM growth</td><td>4%</td><td>8%</td><td>-6%</td><td>6%",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "0ca22c77f97b39f9",
        "value": 0.38,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>31%</td><td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%</td><td>28%</td><td>38%</td><td>37%</td></tr><tr><td>MoM growth</td><td>4%</td><td>8%</td><td>-6%</td><td>6%</td><td>6%<",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "9365c1be7e1e535b",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>36%</td><td>23%</td><td>49%</td><td>38%</td><td>29%</td><td>29%</td><td>28%</td><td>38%</td><td>37%</td></tr><tr><td>MoM growth</td><td>4%</td><td>8%</td><td>-6%</td><td>6%</td><td>6%</td><td>3%</",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "b135f474e13c41fa",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "38%</td><td>29%</td><td>29%</td><td>28%</td><td>38%</td><td>37%</td></tr><tr><td>MoM growth</td><td>4%</td><td>8%</td><td>-6%</td><td>6%</td><td>6%</td><td>3%</td><td>4%</td><td>11%</td><td>-13%</td><",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "1afa342125764a00",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">29%</td><td>29%</td><td>28%</td><td>38%</td><td>37%</td></tr><tr><td>MoM growth</td><td>4%</td><td>8%</td><td>-6%</td><td>6%</td><td>6%</td><td>3%</td><td>4%</td><td>11%</td><td>-13%</td><td>2%</td><",
        "provenance": {
          "page": 30
        }
      },
      {
        "num_id": "c20ea1ad070b8720",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>MoM growth</td><td>55%</td><td>27%</td><td>28%</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td>",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "01b2e0c5c5661217",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>MoM growth</td><td>55%</td><td>27%</td><td>28%</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td><td>4%</td><",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "0350237daecdd19b",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td></td><td></td><td></td><td></td></tr><tr><td>MoM growth</td><td>55%</td><td>27%</td><td>28%</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td><td>4%</td><td>10%</td><",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "d0a9d63293f9fe39",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td><td></td><td></td></tr><tr><td>MoM growth</td><td>55%</td><td>27%</td><td>28%</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td><td>4%</td><td>10%</td><td>9%</td></",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "4bc0c5ea1643124e",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td></tr><tr><td>MoM growth</td><td>55%</td><td>27%</td><td>28%</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td><td>4%</td><td>10%</td><td>9%</td></tr><tr><td>",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "e62e53f1f045e6ee",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td></tr><tr><td>MoM growth</td><td>55%</td><td>27%</td><td>28%</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td><td>4%</td><td>10%</td><td>9%</td></tr><tr><td>IMS Monthly",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "ab900e24a56f6041",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>MoM growth</td><td>55%</td><td>27%</td><td>28%</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td><td>4%</td><td>10%</td><td>9%</td></tr><tr><td>IMS Monthly sales (not ",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "f1408c01353889d4",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "MoM growth</td><td>55%</td><td>27%</td><td>28%</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td><td>4%</td><td>10%</td><td>9%</td></tr><tr><td>IMS Monthly sales (not normalized;",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "05fb0b4ba37c6a5b",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>55%</td><td>27%</td><td>28%</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td><td>4%</td><td>10%</td><td>9%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "deec9c9ca8287ced",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>27%</td><td>28%</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td><td>4%</td><td>10%</td><td>9%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "54fbd1e04119582f",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>28%</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td><td>4%</td><td>10%</td><td>9%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;12</td>",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "8c80db41ea71d740",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>8%</td><td>6%</td><td>10%</td><td>7%</td><td>19%</td><td>4%</td><td>4%</td><td>10%</td><td>9%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;12</td><td>&#36;18<",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "b7bdbf6e2348a0f3",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;32</td><td>&#36;33</td><td>&#36;45</td><td>&#36;39</td></tr><tr><td>MoM growth</td><td>55%</td><td>59%</td><td>2%</td><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "05fd40ca31c53a66",
        "value": 0.59,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";32</td><td>&#36;33</td><td>&#36;45</td><td>&#36;39</td></tr><tr><td>MoM growth</td><td>55%</td><td>59%</td><td>2%</td><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</td><td>4%</t",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "069983dc8024d4a6",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;33</td><td>&#36;45</td><td>&#36;39</td></tr><tr><td>MoM growth</td><td>55%</td><td>59%</td><td>2%</td><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</td><td>4%</td><td>37%</t",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "c4e29a4bee88c036",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;45</td><td>&#36;39</td></tr><tr><td>MoM growth</td><td>55%</td><td>59%</td><td>2%</td><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</td><td>4%</td><td>37%</td><td>-13%<",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "1fe35ab28796776c",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5</td><td>&#36;39</td></tr><tr><td>MoM growth</td><td>55%</td><td>59%</td><td>2%</td><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</td><td>4%</td><td>37%</td><td>-13%</td></tr></",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "b8d4d24aeaf16c4c",
        "value": -0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;39</td></tr><tr><td>MoM growth</td><td>55%</td><td>59%</td><td>2%</td><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</td><td>4%</td><td>37%</td><td>-13%</td></tr></table> Footn",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "ded493611b454db3",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>MoM growth</td><td>55%</td><td>59%</td><td>2%</td><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</td><td>4%</td><td>37%</td><td>-13%</td></tr></table> Footnote: IQVIA sa",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "538cae2e4ca788b3",
        "value": 0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "oM growth</td><td>55%</td><td>59%</td><td>2%</td><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</td><td>4%</td><td>37%</td><td>-13%</td></tr></table> Footnote: IQVIA sales data (N",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "a047b808f87ea14c",
        "value": -0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>55%</td><td>59%</td><td>2%</td><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</td><td>4%</td><td>37%</td><td>-13%</td></tr></table> Footnote: IQVIA sales data (NSP) is captu",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "07e4a375c9ca90a4",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>59%</td><td>2%</td><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</td><td>4%</td><td>37%</td><td>-13%</td></tr></table> Footnote: IQVIA sales data (NSP) is captured weekly, a",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "488fade1875823d3",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>2%</td><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</td><td>4%</td><td>37%</td><td>-13%</td></tr></table> Footnote: IQVIA sales data (NSP) is captured weekly, and grouped ",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "5575deec494d8a88",
        "value": -0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>8%</td><td>32%</td><td>-12%</td><td>7%</td><td>49%</td><td>-17%</td><td>4%</td><td>37%</td><td>-13%</td></tr></table> Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5",
        "provenance": {
          "page": 31
        }
      },
      {
        "num_id": "8dd63651dbc4b834",
        "value": 3.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;385</td><td>&#36;401</td><td>&#36;423</td><td>&#36;416</td></tr><tr><td>YoY growth</td><td>315%</td><td>370%</td><td>473%</td><td>370%</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td>",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "f58089ef56d23948",
        "value": 3.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;401</td><td>&#36;423</td><td>&#36;416</td></tr><tr><td>YoY growth</td><td>315%</td><td>370%</td><td>473%</td><td>370%</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td><td>105%</td>",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "307933ec114f3060",
        "value": 4.73,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "401</td><td>&#36;423</td><td>&#36;416</td></tr><tr><td>YoY growth</td><td>315%</td><td>370%</td><td>473%</td><td>370%</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td><td>105%</td><td>125%</td>",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "484af15bee0ccb0f",
        "value": 3.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "#36;423</td><td>&#36;416</td></tr><tr><td>YoY growth</td><td>315%</td><td>370%</td><td>473%</td><td>370%</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td><td>105%</td><td>125%</td><td>117%</td>",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "72f9fdb6193d9d52",
        "value": 3.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;416</td></tr><tr><td>YoY growth</td><td>315%</td><td>370%</td><td>473%</td><td>370%</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td><td>105%</td><td>125%</td><td>117%</td><td>82%</td><",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "d53c7331350cf6f5",
        "value": 2.67,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>YoY growth</td><td>315%</td><td>370%</td><td>473%</td><td>370%</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td><td>105%</td><td>125%</td><td>117%</td><td>82%</td></tr><tr><td>M",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "ca9308856727de3f",
        "value": 2.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>YoY growth</td><td>315%</td><td>370%</td><td>473%</td><td>370%</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td><td>105%</td><td>125%</td><td>117%</td><td>82%</td></tr><tr><td>MoM growth</td",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "47a77bf9ce3ee0b4",
        "value": 1.64,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>315%</td><td>370%</td><td>473%</td><td>370%</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td><td>105%</td><td>125%</td><td>117%</td><td>82%</td></tr><tr><td>MoM growth</td><td>1%</td><",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "9118d89d7e2ed9f1",
        "value": 1.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>370%</td><td>473%</td><td>370%</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td><td>105%</td><td>125%</td><td>117%</td><td>82%</td></tr><tr><td>MoM growth</td><td>1%</td><td>16%</td><t",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "c76523aeada30021",
        "value": 1.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>473%</td><td>370%</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td><td>105%</td><td>125%</td><td>117%</td><td>82%</td></tr><tr><td>MoM growth</td><td>1%</td><td>16%</td><td>14%</td><td",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "e494f0d1a5c62b6b",
        "value": 1.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>370%</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td><td>105%</td><td>125%</td><td>117%</td><td>82%</td></tr><tr><td>MoM growth</td><td>1%</td><td>16%</td><td>14%</td><td>9%</td><td>4",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "52f7dfcdfcf05fd6",
        "value": 0.82,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>331%</td><td>267%</td><td>216%</td><td>164%</td><td>105%</td><td>125%</td><td>117%</td><td>82%</td></tr><tr><td>MoM growth</td><td>1%</td><td>16%</td><td>14%</td><td>9%</td><td>4%</td><td>8%<",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "b24d695c2cc75443",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>164%</td><td>105%</td><td>125%</td><td>117%</td><td>82%</td></tr><tr><td>MoM growth</td><td>1%</td><td>16%</td><td>14%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><t",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "04e6934d416a3952",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>105%</td><td>125%</td><td>117%</td><td>82%</td></tr><tr><td>MoM growth</td><td>1%</td><td>16%</td><td>14%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><td>4%</td><t",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "2e346110906563f9",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5%</td><td>125%</td><td>117%</td><td>82%</td></tr><tr><td>MoM growth</td><td>1%</td><td>16%</td><td>14%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><td>4%</td><td>5%</td><td",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "259bbd2d7f74a19b",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "25%</td><td>117%</td><td>82%</td></tr><tr><td>MoM growth</td><td>1%</td><td>16%</td><td>14%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><td>4%</td><td>5%</td><td>-2%</td></t",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "0bece1e4a060cb9a",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">117%</td><td>82%</td></tr><tr><td>MoM growth</td><td>1%</td><td>16%</td><td>14%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><td>4%</td><td>5%</td><td>-2%</td></tr><tr><td>I",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "8448e9662ce0a24d",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>82%</td></tr><tr><td>MoM growth</td><td>1%</td><td>16%</td><td>14%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><td>4%</td><td>5%</td><td>-2%</td></tr><tr><td>IMS Monthly ",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "6cd0186987ee9f35",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>MoM growth</td><td>1%</td><td>16%</td><td>14%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><td>4%</td><td>5%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not ",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "dab95754a60df2cf",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>MoM growth</td><td>1%</td><td>16%</td><td>14%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><td>4%</td><td>5%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not normalized;",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "b42b775f8bbc1381",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "h</td><td>1%</td><td>16%</td><td>14%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><td>4%</td><td>5%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 week",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "166478ac5e5db73e",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>16%</td><td>14%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><td>4%</td><td>5%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "eeed901d74a6e34e",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>14%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><td>4%</td><td>5%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;19</td>",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "37a2411461f2a3e1",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4%</td><td>9%</td><td>4%</td><td>8%</td><td>2%</td><td>4%</td><td>-1%</td><td>4%</td><td>5%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;19</td><td>&#36;28",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "840d0581345c8bb2",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;32</td><td>&#36;33</td><td>&#36;44</td><td>&#36;35</td></tr><tr><td>MoM growth</td><td>1%</td><td>45%</td><td>-9%</td><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "285f65f50f82c2e2",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;32</td><td>&#36;33</td><td>&#36;44</td><td>&#36;35</td></tr><tr><td>MoM growth</td><td>1%</td><td>45%</td><td>-9%</td><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</td><td>4%</",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "089eecc70de52399",
        "value": -0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">&#36;33</td><td>&#36;44</td><td>&#36;35</td></tr><tr><td>MoM growth</td><td>1%</td><td>45%</td><td>-9%</td><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</td><td>4%</td><td>32%</",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "6f9ca9d5d961f8dc",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;44</td><td>&#36;35</td></tr><tr><td>MoM growth</td><td>1%</td><td>45%</td><td>-9%</td><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</td><td>4%</td><td>32%</td><td>-21%<",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "e29584163ccc8926",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4</td><td>&#36;35</td></tr><tr><td>MoM growth</td><td>1%</td><td>45%</td><td>-9%</td><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</td><td>4%</td><td>32%</td><td>-21%</td></tr></",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "ea3c59e2be03dfd5",
        "value": -0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;35</td></tr><tr><td>MoM growth</td><td>1%</td><td>45%</td><td>-9%</td><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</td><td>4%</td><td>32%</td><td>-21%</td></tr></table> Footn",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "f74b1ebf4c1ad4d1",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>MoM growth</td><td>1%</td><td>45%</td><td>-9%</td><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</td><td>4%</td><td>32%</td><td>-21%</td></tr></table> Footnote: IQVIA sa",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "0c41fdc21a1b16c0",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "oM growth</td><td>1%</td><td>45%</td><td>-9%</td><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</td><td>4%</td><td>32%</td><td>-21%</td></tr></table> Footnote: IQVIA sales data (N",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "8d16fd8e724ae62d",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>1%</td><td>45%</td><td>-9%</td><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</td><td>4%</td><td>32%</td><td>-21%</td></tr></table> Footnote: IQVIA sales data (NSP) is captu",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "03803344c157bee4",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>45%</td><td>-9%</td><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</td><td>4%</td><td>32%</td><td>-21%</td></tr></table> Footnote: IQVIA sales data (NSP) is captured weekly, a",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "d14737e7b6d0baf5",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-9%</td><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</td><td>4%</td><td>32%</td><td>-21%</td></tr></table> Footnote: IQVIA sales data (NSP) is captured weekly, and grouped ",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "c6eef77d0ad2e591",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>9%</td><td>29%</td><td>-14%</td><td>2%</td><td>29%</td><td>-21%</td><td>4%</td><td>32%</td><td>-21%</td></tr></table> Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5",
        "provenance": {
          "page": 32
        }
      },
      {
        "num_id": "781fb1c9caac2a5b",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;60</td><td>&#36;46</td><td>&#36;54</td><td>&#36;43</td></tr><tr><td>YoY growth</td><td>-2%</td><td>556%</td><td>437%</td><td>267%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><t",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "f63f3fa894c0c60d",
        "value": 5.56,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";60</td><td>&#36;46</td><td>&#36;54</td><td>&#36;43</td></tr><tr><td>YoY growth</td><td>-2%</td><td>556%</td><td>437%</td><td>267%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><td>224%</td><",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "0783cf329b7d813b",
        "value": 4.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "#36;46</td><td>&#36;54</td><td>&#36;43</td></tr><tr><td>YoY growth</td><td>-2%</td><td>556%</td><td>437%</td><td>267%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><td>224%</td><td>76%</td><t",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "75faba1b47efa229",
        "value": 2.67,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;54</td><td>&#36;43</td></tr><tr><td>YoY growth</td><td>-2%</td><td>556%</td><td>437%</td><td>267%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><td>224%</td><td>76%</td><td>98%</td><td",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "2ff30376dd2d8913",
        "value": 1.46,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;43</td></tr><tr><td>YoY growth</td><td>-2%</td><td>556%</td><td>437%</td><td>267%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><td>224%</td><td>76%</td><td>98%</td><td>49%</td></tr",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "c8dc5ea63944bbb4",
        "value": -0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td>YoY growth</td><td>-2%</td><td>556%</td><td>437%</td><td>267%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><td>224%</td><td>76%</td><td>98%</td><td>49%</td></tr><tr><td>MoM ",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "f6dae0169af8d688",
        "value": 1.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>YoY growth</td><td>-2%</td><td>556%</td><td>437%</td><td>267%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><td>224%</td><td>76%</td><td>98%</td><td>49%</td></tr><tr><td>MoM growth</td><t",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "18360fc57c978ee3",
        "value": 0.84,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "h</td><td>-2%</td><td>556%</td><td>437%</td><td>267%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><td>224%</td><td>76%</td><td>98%</td><td>49%</td></tr><tr><td>MoM growth</td><td>-4%</td><td",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "9c723b52d5975c8c",
        "value": 2.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>556%</td><td>437%</td><td>267%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><td>224%</td><td>76%</td><td>98%</td><td>49%</td></tr><tr><td>MoM growth</td><td>-4%</td><td>0%</td><td>",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "5e24f0d45c2b535b",
        "value": 0.76,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>437%</td><td>267%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><td>224%</td><td>76%</td><td>98%</td><td>49%</td></tr><tr><td>MoM growth</td><td>-4%</td><td>0%</td><td>12%</td><td>-",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "896bad932776b6e2",
        "value": 0.98,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7%</td><td>267%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><td>224%</td><td>76%</td><td>98%</td><td>49%</td></tr><tr><td>MoM growth</td><td>-4%</td><td>0%</td><td>12%</td><td>-8%</td><td>2",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "77aefc2342f891be",
        "value": 0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "67%</td><td>146%</td><td>-33%</td><td>170%</td><td>84%</td><td>224%</td><td>76%</td><td>98%</td><td>49%</td></tr><tr><td>MoM growth</td><td>-4%</td><td>0%</td><td>12%</td><td>-8%</td><td>21%</td><td>3",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "e07bea042108ee7c",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>84%</td><td>224%</td><td>76%</td><td>98%</td><td>49%</td></tr><tr><td>MoM growth</td><td>-4%</td><td>0%</td><td>12%</td><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "9b7e3aaf216aeec1",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4%</td><td>224%</td><td>76%</td><td>98%</td><td>49%</td></tr><tr><td>MoM growth</td><td>-4%</td><td>0%</td><td>12%</td><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td><td>-24%</t",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "9ef8f9a5ace53aeb",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "224%</td><td>76%</td><td>98%</td><td>49%</td></tr><tr><td>MoM growth</td><td>-4%</td><td>0%</td><td>12%</td><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td><td>-24%</td><td>17%</",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "f0fbc5b232c93b92",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">76%</td><td>98%</td><td>49%</td></tr><tr><td>MoM growth</td><td>-4%</td><td>0%</td><td>12%</td><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td><td>-24%</td><td>17%</td><td>-20%<",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "eedebdbb8cbcbb51",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">98%</td><td>49%</td></tr><tr><td>MoM growth</td><td>-4%</td><td>0%</td><td>12%</td><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "b1d80323a8d16858",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">49%</td></tr><tr><td>MoM growth</td><td>-4%</td><td>0%</td><td>12%</td><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Mon",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "210ad4e131c26db9",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>MoM growth</td><td>-4%</td><td>0%</td><td>12%</td><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales ",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "33cdbb2d1ca56563",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "oM growth</td><td>-4%</td><td>0%</td><td>12%</td><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales (not normali",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "71d9eb2de260fca2",
        "value": 0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-4%</td><td>0%</td><td>12%</td><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 ",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "7437b07124504255",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>0%</td><td>12%</td><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "32bc877de61bc740",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>12%</td><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;2</td",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "70e3eeddc0255007",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-8%</td><td>21%</td><td>3%</td><td>14%</td><td>3%</td><td>44%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;2</td><td>&#36;3<",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "72673ffbe28de75a",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;4</td><td>&#36;5</td><td>&#36;4</td><td>&#36;4</td><td>&#36;4</td></tr><tr><td>MoM growth</td><td>-4%</td><td>25%</td><td>-11%</td><td>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "84e04acb49c039c4",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;5</td><td>&#36;4</td><td>&#36;4</td><td>&#36;4</td></tr><tr><td>MoM growth</td><td>-4%</td><td>25%</td><td>-11%</td><td>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15%</td><td>-2",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "448ab5a9422665db",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;4</td><td>&#36;4</td><td>&#36;4</td></tr><tr><td>MoM growth</td><td>-4%</td><td>25%</td><td>-11%</td><td>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15%</td><td>-24%</td><td>1",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "19115acf8560c46e",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;4</td><td>&#36;4</td></tr><tr><td>MoM growth</td><td>-4%</td><td>25%</td><td>-11%</td><td>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15%</td><td>-24%</td><td>17%</td><td>-2",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "ae8e044c5c59c950",
        "value": 0.51,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;4</td></tr><tr><td>MoM growth</td><td>-4%</td><td>25%</td><td>-11%</td><td>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15%</td><td>-24%</td><td>17%</td><td>-20%</td></tr>",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "d267469d529f1a1b",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";4</td></tr><tr><td>MoM growth</td><td>-4%</td><td>25%</td><td>-11%</td><td>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>Xosp",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "abb38f67efce650f",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>MoM growth</td><td>-4%</td><td>25%</td><td>-11%</td><td>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>Xospata (Astellas",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "8cf4f6b7f445f399",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rowth</td><td>-4%</td><td>25%</td><td>-11%</td><td>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>Xospata (Astellas)</td><td></",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "8c7855bc8ced17ac",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-4%</td><td>25%</td><td>-11%</td><td>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>Xospata (Astellas)</td><td></td><td></td>",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "74448bd98c3373dd",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>25%</td><td>-11%</td><td>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>Xospata (Astellas)</td><td></td><td></td><td></td><td",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "239c0199cf4af130",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">-11%</td><td>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>Xospata (Astellas)</td><td></td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "4dc95a46dcf7a544",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-8%</td><td>51%</td><td>-18%</td><td>14%</td><td>29%</td><td>15%</td><td>-24%</td><td>17%</td><td>-20%</td></tr><tr><td>Xospata (Astellas)</td><td></td><td></td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "48cccee5d72a4bd4",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;168</td><td>&#36;173</td><td>&#36;213</td><td>&#36;176</td></tr><tr><td>YoY growth</td><td>17%</td><td>28%</td><td>24%</td><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "3b09f443e5296148",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>&#36;173</td><td>&#36;213</td><td>&#36;176</td></tr><tr><td>YoY growth</td><td>17%</td><td>28%</td><td>24%</td><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</td><td>13%</",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "37f8cf8d80e18297",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;173</td><td>&#36;213</td><td>&#36;176</td></tr><tr><td>YoY growth</td><td>17%</td><td>28%</td><td>24%</td><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</td><td>13%</td><td>30%</",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "d3ca82e2bf47f9d9",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;213</td><td>&#36;176</td></tr><tr><td>YoY growth</td><td>17%</td><td>28%</td><td>24%</td><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</td><td>13%</td><td>30%</td><td>13%</",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "faa3865948ac2d83",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&#36;176</td></tr><tr><td>YoY growth</td><td>17%</td><td>28%</td><td>24%</td><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</td><td>13%</td><td>30%</td><td>13%</td></tr><tr>",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "0c58f710521fb05e",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "176</td></tr><tr><td>YoY growth</td><td>17%</td><td>28%</td><td>24%</td><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</td><td>13%</td><td>30%</td><td>13%</td></tr><tr><td>MoM grow",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "0e61ceddbc7cd080",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>17%</td><td>28%</td><td>24%</td><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</td><td>13%</td><td>30%</td><td>13%</td></tr><tr><td>MoM growth</td><td>-",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "a41e6325d7be12a0",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>17%</td><td>28%</td><td>24%</td><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</td><td>13%</td><td>30%</td><td>13%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>7%",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "7d8ad6d55237459d",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>17%</td><td>28%</td><td>24%</td><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</td><td>13%</td><td>30%</td><td>13%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>7%</td><td>-4",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "0a6dbf2e55f22d9d",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>28%</td><td>24%</td><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</td><td>13%</td><td>30%</td><td>13%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>7%</td><td>-4%</td><td>-",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "f58094a665aa6ef0",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>24%</td><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</td><td>13%</td><td>30%</td><td>13%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>7%</td><td>-4%</td><td>-2%</td><td>7",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "3aa9028516263f6d",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>22%</td><td>23%</td><td>24%</td><td>17%</td><td>10%</td><td>0%</td><td>13%</td><td>30%</td><td>13%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>7%</td><td>-4%</td><td>-2%</td><td>7%</td><td>5%",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "ebf67e38470ce84a",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">17%</td><td>10%</td><td>0%</td><td>13%</td><td>30%</td><td>13%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>7%</td><td>-4%</td><td>-2%</td><td>7%</td><td>5%</td><td>-1%</td><td>-3%</td><td>0%</td>",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "1991f6b20ae06949",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">10%</td><td>0%</td><td>13%</td><td>30%</td><td>13%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>7%</td><td>-4%</td><td>-2%</td><td>7%</td><td>5%</td><td>-1%</td><td>-3%</td><td>0%</td><td>3%</td><",
        "provenance": {
          "page": 33
        }
      },
      {
        "num_id": "a9000e3676116f30",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "102</td><td>&#36;3</td><td>&#36;3</td><td>&#36;5</td><td>&#36;4</td></tr><tr><td>YoY growth</td><td>13%</td><td>19%</td><td>17%</td><td>24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "e9ec2a34e72540cb",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;3</td><td>&#36;3</td><td>&#36;5</td><td>&#36;4</td></tr><tr><td>YoY growth</td><td>13%</td><td>19%</td><td>17%</td><td>24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99%</td><td>-9",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "6e4c2385c0f958f4",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;3</td><td>&#36;5</td><td>&#36;4</td></tr><tr><td>YoY growth</td><td>13%</td><td>19%</td><td>17%</td><td>24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99%</td><td>-99%</td><td>-",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "fbb7c64d43b608e6",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>&#36;5</td><td>&#36;4</td></tr><tr><td>YoY growth</td><td>13%</td><td>19%</td><td>17%</td><td>24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99%</td><td>-99%</td><td>-97%</td><td>",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "d6400e74e08ac4dc",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>&#36;4</td></tr><tr><td>YoY growth</td><td>13%</td><td>19%</td><td>17%</td><td>24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99%</td><td>-99%</td><td>-97%</td><td>-98%</td></t",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "336ae4711ccd18f6",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;4</td></tr><tr><td>YoY growth</td><td>13%</td><td>19%</td><td>17%</td><td>24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99%</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>Mo",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "c3dd2c373a53e6bd",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>13%</td><td>19%</td><td>17%</td><td>24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99%</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>MoM growth</td",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "1b3e48228d380fbd",
        "value": -0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>13%</td><td>19%</td><td>17%</td><td>24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99%</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>MoM growth</td><td>-1%</td>",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "d6f8b6fd836d4c66",
        "value": -0.99,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>13%</td><td>19%</td><td>17%</td><td>24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99%</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>2%</td><",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "6a16618e40db93f1",
        "value": -0.99,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>19%</td><td>17%</td><td>24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99%</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>2%</td><td>4%</td><td",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "750b4f10486c5bfb",
        "value": -0.97,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">17%</td><td>24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99%</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>2%</td><td>4%</td><td>7%</td><td>-",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "17d7403ae3a9e069",
        "value": -0.98,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "24%</td><td>-3%</td><td>40%</td><td>32%</td><td>-48%</td><td>-99%</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>2%</td><td>4%</td><td>7%</td><td>-5%</td><td>24",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "2e1666c1ccb5aff3",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-48%</td><td>-99%</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>2%</td><td>4%</td><td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "0deaac49c1ed0631",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-99%</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>2%</td><td>4%</td><td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</td><td>1%</t",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "b980cce01f3a7d72",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>-99%</td><td>-97%</td><td>-98%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>2%</td><td>4%</td><td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</td><td>1%</td><td>89%</",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "f0e0922bbdcc8a0f",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "99%</td><td>-97%</td><td>-98%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>2%</td><td>4%</td><td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</td><td>1%</td><td>89%</td><td>-24%",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "a2a8c15104664c7a",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">-97%</td><td>-98%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>2%</td><td>4%</td><td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</td><td>1%</td><td>89%</td><td>-24%</td></tr><",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "9239badac52a1e41",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-98%</td></tr><tr><td>MoM growth</td><td>-1%</td><td>2%</td><td>4%</td><td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</td><td>1%</td><td>89%</td><td>-24%</td></tr><tr><td>IMS M",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "47b3a7188bd3b1a8",
        "value": -0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>MoM growth</td><td>-1%</td><td>2%</td><td>4%</td><td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</td><td>1%</td><td>89%</td><td>-24%</td></tr><tr><td>IMS Monthly sales",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "f3820318250e5a7c",
        "value": -0.58,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "MoM growth</td><td>-1%</td><td>2%</td><td>4%</td><td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</td><td>1%</td><td>89%</td><td>-24%</td></tr><tr><td>IMS Monthly sales (not normal",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "58102ad39ce4c918",
        "value": -0.97,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>-1%</td><td>2%</td><td>4%</td><td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</td><td>1%</td><td>89%</td><td>-24%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 w",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "e67e451a140d5d3a",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>2%</td><td>4%</td><td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</td><td>1%</td><td>89%</td><td>-24%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "48372d7a45546a48",
        "value": 0.89,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>4%</td><td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</td><td>1%</td><td>89%</td><td>-24%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;16</t",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "8ee568ad0fce1dde",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>7%</td><td>-5%</td><td>24%</td><td>-9%</td><td>-58%</td><td>-97%</td><td>1%</td><td>89%</td><td>-24%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;16</td><td>&#36;2",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "2e3fe8f4471c9d42",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";11</td><td>&#36;0</td><td>&#36;0</td><td>&#36;1</td><td>&#36;0</td></tr><tr><td>MoM growth</td><td>-1%</td><td>28%</td><td>-17%</td><td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "e7b826c8b6234c6b",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;0</td><td>&#36;0</td><td>&#36;1</td><td>&#36;0</td></tr><tr><td>MoM growth</td><td>-1%</td><td>28%</td><td>-17%</td><td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%</td><td>1%<",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "c34ad0219663d059",
        "value": -0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;0</td><td>&#36;1</td><td>&#36;0</td></tr><tr><td>MoM growth</td><td>-1%</td><td>28%</td><td>-17%</td><td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%</td><td>1%</td><td>136%",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "5343d5e8cf8295bb",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;1</td><td>&#36;0</td></tr><tr><td>MoM growth</td><td>-1%</td><td>28%</td><td>-17%</td><td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%</td><td>1%</td><td>136%</td><td>-40%",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "c7c1405d5e5771b0",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>&#36;0</td></tr><tr><td>MoM growth</td><td>-1%</td><td>28%</td><td>-17%</td><td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%</td><td>1%</td><td>136%</td><td>-40%</td></tr><",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "630690392492ae45",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;0</td></tr><tr><td>MoM growth</td><td>-1%</td><td>28%</td><td>-17%</td><td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%</td><td>1%</td><td>136%</td><td>-40%</td></tr></table> Foot",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "f429ddc6d50f939f",
        "value": -0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>MoM growth</td><td>-1%</td><td>28%</td><td>-17%</td><td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%</td><td>1%</td><td>136%</td><td>-40%</td></tr></table> Footnote: IQVIA",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "9c495f9e1855f14f",
        "value": -0.47,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "M growth</td><td>-1%</td><td>28%</td><td>-17%</td><td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%</td><td>1%</td><td>136%</td><td>-40%</td></tr></table> Footnote: IQVIA sales data ",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "7e36c5ea00cd1ddd",
        "value": -0.98,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-1%</td><td>28%</td><td>-17%</td><td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%</td><td>1%</td><td>136%</td><td>-40%</td></tr></table> Footnote: IQVIA sales data (NSP) is capt",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "26eb7a4ff09e04e9",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>28%</td><td>-17%</td><td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%</td><td>1%</td><td>136%</td><td>-40%</td></tr></table> Footnote: IQVIA sales data (NSP) is captured weekly, ",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "5f2c03ef0192d68f",
        "value": 1.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-17%</td><td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%</td><td>1%</td><td>136%</td><td>-40%</td></tr></table> Footnote: IQVIA sales data (NSP) is captured weekly, and grouped",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "be1b973f5fd5a281",
        "value": -0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>7%</td><td>19%</td><td>0%</td><td>-9%</td><td>-47%</td><td>-98%</td><td>1%</td><td>136%</td><td>-40%</td></tr></table> Footnote: IQVIA sales data (NSP) is captured weekly, and grouped into 4- or 5",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "f99e025341d22d83",
        "value": 87.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;59</td><td>&#36;50</td><td>&#36;1</td><td></td></tr><tr><td>% diff.</td><td>NM</td><td>8708%</td><td>148%</td><td>131%</td><td>115%</td><td>24%</td><td>141%</td><td>156%</td><td>150%</td>",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "27796284272005b2",
        "value": 1.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9</td><td>&#36;50</td><td>&#36;1</td><td></td></tr><tr><td>% diff.</td><td>NM</td><td>8708%</td><td>148%</td><td>131%</td><td>115%</td><td>24%</td><td>141%</td><td>156%</td><td>150%</td><td>231%</td><",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "7ac2871fbd3fbc96",
        "value": 1.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;50</td><td>&#36;1</td><td></td></tr><tr><td>% diff.</td><td>NM</td><td>8708%</td><td>148%</td><td>131%</td><td>115%</td><td>24%</td><td>141%</td><td>156%</td><td>150%</td><td>231%</td><td>13498%</td",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "556c150abcf19b11",
        "value": 1.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;1</td><td></td></tr><tr><td>% diff.</td><td>NM</td><td>8708%</td><td>148%</td><td>131%</td><td>115%</td><td>24%</td><td>141%</td><td>156%</td><td>150%</td><td>231%</td><td>13498%</td></tr></table",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "6d2365da397b4a72",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td></tr><tr><td>% diff.</td><td>NM</td><td>8708%</td><td>148%</td><td>131%</td><td>115%</td><td>24%</td><td>141%</td><td>156%</td><td>150%</td><td>231%</td><td>13498%</td></tr></table> Source: Com",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "ab31f827b411cc86",
        "value": 1.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>% diff.</td><td>NM</td><td>8708%</td><td>148%</td><td>131%</td><td>115%</td><td>24%</td><td>141%</td><td>156%</td><td>150%</td><td>231%</td><td>13498%</td></tr></table> Source: Company data, I",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "4a47771ba6c21a44",
        "value": 1.56,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "f.</td><td>NM</td><td>8708%</td><td>148%</td><td>131%</td><td>115%</td><td>24%</td><td>141%</td><td>156%</td><td>150%</td><td>231%</td><td>13498%</td></tr></table> Source: Company data, IQVIA, Morgan ",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "425ff6490ba29d11",
        "value": 1.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>8708%</td><td>148%</td><td>131%</td><td>115%</td><td>24%</td><td>141%</td><td>156%</td><td>150%</td><td>231%</td><td>13498%</td></tr></table> Source: Company data, IQVIA, Morgan Stanley Resea",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "3b0540e190b647fa",
        "value": 2.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>148%</td><td>131%</td><td>115%</td><td>24%</td><td>141%</td><td>156%</td><td>150%</td><td>231%</td><td>13498%</td></tr></table> Source: Company data, IQVIA, Morgan Stanley Research # HER2 Ex",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "42399269fa753cb7",
        "value": 134.98,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>131%</td><td>115%</td><td>24%</td><td>141%</td><td>156%</td><td>150%</td><td>231%</td><td>13498%</td></tr></table> Source: Company data, IQVIA, Morgan Stanley Research # HER2 Exhibit 71: HER",
        "provenance": {
          "page": 34
        }
      },
      {
        "num_id": "fbbee52fcfbe1ad2",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "255</td><td>$2,286</td><td>$2,299</td><td>$2,255</td><td>$2,359</td></tr><tr><td>YoY growth</td><td>55%</td><td>24%</td><td>27%</td><td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%<",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "df9823e3d600c9be",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$2,286</td><td>$2,299</td><td>$2,255</td><td>$2,359</td></tr><tr><td>YoY growth</td><td>55%</td><td>24%</td><td>27%</td><td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%</td><td>26%<",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "f1d2328b6a0da625",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>$2,299</td><td>$2,255</td><td>$2,359</td></tr><tr><td>YoY growth</td><td>55%</td><td>24%</td><td>27%</td><td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%</td><td>26%</td><td>27%<",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "6b0235e96be9ab98",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>$2,255</td><td>$2,359</td></tr><tr><td>YoY growth</td><td>55%</td><td>24%</td><td>27%</td><td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%</td><td>26%</td><td>27%</td><td>31%<",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "cd89e0da28a5f314",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>$2,359</td></tr><tr><td>YoY growth</td><td>55%</td><td>24%</td><td>27%</td><td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%</td><td>26%</td><td>27%</td><td>31%</td></tr><tr",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "45446ec754d12120",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "359</td></tr><tr><td>YoY growth</td><td>55%</td><td>24%</td><td>27%</td><td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "9f0831c417ddcfba",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>55%</td><td>24%</td><td>27%</td><td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "34e4c064328a7c68",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>55%</td><td>24%</td><td>27%</td><td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>MoM growth</td><td>35%</td><td>-",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "edeaae0363a8f694",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>55%</td><td>24%</td><td>27%</td><td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>MoM growth</td><td>35%</td><td>-20%</td><td",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "70988bb7011e41cc",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>24%</td><td>27%</td><td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>MoM growth</td><td>35%</td><td>-20%</td><td>4%</td><td>",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "4c1afb83b2779e16",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>27%</td><td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>MoM growth</td><td>35%</td><td>-20%</td><td>4%</td><td>-2%</td><td>",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "efbbc085a68bbfc2",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>28%</td><td>27%</td><td>30%</td><td>32%</td><td>31%</td><td>30%</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>MoM growth</td><td>35%</td><td>-20%</td><td>4%</td><td>-2%</td><td>6%</td><td>0",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "6588099c831cf342",
        "value": 0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "32%</td><td>31%</td><td>30%</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>MoM growth</td><td>35%</td><td>-20%</td><td>4%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "ee82783280030c2e",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "31%</td><td>30%</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>MoM growth</td><td>35%</td><td>-20%</td><td>4%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><td>1%</td><t",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "6bab666c6edf1a6b",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>26%</td><td>27%</td><td>31%</td></tr><tr><td>MoM growth</td><td>35%</td><td>-20%</td><td>4%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><td>1%</td><td>-2%</td><td",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "5b1f55667ad174e1",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "26%</td><td>27%</td><td>31%</td></tr><tr><td>MoM growth</td><td>35%</td><td>-20%</td><td>4%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><td>1%</td><td>-2%</td><td>5%</td></t",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "2d580ccd87abed87",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "27%</td><td>31%</td></tr><tr><td>MoM growth</td><td>35%</td><td>-20%</td><td>4%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><td>1%</td><td>-2%</td><td>5%</td></tr><tr><td>IM",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "c48520d9d78c5916",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">31%</td></tr><tr><td>MoM growth</td><td>35%</td><td>-20%</td><td>4%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><td>1%</td><td>-2%</td><td>5%</td></tr><tr><td>IMS Monthly s",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "85e14fcc531279ed",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>MoM growth</td><td>35%</td><td>-20%</td><td>4%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><td>1%</td><td>-2%</td><td>5%</td></tr><tr><td>IMS Monthly sales (not n",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "dc6b42a6c0926544",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "MoM growth</td><td>35%</td><td>-20%</td><td>4%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><td>1%</td><td>-2%</td><td>5%</td></tr><tr><td>IMS Monthly sales (not normalized; ",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "c2201fc5712cadaf",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>35%</td><td>-20%</td><td>4%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><td>1%</td><td>-2%</td><td>5%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "1f52996dc2b1a8f1",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-20%</td><td>4%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><td>1%</td><td>-2%</td><td>5%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "5a0822555dac5b88",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>4%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><td>1%</td><td>-2%</td><td>5%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$158</td><td",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "7f98a821ffd090e3",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>-2%</td><td>6%</td><td>0%</td><td>7%</td><td>2%</td><td>1%</td><td>1%</td><td>-2%</td><td>5%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$158</td><td>$201</td><t",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "f34603564c3df95c",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>$235</td><td>$190</td><td>$192</td><td>$235</td><td>$197</td></tr><tr><td>MoM growth</td><td>5%</td><td>28%</td><td>-17%</td><td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "2165a5382a104327",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>$190</td><td>$192</td><td>$235</td><td>$197</td></tr><tr><td>MoM growth</td><td>5%</td><td>28%</td><td>-17%</td><td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%</td><td>1%",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "f911411e4f33f7cd",
        "value": -0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0</td><td>$192</td><td>$235</td><td>$197</td></tr><tr><td>MoM growth</td><td>5%</td><td>28%</td><td>-17%</td><td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%</td><td>1%</td><td>23%",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "584f6b7169764a20",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2</td><td>$235</td><td>$197</td></tr><tr><td>MoM growth</td><td>5%</td><td>28%</td><td>-17%</td><td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%</td><td>1%</td><td>23%</td><td>-16%",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "6a320de2a5670b9d",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "35</td><td>$197</td></tr><tr><td>MoM growth</td><td>5%</td><td>28%</td><td>-17%</td><td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%</td><td>1%</td><td>23%</td><td>-16%</td></tr></",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "518246025b9de933",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "197</td></tr><tr><td>MoM growth</td><td>5%</td><td>28%</td><td>-17%</td><td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%</td><td>1%</td><td>23%</td><td>-16%</td></tr></table> Fot i",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "909b80888cc14359",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>5%</td><td>28%</td><td>-17%</td><td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%</td><td>1%</td><td>23%</td><td>-16%</td></tr></table> Fot i Periodically",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "7a40cdab803826ab",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>5%</td><td>28%</td><td>-17%</td><td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%</td><td>1%</td><td>23%</td><td>-16%</td></tr></table> Fot i Periodically, an extra w",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "0a5f3254f3a90468",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>5%</td><td>28%</td><td>-17%</td><td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%</td><td>1%</td><td>23%</td><td>-16%</td></tr></table> Fot i Periodically, an extra week is adde",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "84e56dd59420452a",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>28%</td><td>-17%</td><td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%</td><td>1%</td><td>23%</td><td>-16%</td></tr></table> Fot i Periodically, an extra week is added in November",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "0dc6126524df4bc3",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-17%</td><td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%</td><td>1%</td><td>23%</td><td>-16%</td></tr></table> Fot i Periodically, an extra week is added in November to ensure ",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "db3aa297f9edc3f8",
        "value": -0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-2%</td><td>32%</td><td>-20%</td><td>7%</td><td>27%</td><td>-19%</td><td>1%</td><td>23%</td><td>-16%</td></tr></table> Fot i Periodically, an extra week is added in November to ensure that DDD rep",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "1f523819abfe0c00",
        "value": 2416.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td></td><td></td><td></td><td></td></tr><tr><td>Annualized (Mar, Jun, Sep, Dec normalized)</td><td>$2,416</td><td>$1,932</td><td>$2,008</td><td>$1,959</td><td>$2,071</td><td>$2,073</td><td>$2,222</td",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "bbc1b384682b9546",
        "value": 1932.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td></td><td></td></tr><tr><td>Annualized (Mar, Jun, Sep, Dec normalized)</td><td>$2,416</td><td>$1,932</td><td>$2,008</td><td>$1,959</td><td>$2,071</td><td>$2,073</td><td>$2,222</td><td>$2,255</td",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "bfb7ded53ddee499",
        "value": 2008.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "></td></tr><tr><td>Annualized (Mar, Jun, Sep, Dec normalized)</td><td>$2,416</td><td>$1,932</td><td>$2,008</td><td>$1,959</td><td>$2,071</td><td>$2,073</td><td>$2,222</td><td>$2,255</td><td>$2,286</td",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "ce3cf82ba735466b",
        "value": 1959.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>Annualized (Mar, Jun, Sep, Dec normalized)</td><td>$2,416</td><td>$1,932</td><td>$2,008</td><td>$1,959</td><td>$2,071</td><td>$2,073</td><td>$2,222</td><td>$2,255</td><td>$2,286</td><td>$2,299</td",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "2329cb948390a3bb",
        "value": 2071.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "(Mar, Jun, Sep, Dec normalized)</td><td>$2,416</td><td>$1,932</td><td>$2,008</td><td>$1,959</td><td>$2,071</td><td>$2,073</td><td>$2,222</td><td>$2,255</td><td>$2,286</td><td>$2,299</td><td>$2,255</td",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "8af18cb65e916330",
        "value": 2073.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "Dec normalized)</td><td>$2,416</td><td>$1,932</td><td>$2,008</td><td>$1,959</td><td>$2,071</td><td>$2,073</td><td>$2,222</td><td>$2,255</td><td>$2,286</td><td>$2,299</td><td>$2,255</td><td>$2,359</td>",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "1d1eee1c0135f7a6",
        "value": 2222.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ")</td><td>$2,416</td><td>$1,932</td><td>$2,008</td><td>$1,959</td><td>$2,071</td><td>$2,073</td><td>$2,222</td><td>$2,255</td><td>$2,286</td><td>$2,299</td><td>$2,255</td><td>$2,359</td></tr><tr><td>Y",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "07fefbd8c5678d9b",
        "value": 2255.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "6</td><td>$1,932</td><td>$2,008</td><td>$1,959</td><td>$2,071</td><td>$2,073</td><td>$2,222</td><td>$2,255</td><td>$2,286</td><td>$2,299</td><td>$2,255</td><td>$2,359</td></tr><tr><td>YoY growth</td><",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "32717bc18f2e6516",
        "value": 2286.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2</td><td>$2,008</td><td>$1,959</td><td>$2,071</td><td>$2,073</td><td>$2,222</td><td>$2,255</td><td>$2,286</td><td>$2,299</td><td>$2,255</td><td>$2,359</td></tr><tr><td>YoY growth</td><td>55%</td><td>",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "817609de3f483428",
        "value": 2299.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "8</td><td>$1,959</td><td>$2,071</td><td>$2,073</td><td>$2,222</td><td>$2,255</td><td>$2,286</td><td>$2,299</td><td>$2,255</td><td>$2,359</td></tr><tr><td>YoY growth</td><td>55%</td><td>24%</td><td>27%",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "925ab08394aa2e7e",
        "value": 2255.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "9</td><td>$2,071</td><td>$2,073</td><td>$2,222</td><td>$2,255</td><td>$2,286</td><td>$2,299</td><td>$2,255</td><td>$2,359</td></tr><tr><td>YoY growth</td><td>55%</td><td>24%</td><td>27%</td><td>28%</t",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "190c7f4fe4957205",
        "value": 2359.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "1</td><td>$2,073</td><td>$2,222</td><td>$2,255</td><td>$2,286</td><td>$2,299</td><td>$2,255</td><td>$2,359</td></tr><tr><td>YoY growth</td><td>55%</td><td>24%</td><td>27%</td><td>28%</td><td>27%</td><",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "3459f181945a2972",
        "value": 158.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ">1%</td><td>-2%</td><td>5%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$158</td><td>$201</td><td>$167</td><td>$163</td><td>$216</td><td>$173</td><td>$185</td><td>$235</td>",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "f73a2fe793708023",
        "value": 201.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2%</td><td>5%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$158</td><td>$201</td><td>$167</td><td>$163</td><td>$216</td><td>$173</td><td>$185</td><td>$235</td><td>$190</td>",
        "provenance": {
          "page": 35
        }
      },
      {
        "num_id": "0f24e3cc9cd935a7",
        "value": 13.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;73</td><td>&#36;69</td></tr><tr><td>YoY growth</td><td></td><td></td><td></td><td></td><td>1348%</td><td>430%</td><td>245%</td><td>193%</td><td>215%</td><td>222%</td><td>170%</td><td>179%</td",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "2c9b8e59e4d874cf",
        "value": 4.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>&#36;69</td></tr><tr><td>YoY growth</td><td></td><td></td><td></td><td></td><td>1348%</td><td>430%</td><td>245%</td><td>193%</td><td>215%</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "5eb5eca8a3175115",
        "value": 2.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>YoY growth</td><td></td><td></td><td></td><td></td><td>1348%</td><td>430%</td><td>245%</td><td>193%</td><td>215%</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>MoM growth</t",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "e7ea8b41d6f172bd",
        "value": 1.93,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>YoY growth</td><td></td><td></td><td></td><td></td><td>1348%</td><td>430%</td><td>245%</td><td>193%</td><td>215%</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>MoM growth</td><td>37%</td",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "0a8385b03890b0a0",
        "value": 2.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "th</td><td></td><td></td><td></td><td></td><td>1348%</td><td>430%</td><td>245%</td><td>193%</td><td>215%</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>MoM growth</td><td>37%</td><td>16%</td>",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "3b5c1309f94e0eaa",
        "value": 2.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td></td><td>1348%</td><td>430%</td><td>245%</td><td>193%</td><td>215%</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>MoM growth</td><td>37%</td><td>16%</td><td>3%</td><t",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "9e22b51cda30cf59",
        "value": 1.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td></td><td>1348%</td><td>430%</td><td>245%</td><td>193%</td><td>215%</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>MoM growth</td><td>37%</td><td>16%</td><td>3%</td><td>-1%</td><td",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "24fc3aff17df7e1b",
        "value": 1.79,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>1348%</td><td>430%</td><td>245%</td><td>193%</td><td>215%</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>MoM growth</td><td>37%</td><td>16%</td><td>3%</td><td>-1%</td><td>10%</td><td>",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "e079a0be69dfe69e",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>193%</td><td>215%</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>MoM growth</td><td>37%</td><td>16%</td><td>3%</td><td>-1%</td><td>10%</td><td>28%</td><td>-</td><td>14%</td><td>4%</td>",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "a88e1763c070aea7",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>215%</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>MoM growth</td><td>37%</td><td>16%</td><td>3%</td><td>-1%</td><td>10%</td><td>28%</td><td>-</td><td>14%</td><td>4%</td><td>8%</td><",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "b2408b1bb90bd46e",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>222%</td><td>170%</td><td>179%</td></tr><tr><td>MoM growth</td><td>37%</td><td>16%</td><td>3%</td><td>-1%</td><td>10%</td><td>28%</td><td>-</td><td>14%</td><td>4%</td><td>8%</td><td>4%</td><t",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "d13e8a17b0215cdf",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2%</td><td>170%</td><td>179%</td></tr><tr><td>MoM growth</td><td>37%</td><td>16%</td><td>3%</td><td>-1%</td><td>10%</td><td>28%</td><td>-</td><td>14%</td><td>4%</td><td>8%</td><td>4%</td><td>-6%</td><",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "949bcb4fbbd1a95b",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "70%</td><td>179%</td></tr><tr><td>MoM growth</td><td>37%</td><td>16%</td><td>3%</td><td>-1%</td><td>10%</td><td>28%</td><td>-</td><td>14%</td><td>4%</td><td>8%</td><td>4%</td><td>-6%</td></tr><tr><td>",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "87d3989596e9d755",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "179%</td></tr><tr><td>MoM growth</td><td>37%</td><td>16%</td><td>3%</td><td>-1%</td><td>10%</td><td>28%</td><td>-</td><td>14%</td><td>4%</td><td>8%</td><td>4%</td><td>-6%</td></tr><tr><td>IMS Monthly ",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "0fd2bf8768405e96",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "MoM growth</td><td>37%</td><td>16%</td><td>3%</td><td>-1%</td><td>10%</td><td>28%</td><td>-</td><td>14%</td><td>4%</td><td>8%</td><td>4%</td><td>-6%</td></tr><tr><td>IMS Monthly sales (not normalized;",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "ea7735d6f12aca69",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>37%</td><td>16%</td><td>3%</td><td>-1%</td><td>10%</td><td>28%</td><td>-</td><td>14%</td><td>4%</td><td>8%</td><td>4%</td><td>-6%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "7d7972d3447e4e76",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>16%</td><td>3%</td><td>-1%</td><td>10%</td><td>28%</td><td>-</td><td>14%</td><td>4%</td><td>8%</td><td>4%</td><td>-6%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "7adf9daa312309e8",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>3%</td><td>-1%</td><td>10%</td><td>28%</td><td>-</td><td>14%</td><td>4%</td><td>8%</td><td>4%</td><td>-6%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;3</td><",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "65826b115aea75ad",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-1%</td><td>10%</td><td>28%</td><td>-</td><td>14%</td><td>4%</td><td>8%</td><td>4%</td><td>-6%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;3</td><td>&#36;4</",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "4ac3df96d7856f59",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;7</td><td>&#36;5</td><td>&#36;6</td><td>&#36;8</td><td>&#36;6</td></tr><tr><td>MoM growth</td><td>37%</td><td>45%</td><td>-17%</td><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "1efee454d3c5f72e",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;5</td><td>&#36;6</td><td>&#36;8</td><td>&#36;6</td></tr><tr><td>MoM growth</td><td>37%</td><td>45%</td><td>-17%</td><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%</td><td>8%<",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "819eaf18e2f2e977",
        "value": -0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;6</td><td>&#36;8</td><td>&#36;6</td></tr><tr><td>MoM growth</td><td>37%</td><td>45%</td><td>-17%</td><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%</td><td>8%</td><td>30%<",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "19e99c7ab298aee8",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;8</td><td>&#36;6</td></tr><tr><td>MoM growth</td><td>37%</td><td>45%</td><td>-17%</td><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%</td><td>8%</td><td>30%</td><td>-24%<",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "ca4d7c88b76cbad9",
        "value": 0.38,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;6</td></tr><tr><td>MoM growth</td><td>37%</td><td>45%</td><td>-17%</td><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%</td><td>8%</td><td>30%</td><td>-24%</td></tr><tr",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "a06f6dc174fd8dfd",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";6</td></tr><tr><td>MoM growth</td><td>37%</td><td>45%</td><td>-17%</td><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%</td><td>8%</td><td>30%</td><td>-24%</td></tr><tr><td>Balvers",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "4298bab014b052ef",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>MoM growth</td><td>37%</td><td>45%</td><td>-17%</td><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%</td><td>8%</td><td>30%</td><td>-24%</td></tr><tr><td>Balversa (Johnson ",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "8f80697ecef62f91",
        "value": 0.42,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>37%</td><td>45%</td><td>-17%</td><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%</td><td>8%</td><td>30%</td><td>-24%</td></tr><tr><td>Balversa (Johnson & Johnson)</t",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "5f845676c86fbcb8",
        "value": -0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>37%</td><td>45%</td><td>-17%</td><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%</td><td>8%</td><td>30%</td><td>-24%</td></tr><tr><td>Balversa (Johnson & Johnson)</td><td></td>",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "9ae8f3285d9d7f8f",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>45%</td><td>-17%</td><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%</td><td>8%</td><td>30%</td><td>-24%</td></tr><tr><td>Balversa (Johnson & Johnson)</td><td></td><td></td><td>",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "e81461c6f6077433",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-17%</td><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%</td><td>8%</td><td>30%</td><td>-24%</td></tr><tr><td>Balversa (Johnson & Johnson)</td><td></td><td></td><td></td><td></",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "5d15aadc2df4fbc1",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-1%</td><td>38%</td><td>2%</td><td>-3%</td><td>42%</td><td>-17%</td><td>8%</td><td>30%</td><td>-24%</td></tr><tr><td>Balversa (Johnson & Johnson)</td><td></td><td></td><td></td><td></td><td></td>",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "91ec8ad5ad189f84",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;65</td><td>&#36;54</td><td>&#36;71</td><td>&#36;70</td></tr><tr><td>YoY growth</td><td>19%</td><td>32%</td><td>17%</td><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "82cba59e1864e18a",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";65</td><td>&#36;54</td><td>&#36;71</td><td>&#36;70</td></tr><tr><td>YoY growth</td><td>19%</td><td>32%</td><td>17%</td><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</td><td>8%</t",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "8c661726bc002704",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;54</td><td>&#36;71</td><td>&#36;70</td></tr><tr><td>YoY growth</td><td>19%</td><td>32%</td><td>17%</td><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</td><td>8%</td><td>41%</t",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "13898f81164480fb",
        "value": 0.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;71</td><td>&#36;70</td></tr><tr><td>YoY growth</td><td>19%</td><td>32%</td><td>17%</td><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</td><td>8%</td><td>41%</td><td>55%</t",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "f792685a8791dd12",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;70</td></tr><tr><td>YoY growth</td><td>19%</td><td>32%</td><td>17%</td><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "691c7bb1a9ebe24b",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;70</td></tr><tr><td>YoY growth</td><td>19%</td><td>32%</td><td>17%</td><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>MoM grow",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "15b0dadb4c858b88",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>YoY growth</td><td>19%</td><td>32%</td><td>17%</td><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>MoM growth</td><td>-",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "04476f41752a11db",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Y growth</td><td>19%</td><td>32%</td><td>17%</td><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>MoM growth</td><td>-11%</td><td>",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "7bd63adfff901195",
        "value": 0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>19%</td><td>32%</td><td>17%</td><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>MoM growth</td><td>-11%</td><td>17%</td><td>",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "e87ae7638ea9a7ea",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>32%</td><td>17%</td><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>MoM growth</td><td>-11%</td><td>17%</td><td>-8%</td><td>",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "cf692f3144807ea3",
        "value": 0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>17%</td><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>MoM growth</td><td>-11%</td><td>17%</td><td>-8%</td><td>20%</td><td",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "ce412513a21890cd",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>54%</td><td>4%</td><td>13%</td><td>13%</td><td>-3%</td><td>35%</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>MoM growth</td><td>-11%</td><td>17%</td><td>-8%</td><td>20%</td><td>-9%</td><td",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "f9a29b887d17ee83",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">13%</td><td>-3%</td><td>35%</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>MoM growth</td><td>-11%</td><td>17%</td><td>-8%</td><td>20%</td><td>-9%</td><td>11%</td><td>13%</td><td>-1%</td><td>21%",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "1800bb3ea4b5bded",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-3%</td><td>35%</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>MoM growth</td><td>-11%</td><td>17%</td><td>-8%</td><td>20%</td><td>-9%</td><td>11%</td><td>13%</td><td>-1%</td><td>21%</td><td>-17%",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "422625900e736670",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "35%</td><td>8%</td><td>41%</td><td>55%</td></tr><tr><td>MoM growth</td><td>-11%</td><td>17%</td><td>-8%</td><td>20%</td><td>-9%</td><td>11%</td><td>13%</td><td>-1%</td><td>21%</td><td>-17%</td><td>32%",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "dda5443221229e74",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8%</td><td>41%</td><td>55%</td></tr><tr><td>MoM growth</td><td>-11%</td><td>17%</td><td>-8%</td><td>20%</td><td>-9%</td><td>11%</td><td>13%</td><td>-1%</td><td>21%</td><td>-17%</td><td>32%</td><td>-1%",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "b7376cd6d4baeb3d",
        "value": -0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1%</td><td>55%</td></tr><tr><td>MoM growth</td><td>-11%</td><td>17%</td><td>-8%</td><td>20%</td><td>-9%</td><td>11%</td><td>13%</td><td>-1%</td><td>21%</td><td>-17%</td><td>32%</td><td>-1%</td></tr><t",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "e5a0d0347c9dad63",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5%</td></tr><tr><td>MoM growth</td><td>-11%</td><td>17%</td><td>-8%</td><td>20%</td><td>-9%</td><td>11%</td><td>13%</td><td>-1%</td><td>21%</td><td>-17%</td><td>32%</td><td>-1%</td></tr><tr><td>IMS Mo",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "f206b0771e3a180c",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>-11%</td><td>17%</td><td>-8%</td><td>20%</td><td>-9%</td><td>11%</td><td>13%</td><td>-1%</td><td>21%</td><td>-17%</td><td>32%</td><td>-1%</td></tr><tr><td>IMS Monthly sales ",
        "provenance": {
          "page": 36
        }
      },
      {
        "num_id": "a3f5f1e102f92541",
        "value": 13.68,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>$217</td><td>$210</td><td>$211</td><td>$212</td><td>$219</td></tr><tr><td>YoY growth</td><td>1368%</td><td>1298%</td><td>4629%</td><td>5996%</td><td>4755%</td><td>3794%</td><td>5085%</td><td>44",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "ef04baf2cdfaa576",
        "value": 12.98,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>$210</td><td>$211</td><td>$212</td><td>$219</td></tr><tr><td>YoY growth</td><td>1368%</td><td>1298%</td><td>4629%</td><td>5996%</td><td>4755%</td><td>3794%</td><td>5085%</td><td>4454%</td><td>38",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "86858b7d71f68356",
        "value": 46.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>$211</td><td>$212</td><td>$219</td></tr><tr><td>YoY growth</td><td>1368%</td><td>1298%</td><td>4629%</td><td>5996%</td><td>4755%</td><td>3794%</td><td>5085%</td><td>4454%</td><td>3868%</td><td>39",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "e182c84e46c1005b",
        "value": 59.96,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>$212</td><td>$219</td></tr><tr><td>YoY growth</td><td>1368%</td><td>1298%</td><td>4629%</td><td>5996%</td><td>4755%</td><td>3794%</td><td>5085%</td><td>4454%</td><td>3868%</td><td>3968%</td><td>13",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "16ef5e23ab81b5e5",
        "value": 47.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>$219</td></tr><tr><td>YoY growth</td><td>1368%</td><td>1298%</td><td>4629%</td><td>5996%</td><td>4755%</td><td>3794%</td><td>5085%</td><td>4454%</td><td>3868%</td><td>3968%</td><td>1367%</td></tr><",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "fd8ff6b41ad767c5",
        "value": 37.94,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>YoY growth</td><td>1368%</td><td>1298%</td><td>4629%</td><td>5996%</td><td>4755%</td><td>3794%</td><td>5085%</td><td>4454%</td><td>3868%</td><td>3968%</td><td>1367%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "c553b011478dcb3b",
        "value": 50.85,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>1368%</td><td>1298%</td><td>4629%</td><td>5996%</td><td>4755%</td><td>3794%</td><td>5085%</td><td>4454%</td><td>3868%</td><td>3968%</td><td>1367%</td></tr><tr><td>MoM growth</td><td>-2%",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "8c7de5b351c50383",
        "value": 44.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>1368%</td><td>1298%</td><td>4629%</td><td>5996%</td><td>4755%</td><td>3794%</td><td>5085%</td><td>4454%</td><td>3868%</td><td>3968%</td><td>1367%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>3%</",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "caabfffdbf19a37a",
        "value": 38.68,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>1298%</td><td>4629%</td><td>5996%</td><td>4755%</td><td>3794%</td><td>5085%</td><td>4454%</td><td>3868%</td><td>3968%</td><td>1367%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>3%</td><td>490%</t",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "8a0ac41c315dd33e",
        "value": 39.68,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>4629%</td><td>5996%</td><td>4755%</td><td>3794%</td><td>5085%</td><td>4454%</td><td>3868%</td><td>3968%</td><td>1367%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>3%</td><td>490%</td><td>32%</td>",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "b64ed125bac507a8",
        "value": 13.67,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>5996%</td><td>4755%</td><td>3794%</td><td>5085%</td><td>4454%</td><td>3868%</td><td>3968%</td><td>1367%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>3%</td><td>490%</td><td>32%</td><td>6%</td><td",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "a0e08f3a1d78ae72",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>5085%</td><td>4454%</td><td>3868%</td><td>3968%</td><td>1367%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>3%</td><td>490%</td><td>32%</td><td>6%</td><td>23%</td><td>12%</td><td>-3%</td><td>1%</t",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "dd794c3c7920600b",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>4454%</td><td>3868%</td><td>3968%</td><td>1367%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>3%</td><td>490%</td><td>32%</td><td>6%</td><td>23%</td><td>12%</td><td>-3%</td><td>1%</td><td>1%</td",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "2ddd6e0b368b43d0",
        "value": 4.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>3868%</td><td>3968%</td><td>1367%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>3%</td><td>490%</td><td>32%</td><td>6%</td><td>23%</td><td>12%</td><td>-3%</td><td>1%</td><td>1%</td><td>-3%</t",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "a1f1838e698946c7",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>3968%</td><td>1367%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>3%</td><td>490%</td><td>32%</td><td>6%</td><td>23%</td><td>12%</td><td>-3%</td><td>1%</td><td>1%</td><td>-3%</td></tr><tr><t",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "c680ddaa162462bc",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>1367%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>3%</td><td>490%</td><td>32%</td><td>6%</td><td>23%</td><td>12%</td><td>-3%</td><td>1%</td><td>1%</td><td>-3%</td></tr><tr><td>IMS Monthl",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "e65e7285b42b0920",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "367%</td></tr><tr><td>MoM growth</td><td>-2%</td><td>3%</td><td>490%</td><td>32%</td><td>6%</td><td>23%</td><td>12%</td><td>-3%</td><td>1%</td><td>1%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (no",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "7f1e804fdf63ca59",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>MoM growth</td><td>-2%</td><td>3%</td><td>490%</td><td>32%</td><td>6%</td><td>23%</td><td>12%</td><td>-3%</td><td>1%</td><td>1%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "17e51b56da6d4b8d",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "M growth</td><td>-2%</td><td>3%</td><td>490%</td><td>32%</td><td>6%</td><td>23%</td><td>12%</td><td>-3%</td><td>1%</td><td>1%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 week",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "3f8ca96237940385",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-2%</td><td>3%</td><td>490%</td><td>32%</td><td>6%</td><td>23%</td><td>12%</td><td>-3%</td><td>1%</td><td>1%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "a81f48f6fb0155b4",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>3%</td><td>490%</td><td>32%</td><td>6%</td><td>23%</td><td>12%</td><td>-3%</td><td>1%</td><td>1%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$2</td><td>$",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "f18a10cfb72b507b",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>490%</td><td>32%</td><td>6%</td><td>23%</td><td>12%</td><td>-3%</td><td>1%</td><td>1%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$2</td><td>$2</td><td>$",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "cf6a7117824fe3c8",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$16</td><td>$18</td><td>$22</td><td>$18</td><td>$18</td><td>$23</td></tr><tr><td>MoM growth</td><td>-2%</td><td>29%</td><td>372%</td><td>32%</td><td>32%</td><td>-2%</td><td>12%</td><td>21%</td><td>-20",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "79391a503d7f9860",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$18</td><td>$22</td><td>$18</td><td>$18</td><td>$23</td></tr><tr><td>MoM growth</td><td>-2%</td><td>29%</td><td>372%</td><td>32%</td><td>32%</td><td>-2%</td><td>12%</td><td>21%</td><td>-20%</td><td>1%",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "8fcd135502f51178",
        "value": 3.72,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$22</td><td>$18</td><td>$18</td><td>$23</td></tr><tr><td>MoM growth</td><td>-2%</td><td>29%</td><td>372%</td><td>32%</td><td>32%</td><td>-2%</td><td>12%</td><td>21%</td><td>-20%</td><td>1%</td><td>29%",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "b147cffa0ec8aa9a",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "18</td><td>$18</td><td>$23</td></tr><tr><td>MoM growth</td><td>-2%</td><td>29%</td><td>372%</td><td>32%</td><td>32%</td><td>-2%</td><td>12%</td><td>21%</td><td>-20%</td><td>1%</td><td>29%</td></tr><tr",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "fc891c53bb040bc7",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "18</td><td>$23</td></tr><tr><td>MoM growth</td><td>-2%</td><td>29%</td><td>372%</td><td>32%</td><td>32%</td><td>-2%</td><td>12%</td><td>21%</td><td>-20%</td><td>1%</td><td>29%</td></tr><tr><td>Lumakra",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "783560ce15034536",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "23</td></tr><tr><td>MoM growth</td><td>-2%</td><td>29%</td><td>372%</td><td>32%</td><td>32%</td><td>-2%</td><td>12%</td><td>21%</td><td>-20%</td><td>1%</td><td>29%</td></tr><tr><td>Lumakras (Amgen)</t",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "cf0151f2caf0ff3f",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>-2%</td><td>29%</td><td>372%</td><td>32%</td><td>32%</td><td>-2%</td><td>12%</td><td>21%</td><td>-20%</td><td>1%</td><td>29%</td></tr><tr><td>Lumakras (Amgen)</td><td></td><",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "b70d683e805db0af",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>-2%</td><td>29%</td><td>372%</td><td>32%</td><td>32%</td><td>-2%</td><td>12%</td><td>21%</td><td>-20%</td><td>1%</td><td>29%</td></tr><tr><td>Lumakras (Amgen)</td><td></td><td></td><td>",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "7aa5127f7f252e71",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-2%</td><td>29%</td><td>372%</td><td>32%</td><td>32%</td><td>-2%</td><td>12%</td><td>21%</td><td>-20%</td><td>1%</td><td>29%</td></tr><tr><td>Lumakras (Amgen)</td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "e377b728f08f0c85",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>29%</td><td>372%</td><td>32%</td><td>32%</td><td>-2%</td><td>12%</td><td>21%</td><td>-20%</td><td>1%</td><td>29%</td></tr><tr><td>Lumakras (Amgen)</td><td></td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "199febc0d12bbb42",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>372%</td><td>32%</td><td>32%</td><td>-2%</td><td>12%</td><td>21%</td><td>-20%</td><td>1%</td><td>29%</td></tr><tr><td>Lumakras (Amgen)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "5bc49c0849302e09",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>$212</td><td>$195</td><td>$197</td><td>$198</td><td>$209</td></tr><tr><td>YoY growth</td><td>10%</td><td>-1%</td><td>16%</td><td>-2%</td><td>3%</td><td>12%</td><td>9%</td><td>3%</td><td>6%</td>",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "44a2fa345dc842a9",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>$195</td><td>$197</td><td>$198</td><td>$209</td></tr><tr><td>YoY growth</td><td>10%</td><td>-1%</td><td>16%</td><td>-2%</td><td>3%</td><td>12%</td><td>9%</td><td>3%</td><td>6%</td><td>15%</td>",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "91e02537bdb647c1",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>$197</td><td>$198</td><td>$209</td></tr><tr><td>YoY growth</td><td>10%</td><td>-1%</td><td>16%</td><td>-2%</td><td>3%</td><td>12%</td><td>9%</td><td>3%</td><td>6%</td><td>15%</td><td>27%</td>",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "87bd5aa503f463b5",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7</td><td>$198</td><td>$209</td></tr><tr><td>YoY growth</td><td>10%</td><td>-1%</td><td>16%</td><td>-2%</td><td>3%</td><td>12%</td><td>9%</td><td>3%</td><td>6%</td><td>15%</td><td>27%</td></tr><tr><td",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "f13a1a7ed9ded3cb",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "98</td><td>$209</td></tr><tr><td>YoY growth</td><td>10%</td><td>-1%</td><td>16%</td><td>-2%</td><td>3%</td><td>12%</td><td>9%</td><td>3%</td><td>6%</td><td>15%</td><td>27%</td></tr><tr><td>MoM growth<",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "21f8a263d2992be7",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$209</td></tr><tr><td>YoY growth</td><td>10%</td><td>-1%</td><td>16%</td><td>-2%</td><td>3%</td><td>12%</td><td>9%</td><td>3%</td><td>6%</td><td>15%</td><td>27%</td></tr><tr><td>MoM growth</td><td>4%<",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "37273a30d22db454",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>YoY growth</td><td>10%</td><td>-1%</td><td>16%</td><td>-2%</td><td>3%</td><td>12%</td><td>9%</td><td>3%</td><td>6%</td><td>15%</td><td>27%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-3%<",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "a61ff29bb72a5e1f",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "oY growth</td><td>10%</td><td>-1%</td><td>16%</td><td>-2%</td><td>3%</td><td>12%</td><td>9%</td><td>3%</td><td>6%</td><td>15%</td><td>27%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-3%</td><td>-5%",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "bf3c5e5485a453f4",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>10%</td><td>-1%</td><td>16%</td><td>-2%</td><td>3%</td><td>12%</td><td>9%</td><td>3%</td><td>6%</td><td>15%</td><td>27%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-3%</td><td>-5%</td><td>6%",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "c15ff53809995c6d",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-1%</td><td>16%</td><td>-2%</td><td>3%</td><td>12%</td><td>9%</td><td>3%</td><td>6%</td><td>15%</td><td>27%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-3%</td><td>-5%</td><td>6%</td><td>3%",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "4418ec035f68c055",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>16%</td><td>-2%</td><td>3%</td><td>12%</td><td>9%</td><td>3%</td><td>6%</td><td>15%</td><td>27%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-3%</td><td>-5%</td><td>6%</td><td>3%</td><td>17%",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "f4c1dc00ac9b4c7f",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>12%</td><td>9%</td><td>3%</td><td>6%</td><td>15%</td><td>27%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-3%</td><td>-5%</td><td>6%</td><td>3%</td><td>17%</td><td>3%</td><td>-8%</td><td>1%</td><",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "1d1f4da881c7abda",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>9%</td><td>3%</td><td>6%</td><td>15%</td><td>27%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-3%</td><td>-5%</td><td>6%</td><td>3%</td><td>17%</td><td>3%</td><td>-8%</td><td>1%</td><td>1%</td><",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "5aa7edf613561435",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>3%</td><td>6%</td><td>15%</td><td>27%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-3%</td><td>-5%</td><td>6%</td><td>3%</td><td>17%</td><td>3%</td><td>-8%</td><td>1%</td><td>1%</td><td>6%</td></",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "e3188da2b45562c0",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>6%</td><td>15%</td><td>27%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-3%</td><td>-5%</td><td>6%</td><td>3%</td><td>17%</td><td>3%</td><td>-8%</td><td>1%</td><td>1%</td><td>6%</td></tr><tr><td>I",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "593469020561f7a6",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>15%</td><td>27%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-3%</td><td>-5%</td><td>6%</td><td>3%</td><td>17%</td><td>3%</td><td>-8%</td><td>1%</td><td>1%</td><td>6%</td></tr><tr><td>IMS Monthly ",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "6da28f7da0e8fe57",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>27%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-3%</td><td>-5%</td><td>6%</td><td>3%</td><td>17%</td><td>3%</td><td>-8%</td><td>1%</td><td>1%</td><td>6%</td></tr><tr><td>IMS Monthly sales (not ",
        "provenance": {
          "page": 38
        }
      },
      {
        "num_id": "d90cb7d013df823b",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";1,266</td><td>&#36;1,272</td><td>&#36;1,350</td><td>&#36;1,319</td></tr><tr><td>YoY growth</td><td>11%</td><td>11%</td><td>16%</td><td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%<",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "4d7f79240c1f8003",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;1,272</td><td>&#36;1,350</td><td>&#36;1,319</td></tr><tr><td>YoY growth</td><td>11%</td><td>11%</td><td>16%</td><td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%</td><td>19%<",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "dacd30248cc91717",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2</td><td>&#36;1,350</td><td>&#36;1,319</td></tr><tr><td>YoY growth</td><td>11%</td><td>11%</td><td>16%</td><td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%</td><td>19%</td><td>24%<",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "f55d2d81c31939da",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;1,350</td><td>&#36;1,319</td></tr><tr><td>YoY growth</td><td>11%</td><td>11%</td><td>16%</td><td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%</td><td>19%</td><td>24%</td><td>19%<",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "c3b8f3001a396635",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;1,319</td></tr><tr><td>YoY growth</td><td>11%</td><td>11%</td><td>16%</td><td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%</td><td>19%</td><td>24%</td><td>19%</td></tr><tr",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "b68d5c6b4b3b71fa",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "319</td></tr><tr><td>YoY growth</td><td>11%</td><td>11%</td><td>16%</td><td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>MoM gro",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "e1beca9d112fed39",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>11%</td><td>11%</td><td>16%</td><td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>MoM growth</td><td>",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "b479044361a38ae0",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>11%</td><td>11%</td><td>16%</td><td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>MoM growth</td><td>3%</td><td>0%",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "8ea07f1519e26273",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>11%</td><td>11%</td><td>16%</td><td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>MoM growth</td><td>3%</td><td>0%</td><td>1%",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "6905b9d003c99183",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>11%</td><td>16%</td><td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>MoM growth</td><td>3%</td><td>0%</td><td>1%</td><td>-1%",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "c32f24a94532991a",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>16%</td><td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>MoM growth</td><td>3%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%<",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "2508d18182b0de4a",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>17%</td><td>12%</td><td>23%</td><td>21%</td><td>17%</td><td>17%</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>MoM growth</td><td>3%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "99547fcdb0980293",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "21%</td><td>17%</td><td>17%</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>MoM growth</td><td>3%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "046d06db5a24ec4f",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">17%</td><td>17%</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>MoM growth</td><td>3%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td>0%</td><td",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "c128794bb2b2504d",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>17%</td><td>19%</td><td>24%</td><td>19%</td></tr><tr><td>MoM growth</td><td>3%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td>0%</td><td>6%</td><td",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "dc7049cd39203119",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>19%</td><td>24%</td><td>19%</td></tr><tr><td>MoM growth</td><td>3%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td>0%</td><td>6%</td><td>-2%</td></",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "c1a1766e2146ce75",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>24%</td><td>19%</td></tr><tr><td>MoM growth</td><td>3%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>I",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "4dd020c55b640b41",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>19%</td></tr><tr><td>MoM growth</td><td>3%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>IMS Monthly ",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "3afc4e98aafa7c14",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>MoM growth</td><td>3%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not ",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "d531e4844dc35b57",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>MoM growth</td><td>3%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not normalized;",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "7c3ea7c15a006821",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "h</td><td>3%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "2357e39d6cbdcc3e",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>0%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "6a1ba8e9efb3e7e0",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>1%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;95</td>",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "9f813f772afa6a40",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>-1%</td><td>3%</td><td>5%</td><td>5%</td><td>-2%</td><td>0%</td><td>0%</td><td>6%</td><td>-2%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;95</td><td>&#36;11",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "85706b8e297a9bc0",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;106</td><td>&#36;106</td><td>&#36;141</td><td>&#36;110</td></tr><tr><td>MoM growth</td><td>3%</td><td>25%</td><td>-19%</td><td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "72e7ee772828914f",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6</td><td>&#36;106</td><td>&#36;141</td><td>&#36;110</td></tr><tr><td>MoM growth</td><td>3%</td><td>25%</td><td>-19%</td><td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%</td><td>0%",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "2eb5181b8be2df40",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;106</td><td>&#36;141</td><td>&#36;110</td></tr><tr><td>MoM growth</td><td>3%</td><td>25%</td><td>-19%</td><td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%</td><td>0%</td><td>33%",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "6f1bf1735a80ea86",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;141</td><td>&#36;110</td></tr><tr><td>MoM growth</td><td>3%</td><td>25%</td><td>-19%</td><td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%</td><td>0%</td><td>33%</td><td>-22%",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "60a8ed4433268ba5",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&#36;110</td></tr><tr><td>MoM growth</td><td>3%</td><td>25%</td><td>-19%</td><td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%</td><td>0%</td><td>33%</td><td>-22%</td></tr><t",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "30851c6c3b33c57a",
        "value": -0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "110</td></tr><tr><td>MoM growth</td><td>3%</td><td>25%</td><td>-19%</td><td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%</td><td>0%</td><td>33%</td><td>-22%</td></tr><tr><td>Rubrac",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "675d66a1a612b08c",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>3%</td><td>25%</td><td>-19%</td><td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%</td><td>0%</td><td>33%</td><td>-22%</td></tr><tr><td>Rubraca (Clovis)</t",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "8f385ec5ea0421f8",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>3%</td><td>25%</td><td>-19%</td><td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%</td><td>0%</td><td>33%</td><td>-22%</td></tr><tr><td>Rubraca (Clovis)</td><td></td><",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "e023c1a4a36aa68d",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>3%</td><td>25%</td><td>-19%</td><td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%</td><td>0%</td><td>33%</td><td>-22%</td></tr><tr><td>Rubraca (Clovis)</td><td></td><td></td><td",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "6b72042313d49b06",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>25%</td><td>-19%</td><td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%</td><td>0%</td><td>33%</td><td>-22%</td></tr><tr><td>Rubraca (Clovis)</td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "9d23913ac73f4295",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-19%</td><td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%</td><td>0%</td><td>33%</td><td>-22%</td></tr><tr><td>Rubraca (Clovis)</td><td></td><td></td><td></td><td></td><td></td>",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "9f1ef18a4449e53d",
        "value": -0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-1%</td><td>29%</td><td>-16%</td><td>5%</td><td>23%</td><td>-20%</td><td>0%</td><td>33%</td><td>-22%</td></tr><tr><td>Rubraca (Clovis)</td><td></td><td></td><td></td><td></td><td></td><td></td><td",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "91bd18004d9b2896",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;35</td><td>&#36;30</td><td>&#36;32</td><td>&#36;31</td></tr><tr><td>YoY growth</td><td>-3%</td><td>-4%</td><td>-10%</td><td>9%</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "3adfc3f1a9dae8cb",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";35</td><td>&#36;30</td><td>&#36;32</td><td>&#36;31</td></tr><tr><td>YoY growth</td><td>-3%</td><td>-4%</td><td>-10%</td><td>9%</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>-13%</td><td",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "f3ac73d783e4d229",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;30</td><td>&#36;32</td><td>&#36;31</td></tr><tr><td>YoY growth</td><td>-3%</td><td>-4%</td><td>-10%</td><td>9%</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>-13%</td><td>-24%</td><t",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "9c903e72a5d4b123",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;32</td><td>&#36;31</td></tr><tr><td>YoY growth</td><td>-3%</td><td>-4%</td><td>-10%</td><td>9%</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>-13%</td><td>-24%</td><td>-17%</td><t",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "7b0e54a92fbe95f4",
        "value": -0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>&#36;31</td></tr><tr><td>YoY growth</td><td>-3%</td><td>-4%</td><td>-10%</td><td>9%</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>-13%</td><td>-24%</td><td>-17%</td><td>-20%</td>",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "72d60cf62f4ee18f",
        "value": -0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "31</td></tr><tr><td>YoY growth</td><td>-3%</td><td>-4%</td><td>-10%</td><td>9%</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>-13%</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "e0424b63afb7d7e8",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>YoY growth</td><td>-3%</td><td>-4%</td><td>-10%</td><td>9%</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>-13%</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>MoM growth</t",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "be76b64213723a82",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "owth</td><td>-3%</td><td>-4%</td><td>-10%</td><td>9%</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>-13%</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>MoM growth</td><td>7%</td>",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "7d76ca1da8b1a8ae",
        "value": -0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-3%</td><td>-4%</td><td>-10%</td><td>9%</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>-13%</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>MoM growth</td><td>7%</td><td>1%</td><t",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "d47f403e1a8cf9a6",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4%</td><td>-10%</td><td>9%</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>-13%</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>MoM growth</td><td>7%</td><td>1%</td><td>-10%</td><t",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "1dfaa6490832a58e",
        "value": -0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%</td><td>9%</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>-13%</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>MoM growth</td><td>7%</td><td>1%</td><td>-10%</td><td>13%</td><td",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "3fe87d39a2dae2eb",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-13%</td><td>-13%</td><td>-15%</td><td>-10%</td><td>-13%</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>MoM growth</td><td>7%</td><td>1%</td><td>-10%</td><td>13%</td><td>-12%</td><td",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "3db950183f84381a",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-10%</td><td>-13%</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>MoM growth</td><td>7%</td><td>1%</td><td>-10%</td><td>13%</td><td>-12%</td><td>0%</td><td>1%</td><td>-4%</td><td>-6%</t",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "d95a7df3487f0fc0",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-13%</td><td>-24%</td><td>-17%</td><td>-20%</td></tr><tr><td>MoM growth</td><td>7%</td><td>1%</td><td>-10%</td><td>13%</td><td>-12%</td><td>0%</td><td>1%</td><td>-4%</td><td>-6%</td><td>-13%<",
        "provenance": {
          "page": 39
        }
      },
      {
        "num_id": "aa2d81e0ace2d1e2",
        "value": 3.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7</td><td>5298</td><td>5305</td><td>5314</td><td>5343</td><td>5354</td></tr><tr><td>% diff.</td><td>335%</td><td>27.9%</td><td>89%</td><td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>1",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "2cad4575753edf5f",
        "value": 0.27899999999999997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8</td><td>5305</td><td>5314</td><td>5343</td><td>5354</td></tr><tr><td>% diff.</td><td>335%</td><td>27.9%</td><td>89%</td><td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "9b28517d401580a5",
        "value": 0.89,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>5314</td><td>5343</td><td>5354</td></tr><tr><td>% diff.</td><td>335%</td><td>27.9%</td><td>89%</td><td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "23c164a42729ccf5",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4</td><td>5343</td><td>5354</td></tr><tr><td>% diff.</td><td>335%</td><td>27.9%</td><td>89%</td><td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "265491f44885000d",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "43</td><td>5354</td></tr><tr><td>% diff.</td><td>335%</td><td>27.9%</td><td>89%</td><td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "0c5072d964ad3412",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "354</td></tr><tr><td>% diff.</td><td>335%</td><td>27.9%</td><td>89%</td><td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "6734df6b8ef85861",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>% diff.</td><td>335%</td><td>27.9%</td><td>89%</td><td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "a3b49628b303c4c4",
        "value": 0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "iff.</td><td>335%</td><td>27.9%</td><td>89%</td><td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "20f98b9f68c08b09",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">335%</td><td>27.9%</td><td>89%</td><td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "e095319017b6282a",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>27.9%</td><td>89%</td><td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "2ef4d0eff5457319",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>89%</td><td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "ad9ab2e52dc85f1a",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>55%</td><td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "c5d8b0cd95a5f438",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>31%</td><td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "56613b47a09f758b",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>37%</td><td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "ade149ff8e670cea",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>26%</td><td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "d75504e05feb8e0b",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>49%</td><td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%<",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "17d9e2b7af49b526",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>18%</td><td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "ef1a90c499a0be0b",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>26%</td><td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "9cf170a2e3ca2703",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>32%</td><td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "41c8b2a85642c138",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>32%</td><td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "cccb23e59092858d",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>18%</td><td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</t",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "d5d6bdb94058366c",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>21%</td><td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "935c450791e3546d",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>18%</td><td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "970d05c4d15bd63c",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>19%</td><td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td><td>20%</td",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "afd1f559c38cd19f",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>19%</td><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td><td>20%</td><td>-9%</td",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "8d1dcea8049e1f75",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>23%</td><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td><td>20%</td><td>-9%</td><td>7%</td",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "6417deab090d39a2",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>20%</td><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td><td>20%</td><td>-9%</td><td>7%</td></tr><tr><t",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "8cda07d4e9e27b33",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>25%</td><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td><td>20%</td><td>-9%</td><td>7%</td></tr><tr><td>Talzenna</",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "567460e92cb9a947",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>10%</td><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td><td>20%</td><td>-9%</td><td>7%</td></tr><tr><td>Talzenna</td><td></td>",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "a3b0fd4cf9b0baff",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>18%</td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td><td>20%</td><td>-9%</td><td>7%</td></tr><tr><td>Talzenna</td><td></td><td></td><t",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "2b18b17c722773e0",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>21%</td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td><td>20%</td><td>-9%</td><td>7%</td></tr><tr><td>Talzenna</td><td></td><td></td><td></td><td>",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "770a199934364658",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>26%</td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td><td>20%</td><td>-9%</td><td>7%</td></tr><tr><td>Talzenna</td><td></td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "1df55380bbae4358",
        "value": -0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>0%</td><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td><td>20%</td><td>-9%</td><td>7%</td></tr><tr><td>Talzenna</td><td></td><td></td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "1aa6a1b4fefed48e",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>15%</td><td>17%</td><td>29%</td><td>0%</td><td>7%</td><td>14%</td><td>20%</td><td>-9%</td><td>7%</td></tr><tr><td>Talzenna</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>",
        "provenance": {
          "page": 40
        }
      },
      {
        "num_id": "deded538d45c33b1",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;788</td><td>&#36;843</td><td>&#36;988</td><td>&#36;788</td></tr><tr><td>YoY growth</td><td>4%</td><td>-2%</td><td>6%</td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "281ac73a65cce5b9",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8</td><td>&#36;843</td><td>&#36;988</td><td>&#36;788</td></tr><tr><td>YoY growth</td><td>4%</td><td>-2%</td><td>6%</td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><td>-6%</td>",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "3fc4296803533597",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;843</td><td>&#36;988</td><td>&#36;788</td></tr><tr><td>YoY growth</td><td>4%</td><td>-2%</td><td>6%</td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><td>-6%</td><td>13%</td>",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "58b1cad3ffada9ab",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;988</td><td>&#36;788</td></tr><tr><td>YoY growth</td><td>4%</td><td>-2%</td><td>6%</td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><td>-6%</td><td>13%</td><td>-8%</td",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "12c39551a5a3d5dc",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8</td><td>&#36;788</td></tr><tr><td>YoY growth</td><td>4%</td><td>-2%</td><td>6%</td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><td>-6%</td><td>13%</td><td>-8%</td></tr><tr><",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "8f8d0b0d77e5d8e5",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;788</td></tr><tr><td>YoY growth</td><td>4%</td><td>-2%</td><td>6%</td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><td>-6%</td><td>13%</td><td>-8%</td></tr><tr><td>MoM growt",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "a73a30d26a35c047",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>YoY growth</td><td>4%</td><td>-2%</td><td>6%</td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><td>-6%</td><td>13%</td><td>-8%</td></tr><tr><td>MoM growth</td><td>4%",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "12317503dbb41166",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">YoY growth</td><td>4%</td><td>-2%</td><td>6%</td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><td>-6%</td><td>13%</td><td>-8%</td></tr><tr><td>MoM growth</td><td>4%</td><td>7%",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "6e252f2d53075ff3",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>4%</td><td>-2%</td><td>6%</td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><td>-6%</td><td>13%</td><td>-8%</td></tr><tr><td>MoM growth</td><td>4%</td><td>7%</td><td>-1",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "d82a15835a1db284",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-2%</td><td>6%</td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><td>-6%</td><td>13%</td><td>-8%</td></tr><tr><td>MoM growth</td><td>4%</td><td>7%</td><td>-11%</td><td>4",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "8c0789189100c654",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>6%</td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><td>-6%</td><td>13%</td><td>-8%</td></tr><tr><td>MoM growth</td><td>4%</td><td>7%</td><td>-11%</td><td>4%</td><td>8%",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "7e641afa26824772",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>4%</td><td>10%</td><td>-8%</td><td>1%</td><td>6%</td><td>-6%</td><td>-6%</td><td>13%</td><td>-8%</td></tr><tr><td>MoM growth</td><td>4%</td><td>7%</td><td>-11%</td><td>4%</td><td>8%</td><td>-19",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "5c5c8e2895f9642b",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>1%</td><td>6%</td><td>-6%</td><td>-6%</td><td>13%</td><td>-8%</td></tr><tr><td>MoM growth</td><td>4%</td><td>7%</td><td>-11%</td><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "db9d23fa6bb6bff8",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>6%</td><td>-6%</td><td>-6%</td><td>13%</td><td>-8%</td></tr><tr><td>MoM growth</td><td>4%</td><td>7%</td><td>-11%</td><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</td><td>7%</",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "10d92a08d81f5abd",
        "value": -0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-6%</td><td>-6%</td><td>13%</td><td>-8%</td></tr><tr><td>MoM growth</td><td>4%</td><td>7%</td><td>-11%</td><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</td><td>7%</td><td>17%<",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "f3437c7dc6c70ff7",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">-6%</td><td>13%</td><td>-8%</td></tr><tr><td>MoM growth</td><td>4%</td><td>7%</td><td>-11%</td><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</td><td>7%</td><td>17%</td><td>-20%<",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "2056eabc713838eb",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>13%</td><td>-8%</td></tr><tr><td>MoM growth</td><td>4%</td><td>7%</td><td>-11%</td><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</td><td>7%</td><td>17%</td><td>-20%</td></tr><t",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "72bf0077c6569ba7",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-8%</td></tr><tr><td>MoM growth</td><td>4%</td><td>7%</td><td>-11%</td><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS M",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "a9a13cbd19c4b80a",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>MoM growth</td><td>4%</td><td>7%</td><td>-11%</td><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales ",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "c33a9fc84f60f7c4",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "oM growth</td><td>4%</td><td>7%</td><td>-11%</td><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales (not normali",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "c505f71d5ce8f06f",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>4%</td><td>7%</td><td>-11%</td><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 w",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "a82cb1bc42b02773",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>7%</td><td>-11%</td><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "f09bc9610bfbe636",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-11%</td><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;74</t",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "f97ef8cc861d508f",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>4%</td><td>8%</td><td>-19%</td><td>14%</td><td>18%</td><td>-24%</td><td>7%</td><td>17%</td><td>-20%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;74</td><td>&#36;9",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "a3e9c36a6baba1e2",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&#36;66</td><td>&#36;70</td><td>&#36;103</td><td>&#36;66</td></tr><tr><td>MoM growth</td><td>4%</td><td>34%</td><td>-28%</td><td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "72da89045623bb0d",
        "value": 0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";66</td><td>&#36;70</td><td>&#36;103</td><td>&#36;66</td></tr><tr><td>MoM growth</td><td>4%</td><td>34%</td><td>-28%</td><td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%</td><td>7%",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "c5c0895cb937e74d",
        "value": -0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;70</td><td>&#36;103</td><td>&#36;66</td></tr><tr><td>MoM growth</td><td>4%</td><td>34%</td><td>-28%</td><td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%</td><td>7%</td><td>46%",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "746514f93763c6d6",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;103</td><td>&#36;66</td></tr><tr><td>MoM growth</td><td>4%</td><td>34%</td><td>-28%</td><td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%</td><td>7%</td><td>46%</td><td>-36%",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "8adbe7f7fa6866c1",
        "value": 0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>&#36;66</td></tr><tr><td>MoM growth</td><td>4%</td><td>34%</td><td>-28%</td><td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%</td><td>7%</td><td>46%</td><td>-36%</td></tr><",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "dbac59298c0c80b0",
        "value": -0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6;66</td></tr><tr><td>MoM growth</td><td>4%</td><td>34%</td><td>-28%</td><td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%</td><td>7%</td><td>46%</td><td>-36%</td></tr><tr><td>Ninla",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "f5a11d9d7f9f74e2",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>MoM growth</td><td>4%</td><td>34%</td><td>-28%</td><td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%</td><td>7%</td><td>46%</td><td>-36%</td></tr><tr><td>Ninlaro (Takeda)</",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "033788b425d0c7be",
        "value": 0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>4%</td><td>34%</td><td>-28%</td><td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%</td><td>7%</td><td>46%</td><td>-36%</td></tr><tr><td>Ninlaro (Takeda)</td><td></td><",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "d9d83d36775cec6b",
        "value": -0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>4%</td><td>34%</td><td>-28%</td><td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%</td><td>7%</td><td>46%</td><td>-36%</td></tr><tr><td>Ninlaro (Takeda)</td><td></td><td></td><td",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "326699d35c71694d",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>34%</td><td>-28%</td><td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%</td><td>7%</td><td>46%</td><td>-36%</td></tr><tr><td>Ninlaro (Takeda)</td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "c0dd8585eeb791bb",
        "value": 0.46,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-28%</td><td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%</td><td>7%</td><td>46%</td><td>-36%</td></tr><tr><td>Ninlaro (Takeda)</td><td></td><td></td><td></td><td></td><td></td>",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "8182cf53fcf88ba8",
        "value": -0.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>4%</td><td>35%</td><td>-35%</td><td>14%</td><td>48%</td><td>-39%</td><td>7%</td><td>46%</td><td>-36%</td></tr><tr><td>Ninlaro (Takeda)</td><td></td><td></td><td></td><td></td><td></td><td></td><td",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "755856fcb3e20771",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;229</td><td>&#36;230</td><td>&#36;245</td><td>&#36;230</td></tr><tr><td>YoY growth</td><td>-8%</td><td>-15%</td><td>-19%</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</t",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "eb717c96dd8d89c2",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>&#36;230</td><td>&#36;245</td><td>&#36;230</td></tr><tr><td>YoY growth</td><td>-8%</td><td>-15%</td><td>-19%</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</td><td>9%</td",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "fd2b9353ab0150f3",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";230</td><td>&#36;245</td><td>&#36;230</td></tr><tr><td>YoY growth</td><td>-8%</td><td>-15%</td><td>-19%</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</td><td>9%</td><td>10%</td>",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "dea7f216f033e5a5",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;245</td><td>&#36;230</td></tr><tr><td>YoY growth</td><td>-8%</td><td>-15%</td><td>-19%</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</td><td>9%</td><td>10%</td><td>7%</td></",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "587f9401042f09fd",
        "value": 0.43,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>&#36;230</td></tr><tr><td>YoY growth</td><td>-8%</td><td>-15%</td><td>-19%</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</td><td>9%</td><td>10%</td><td>7%</td></tr><tr><td>M",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "6d3d011998dcdb87",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0</td></tr><tr><td>YoY growth</td><td>-8%</td><td>-15%</td><td>-19%</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</td><td>9%</td><td>10%</td><td>7%</td></tr><tr><td>MoM growth</t",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "f116ff9d00ada591",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>YoY growth</td><td>-8%</td><td>-15%</td><td>-19%</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</td><td>9%</td><td>10%</td><td>7%</td></tr><tr><td>MoM growth</td><td>-3%</",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "0c11f64798201b3a",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>-8%</td><td>-15%</td><td>-19%</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</td><td>9%</td><td>10%</td><td>7%</td></tr><tr><td>MoM growth</td><td>-3%</td><td>-2%</",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "ce33d046063daf7d",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-8%</td><td>-15%</td><td>-19%</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</td><td>9%</td><td>10%</td><td>7%</td></tr><tr><td>MoM growth</td><td>-3%</td><td>-2%</td><td>-2%",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "1e05151e0c7fde8d",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>-15%</td><td>-19%</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</td><td>9%</td><td>10%</td><td>7%</td></tr><tr><td>MoM growth</td><td>-3%</td><td>-2%</td><td>-2%</td><td>47",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "124efca8b13b3802",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-19%</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</td><td>9%</td><td>10%</td><td>7%</td></tr><tr><td>MoM growth</td><td>-3%</td><td>-2%</td><td>-2%</td><td>47%</td><td>1",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "642165e32b16fad9",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>37%</td><td>43%</td><td>5%</td><td>1%</td><td>0%</td><td>0%</td><td>9%</td><td>10%</td><td>7%</td></tr><tr><td>MoM growth</td><td>-3%</td><td>-2%</td><td>-2%</td><td>47%</td><td>17%</td><td>-",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "b7c554933c6afa0f",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>1%</td><td>0%</td><td>0%</td><td>9%</td><td>10%</td><td>7%</td></tr><tr><td>MoM growth</td><td>-3%</td><td>-2%</td><td>-2%</td><td>47%</td><td>17%</td><td>-33%</td><td>2%</td><td>-3%</td><td>0%</",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "152845eabaecc2ea",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>0%</td><td>0%</td><td>9%</td><td>10%</td><td>7%</td></tr><tr><td>MoM growth</td><td>-3%</td><td>-2%</td><td>-2%</td><td>47%</td><td>17%</td><td>-33%</td><td>2%</td><td>-3%</td><td>0%</td><td>0%</t",
        "provenance": {
          "page": 41
        }
      },
      {
        "num_id": "00d7224434adb1a3",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>$164</td><td>$148</td><td>$142</td><td>$151</td><td>$147</td></tr><tr><td>YoY growth</td><td>-2%</td><td>-3%</td><td>-6%</td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "6ca585c96971067a",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>$148</td><td>$142</td><td>$151</td><td>$147</td></tr><tr><td>YoY growth</td><td>-2%</td><td>-3%</td><td>-6%</td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td><td>-7%</td",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "fa826885b3cdfa06",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>$142</td><td>$151</td><td>$147</td></tr><tr><td>YoY growth</td><td>-2%</td><td>-3%</td><td>-6%</td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td><td>-7%</td><td>1%</td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "aa0ea27f9cdff84d",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2</td><td>$151</td><td>$147</td></tr><tr><td>YoY growth</td><td>-2%</td><td>-3%</td><td>-6%</td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td><td>-7%</td><td>1%</td><td>-12%</td",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "82a56c67dd6c3fc2",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "151</td><td>$147</td></tr><tr><td>YoY growth</td><td>-2%</td><td>-3%</td><td>-6%</td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td><td>-7%</td><td>1%</td><td>-12%</td></tr><tr><",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "b72f40d3625b04c5",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$147</td></tr><tr><td>YoY growth</td><td>-2%</td><td>-3%</td><td>-6%</td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td><td>-7%</td><td>1%</td><td>-12%</td></tr><tr><td>MoM growt",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "adabde1642bc6d19",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>YoY growth</td><td>-2%</td><td>-3%</td><td>-6%</td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td><td>-7%</td><td>1%</td><td>-12%</td></tr><tr><td>MoM growth</td><td>-",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "87f76a4ea569b16f",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "oY growth</td><td>-2%</td><td>-3%</td><td>-6%</td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td><td>-7%</td><td>1%</td><td>-12%</td></tr><tr><td>MoM growth</td><td>-8%</td><td>0",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "348a7fb77e8d71c2",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-2%</td><td>-3%</td><td>-6%</td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td><td>-7%</td><td>1%</td><td>-12%</td></tr><tr><td>MoM growth</td><td>-8%</td><td>0%</td><td>0",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "794cd19d367ac555",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-3%</td><td>-6%</td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td><td>-7%</td><td>1%</td><td>-12%</td></tr><tr><td>MoM growth</td><td>-8%</td><td>0%</td><td>0%</td><td>2%",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "9b50a7b68414ba7b",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-6%</td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td><td>-7%</td><td>1%</td><td>-12%</td></tr><tr><td>MoM growth</td><td>-8%</td><td>0%</td><td>0%</td><td>2%</td><td>-2%",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "3458c6fd9c2480be",
        "value": -0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>0%</td><td>-4%</td><td>0%</td><td>-2%</td><td>6%</td><td>-1%</td><td>-7%</td><td>1%</td><td>-12%</td></tr><tr><td>MoM growth</td><td>-8%</td><td>0%</td><td>0%</td><td>2%</td><td>-2%</td><td>0%",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "9f146d9c3b0c07de",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">-2%</td><td>6%</td><td>-1%</td><td>-7%</td><td>1%</td><td>-12%</td></tr><tr><td>MoM growth</td><td>-8%</td><td>0%</td><td>0%</td><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "a834c47abd832e16",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">6%</td><td>-1%</td><td>-7%</td><td>1%</td><td>-12%</td></tr><tr><td>MoM growth</td><td>-8%</td><td>0%</td><td>0%</td><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td><td>-4%</td",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "1351716cba3b6763",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">-1%</td><td>-7%</td><td>1%</td><td>-12%</td></tr><tr><td>MoM growth</td><td>-8%</td><td>0%</td><td>0%</td><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td><td>-4%</td><td>7%</td",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "e123e515aab4e700",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-7%</td><td>1%</td><td>-12%</td></tr><tr><td>MoM growth</td><td>-8%</td><td>0%</td><td>0%</td><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td><td>-4%</td><td>7%</td><td>-3%</t",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "3c19f3323600bdc7",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>1%</td><td>-12%</td></tr><tr><td>MoM growth</td><td>-8%</td><td>0%</td><td>0%</td><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td><td>-4%</td><td>7%</td><td>-3%</td></tr><tr>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "fd277d3b023bc8de",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-12%</td></tr><tr><td>MoM growth</td><td>-8%</td><td>0%</td><td>0%</td><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td><td>-4%</td><td>7%</td><td>-3%</td></tr><tr><td>IMS Mont",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "a73e2dcf6fdb5101",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>MoM growth</td><td>-8%</td><td>0%</td><td>0%</td><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td><td>-4%</td><td>7%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "7f8e007231dd5e8c",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">MoM growth</td><td>-8%</td><td>0%</td><td>0%</td><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td><td>-4%</td><td>7%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normaliz",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "19e5735945eb32cd",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-8%</td><td>0%</td><td>0%</td><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td><td>-4%</td><td>7%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 we",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "a959c9f4d975f707",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>0%</td><td>0%</td><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td><td>-4%</td><td>7%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "37c2e59aee5bc91d",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>0%</td><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td><td>-4%</td><td>7%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$13</td><td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "2d7ec0ba6f504180",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>2%</td><td>-2%</td><td>0%</td><td>-4%</td><td>12%</td><td>-10%</td><td>-4%</td><td>7%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$13</td><td>$16</td><td",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "f3609666577b3a21",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$12</td><td>$17</td><td>$12</td><td>$12</td><td>$16</td><td>$12</td></tr><tr><td>MoM growth</td><td>-8%</td><td>25%</td><td>-20%</td><td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "f034fc787ca4c010",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$17</td><td>$12</td><td>$12</td><td>$16</td><td>$12</td></tr><tr><td>MoM growth</td><td>-8%</td><td>25%</td><td>-20%</td><td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28%</td><td>-4",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "af91a23b837af9fa",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$12</td><td>$12</td><td>$16</td><td>$12</td></tr><tr><td>MoM growth</td><td>-8%</td><td>25%</td><td>-20%</td><td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28%</td><td>-4%</td><td>33",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "3deea1b31b961c1b",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "12</td><td>$16</td><td>$12</td></tr><tr><td>MoM growth</td><td>-8%</td><td>25%</td><td>-20%</td><td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28%</td><td>-4%</td><td>33%</td><td>-22",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "32ec9e1308b4393c",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$16</td><td>$12</td></tr><tr><td>MoM growth</td><td>-8%</td><td>25%</td><td>-20%</td><td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28%</td><td>-4%</td><td>33%</td><td>-22%</td></tr>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "96810e22eabbe40d",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$12</td></tr><tr><td>MoM growth</td><td>-8%</td><td>25%</td><td>-20%</td><td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28%</td><td>-4%</td><td>33%</td><td>-22%</td></tr></table> Fot",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "bec4dcbc46a478fd",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>-8%</td><td>25%</td><td>-20%</td><td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28%</td><td>-4%</td><td>33%</td><td>-22%</td></tr></table> Fotot: QIA sales",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "a9b58ece8af70792",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>-8%</td><td>25%</td><td>-20%</td><td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28%</td><td>-4%</td><td>33%</td><td>-22%</td></tr></table> Fotot: QIA sales data (NSP) ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "ca3272040890adce",
        "value": -0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-8%</td><td>25%</td><td>-20%</td><td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28%</td><td>-4%</td><td>33%</td><td>-22%</td></tr></table> Fotot: QIA sales data (NSP) is captured ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "539a65f4a264f903",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>25%</td><td>-20%</td><td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28%</td><td>-4%</td><td>33%</td><td>-22%</td></tr></table> Fotot: QIA sales data (NSP) is captured weekly, and g",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "62a3e871235f2ba0",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-20%</td><td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28%</td><td>-4%</td><td>33%</td><td>-22%</td></tr></table> Fotot: QIA sales data (NSP) is captured weekly, and grouped into ",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "0ce71e9e006baf65",
        "value": -0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>2%</td><td>22%</td><td>-20%</td><td>-4%</td><td>40%</td><td>-28%</td><td>-4%</td><td>33%</td><td>-22%</td></tr></table> Fotot: QIA sales data (NSP) is captured weekly, and grouped into 4- or 5-week",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "74d3519972d3b1ad",
        "value": 153.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td></td><td></td><td></td><td></td></tr><tr><td>Annualized (Mar, Jun, Sep, Dec normalized)</td><td>$153</td><td>$154</td><td>$153</td><td>$156</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "f0fa3330953b4d2e",
        "value": 154.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td></td><td></td></tr><tr><td>Annualized (Mar, Jun, Sep, Dec normalized)</td><td>$153</td><td>$154</td><td>$153</td><td>$156</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td><td>$148</td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "cc60f848ea96c62a",
        "value": 153.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td></td></tr><tr><td>Annualized (Mar, Jun, Sep, Dec normalized)</td><td>$153</td><td>$154</td><td>$153</td><td>$156</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td><td>$148</td><td>$142</td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "c8619ec69dc05a47",
        "value": 156.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "r><tr><td>Annualized (Mar, Jun, Sep, Dec normalized)</td><td>$153</td><td>$154</td><td>$153</td><td>$156</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td><td>$148</td><td>$142</td><td>$151</td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "528df9e2e7dbb5e2",
        "value": 153.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ualized (Mar, Jun, Sep, Dec normalized)</td><td>$153</td><td>$154</td><td>$153</td><td>$156</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td><td>$148</td><td>$142</td><td>$151</td><td>$147</td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "81c32bcfd4f552e7",
        "value": 153.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "Jun, Sep, Dec normalized)</td><td>$153</td><td>$154</td><td>$153</td><td>$156</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td><td>$148</td><td>$142</td><td>$151</td><td>$147</td></tr><tr><td>Y",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "10a372c85d53d260",
        "value": 146.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "c normalized)</td><td>$153</td><td>$154</td><td>$153</td><td>$156</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td><td>$148</td><td>$142</td><td>$151</td><td>$147</td></tr><tr><td>YoY growth</t",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "4c702ace0afc1cd0",
        "value": 164.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$153</td><td>$154</td><td>$153</td><td>$156</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td><td>$148</td><td>$142</td><td>$151</td><td>$147</td></tr><tr><td>YoY growth</td><td>-2%</td",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "704a72a154f0aa87",
        "value": 148.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$154</td><td>$153</td><td>$156</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td><td>$148</td><td>$142</td><td>$151</td><td>$147</td></tr><tr><td>YoY growth</td><td>-2%</td><td>-3%</td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "8b0067a0224e001e",
        "value": 142.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$153</td><td>$156</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td><td>$148</td><td>$142</td><td>$151</td><td>$147</td></tr><tr><td>YoY growth</td><td>-2%</td><td>-3%</td><td>-6%</td><",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "cac9dfadbaa4395e",
        "value": 151.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$156</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td><td>$148</td><td>$142</td><td>$151</td><td>$147</td></tr><tr><td>YoY growth</td><td>-2%</td><td>-3%</td><td>-6%</td><td>0%</td><td",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "28c7ce1daaca88b8",
        "value": 147.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$153</td><td>$153</td><td>$146</td><td>$164</td><td>$148</td><td>$142</td><td>$151</td><td>$147</td></tr><tr><td>YoY growth</td><td>-2%</td><td>-3%</td><td>-6%</td><td>0%</td><td>-4%</td><td>",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "4b035d1bdfc8ed6e",
        "value": 13.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "-4%</td><td>7%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$13</td><td>$16</td><td>$13</td><td>$13</td><td>$16</td><td>$13</td><td>$12</td><td>$17</td><td>$12<",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "af1265655900b61c",
        "value": 16.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "7%</td><td>-3%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$13</td><td>$16</td><td>$13</td><td>$13</td><td>$16</td><td>$13</td><td>$12</td><td>$17</td><td>$12</td><td>$12<",
        "provenance": {
          "page": 42
        }
      },
      {
        "num_id": "c063240016ad4310",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>$848</td><td>$832</td><td>$824</td><td>$857</td><td>$853</td></tr><tr><td>YoY growth</td><td>12%</td><td>12%</td><td>10%</td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "db1ecb663e81ad78",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>$832</td><td>$824</td><td>$857</td><td>$853</td></tr><tr><td>YoY growth</td><td>12%</td><td>12%</td><td>10%</td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "68a594fcd0f38e01",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>$824</td><td>$857</td><td>$853</td></tr><tr><td>YoY growth</td><td>12%</td><td>12%</td><td>10%</td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td>",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "4bb14a5e7f76a53a",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4</td><td>$857</td><td>$853</td></tr><tr><td>YoY growth</td><td>12%</td><td>12%</td><td>10%</td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td><td>4%</td><",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "04857ff2ee329d9b",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "857</td><td>$853</td></tr><tr><td>YoY growth</td><td>12%</td><td>12%</td><td>10%</td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td><td>4%</td></tr><tr><td",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "76af59a2903491e7",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$853</td></tr><tr><td>YoY growth</td><td>12%</td><td>12%</td><td>10%</td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td><td>4%</td></tr><tr><td>MoM growth<",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "1fced4fe3a45b08e",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>YoY growth</td><td>12%</td><td>12%</td><td>10%</td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td><td>4%</td></tr><tr><td>MoM growth</td><td>7%<",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "46249d8fcb48fb0a",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "YoY growth</td><td>12%</td><td>12%</td><td>10%</td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td><td>4%</td></tr><tr><td>MoM growth</td><td>7%</td><td>0%<",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "81ddbd861d6ec6f9",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>12%</td><td>12%</td><td>10%</td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td><td>4%</td></tr><tr><td>MoM growth</td><td>7%</td><td>0%</td><td>-2%<",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "5ee6de2fdbf60f7e",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>12%</td><td>10%</td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td><td>4%</td></tr><tr><td>MoM growth</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%<",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "fbf95f584e652b2d",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>10%</td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td><td>4%</td></tr><tr><td>MoM growth</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "bafd2e80b9a2b753",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>4%</td><td>-1%</td><td>1%</td><td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td><td>4%</td></tr><tr><td>MoM growth</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%<",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "3413422f41bcb61a",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>2%</td><td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td><td>4%</td></tr><tr><td>MoM growth</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "e734ae1e584d3dc2",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-1%</td><td>-2%</td><td>-7%</td><td>1%</td><td>4%</td></tr><tr><td>MoM growth</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><td>-1%</td>",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "264d307a70806e9b",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-2%</td><td>-7%</td><td>1%</td><td>4%</td></tr><tr><td>MoM growth</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><td>-1%</td><td>4%</td>",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "12658ff53a99de57",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-7%</td><td>1%</td><td>4%</td></tr><tr><td>MoM growth</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><td>-1%</td><td>4%</td><td>0%</td><",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "5e4a5f2553a27a91",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>1%</td><td>4%</td></tr><tr><td>MoM growth</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><td>-1%</td><td>4%</td><td>0%</td></tr><tr><td>",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "3a3edb30e4d64b0a",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>4%</td></tr><tr><td>MoM growth</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><td>-1%</td><td>4%</td><td>0%</td></tr><tr><td>IMS Monthly",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "9f49a1f2ed328729",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>MoM growth</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><td>-1%</td><td>4%</td><td>0%</td></tr><tr><td>IMS Monthly sales (not ",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "4f791de7a5564db9",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">MoM growth</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><td>-1%</td><td>4%</td><td>0%</td></tr><tr><td>IMS Monthly sales (not normalized;",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "d6f8ab5cc7ecb1b3",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>7%</td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><td>-1%</td><td>4%</td><td>0%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 week",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "557da3298d7c33ba",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>0%</td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><td>-1%</td><td>4%</td><td>0%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "ff9d8c4557dd13db",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-2%</td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><td>-1%</td><td>4%</td><td>0%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$73</td><td>$",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "97faeb2544d2f61d",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-4%</td><td>3%</td><td>-4%</td><td>0%</td><td>2%</td><td>-2%</td><td>-1%</td><td>4%</td><td>0%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>$73</td><td>$92</td><td>",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "94785601bb651cfd",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$69</td><td>$88</td><td>$69</td><td>$69</td><td>$89</td><td>$71</td></tr><tr><td>MoM growth</td><td>7%</td><td>25%</td><td>-21%</td><td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "1033d2a5578583a5",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">$88</td><td>$69</td><td>$69</td><td>$89</td><td>$71</td></tr><tr><td>MoM growth</td><td>7%</td><td>25%</td><td>-21%</td><td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%</td><td>-1",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "9683ccfa0d9900f1",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">$69</td><td>$69</td><td>$89</td><td>$71</td></tr><tr><td>MoM growth</td><td>7%</td><td>25%</td><td>-21%</td><td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%</td><td>-1%</td><td>30",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "7fe247509824a23c",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$69</td><td>$89</td><td>$71</td></tr><tr><td>MoM growth</td><td>7%</td><td>25%</td><td>-21%</td><td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%</td><td>-1%</td><td>30%</td><td>-20",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "4511bc5c9905032b",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$89</td><td>$71</td></tr><tr><td>MoM growth</td><td>7%</td><td>25%</td><td>-21%</td><td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%</td><td>-1%</td><td>30%</td><td>-20%</td></tr><",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "f2041ecb184abc20",
        "value": -0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "$71</td></tr><tr><td>MoM growth</td><td>7%</td><td>25%</td><td>-21%</td><td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%</td><td>-1%</td><td>30%</td><td>-20%</td></tr></table> Foto",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "e3d9fd9b1cb19657",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>7%</td><td>25%</td><td>-21%</td><td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%</td><td>-1%</td><td>30%</td><td>-20%</td></tr></table> Fotot: QVAs s dat",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "04741e4cd5a21a48",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>7%</td><td>25%</td><td>-21%</td><td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%</td><td>-1%</td><td>30%</td><td>-20%</td></tr></table> Fotot: QVAs s data (NSP) is c",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "c0626dc1363e27a7",
        "value": -0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>7%</td><td>25%</td><td>-21%</td><td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%</td><td>-1%</td><td>30%</td><td>-20%</td></tr></table> Fotot: QVAs s data (NSP) is captured wee",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "6d9de7dd0de6eb11",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>25%</td><td>-21%</td><td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%</td><td>-1%</td><td>30%</td><td>-20%</td></tr></table> Fotot: QVAs s data (NSP) is captured weekly, and grou",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "a4d88e01a6196803",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-21%</td><td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%</td><td>-1%</td><td>30%</td><td>-20%</td></tr></table> Fotot: QVAs s data (NSP) is captured weekly, and grouped into 4- ",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "a98d2c6b0414c039",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-4%</td><td>29%</td><td>-23%</td><td>0%</td><td>28%</td><td>-22%</td><td>-1%</td><td>30%</td><td>-20%</td></tr></table> Fotot: QVAs s data (NSP) is captured weekly, and grouped into 4- or 5-week mo",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "8d34d958bf06cddb",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7</td><td>$237</td><td>$234</td><td>$231</td><td>$227</td><td>$228</td></tr><tr><td>% diff.</td><td>7%</td><td>8%</td><td>-24%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><t",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "dea81fbe7f7ae4fa",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "237</td><td>$234</td><td>$231</td><td>$227</td><td>$228</td></tr><tr><td>% diff.</td><td>7%</td><td>8%</td><td>-24%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><t",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "fe0a29d99ff797fb",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">$234</td><td>$231</td><td>$227</td><td>$228</td></tr><tr><td>% diff.</td><td>7%</td><td>8%</td><td>-24%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "527e343a5151ff0a",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">$231</td><td>$227</td><td>$228</td></tr><tr><td>% diff.</td><td>7%</td><td>8%</td><td>-24%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><td>-4%</td><t",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "d6afaa316eeb1ea5",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>$227</td><td>$228</td></tr><tr><td>% diff.</td><td>7%</td><td>8%</td><td>-24%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><td>-4%</td><td>-4%</td><",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "09ae91487d1c2d09",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>$228</td></tr><tr><td>% diff.</td><td>7%</td><td>8%</td><td>-24%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><td>-4%</td><td>-4%</td><td>-4%</td>",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "068ac947cd07ba54",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>% diff.</td><td>7%</td><td>8%</td><td>-24%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><td>-4%</td><td>-4%</td><td>-4%</td><td>1%</td>",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "4e44f73e0abaa2a1",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>% diff.</td><td>7%</td><td>8%</td><td>-24%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><td>-4%</td><td>-4%</td><td>-4%</td><td>1%</td><td>-9%</td",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "60866563a979202e",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".</td><td>7%</td><td>8%</td><td>-24%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><td>-4%</td><td>-4%</td><td>-4%</td><td>1%</td><td>-9%</td><td>-6%</t",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "9f746d5534bfbe76",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>8%</td><td>-24%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><td>-4%</td><td>-4%</td><td>-4%</td><td>1%</td><td>-9%</td><td>-6%</td><td>-3%</t",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "27539ec6e73299ed",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>-24%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><td>-4%</td><td>-4%</td><td>-4%</td><td>1%</td><td>-9%</td><td>-6%</td><td>-3%</td><td>7%</t",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "3fa1a577e5da3517",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>0%</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><td>-4%</td><td>-4%</td><td>-4%</td><td>1%</td><td>-9%</td><td>-6%</td><td>-3%</td><td>7%</td><td>-20%</",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "54d4fa36acb1d23c",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1%</td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><td>-4%</td><td>-4%</td><td>-4%</td><td>1%</td><td>-9%</td><td>-6%</td><td>-3%</td><td>7%</td><td>-20%</td><td>-2%</",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "9f42c95aad60f437",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>5%</td><td>0%</td><td>0%</td><td>-5%</td><td>1%</td><td>-5%</td><td>-4%</td><td>-4%</td><td>-4%</td><td>1%</td><td>-9%</td><td>-6%</td><td>-3%</td><td>7%</td><td>-20%</td><td>-2%</td></tr></ta",
        "provenance": {
          "page": 43
        }
      },
      {
        "num_id": "064758e6abfc68d6",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";3,008</td><td>&#36;3,073</td><td>&#36;3,926</td><td>&#36;2,981</td></tr><tr><td>YoY growth</td><td>28%</td><td>26%</td><td>20%</td><td>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "33d3101d2cd9e5fa",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>&#36;3,073</td><td>&#36;3,926</td><td>&#36;2,981</td></tr><tr><td>YoY growth</td><td>28%</td><td>26%</td><td>20%</td><td>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%</td><td>67%",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "3fe89687d18106b1",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3</td><td>&#36;3,926</td><td>&#36;2,981</td></tr><tr><td>YoY growth</td><td>28%</td><td>26%</td><td>20%</td><td>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%</td><td>67%</td><td>109",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "2bba5981eccfcd47",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;3,926</td><td>&#36;2,981</td></tr><tr><td>YoY growth</td><td>28%</td><td>26%</td><td>20%</td><td>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%</td><td>67%</td><td>109%</td><td>62",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "66e669af7708fbba",
        "value": 0.97,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;2,981</td></tr><tr><td>YoY growth</td><td>28%</td><td>26%</td><td>20%</td><td>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%</td><td>67%</td><td>109%</td><td>62%</td></tr><t",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "e162362f0d1982c8",
        "value": 0.52,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "81</td></tr><tr><td>YoY growth</td><td>28%</td><td>26%</td><td>20%</td><td>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%</td><td>67%</td><td>109%</td><td>62%</td></tr><tr><td>MoM gr",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "68256fc988be49b9",
        "value": 0.63,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>YoY growth</td><td>28%</td><td>26%</td><td>20%</td><td>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%</td><td>67%</td><td>109%</td><td>62%</td></tr><tr><td>MoM growth</td><td",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "4267dfdc46d1d900",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>28%</td><td>26%</td><td>20%</td><td>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%</td><td>67%</td><td>109%</td><td>62%</td></tr><tr><td>MoM growth</td><td>4%</td><td>",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "c7dfc87df0e81cb2",
        "value": 0.64,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>28%</td><td>26%</td><td>20%</td><td>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%</td><td>67%</td><td>109%</td><td>62%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-1%</td><td>",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "8ae823db8e122936",
        "value": 0.67,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>26%</td><td>20%</td><td>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%</td><td>67%</td><td>109%</td><td>62%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-1%</td><td>2%</td><td>5",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "192248c055b7ca92",
        "value": 1.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>20%</td><td>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%</td><td>67%</td><td>109%</td><td>62%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-1%</td><td>2%</td><td>59%</td><td>4",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "44188d2d22ae78b8",
        "value": 0.62,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>100%</td><td>97%</td><td>52%</td><td>63%</td><td>75%</td><td>64%</td><td>67%</td><td>109%</td><td>62%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-1%</td><td>2%</td><td>59%</td><td>4%</td><td>-18",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "3b0ef3e705163fa1",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3%</td><td>75%</td><td>64%</td><td>67%</td><td>109%</td><td>62%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-1%</td><td>2%</td><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</t",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "fc34fa3b1f824693",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "75%</td><td>64%</td><td>67%</td><td>109%</td><td>62%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-1%</td><td>2%</td><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</td><td>2%</t",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "6801a390046e16b9",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "64%</td><td>67%</td><td>109%</td><td>62%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-1%</td><td>2%</td><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</td><td>2%</td><td>28%</t",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "5410c5be578b072f",
        "value": 0.59,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">67%</td><td>109%</td><td>62%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-1%</td><td>2%</td><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</td><td>2%</td><td>28%</td><td>-24%<",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "25995f937541184a",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">109%</td><td>62%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-1%</td><td>2%</td><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "6423ba34b7759d87",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>62%</td></tr><tr><td>MoM growth</td><td>4%</td><td>-1%</td><td>2%</td><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>IMS Mo",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "c953675f04c63a3a",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>MoM growth</td><td>4%</td><td>-1%</td><td>2%</td><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>IMS Monthly sales (",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "3ceedc92ec6d2ef0",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "oM growth</td><td>4%</td><td>-1%</td><td>2%</td><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>IMS Monthly sales (not normaliz",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "cb3e838a951356c4",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>4%</td><td>-1%</td><td>2%</td><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 we",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "7a75bedc216ffaed",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-1%</td><td>2%</td><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "b61971a09857284a",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>2%</td><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;159</",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "038c4854262e0c96",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>59%</td><td>4%</td><td>-18%</td><td>14%</td><td>10%</td><td>-7%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>IMS Monthly sales (not normalized; 4-4-5 weeks)</td><td>&#36;159</td><td>&#36;",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "55cb7ecc70ed42c8",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;251</td><td>&#36;256</td><td>&#36;327</td><td>&#36;248</td></tr><tr><td>MoM growth</td><td>4%</td><td>24%</td><td>-19%</td><td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "f858ee18d16087e5",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1</td><td>&#36;256</td><td>&#36;327</td><td>&#36;248</td></tr><tr><td>MoM growth</td><td>4%</td><td>24%</td><td>-19%</td><td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25%</td><td>2",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "0c3c0617f6df7876",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;256</td><td>&#36;327</td><td>&#36;248</td></tr><tr><td>MoM growth</td><td>4%</td><td>24%</td><td>-19%</td><td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25%</td><td>2%</td><td>28",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "953df663ab60a118",
        "value": 0.59,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>&#36;327</td><td>&#36;248</td></tr><tr><td>MoM growth</td><td>4%</td><td>24%</td><td>-19%</td><td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25%</td><td>2%</td><td>28%</td><td>-24",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "feb87b0dc3d0c9df",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>&#36;248</td></tr><tr><td>MoM growth</td><td>4%</td><td>24%</td><td>-19%</td><td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25%</td><td>2%</td><td>28%</td><td>-24%</td></tr><",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "589544bb415806f0",
        "value": -0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "248</td></tr><tr><td>MoM growth</td><td>4%</td><td>24%</td><td>-19%</td><td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>Revli",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "b554bdfe3cd85a2a",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>MoM growth</td><td>4%</td><td>24%</td><td>-19%</td><td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>Revlimid (Bristol ",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "2beab231d9b8ccd9",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>4%</td><td>24%</td><td>-19%</td><td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>Revlimid (Bristol Myers)</td><",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "02a44ec55e9e4e67",
        "value": -0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>4%</td><td>24%</td><td>-19%</td><td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>Revlimid (Bristol Myers)</td><td></td><td>",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "be378b841f9191b6",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">24%</td><td>-19%</td><td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>Revlimid (Bristol Myers)</td><td></td><td></td><td></td",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "02f771d41a40b1a9",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-19%</td><td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>Revlimid (Bristol Myers)</td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "90987f2a762992f0",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>59%</td><td>30%</td><td>-35%</td><td>14%</td><td>37%</td><td>-25%</td><td>2%</td><td>28%</td><td>-24%</td></tr><tr><td>Revlimid (Bristol Myers)</td><td></td><td></td><td></td><td></td><td></td><td>",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "497fbc3945bafa67",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";4,177</td><td>&#36;3,988</td><td>&#36;5,371</td><td>&#36;3,150</td></tr><tr><td>YoY growth</td><td>6%</td><td>10%</td><td>3%</td><td>148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%<",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "4dccab37aebe2575",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>&#36;3,988</td><td>&#36;5,371</td><td>&#36;3,150</td></tr><tr><td>YoY growth</td><td>6%</td><td>10%</td><td>3%</td><td>148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%</td><td>45%",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "9132311dd9f38329",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "88</td><td>&#36;5,371</td><td>&#36;3,150</td></tr><tr><td>YoY growth</td><td>6%</td><td>10%</td><td>3%</td><td>148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%</td><td>45%</td><td>113",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "2004d183ae0fb123",
        "value": 1.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "&#36;5,371</td><td>&#36;3,150</td></tr><tr><td>YoY growth</td><td>6%</td><td>10%</td><td>3%</td><td>148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%</td><td>45%</td><td>113%</td><td>2",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "c78ec8a56128def5",
        "value": 1.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>&#36;3,150</td></tr><tr><td>YoY growth</td><td>6%</td><td>10%</td><td>3%</td><td>148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%</td><td>45%</td><td>113%</td><td>22%</td></tr><",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "827c36355c894f28",
        "value": 0.78,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "150</td></tr><tr><td>YoY growth</td><td>6%</td><td>10%</td><td>3%</td><td>148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%</td><td>45%</td><td>113%</td><td>22%</td></tr><tr><td>MoM gr",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "4b8ff08c17ab8bd3",
        "value": 0.64,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>YoY growth</td><td>6%</td><td>10%</td><td>3%</td><td>148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%</td><td>45%</td><td>113%</td><td>22%</td></tr><tr><td>MoM growth</td><td",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "2c7f9826f2faf510",
        "value": 0.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth</td><td>6%</td><td>10%</td><td>3%</td><td>148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%</td><td>45%</td><td>113%</td><td>22%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "4e245f5f539264bf",
        "value": 0.57,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>6%</td><td>10%</td><td>3%</td><td>148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%</td><td>45%</td><td>113%</td><td>22%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>1%</td><td>",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "d34b89e0e45a5996",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>10%</td><td>3%</td><td>148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%</td><td>45%</td><td>113%</td><td>22%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>1%</td><td>1%</td><td>1",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "07f31f407297a73f",
        "value": 1.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>3%</td><td>148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%</td><td>45%</td><td>113%</td><td>22%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>1%</td><td>1%</td><td>123%</td><td>",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "b6e1abf021c9e4c2",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">148%</td><td>129%</td><td>78%</td><td>64%</td><td>54%</td><td>57%</td><td>45%</td><td>113%</td><td>22%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>1%</td><td>1%</td><td>123%</td><td>-6%</td><td>-",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "4beb7a814018c01f",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4%</td><td>54%</td><td>57%</td><td>45%</td><td>113%</td><td>22%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>1%</td><td>1%</td><td>123%</td><td>-6%</td><td>-21%</td><td>6%</td><td>-1%</td><td>-4%</",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "939ce7b534a21ab8",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4%</td><td>57%</td><td>45%</td><td>113%</td><td>22%</td></tr><tr><td>MoM growth</td><td>-5%</td><td>1%</td><td>1%</td><td>123%</td><td>-6%</td><td>-21%</td><td>6%</td><td>-1%</td><td>-4%</td><td>-5%</",
        "provenance": {
          "page": 44
        }
      },
      {
        "num_id": "e9cc69f891e54529",
        "value": 2.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "63</td><td>$452</td><td>$465</td><td>$501</td><td>$512</td><td>$544</td></tr><tr><td>% diff</td><td>205%</td><td>247%</td><td>240%</td><td>237%</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "58bdbd85e2c6e5e6",
        "value": 2.47,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "52</td><td>$465</td><td>$501</td><td>$512</td><td>$544</td></tr><tr><td>% diff</td><td>205%</td><td>247%</td><td>240%</td><td>237%</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "9f020492616bf22f",
        "value": 2.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "65</td><td>$501</td><td>$512</td><td>$544</td></tr><tr><td>% diff</td><td>205%</td><td>247%</td><td>240%</td><td>237%</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "236d8f7a97f1239f",
        "value": 2.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "01</td><td>$512</td><td>$544</td></tr><tr><td>% diff</td><td>205%</td><td>247%</td><td>240%</td><td>237%</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "60abd9372b72089e",
        "value": 2.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "12</td><td>$544</td></tr><tr><td>% diff</td><td>205%</td><td>247%</td><td>240%</td><td>237%</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "3ae01a7a837237a0",
        "value": 2.51,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "44</td></tr><tr><td>% diff</td><td>205%</td><td>247%</td><td>240%</td><td>237%</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "79f3137c785f51ce",
        "value": 2.47,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>% diff</td><td>205%</td><td>247%</td><td>240%</td><td>237%</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td><td>247%</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "a2ee6bc66b2b2a73",
        "value": 2.58,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>205%</td><td>247%</td><td>240%</td><td>237%</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td><td>247%</td><td>220%</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "3ccb9caa363afa21",
        "value": 2.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>247%</td><td>240%</td><td>237%</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td><td>247%</td><td>220%</td><td>237%</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "5b843a11b23fb574",
        "value": 2.57,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>240%</td><td>237%</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td><td>247%</td><td>220%</td><td>237%</td><td>215%</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "9557f40b2acd72da",
        "value": 2.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>237%</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td><td>247%</td><td>220%</td><td>237%</td><td>215%</td></tr></table>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "1616fbf828059339",
        "value": 2.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>275%</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td><td>247%</td><td>220%</td><td>237%</td><td>215%</td></tr></table> Source: IQVI",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "d1f65445202e3324",
        "value": 2.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>251%</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td><td>247%</td><td>220%</td><td>237%</td><td>215%</td></tr></table> Source: IQVIA, Company re",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "ed54bc70f7c0ea0b",
        "value": 2.47,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>247%</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td><td>247%</td><td>220%</td><td>237%</td><td>215%</td></tr></table> Source: IQVIA, Company reported<｜end▁o",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "460c4e0540106ee9",
        "value": 2.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>258%</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td><td>247%</td><td>220%</td><td>237%</td><td>215%</td></tr></table> Source: IQVIA, Company reported<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "9fd71d3ed8f2d2e6",
        "value": 2.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>225%</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td><td>247%</td><td>220%</td><td>237%</td><td>215%</td></tr></table> Source: IQVIA, Company reported<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "950ee6725543dafd",
        "value": 2.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>257%</td><td>254%</td><td>218%</td><td>220%</td><td>247%</td><td>220%</td><td>237%</td><td>215%</td></tr></table> Source: IQVIA, Company reported<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "db724c9f7148b982",
        "value": 911.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Actual</td><td>$911</td><td>$873</td><td>$895</td><td>$866</td><td>$937</td><td>$1,030</td><td>$1,153</td><td>$1,18",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "80cb82f7c9fc0141",
        "value": 873.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Actual</td><td>$911</td><td>$873</td><td>$895</td><td>$866</td><td>$937</td><td>$1,030</td><td>$1,153</td><td>$1,180</td><td>$1,",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "8b793d0cccd0bb7b",
        "value": 895.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Actual</td><td>$911</td><td>$873</td><td>$895</td><td>$866</td><td>$937</td><td>$1,030</td><td>$1,153</td><td>$1,180</td><td>$1,234</td><td>$",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "07eae77b09f9f5d4",
        "value": 866.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "></td><td></td><td></td><td></td></tr><tr><td>Actual</td><td>$911</td><td>$873</td><td>$895</td><td>$866</td><td>$937</td><td>$1,030</td><td>$1,153</td><td>$1,180</td><td>$1,234</td><td>$1,350</td><td",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "32187d6586cea256",
        "value": 937.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td></td><td></td></tr><tr><td>Actual</td><td>$911</td><td>$873</td><td>$895</td><td>$866</td><td>$937</td><td>$1,030</td><td>$1,153</td><td>$1,180</td><td>$1,234</td><td>$1,350</td><td>$1,361</td><",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "0cb0cad437ea13f4",
        "value": 1030.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d></td></tr><tr><td>Actual</td><td>$911</td><td>$873</td><td>$895</td><td>$866</td><td>$937</td><td>$1,030</td><td>$1,153</td><td>$1,180</td><td>$1,234</td><td>$1,350</td><td>$1,361</td><td>$1,473</td",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "e5a3ea6a5cd00d5e",
        "value": 1153.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>Actual</td><td>$911</td><td>$873</td><td>$895</td><td>$866</td><td>$937</td><td>$1,030</td><td>$1,153</td><td>$1,180</td><td>$1,234</td><td>$1,350</td><td>$1,361</td><td>$1,473</td><td>$1,447</td",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "e82e11dd2c2c402b",
        "value": 1180.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>$911</td><td>$873</td><td>$895</td><td>$866</td><td>$937</td><td>$1,030</td><td>$1,153</td><td>$1,180</td><td>$1,234</td><td>$1,350</td><td>$1,361</td><td>$1,473</td><td>$1,447</td><td>$1,558</td",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "126e27c694f77ca0",
        "value": 1234.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "td>$873</td><td>$895</td><td>$866</td><td>$937</td><td>$1,030</td><td>$1,153</td><td>$1,180</td><td>$1,234</td><td>$1,350</td><td>$1,361</td><td>$1,473</td><td>$1,447</td><td>$1,558</td><td>$1,667</td",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "e7a20b2a66175bdc",
        "value": 1350.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ">$895</td><td>$866</td><td>$937</td><td>$1,030</td><td>$1,153</td><td>$1,180</td><td>$1,234</td><td>$1,350</td><td>$1,361</td><td>$1,473</td><td>$1,447</td><td>$1,558</td><td>$1,667</td><td>$1,729</td",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "263bb1015ccafcd8",
        "value": 1361.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "866</td><td>$937</td><td>$1,030</td><td>$1,153</td><td>$1,180</td><td>$1,234</td><td>$1,350</td><td>$1,361</td><td>$1,473</td><td>$1,447</td><td>$1,558</td><td>$1,667</td><td>$1,729</td><td>$1,886</td",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "d155d15eed6a7a52",
        "value": 1473.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "7</td><td>$1,030</td><td>$1,153</td><td>$1,180</td><td>$1,234</td><td>$1,350</td><td>$1,361</td><td>$1,473</td><td>$1,447</td><td>$1,558</td><td>$1,667</td><td>$1,729</td><td>$1,886</td></tr><tr><td>I",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "d14e7ccd1070e298",
        "value": 1447.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "0</td><td>$1,153</td><td>$1,180</td><td>$1,234</td><td>$1,350</td><td>$1,361</td><td>$1,473</td><td>$1,447</td><td>$1,558</td><td>$1,667</td><td>$1,729</td><td>$1,886</td></tr><tr><td>IMS</td><td>$290",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "af8458334aad92d3",
        "value": 1558.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "3</td><td>$1,180</td><td>$1,234</td><td>$1,350</td><td>$1,361</td><td>$1,473</td><td>$1,447</td><td>$1,558</td><td>$1,667</td><td>$1,729</td><td>$1,886</td></tr><tr><td>IMS</td><td>$290</td><td>$252</",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "f151ae61d776c638",
        "value": 1667.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "0</td><td>$1,234</td><td>$1,350</td><td>$1,361</td><td>$1,473</td><td>$1,447</td><td>$1,558</td><td>$1,667</td><td>$1,729</td><td>$1,886</td></tr><tr><td>IMS</td><td>$290</td><td>$252</td><td>$257</td",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "b1c8b8c7ac9189ce",
        "value": 1729.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "4</td><td>$1,350</td><td>$1,361</td><td>$1,473</td><td>$1,447</td><td>$1,558</td><td>$1,667</td><td>$1,729</td><td>$1,886</td></tr><tr><td>IMS</td><td>$290</td><td>$252</td><td>$257</td><td>$257</td><",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "5abb7e4cd7ecd4b7",
        "value": 1886.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "0</td><td>$1,361</td><td>$1,473</td><td>$1,447</td><td>$1,558</td><td>$1,667</td><td>$1,729</td><td>$1,886</td></tr><tr><td>IMS</td><td>$290</td><td>$252</td><td>$257</td><td>$257</td><td>$258</td><td",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "27791dcf5fefdf76",
        "value": 290.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>$1,447</td><td>$1,558</td><td>$1,667</td><td>$1,729</td><td>$1,886</td></tr><tr><td>IMS</td><td>$290</td><td>$252</td><td>$257</td><td>$257</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "1fa5d7e46867ecc7",
        "value": 252.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>$1,558</td><td>$1,667</td><td>$1,729</td><td>$1,886</td></tr><tr><td>IMS</td><td>$290</td><td>$252</td><td>$257</td><td>$257</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "6bf521b029ab4227",
        "value": 257.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$1,667</td><td>$1,729</td><td>$1,886</td></tr><tr><td>IMS</td><td>$290</td><td>$252</td><td>$257</td><td>$257</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "fcbbefe7d1355199",
        "value": 257.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "7</td><td>$1,729</td><td>$1,886</td></tr><tr><td>IMS</td><td>$290</td><td>$252</td><td>$257</td><td>$257</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "43d16fdc3ba23037",
        "value": 258.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "729</td><td>$1,886</td></tr><tr><td>IMS</td><td>$290</td><td>$252</td><td>$257</td><td>$257</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "271c62f858cc057a",
        "value": 337.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "1,886</td></tr><tr><td>IMS</td><td>$290</td><td>$252</td><td>$257</td><td>$257</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td><td>$452</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "97aa741258eb9f20",
        "value": 333.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "r><tr><td>IMS</td><td>$290</td><td>$252</td><td>$257</td><td>$257</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td><td>$452</td><td>$465</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "038699d25e1a6aee",
        "value": 333.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$290</td><td>$252</td><td>$257</td><td>$257</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td><td>$452</td><td>$465</td><td>$501</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "da7f03768fa77236",
        "value": 372.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$252</td><td>$257</td><td>$257</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td><td>$452</td><td>$465</td><td>$501</td><td>$512</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "e375ad785745284a",
        "value": 300.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$257</td><td>$257</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td><td>$452</td><td>$465</td><td>$501</td><td>$512</td><td>$544</td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "f39c01bb3128510d",
        "value": 447.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$257</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td><td>$452</td><td>$465</td><td>$501</td><td>$512</td><td>$544</td></tr><tr><td>",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "2b65bea8531e1c42",
        "value": 463.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$258</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td><td>$452</td><td>$465</td><td>$501</td><td>$512</td><td>$544</td></tr><tr><td>% diff</td><t",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "7954aa60300a899e",
        "value": 452.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$337</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td><td>$452</td><td>$465</td><td>$501</td><td>$512</td><td>$544</td></tr><tr><td>% diff</td><td>205%</td><t",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "49c7a072006a567f",
        "value": 465.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$333</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td><td>$452</td><td>$465</td><td>$501</td><td>$512</td><td>$544</td></tr><tr><td>% diff</td><td>205%</td><td>247%</td><t",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "168f3ef722afc0f8",
        "value": 501.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$333</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td><td>$452</td><td>$465</td><td>$501</td><td>$512</td><td>$544</td></tr><tr><td>% diff</td><td>205%</td><td>247%</td><td>240%</td><t",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "ef2b3336e2721124",
        "value": 512.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$372</td><td>$300</td><td>$447</td><td>$463</td><td>$452</td><td>$465</td><td>$501</td><td>$512</td><td>$544</td></tr><tr><td>% diff</td><td>205%</td><td>247%</td><td>240%</td><td>237%</td><t",
        "provenance": {
          "page": 45
        }
      },
      {
        "num_id": "2d9bb863de7125c8",
        "value": 0.88,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "atabase. What that means is IQVIA collects the data from the sample (which for NSP represents about 88%) and using IQVIA methodology, the data is projected to 100% of the universe. The prices reflecte",
        "provenance": {
          "page": 51
        }
      },
      {
        "num_id": "9172a06655123da4",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e sample (which for NSP represents about 88%) and using IQVIA methodology, the data is projected to 100% of the universe. The prices reflected in IQVIA National Sales Perspectives\" are the prices outl",
        "provenance": {
          "page": 51
        }
      },
      {
        "num_id": "58346a542e56f3dc",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ry</td><td>Count</td><td>% of Total Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "508cf72c439d3fa3",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">% of Total Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%<",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "a50c62ca2560afb8",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374<",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "515e648fb604a201",
        "value": 0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%<",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "15d19a03f199f359",
        "value": 0.43,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td>",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "231811e70e9b5ece",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "3d42f393af3a7915",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "ff111f861a95a6d7",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "5ae913408ae023e3",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>58",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "f97508ec70c38a52",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "d3033769bce2e3ed",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "06fadc17235c3ab2",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td>",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "5e3e1fb159e34fa7",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695<",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "ad64cea638810c2a",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</t",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "78334673bb26a7cf",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</td><td></td><",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "f196a4e02d64477b",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</td><td></td><td></td><td>1705</td><td",
        "provenance": {
          "page": 53
        }
      },
      {
        "num_id": "332587f0686b39c6",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "mpanies' section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentione",
        "provenance": {
          "page": 54
        }
      },
      {
        "num_id": "a6da9732cb54578a",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them",
        "provenance": {
          "page": 54
        }
      },
      {
        "num_id": "faec8571ea49028d",
        "value": 13.75,
        "unit": "$",
        "metric_type": "currency",
        "context": "<table><tr><td>Dyne Therapeutics Inc (DYN.O)</td><td>O (04/30/2024)</td><td>$13.75</td></tr><tr><td>Fractyl Health Inc (GUTS.O)</td><td>O (02/27/2024)</td><td>$0.99</td></tr><tr><td>",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "d9d91dbe6c2fc3f5",
        "value": 0.99,
        "unit": "$",
        "metric_type": "currency",
        "context": "30/2024)</td><td>$13.75</td></tr><tr><td>Fractyl Health Inc (GUTS.O)</td><td>O (02/27/2024)</td><td>$0.99</td></tr><tr><td>IO Biotech (IOBT.O)</td><td>O (11/30/2021)</td><td>$1.58</td></tr><tr><td>Ion",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "12ea8857b8b92860",
        "value": 1.58,
        "unit": "$",
        "metric_type": "currency",
        "context": "td>O (02/27/2024)</td><td>$0.99</td></tr><tr><td>IO Biotech (IOBT.O)</td><td>O (11/30/2021)</td><td>$1.58</td></tr><tr><td>Ionis Pharmaceuticals Inc (IONS.O)</td><td>O (07/30/2025)</td><td>$42.62</td>",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "cc3dce8cb3d703c4",
        "value": 42.62,
        "unit": "$",
        "metric_type": "currency",
        "context": "1)</td><td>$1.58</td></tr><tr><td>Ionis Pharmaceuticals Inc (IONS.O)</td><td>O (07/30/2025)</td><td>$42.62</td></tr><tr><td>Kyverna Therapeutics (KYTX.O)</td><td>O (03/04/2024)</td><td>$3.70</td></tr>",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "cf1232b79a8130e5",
        "value": 3.7,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2025)</td><td>$42.62</td></tr><tr><td>Kyverna Therapeutics (KYTX.O)</td><td>O (03/04/2024)</td><td>$3.70</td></tr><tr><td>Mirum Pharmaceuticals (MIRM.O)</td><td>O (11/13/2023)</td><td>$75.53</td></tr",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "83068439c899f8fe",
        "value": 75.53,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2024)</td><td>$3.70</td></tr><tr><td>Mirum Pharmaceuticals (MIRM.O)</td><td>O (11/13/2023)</td><td>$75.53</td></tr><tr><td>Rhythm Pharmaceuticals Inc (RYTM.O)</td><td>O (12/19/2023)</td><td>$104.23</",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "1950a304d50deed1",
        "value": 104.23,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$75.53</td></tr><tr><td>Rhythm Pharmaceuticals Inc (RYTM.O)</td><td>O (12/19/2023)</td><td>$104.23</td></tr><tr><td>Rocket Pharmaceuticals Inc (RCKT.O)</td><td>E (05/27/2025)</td><td>$3.35</t",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "19f2d70ec54bd678",
        "value": 3.35,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$104.23</td></tr><tr><td>Rocket Pharmaceuticals Inc (RCKT.O)</td><td>E (05/27/2025)</td><td>$3.35</td></tr><tr><td>Sarepta Therapeutics Inc (SRPT.O)</td><td>E (06/16/2025)</td><td>$18.34</td><",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "a11208f59e7deebf",
        "value": 18.34,
        "unit": "$",
        "metric_type": "currency",
        "context": "25)</td><td>$3.35</td></tr><tr><td>Sarepta Therapeutics Inc (SRPT.O)</td><td>E (06/16/2025)</td><td>$18.34</td></tr><tr><td>Silence Therapeutics Plc (SLN.O)</td><td>O (05/08/2023)</td><td>$5.10</td></",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "1a8bfc4de1fd1e73",
        "value": 5.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "25)</td><td>$18.34</td></tr><tr><td>Silence Therapeutics Plc (SLN.O)</td><td>O (05/08/2023)</td><td>$5.10</td></tr><tr><td>Tenaya Therapeutics Inc (TNYA.O)</td><td>O (08/24/2021)</td><td>$1.13</td></t",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "347330468ba1e177",
        "value": 1.13,
        "unit": "$",
        "metric_type": "currency",
        "context": "023)</td><td>$5.10</td></tr><tr><td>Tenaya Therapeutics Inc (TNYA.O)</td><td>O (08/24/2021)</td><td>$1.13</td></tr><tr><td>Viking Therapeutics Inc (VKTX.O)</td><td>O (06/27/2024)</td><td>$27.58</td></",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "b23111dc23393d89",
        "value": 27.58,
        "unit": "$",
        "metric_type": "currency",
        "context": "021)</td><td>$1.13</td></tr><tr><td>Viking Therapeutics Inc (VKTX.O)</td><td>O (06/27/2024)</td><td>$27.58</td></tr><tr><td>Vir Biotechnology Inc (VIR.O)</td><td>O (01/08/2025)</td><td>$5.04</td></tr>",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "7509a7a8a233f9a4",
        "value": 5.04,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2024)</td><td>$27.58</td></tr><tr><td>Vir Biotechnology Inc (VIR.O)</td><td>O (01/08/2025)</td><td>$5.04</td></tr><tr><td>Y-mABs Therapeutics Inc. (YMAB.O)</td><td>E (08/05/2025)</td><td>$8.54</td></",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "1a7a525514e3da68",
        "value": 8.54,
        "unit": "$",
        "metric_type": "currency",
        "context": "25)</td><td>$5.04</td></tr><tr><td>Y-mABs Therapeutics Inc. (YMAB.O)</td><td>E (08/05/2025)</td><td>$8.54</td></tr><tr><td>Zentalis Pharmaceuticals Inc (ZNTL.O)</td><td>E (06/18/2024)</td><td>$1.76</t",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "79dcf142807aa25e",
        "value": 1.76,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$8.54</td></tr><tr><td>Zentalis Pharmaceuticals Inc (ZNTL.O)</td><td>E (06/18/2024)</td><td>$1.76</td></tr></table> # Sean Laaman, Ph.D. <table><tr><td>ABSCI CORP (ABSI.O)</td><td>O (07/03/202",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "fbb9d9780eff83e8",
        "value": 2.47,
        "unit": "$",
        "metric_type": "currency",
        "context": "r></table> # Sean Laaman, Ph.D. <table><tr><td>ABSCI CORP (ABSI.O)</td><td>O (07/03/2024)</td><td>$2.47</td></tr><tr><td>Acadia Pharmaceuticals Inc (ACAD.O)</td><td>E (08/06/2024)</td><td>$26.23</td><",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "c3555bf03d7cad90",
        "value": 26.23,
        "unit": "$",
        "metric_type": "currency",
        "context": ")</td><td>$2.47</td></tr><tr><td>Acadia Pharmaceuticals Inc (ACAD.O)</td><td>E (08/06/2024)</td><td>$26.23</td></tr><tr><td>Alector Inc (ALEC.O)</td><td>U (11/26/2024)</td><td>$2.39</td></tr><tr><td>a",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "64a69b4789fd6c65",
        "value": 2.39,
        "unit": "$",
        "metric_type": "currency",
        "context": ">E (08/06/2024)</td><td>$26.23</td></tr><tr><td>Alector Inc (ALEC.O)</td><td>U (11/26/2024)</td><td>$2.39</td></tr><tr><td>argenx SE (ARGX.O)</td><td>O (07/02/2025)</td><td>$704.07</td></tr><tr><td>Ax",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "07e15dcd8c6d4c4d",
        "value": 704.07,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>U (11/26/2024)</td><td>$2.39</td></tr><tr><td>argenx SE (ARGX.O)</td><td>O (07/02/2025)</td><td>$704.07</td></tr><tr><td>Axsome Therapeutics (AXSM.O)</td><td>O (04/29/2024)</td><td>$121.75</td></t",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "7aca1101dd0d91e9",
        "value": 121.75,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2025)</td><td>$704.07</td></tr><tr><td>Axsome Therapeutics (AXSM.O)</td><td>O (04/29/2024)</td><td>$121.75</td></tr><tr><td>BeOne Medicines (ONC.O)</td><td>O (12/02/2024)</td><td>$297.96</td></tr><tr",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "6124207d4de00947",
        "value": 297.96,
        "unit": "$",
        "metric_type": "currency",
        "context": "04/29/2024)</td><td>$121.75</td></tr><tr><td>BeOne Medicines (ONC.O)</td><td>O (12/02/2024)</td><td>$297.96</td></tr><tr><td>Biomarin Pharmaceutical Inc (BMRN.O)</td><td>O (07/02/2025)</td><td>$57.68<",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "8aff8a25904715c9",
        "value": 57.68,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$297.96</td></tr><tr><td>Biomarin Pharmaceutical Inc (BMRN.O)</td><td>O (07/02/2025)</td><td>$57.68</td></tr><tr><td>Centessa Pharmaceuticals, Inc (CNTA.O)</td><td>O (09/19/2024)</td><td>$16.56",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "4b13116e6bb0d240",
        "value": 16.56,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>$57.68</td></tr><tr><td>Centessa Pharmaceuticals, Inc (CNTA.O)</td><td>O (09/19/2024)</td><td>$16.56</td></tr><tr><td>Certara Inc (CERT.O)</td><td>E (01/05/2021)</td><td>$10.87</td></tr><tr><td>",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "4e6a97ce404480ff",
        "value": 10.87,
        "unit": "$",
        "metric_type": "currency",
        "context": ">O (09/19/2024)</td><td>$16.56</td></tr><tr><td>Certara Inc (CERT.O)</td><td>E (01/05/2021)</td><td>$10.87</td></tr><tr><td>CG Oncology (CGON.O)</td><td>O (02/19/2024)</td><td>$26.72</td></tr><tr><td>",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "851f042fe0ea518c",
        "value": 26.72,
        "unit": "$",
        "metric_type": "currency",
        "context": ">E (01/05/2021)</td><td>$10.87</td></tr><tr><td>CG Oncology (CGON.O)</td><td>O (02/19/2024)</td><td>$26.72</td></tr><tr><td>Contineum Therapeutics (CTNM.O)</td><td>O (04/30/2024)</td><td>$10.05</td></",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "af944839f29a1a19",
        "value": 10.05,
        "unit": "$",
        "metric_type": "currency",
        "context": "024)</td><td>$26.72</td></tr><tr><td>Contineum Therapeutics (CTNM.O)</td><td>O (04/30/2024)</td><td>$10.05</td></tr><tr><td>Cullinan Therapeutics (CGEM.O)</td><td>O (03/06/2025)</td><td>$7.61</td></tr",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "356e54bc2543f19a",
        "value": 7.61,
        "unit": "$",
        "metric_type": "currency",
        "context": "2024)</td><td>$10.05</td></tr><tr><td>Cullinan Therapeutics (CGEM.O)</td><td>O (03/06/2025)</td><td>$7.61</td></tr><tr><td>Denali Therapeutics Inc (DNLI.O)</td><td>O (03/06/2025)</td><td>$15.65</td></",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "2815b006eadb02d1",
        "value": 15.65,
        "unit": "$",
        "metric_type": "currency",
        "context": "025)</td><td>$7.61</td></tr><tr><td>Denali Therapeutics Inc (DNLI.O)</td><td>O (03/06/2025)</td><td>$15.65</td></tr><tr><td>Disc Medicine Inc (IRON.O)</td><td>O (11/04/2024)</td><td>$59.66</td></tr><t",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "6195c611d3a9986a",
        "value": 59.66,
        "unit": "$",
        "metric_type": "currency",
        "context": "/06/2025)</td><td>$15.65</td></tr><tr><td>Disc Medicine Inc (IRON.O)</td><td>O (11/04/2024)</td><td>$59.66</td></tr><tr><td>Erasca, Inc. (ERAS.O)</td><td>E (08/17/2025)</td><td>$1.57</td></tr><tr><td>",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "5eacb63edd4a92f8",
        "value": 1.57,
        "unit": "$",
        "metric_type": "currency",
        "context": "O (11/04/2024)</td><td>$59.66</td></tr><tr><td>Erasca, Inc. (ERAS.O)</td><td>E (08/17/2025)</td><td>$1.57</td></tr><tr><td>Exelixis Inc. (EXEL.O)</td><td>O (01/26/2025)</td><td>$37.90</td></tr><tr><td",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "02c1ab4b3fa8786c",
        "value": 37.9,
        "unit": "$",
        "metric_type": "currency",
        "context": "E (08/17/2025)</td><td>$1.57</td></tr><tr><td>Exelixis Inc. (EXEL.O)</td><td>O (01/26/2025)</td><td>$37.90</td></tr><tr><td>Halozyme Therapeutics, Inc (HALO.O)</td><td>O (08/05/2025)</td><td>$72.81</t",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "68a22bc98e00e9b5",
        "value": 72.81,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$37.90</td></tr><tr><td>Halozyme Therapeutics, Inc (HALO.O)</td><td>O (08/05/2025)</td><td>$72.81</td></tr><tr><td>Immunocore Holdings Ltd (IMCR.O)</td><td>E (12/12/2024)</td><td>$32.24</td><",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "c04deb3509eed383",
        "value": 32.24,
        "unit": "$",
        "metric_type": "currency",
        "context": "25)</td><td>$72.81</td></tr><tr><td>Immunocore Holdings Ltd (IMCR.O)</td><td>E (12/12/2024)</td><td>$32.24</td></tr><tr><td>Neurocrine Biosciences Inc (NBIX.O)</td><td>O (03/06/2025)</td><td>$138.94</",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "7f428d8a9ac05c5d",
        "value": 138.94,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$32.24</td></tr><tr><td>Neurocrine Biosciences Inc (NBIX.O)</td><td>O (03/06/2025)</td><td>$138.94</td></tr><tr><td>Recursion Pharmaceuticals Inc (RXRX.O)</td><td>E (05/22/2023)</td><td>$4.87",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "b2c453ba9c8318bc",
        "value": 4.87,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>$138.94</td></tr><tr><td>Recursion Pharmaceuticals Inc (RXRX.O)</td><td>E (05/22/2023)</td><td>$4.87</td></tr><tr><td>Schrodinger Inc. (SDGR.O)</td><td>E (11/19/2021)</td><td>$19.76</td></tr></ta",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "b8a158bc506774f9",
        "value": 19.76,
        "unit": "$",
        "metric_type": "currency",
        "context": "05/22/2023)</td><td>$4.87</td></tr><tr><td>Schrodinger Inc. (SDGR.O)</td><td>E (11/19/2021)</td><td>$19.76</td></tr></table> # Terence C Flynn, Ph.D. <table><tr><td>Alumis Inc. (ALMS.O)</td><td>O (05/",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "6b23fd862f11520f",
        "value": 4.7,
        "unit": "$",
        "metric_type": "currency",
        "context": "able> # Terence C Flynn, Ph.D. <table><tr><td>Alumis Inc. (ALMS.O)</td><td>O (05/30/2025)</td><td>$4.70</td></tr><tr><td>Amgen Inc. (AMGN.O)</td><td>E (10/16/2023)</td><td>$285.61</td></tr><tr><td>Arc",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "34a2ef5ed9526527",
        "value": 285.61,
        "unit": "$",
        "metric_type": "currency",
        "context": "td>O (05/30/2025)</td><td>$4.70</td></tr><tr><td>Amgen Inc. (AMGN.O)</td><td>E (10/16/2023)</td><td>$285.61</td></tr><tr><td>Arcus Biosciences Inc. (RCUS.N)</td><td>O (10/11/2022)</td><td>$10.61</td><",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "4030ade70bbe148e",
        "value": 10.61,
        "unit": "$",
        "metric_type": "currency",
        "context": "23)</td><td>$285.61</td></tr><tr><td>Arcus Biosciences Inc. (RCUS.N)</td><td>O (10/11/2022)</td><td>$10.61</td></tr><tr><td>Arvinas Inc (ARVN.O)</td><td>E (04/06/2022)</td><td>$7.76</td></tr><tr><td>B",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "f9487e10641c6866",
        "value": 7.76,
        "unit": "$",
        "metric_type": "currency",
        "context": ">O (10/11/2022)</td><td>$10.61</td></tr><tr><td>Arvinas Inc (ARVN.O)</td><td>E (04/06/2022)</td><td>$7.76</td></tr><tr><td>Biogen Inc (BIIB.O)</td><td>E (10/31/2024)</td><td>$132.65</td></tr><tr><td>B",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "f000b356115ac2d1",
        "value": 132.65,
        "unit": "$",
        "metric_type": "currency",
        "context": "td>E (04/06/2022)</td><td>$7.76</td></tr><tr><td>Biogen Inc (BIIB.O)</td><td>E (10/31/2024)</td><td>$132.65</td></tr><tr><td>Biohaven Ltd (BHVN.N)</td><td>O (07/24/2024)</td><td>$15.52</td></tr><tr><t",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "c8fed1328c23d6b6",
        "value": 15.52,
        "unit": "$",
        "metric_type": "currency",
        "context": "(10/31/2024)</td><td>$132.65</td></tr><tr><td>Biohaven Ltd (BHVN.N)</td><td>O (07/24/2024)</td><td>$15.52</td></tr><tr><td>BioNTech SE (BNTX.O)</td><td>O (09/23/2024)</td><td>$101.93</td></tr><tr><td>",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "59dd6ca72e1182c2",
        "value": 101.93,
        "unit": "$",
        "metric_type": "currency",
        "context": ">O (07/24/2024)</td><td>$15.52</td></tr><tr><td>BioNTech SE (BNTX.O)</td><td>O (09/23/2024)</td><td>$101.93</td></tr><tr><td>C4 Therapeutics (CCCC.O)</td><td>E (11/06/2023)</td><td>$2.55</td></tr><tr>",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "ca1eaa4a7a78c571",
        "value": 2.55,
        "unit": "$",
        "metric_type": "currency",
        "context": "9/23/2024)</td><td>$101.93</td></tr><tr><td>C4 Therapeutics (CCCC.O)</td><td>E (11/06/2023)</td><td>$2.55</td></tr><tr><td>CRISPR Therapeutics AG (CRSP.O)</td><td>U (10/11/2022)</td><td>$53.05</td></t",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "f0f5f96384ac07e6",
        "value": 53.05,
        "unit": "$",
        "metric_type": "currency",
        "context": "2023)</td><td>$2.55</td></tr><tr><td>CRISPR Therapeutics AG (CRSP.O)</td><td>U (10/11/2022)</td><td>$53.05</td></tr><tr><td>Gilead Sciences Inc. (GILD.O)</td><td>O (01/10/2025)</td><td>$112.56</td></t",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "516af01d76fcbbd2",
        "value": 112.56,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2022)</td><td>$53.05</td></tr><tr><td>Gilead Sciences Inc. (GILD.O)</td><td>O (01/10/2025)</td><td>$112.56</td></tr><tr><td>Intellia Therapeutics Inc (NTLA.O)</td><td>E (01/26/2025)</td><td>$11.60</t",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "3b4951fe9eead4b5",
        "value": 11.6,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$112.56</td></tr><tr><td>Intellia Therapeutics Inc (NTLA.O)</td><td>E (01/26/2025)</td><td>$11.60</td></tr><tr><td>Legend Biotech Corp (LEGN.O)</td><td>O (01/31/2022)</td><td>$34.37</td></tr>",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "2d828ff088ff21cb",
        "value": 34.37,
        "unit": "$",
        "metric_type": "currency",
        "context": "6/2025)</td><td>$11.60</td></tr><tr><td>Legend Biotech Corp (LEGN.O)</td><td>O (01/31/2022)</td><td>$34.37</td></tr><tr><td>Moderna Inc (MRNA.O)</td><td>E (12/16/2020)</td><td>$24.47</td></tr><tr><td>",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "1fb02dfe958230c1",
        "value": 24.47,
        "unit": "$",
        "metric_type": "currency",
        "context": ">O (01/31/2022)</td><td>$34.37</td></tr><tr><td>Moderna Inc (MRNA.O)</td><td>E (12/16/2020)</td><td>$24.47</td></tr><tr><td>Nurix Therapeutics Inc. (NRIX.O)</td><td>E (10/11/2022)</td><td>$9.41</td></",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "f00697a196cfc0b6",
        "value": 9.41,
        "unit": "$",
        "metric_type": "currency",
        "context": "20)</td><td>$24.47</td></tr><tr><td>Nurix Therapeutics Inc. (NRIX.O)</td><td>E (10/11/2022)</td><td>$9.41</td></tr><tr><td>Prime Medicine Inc (PRME.O)</td><td>E (11/14/2022)</td><td>$3.44</td></tr><tr",
        "provenance": {
          "page": 57
        }
      },
      {
        "num_id": "4e3915c4d2b1534a",
        "value": 307.24,
        "unit": "$",
        "metric_type": "currency",
        "context": "United Therapeutics Corp (UTHR.O) E (07/11/2024) \\$307.24 Vertex Pharmaceuticals (VRTX.O) E (05/03/2022) \\$392.05 Stock Ratings are subject to change. Please",
        "provenance": {
          "page": 58
        }
      },
      {
        "num_id": "5a9ab422868f8b8b",
        "value": 392.05,
        "unit": "$",
        "metric_type": "currency",
        "context": "Therapeutics Corp (UTHR.O) E (07/11/2024) \\$307.24 Vertex Pharmaceuticals (VRTX.O) E (05/03/2022) \\$392.05 Stock Ratings are subject to change. Please see latest research for each company. * Historica",
        "provenance": {
          "page": 58
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 40,
      "tables_count": 0,
      "numerical_data_count": 1382,
      "passages_count": 319,
      "entities_count": 20
    }
  }
}